

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 237/14, A61K 31/50, C07D 405/04, 409/04</p>	A1	<p>(11) International Publication Number: WO 00/24719</p> <p>(43) International Publication Date: 4 May 2000 (04.05.00)</p>														
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/US99/25234</p> <p>(22) International Filing Date: 27 October 1999 (27.10.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">09/179,605</td> <td style="width: 30%;">27 October 1998 (27.10.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>09/261,872</td> <td>3 March 1999 (03.03.99)</td> <td>US</td> </tr> <tr> <td>09/298,490</td> <td>23 April 1999 (23.04.99)</td> <td>US</td> </tr> <tr> <td>09/427,768</td> <td>27 October 1999 (27.10.99)</td> <td>US</td> </tr> </table> <p>(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(72) Inventors: BLACK, Lawrence, A.; 1173 Tamarack Lane, Libertyville, IL 60048 (US). BASHA, Anwer, 41 Heron Road, Lake Forest, IL 60045 (US). KOLASA, Teodozyj; 118 Walden, Lake Villa, IL 60046 (US). KORT, Michael, E.; 507 N. Green Avenue, Lake Bluff, IL 60044 (US). LIU, Huaqing; 2230 Apple Hill Court S, Buffalo Grove, IL 60089 (US). MCCARTY, Catherine, M.; 430 Park Avenue, Highland Park, IL 60035 (US). PATEL, Meena, V.; 605 W. Madison Street, Chicago, IL 60661 (US). ROHDE, Jeffrey, J.; 1621 Ridge Avenue, Evanston, IL 60201 (US). COGHLAN, Michael, J.; 307 Fairfax Lane, Grayslake, IL 60030 (US). STEWART, Andrew, O.; 1289 Thornbury Lane, Libertyville, IL 60048 (US).</p> <p>(74) Agents: MILLER, Robert, A. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p style="text-align: center;">Published <i>With international search report.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/US99/25234</p> <p>(22) International Filing Date: 27 October 1999 (27.10.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">09/179,605</td> <td style="width: 30%;">27 October 1998 (27.10.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>09/261,872</td> <td>3 March 1999 (03.03.99)</td> <td>US</td> </tr> <tr> <td>09/298,490</td> <td>23 April 1999 (23.04.99)</td> <td>US</td> </tr> <tr> <td>09/427,768</td> <td>27 October 1999 (27.10.99)</td> <td>US</td> </tr> </table> <p>(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).</p>	09/179,605	27 October 1998 (27.10.98)	US	09/261,872	3 March 1999 (03.03.99)	US	09/298,490	23 April 1999 (23.04.99)	US	09/427,768	27 October 1999 (27.10.99)	US	<p>(72) Inventors: BLACK, Lawrence, A.; 1173 Tamarack Lane, Libertyville, IL 60048 (US). BASHA, Anwer, 41 Heron Road, Lake Forest, IL 60045 (US). KOLASA, Teodozyj; 118 Walden, Lake Villa, IL 60046 (US). KORT, Michael, E.; 507 N. Green Avenue, Lake Bluff, IL 60044 (US). LIU, Huaqing; 2230 Apple Hill Court S, Buffalo Grove, IL 60089 (US). MCCARTY, Catherine, M.; 430 Park Avenue, Highland Park, IL 60035 (US). PATEL, Meena, V.; 605 W. Madison Street, Chicago, IL 60661 (US). ROHDE, Jeffrey, J.; 1621 Ridge Avenue, Evanston, IL 60201 (US). COGHLAN, Michael, J.; 307 Fairfax Lane, Grayslake, IL 60030 (US). STEWART, Andrew, O.; 1289 Thornbury Lane, Libertyville, IL 60048 (US).</p> <p>(74) Agents: MILLER, Robert, A. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p style="text-align: center;">Published <i>With international search report.</i></p>
<p>(21) International Application Number: PCT/US99/25234</p> <p>(22) International Filing Date: 27 October 1999 (27.10.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">09/179,605</td> <td style="width: 30%;">27 October 1998 (27.10.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>09/261,872</td> <td>3 March 1999 (03.03.99)</td> <td>US</td> </tr> <tr> <td>09/298,490</td> <td>23 April 1999 (23.04.99)</td> <td>US</td> </tr> <tr> <td>09/427,768</td> <td>27 October 1999 (27.10.99)</td> <td>US</td> </tr> </table> <p>(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).</p>	09/179,605	27 October 1998 (27.10.98)	US	09/261,872	3 March 1999 (03.03.99)	US	09/298,490	23 April 1999 (23.04.99)	US	09/427,768	27 October 1999 (27.10.99)	US	<p>(72) Inventors: BLACK, Lawrence, A.; 1173 Tamarack Lane, Libertyville, IL 60048 (US). BASHA, Anwer, 41 Heron Road, Lake Forest, IL 60045 (US). KOLASA, Teodozyj; 118 Walden, Lake Villa, IL 60046 (US). KORT, Michael, E.; 507 N. Green Avenue, Lake Bluff, IL 60044 (US). LIU, Huaqing; 2230 Apple Hill Court S, Buffalo Grove, IL 60089 (US). MCCARTY, Catherine, M.; 430 Park Avenue, Highland Park, IL 60035 (US). PATEL, Meena, V.; 605 W. Madison Street, Chicago, IL 60661 (US). ROHDE, Jeffrey, J.; 1621 Ridge Avenue, Evanston, IL 60201 (US). COGHLAN, Michael, J.; 307 Fairfax Lane, Grayslake, IL 60030 (US). STEWART, Andrew, O.; 1289 Thornbury Lane, Libertyville, IL 60048 (US).</p> <p>(74) Agents: MILLER, Robert, A. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p style="text-align: center;">Published <i>With international search report.</i></p>			
09/179,605	27 October 1998 (27.10.98)	US														
09/261,872	3 March 1999 (03.03.99)	US														
09/298,490	23 April 1999 (23.04.99)	US														
09/427,768	27 October 1999 (27.10.99)	US														
<p>(54) Title: PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS</p> <p>(57) Abstract</p> <p>The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).</p>																
<div style="display: flex; justify-content: space-between; align-items: center; margin-top: 10px;"> <div style="text-align: center;"> <chem>R3C1=NC(R)C(=X)C(R1)=C(R2)N1</chem> </div> <div style="text-align: right;">(I)</div> </div>																

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CJ	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS

This application is a continuation-in-part application of copending U.S. Serial No. 09/261,872 filed March 3, 1999 which is a continuation-in-part of copending U.S. Serial No. 09/179,605, filed October 27, 1998, which is a continuation-in-part application of copending U.S. Serial No 09/129,570 filed August 5, 1998, now abandoned, which in-turn is based in-part on provisional application 60/056,733 filed August 22, 1997.

TECHNICAL FIELD

The present invention encompasses novel pyridazinone compounds useful in the treatment of cyclooxygenase-2 mediated diseases. More particularly, this invention concerns a method of inhibiting prostaglandin biosynthesis, particularly the induced prostaglandin endoperoxide H synthase (PGHS-2, cyclooxygenase-2, COX-2) protein.

BACKGROUND OF THE INVENTION

The prostaglandins are extremely potent substances which produce a wide variety of biological effects, often in the nanomolar to picomolar concentration range. The discovery of two forms of prostaglandin endoperoxide H synthase, isoenzymes PGHS-1 and PGHS-2, that catalyze the oxidation of arachidonic acid leading to prostaglandin biosynthesis has resulted in renewed research to delineate the role of these two isozymes in physiology and pathophysiology. These isozymes have been shown to have different gene regulation and represent distinctly different prostaglandin biosynthesis pathways. The PGHS-1 pathway is expressed constitutively in most cell types. It responds to produce prostaglandins that regulate acute events in vascular homeostasis and also has a role in maintaining normal stomach and renal function. The PGHS-2 pathway involves an induction mechanism which has been linked to inflammation, mitogenesis and ovulation phenomena.


Prostaglandin inhibitors provide therapy for pain, fever, and inflammation, and are useful therapies, for example in the treatment of rheumatoid arthritis and osteoarthritis. The non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen and fenamates inhibit both isozymes. Inhibition of the constitutive enzyme PGHS-1 results in
5 gastrointestinal side effects including ulcers and bleeding and incidence of renal problems with chronic therapy. Inhibitors of the induced isozyme PGHS-2 may provide anti-inflammatory activity without the side effects of PGHS-1 inhibitors.

The problem of side-effects associated with NSAID administration has never completely been solved in the past. Enteric coated tablets and co-administration with
10 misoprostol, a prostaglandin derivative, have been tried in an attempt to minimize stomach toxicity. It would be advantageous to provide compounds which are selective inhibitors of the induced isozyme PGHS-2.

The present invention discloses novel compounds which are selective inhibitors of PGHS-2.

SUMMARY OF THE INVENTION

The present invention discloses pyridazinone compounds which are selective inhibitors of cyclooxygenase-2 (COX-2). The compounds of the present invention have the formula I:



or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

X is selected from the group consisting of O, S, -NR⁴, -NOR^a, and -NNR^bR^c;

R⁴ is selected from the group consisting of alkenyl, alkyl, aryl, arylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclic, and heterocyclic alkyl;

R^a , R^b , and R^c are independently selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, and cycloalkylalkyl;

R is selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxyiminoalkoxy, alkyl, alkylcarbonylalkyl, alkylsulfonylalkyl, alkynyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, arylalkynyl, arylhaloalkyl, arylhydroxyalkyl, aryloxy, aryloxyhaloalkyl, aryloxyhydroxyalkyl, arylcarbonylalkyl, carboxyalkyl, cyanoalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylidenealkyl, haloalkenyl, haloalkoxyhydroxyalkyl, haloalkyl, haloalkynyl, heterocyclic, heterocyclic alkoxy, heterocyclic alkyl, heterocyclic oxy, hydroxyalkyl, hydroxyiminoalkoxy, -
 5 $(CH_2)_n C(O)R^5$, $-(CH_2)_n CH(OH)R^5$, $-(CH_2)_n C(NOR^d)R^5$, $-(CH_2)_n CH(NOR^d)R^5$, -
 $(CH_2)_n CH(NR^d R^e)R^5$, $-R^6 R^7$, $-(CH_2)_n C \equiv CR^7$,
 10 $-(CH_2)_n [CH(CX'_3)]_m (CH_2)_p R^7$, $-(CH_2)_n (CX'_2)_m (CH_2)_p R^7$, and $-(CH_2)_n (CHX')_m (CH_2)_p R^7$;

R^5 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkenyl, haloalkyl, haloalkynyl, heterocyclic, and
 15 heterocyclic alkyl;

R^6 is selected from the group consisting of alkenylene, alkylene, halo-substituted alkenylene, and halo-substituted alkylene;

R^7 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclic, and heterocyclic alkyl;
 20

R^d and R^e are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

X' is halogen;

25 m is an integer from 0-5;


n is an integer from 0-10; and

p is an integer from 0-10; and

R^1 , R^2 , and R^3 are independently selected from the group consisting of hydrogen,

alkenyl, alkoxyalkyl, alkoxyiminoalkoxy, alkoxyiminoalkyl, alkyl, alkynyl, alkylcarbonylalkoxy, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminoalkoxy, aminoalkylcarbonyloxyalkoxy aminocarbonylalkyl, aryl, arylalkenyl, arylalkyl, arylalkynyl, carboxyalkylcarbonyloxyalkoxy, cyano, cycloalkenyl, cycloalkyl, cycloalkylidenealkyl, haloalkenyloxy, haloalkoxy, haloalkyl, halogen, heterocyclic, hydroxyalkoxy, hydroxyiminoalkoxy, hydroxyiminoalkyl, mercaptoalkoxy, nitro, phosphonatoalkoxy, Y, and W; provided that one of R^1 , R^2 , or R^3 must be W, and further provided that only one of R^1 , R^2 , or R^3 is W;

W is selected from the group consisting of



X^1 is selected from the group consisting of $S(O)_2$, $S(O)(NR^{10})$, $S(O)$, $Se(O)_2$, $P(O)(OR^{11})$, and $P(O)(NR^{12}R^{13})$;

X^2 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl and halogen;

R^9 is selected from the group consisting of alkenyl, alkoxy, alkyl, alkylamino, alkylcarbonylamino, alkynyl, amino, cycloalkenyl, cycloalkyl, dialkylamino, $-NHNH_2$, and $-NCHN(R^{10})R^{11}$;

R^{10} , R^{11} , R^{12} , and R^{13} are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl, or R^{12} and R^{13} can be taken together, with the nitrogen to which they are attached, to form a 3-6 membered ring containing 1 or 2 heteroatoms selected from the group consisting of O, S, and NR^7 ;

Y is selected from the group consisting of $-OR^{14}$, $-SR^{14}$, $-C(R^{16})(R^{17})R^{14}$, $-C(O)R^{14}$, $-C(O)OR^{14}$, $-N(R^{16})C(O)R^{14}$, $-NC(R^{16})R^{14}$, and $-N(R^{16})R^{14}$;

R^{14} is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylthioalkyl, alkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, heterocyclic alkyl, hydroxyalkyl, and $NR^{18}R^{19}$; and

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, cycloalkenyl, cycloalkyl, aryl, arylalkyl, heterocyclic, and heterocyclic alkyl.

DETAILED DESCRIPTION OF THE INVENTION

All patents, patent applications, and literature references cited in the specification are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure, including definitions, will prevail.

In one embodiment, compounds of the present invention have formula I wherein,

R^2 is W;

X^1 is selected from $S(O)_2$, $S(O)$, $Se(O)_2$, and $S(O)(NR^{10})$;


R^9 is selected from alkenyl, alkoxy, alkyl, alkylamino, alkylcarbonylamino, alkynyl, amino, cycloalkenyl, cycloalkyl, and dialkylamino; and

X, X^2 , R, R^1 , R^3 , and R^{10} are as defined in formula I.

In another embodiment, compounds of the present invention have formula I wherein,

R^2 is W;

W is



X^1 is selected from $S(O)_2$, $S(O)$, $Se(O)_2$, and $S(O)(NR^{10})$;


R^9 is selected from alkenyl, alkoxy, alkyl, alkylamino, alkylcarbonylamino, alkynyl, amino, cycloalkenyl, cycloalkyl, and dialkylamino; and

X, X^2 , R, R^1 , R^3 , and R^{10} are as defined in formula I.

In another embodiment, compounds of the present invention have formula I wherein,

R^2 is W;

W is



X^2 is selected from hydrogen and halogen;

R is selected from hydrogen, alkenyl, alkyl, alkynyl, alkylcarbonylalkyl, alkylsulfonylalkyl, carboxyalkyl, cyanoalkyl, haloalkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkenyl, arylalkynyl, heterocyclic, heterocyclic alkyl, arylalkyl, -
 10 $(CH_2)_n C(O)R^5$, $-(CH_2)_n C \equiv CR^7$, and $-(CH_2)_n [CH(CX'_3)]_m (CH_2)_p R^7$;


R^1 and R^3 are independently selected from hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminocarbonylalkyl, aryl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, halogen, nitro, and
 Y; and

15 X , X^1 , X' , R^5 , R^7 , R^9 , n , m , p , and Y are as defined in formula I.

In another embodiment, compounds of the present invention have formula I wherein,

R^2 is W;

20 W is



X^2 is selected from hydrogen and halogen;

R is selected from hydrogen, alkenyl, alkyl, alkynyl, alkylcarbonylalkyl, alkylsulfonylalkyl, carboxyalkyl, cyanoalkyl, haloalkyl, hydroxyalkyl, cycloalkyl,

cycloalkylalkyl, aryl, arylalkenyl, arylalkynyl, heterocyclic, heterocyclic alkyl, arylalkyl, and $-(CH_2)_nC(O)R^5$;

R^1 and R^3 are independently selected from hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminocarbonylalkyl, aryl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, halogen, heterocyclic, heterocyclic alkyl, nitro, and Y; and


X, X^1 , R^5 , R^9 , n, and Y are as defined in formula I.

In another embodiment, compounds of the present invention have formula I

wherein,

R^2 is W;

W is



X^2 is selected from hydrogen and halogen;

R is selected from hydrogen, alkyl, aryl, haloalkyl, heterocyclic, heterocyclic alkyl, and $-(CH_2)_nC(O)R^5$;

R^1 and R^3 are independently selected from hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminocarbonylalkyl, aryl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, halogen, heterocyclic, heterocyclic alkyl, nitro, and Y; and


X, X^1 , R^5 , R^9 , n, and Y are as defined in formula I.

In another embodiment, compounds of the present invention have formula I

wherein,

R^2 is W;

W is



X^2 is selected from hydrogen and halogen;

R is selected from alkyl, aryl, haloalkyl, heterocyclic, heterocyclic alkyl, and arylalkyl wherein the aryl portion is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halogen; and


R^1 is selected from aryl, arylalkyl, heterocyclic, heterocyclic alkyl, hydroxyalkoxy, and Y; and

X, X^1 , R^3 , R^9 , and Y are as defined in formula I.

10 In another embodiment, compounds of the present invention have formula I wherein,

R^2 is W;

W is



15 X^2 is selected hydrogen and halogen;

R is selected from the group consisting of alkyl, aryl, haloalkyl, heterocyclic, heterocyclic alkyl and arylalkyl wherein the aryl portion is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halogen;

R^1 is selected from the group consisting of aryl, arylalkyl, heterocyclic, heterocyclic alkyl, hydroxyalkoxy, and Y;

20 Y is $-OR^{14}$;

R^{14} is selected from the group consisting of alkenyl, alkyl, and aryl;


R^3 is hydrogen; and

X, X^1 , and R^9 are as defined in formula I.

In another embodiment, compounds of the present invention have formula I
wherein,

R^2 is W;

5 W is



X^1 is $S(O)_2$;

X^2 is selected from hydrogen and halogen;

R is selected from aryl, haloalkyl, heterocyclic, heterocyclic alkyl and arylalkyl
10 wherein the aryl portion is optionally substituted with 1, 2, 3, 4, or 5 substituents selected
from halogen;

R^1 is aryl optionally substituted with 1, 2, or 3 substituents independently selected
from chlorine and fluorine;


R^3 is hydrogen; and

15 X and R^9 are as defined in formula I.

In another embodiment, compounds of the present invention have formula I
wherein,

R^2 is W;

20 W is



X is O;

X^1 is $S(O)_2$;

R^9 is selected from the group consisting of alkyl and amino;

X^2 is selected from hydrogen and halogen;

R is selected from alkenyl, alkyl, alkynyl, aryl, arylalkyl, and haloalkyl;

R^1 is selected from alkyl, aryl, arylalkyl, haloalkoxy, hydroxyalkoxy, and Y;

Y is $-OR^{14}$;


5 R^{14} is selected from alkenyl, alkyl, and aryl; and

R^3 is hydrogen.

In another embodiment, compounds of the present invention have formula I wherein,

10 R^2 is W;

W is



X^1 is $S(O)_2$;

R^9 is selected from alkyl and amino;

15 X^2 is selected from hydrogen and fluorine;

R is selected from haloalkyl, aryl, and alkyl;

R^1 is selected from isobutyloxy, isopentyloxy, 1-(3-methyl-3-butenyl)oxy, 2-hydroxy-2-methyl-propyloxy, 3-hydroxy-3-methylbutoxy, neopentyloxy, isopentyl, aryloxy, 4-fluorophenoxy, and aryl optionally substituted with 1, 2, or 3 substituents

20 independently selected from the group consisting of chlorine and fluorine;


R^3 is hydrogen; and

X is as defined in formula I.

In another embodiment, compounds of the present invention have formula I wherein,

25 R^2 is W;

W is



X is O;

X^1 is selected from $S(O)_2$ and $S(O)(NR^{10})$;

5 R^9 is alkyl;

X^2 is selected from hydrogen and fluorine;

R is selected from alkenyl, alkyl, alkynyl, aryl, arylalkyl and haloalkyl;

R^1 is selected from alkyl, aryl, hydroxyalkoxy and Y;

Y is $-OR^{14}$;

10 R^{14} is selected from alkenyl, alkyl, and aryl;

R^3 is hydrogen; and


R^{10} is as defined in formula I.

In another embodiment, compounds of the present invention have formula I

15 wherein,

R^2 is W;

W is



X is O;

20 X^1 is $S(O)_2$;

R^9 is amino;

X^2 is selected from hydrogen and fluorine;

R is selected from alkenyl, alkyl, alkynyl, aryl, arylalkyl, and haloalkyl;

R^1 is selected from alkyl, aryl, hydroxyalkoxy and Y;

Y is -OR¹⁴;


R¹⁴ is selected from alkenyl, alkyl, and aryl; and

R³ is hydrogen.

5 In another embodiment, compounds of the present invention have formula I wherein,

R² is W;

W is



10 X is O;

X¹ is SO₂;

R⁹ is methyl;

X² is hydrogen;

15 R is selected from t-butyl, 3-chlorophenyl, 3,4-difluorophenyl, 4-fluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, and 2,2,2-trifluoroethyl;

R¹ is selected from isobutoxy, isopentyloxy, (3-methyl-3-butenyl)oxy, 2-hydroxy-2-methyl-propoxy, 3-hydroxy-3-methylbutoxy, neopentyloxy, isopentyl, 4-fluorophenyl, 4-chlorophenyl, 4-chloro-3-fluoro-phenyl, 4-fluorophenoxy and Y;

Y is -OR¹⁴;


20 R¹⁴ is aryl; and

R³ is hydrogen.

In another embodiment, compounds of the present invention have formula I wherein,

25 R² is W;

W is



X is O;

X¹ is S(O)₂;

R⁹ is amino;

5 X² is hydrogen;

R is selected from t-butyl, 3-chlorophenyl, 3,4-difluorophenyl, 4-fluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, and 2,2,2-trifluoroethyl;

R¹ is selected consisting of isobutoxy, isopentyloxy, (3-methyl-3-butenyl)oxy, 2-hydroxy-2-methyl-propoxy, 3-hydroxy-3-methylbutoxy, neopentyloxy, isopentyl, 4-fluorophenyl, 4-chlorophenyl, 4-chloro-3-fluoro-phenyl, 4-fluorophenoxy, and Y;

10 Y is -OR¹⁴;

R¹⁴ is aryl; and

R³ is hydrogen.

15 Another embodiment of the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier for inhibiting prostaglandin biosynthesis.

Another embodiment of the invention relates to a method of inhibiting
20 prostaglandin biosynthesis comprising administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.


Another embodiment of the invention relates to a method of treating pain, fever, inflammation, rheumatoid arthritis, osteoarthritis, adhesions, and cancer comprising
25 administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Another embodiment of the present invention relates to a method of preparing a compound of formula I wherein,

R^2 is W;

5

W is




X, X^1 , X^2 , R, R^1 , and R^3 are as defined in formula I; comprising the step of treating a compound of formula I wherein R is hydrogen with an alkylating agent.

10

Another embodiment of the present invention relates to a method of preparing a compound of formula I wherein,

R^2 is W;

W is



15

X, X^1 , X^2 , R, R^1 , R^2 , and R^3 are as defined in formula I;

comprising the step of treating a compound of formula I wherein R is hydrogen with an alkylating agent, wherein the alkylating agent has the formula R^{99} -Q wherein Q is a leaving group and R^{99} is selected from the group consisting of methyl, ethyl, 1,1,1-trifluoroethyl, cyclopropylmethyl, 3-(2-methyl)propenyl, 4-(2-methyl)but-2-enyl, 1,1-dichloropropen-3-yl, 2,2-dimethyl-3-oxo-4-butyl, 2,3,3,4,4,4-hexafluorobuten-1-yl, propargyl, phenylpropargyl, phenyl, phenethyl, 1-phenylpropen-3-yl, benzyl, α -methyl-4-fluorobenzyl, 2,3,4,5,6-pentafluorobenzyl, 4-trifluomethoxyphenacyl, 4-fluorobenzyl, 4-fluorophenyl, 2-trifluoromethylbenzyl, 2,4-difluorobenzyl, 2,4-difluorophenacyl, 4-


20

trifluomethylphenacyl, phenacyl, 4-carboxyphenacyl, 4-chlorophenacyl, 4-cyanophenacyl, 4-diethylaminophenacyl, 3-thienylmethyl, 5-methylthien-2-ylmethyl, 5-chlorothien-2-ylmethyl, 2-benzo[b]thienylmethyl, 3-benzothienacyl, 5-chlorothiazol-2-ylmethyl, 5-methylthiazol-2-ylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, quinolin-2-ylmethyl, and fluoroquinolin-2-ylmethyl.

Another embodiment of the present invention relates to a method of preparing a compound of formula I wherein,

R^2 is W;

W is




X, X^1 , X^2 , R, R^1 , R^2 , and R^3 are as defined in formula I;

comprising the step of treating a compound of formula I wherein R is hydrogen with an alkylating agent, wherein the alkylating agent has the formula R^{99} -Q wherein Q is a leaving group and R^{99} is selected from the group consisting of methyl, ethyl, 1,1,1-trifluoroethyl, cyclopropylmethyl, 3-(2-methyl)propenyl, 4-(2-methyl)but-2-enyl, 1,1-dichloropropen-3-yl, 2,3,3,4,4,4-hexafluorobuten-1-yl, propargyl, phenylpropargyl, phenyl, phenethyl, 1-phenylpropen-3-yl, benzyl, α -methyl-4-fluorobenzyl, 2,3,4,5,6-pentafluorobenzyl, 4-trifluomethoxyphenacyl, 4-fluorobenzyl, 4-fluorophenyl, 2,4-difluorobenzyl, 2,4-difluorophenacyl, 4-trifluomethylphenacyl, phenacyl, 4-carboxyphenacyl, 4-chlorophenacyl, 4-cyanophenacyl, 4-diethylaminophenacyl, 3-thienylmethyl, 5-methylthien-2-ylmethyl, 5-chlorothien-2-ylmethyl, 2-benzo[b]thienylmethyl, and 3-benzothienacyl.

Another embodiment of the present invention relates to a method of preparing a compound of formula I wherein,

R^2 is W;

W is




X, X^1 , X^2 , R, R^1 , R^2 , and R^3 are as defined in formula I;

- 5 comprising the step of treating a compound of formula I wherein R is hydrogen with an alkylating agent, wherein the alkylating agent has the formula R^{99} -Q wherein Q is a leaving group and R^{99} is selected from the group consisting of 1,1,1-trifluoroethyl, 3-(2-methyl)propenyl, 4-(2-methyl)but-2-enyl, 1,1-dichloropropen-3-yl, 2,3,3,4,4,4-hexafluorobuten-1-yl, propargyl, phenylpropargyl, phenyl, benzyl, α -methyl-4-fluorobenzyl, 2,3,4,5,6-pentafluorobenzyl, 4-fluorobenzyl, 4-fluorophenyl, 2,4-difluorobenzyl, 3-thienylmethyl, 5-methylthien-2-ylmethyl, 5-chlorothien-2-ylmethyl, and 2-benzo[b]thienylmethyl.
- 10

- Another embodiment of the present invention relates to a method of preparing a compound of formula I wherein,
- 15

R^2 is W;

W is




X, X^1 , X^2 , R, R^1 , R^2 , and R^3 are as defined in formula I;

- 20 comprising the step of treating a compound of formula I wherein R is hydrogen with an alkylating agent, wherein the alkylating agent has the formula R^{99} -Q wherein Q is a leaving group and R^{99} is selected from the group consisting of 1,1,1-trifluoroethyl, phenyl, benzyl, α -methyl-4-fluorobenzyl, 4-fluorobenzyl, 4-fluorophenyl, and 2,4-difluorobenzyl.

Another embodiment of the present invention relates to a method of preparing a compound of formula I wherein,

R² is W;

5 W is




X, X¹, X², R, R¹, R², and R³ are as defined in formula I;

comprising the step of treating a compound of formula I wherein R is hydrogen with an alkylating agent, wherein the alkylating agent has the formula R⁹⁹-Q wherein Q is a leaving group and R⁹⁹ is selected from the group consisting of 1,1,1-trifluoroethyl, benzyl, and 4-fluorophenyl.

10

Another embodiment of the present invention relates to a method for regioselectively preparing a 4,5-disubstituted pyridazinone comprising the steps of

15 a) treating a compound of formula IV



IV,

wherein R⁹⁸ is an alkyl or aryl group; and X is a leaving group;


20 with a nucleophilic agent to displace the X group;

b) converting the -OR⁹⁸ to a leaving group; and

c) treating the compound with a second nucleophilic agent to provide the 4,5-disubstituted pyridazinone.

Another embodiment of the present invention relates to a method for regioselectively preparing a 4,5-disubstituted pyridazinone comprising the steps of

a) treating a compound of formula IV



IV,


wherein R^{98} is an alkyl or aryl group; and X is a leaving group;

with a nucleophilic agent to displace the X group;

b) converting the $-OR^{98}$ to a leaving group; and

c) treating the compound with a second nucleophilic agent to provide the 4,5-disubstituted pyridazinone wherein the benzyl group is removed using a Lewis acid.

Another embodiment of the present invention relates to a method for regioselectively preparing a 4,5-disubstituted pyridazinone comprising the steps of treating a compound of formula V



V,

wherein

R^1 and R^3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminoalkoxy, alkylcarbonylalkoxy, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyl, arylalkynyl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl,

cycloalkylidenealkyl, haloalkenyloxy, haloalkoxy, haloalkyl, halogen, heterocyclic, heterocyclic alkyl, hydroxyalkoxy, hydroxyalkylamino, hydroxyalkylthio, mercaptoalkoxy, nitro, and Y;

Y is selected from the group consisting of $-OR^{14}$, $-SR^{14}$, $-C(R^{16})(R^{17})R^{14}$, $-C(O)R^{14}$,
 5 $-C(O)OR^{14}$, $-N(R^{16})C(O)R^{14}$, $-NC(R^{16})R^{14}$, and $-N(R^{16})R^{14}$;

R^{14} is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylthioalkyl, alkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, heterocyclic alkyl and $NR^{18}R^{19}$; and

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of
 10 hydrogen, alkenyl, alkoxy, alkyl, cycloalkenyl, cycloalkyl, aryl, arylalkyl, heterocyclic, and heterocyclic alkyl;

X^1 is selected from the group consisting of $S(O)_2$, $S(O)(NR^{10})$, $S(O)$, $Se(O)_2$, $P(O)(OR^{11})$, and $P(O)(NR^{12}R^{13})$;

15 R^9 is selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, amino, cycloalkenyl, cycloalkyl, dialkylamino, $-NHNH_2$, and $-NCHN(R^{10})R^{11}$; and

R^{10} , R^{11} , R^{12} , and R^{13} are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl, or R^{12} and R^{13} can be taken together, with the nitrogen to which they are attached, to form a 3-6 membered ring containing 1 or 2 heteroatoms
 20 selected from the group consisting of O, S, and NR^7 ;

R^7 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

with a hydrazine having the formula $RNHNH_2$, wherein R is selected from the
 25 group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, alkylcarbonylalkyl, alkylsulfonylalkyl, alkynyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, arylalkynyl, arylhaloalkyl, arylhydroxyalkyl, aryloxy, aryloxyhaloalkyl, aryloxyhydroxyalkyl, arylcarbonylalkyl, carboxyalkyl, cyanoalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkenyl, haloalkoxyhydroxyalkyl, haloalkyl, haloalkynyl,

heterocyclic, heterocyclic alkoxy, heterocyclic alkyl, heterocyclic oxy, hydroxyalkyl, -
 $(\text{CH}_2)_n\text{C}(\text{O})\text{R}^5$, $-(\text{CH}_2)_n\text{CH}(\text{OH})\text{R}^5$, $-(\text{CH}_2)_n\text{C}(\text{NOR}^d)\text{R}^5$, $-(\text{CH}_2)_n\text{CH}(\text{NOR}^d)\text{R}^5$, -
 $(\text{CH}_2)_n\text{CH}(\text{NR}^d\text{R}^e)\text{R}^5$, $-\text{R}^6\text{R}^7$, $-(\text{CH}_2)_n\text{C}\equiv\text{CR}^7$, $-(\text{CH}_2)_n[\text{CH}(\text{CX}'_3)]_m(\text{CH}_2)_n\text{R}^7$, -
 $(\text{CH}_2)_n(\text{CX}'_2)_m(\text{CH}_2)_n\text{R}^7$, and $-(\text{CH}_2)_n(\text{CHX}')_m(\text{CH}_2)_n\text{R}^7$;

5 R^5 is selected from the group consisting of alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkenyl, haloalkyl, haloalkynyl, heterocyclic, and heterocyclic alkyl;

R^6 is selected from the group consisting of alkenylene, alkylene, halo-substituted alkenylene, and halo-substituted alkylene;

10 R^7 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

R^d and R^e are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkyl, heterocyclic, and heterocyclic alkyl;


15 X' is halogen;

n is an integer from 0-10;

m is an integer from 0-5;

to furnish the pyridazinone of formula III

20



III,

wherein X^1 , R , R^1 , R^3 , and R^9 are as previously defined;

X is selected from the group consisting of O , S , $-\text{NR}^4$, $-\text{NOR}^a$, and $-\text{NNR}^b\text{R}^c$;


R^4 is selected from the group consisting of alkenyl, alkyl, aryl, arylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclic, and heterocyclic alkyl;

R^a , R^b , and R^c are independently selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, and cycloalkylalkyl; and

X^2 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl and halogen.

A preferred embodiment of the present invention relates to a compound of formula

10 VI



VI,

or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

R is selected from alkyl, aryl, arylalkyl, haloalkyl, and haloalkenyl;

15 R^1 is selected from alkoxy, aminoalkylcarbonyloxyalkoxy, carboxyalkylcarbonyloxyalkoxy, hydroxyalkyl, hydroxyalkoxy, and phosphonatoalkoxy,

R^9 is selected from alkyl, alkylcarbonylamino, and amino.

20 Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is aryl;

R^1 is hydroxyalkoxy; and

R^9 is selected from alkyl and amino.

Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is aryl;

R¹ is hydroxyalkoxy; and

5 R⁹ is methyl.

Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

10 R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halogen and haloalkyl;

R¹ is hydroxyalkoxy; and

R⁹ is selected from alkyl and amino.

15 Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is phenyl optionally substituted with 1 or 2 substituents independently selected from chlorine and fluorine;

R¹ is hydroxyalkoxy; and

20 R⁹ is selected from alkyl and amino.

Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is haloalkyl; and

R¹ is hydroxyalkoxy; and

25 R⁹ is selected from alkyl and amino.

Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halogen and haloalkyl;

R¹ is aminoalkylcarbonyloxyalkoxy; and

R⁹ is selected from alkyl and amino.

5

Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halogen and haloalkyl;

10 R¹ is carboxyalkylcarbonyloxyalkoxy; and

R⁹ is selected from alkyl and amino.

Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

15 R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halogen and haloalkyl;

R¹ is phosphonatoalkoxy; and

R⁹ is selected from alkyl and amino.

20 Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halogen and haloalkyl;

R¹ is hydroxyalkoxy; and

25 R⁹ is alkylcarbonylamino.

Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is selected from haloalkyl and phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halogen and haloalkyl;

R¹ is alkoxy; and

R⁹ is selected from the group consisting of alkyl, alkylcarbonylamino, and amino.

5

Another preferred embodiment of the present invention relates to a compound of formula VI wherein,

R is tert-butyl;

R¹ is selected from the group consisting of aminoalkylcarbonyloxyalkoxy, carboxyalkylcarbonyloxyalkoxy, hydroxyalkoxy, and phosphonatoalkoxy; and
10 R⁹ is selected from the group consisting of alkyl, alkylcarbonylamino, and amino.

Another preferred embodiment of the present invention relates to 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
15 pyridazinone or a pharmaceutically acceptable salt, ester, or prodrug thereof.

Definitions of Terms

As used throughout this specification and the appended claims, the following terms have the following meanings:

20 The term "alkenyl," as used herein, refers to a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl and the like.

25 The term "alkenylene," denotes a divalent group derived from a straight or branched chain hydrocarbon of from 2 to 10 carbon atoms containing at least one double bond. Representative examples of alkenylene include, but are not limited to, -CH=CH-, -CH=CH₂CH₂-, -CH=C(CH₃)CH₂-, and the like.

The term "alkoxy," as used herein, refers to an alkyl group, as defined herein,

appended to the parent molecular moiety through an oxy moiety, as defined herein.

Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy and the like.

5 The term "alkoxyalkoxy," as used herein, refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through another alkoxy group, as defined herein. Representative examples of alkoxyalkoxy include, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy, 2-methoxyethoxy, methoxymethoxy, and the like.

10 The term "alkoxyalkoxyalkyl," as used herein, refers to an alkoxyalkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxyalkoxyalkyl include, but are not limited to, tert-butoxymethoxymethyl, ethoxymethoxymethyl, (2-methoxyethoxy)methyl, 2-(2-methoxyethoxy)ethyl, and the like.

15 The term "alkoxyalkyl," as used herein, refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, methoxymethyl, and the like.

20 The term "alkoxyalkylcarbonyl," as used herein, refers to an alkoxyalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkoxyalkylcarbonyl include, but are not limited to, tert-butoxymethylcarbonyl, 2-ethoxyethylcarbonyl, 2-methoxyethylcarbonyl, methoxymethylcarbonyl, and the like.

25 The term "alkoxycarbonyl," as used herein, refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, and the like.

The term "alkoxycarbonylalkenyl," as used herein, refers to an alkoxycarbonyl group, as defined herein, appended to the parent molecular moiety through an alkenyl group, as defined herein. Representative examples of alkoxycarbonylalkenyl include, but are not limited to, 3-methoxycarbonyl-1-propenyl, 4-ethoxycarbonyl-2-butenyl, and the

like.

The term "alkoxycarbonylalkyl," as used herein, refers to an alkoxycarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxycarbonylalkyl include, but are not limited to, 3-methoxycarbonylpropyl, 4-ethoxycarbonylbutyl, 2-tert-butoxycarbonylethyl, and the like.

The term "alkoxycarbonylalkylthio," as used herein, refers to an alkoxycarbonylalkyl group, as defined herein, appended to the parent molecular moiety through a thio moiety, as defined herein. Representative examples of alkoxycarbonylalkylthio include, but are not limited to, 3-methoxycarbonylpropylsulfanyl, 4-ethoxycarbonylbutylsulfanyl, and the like.

The term "alkoxyimino," refers to a $R_{85}ON=$ group wherein R_{85} is alkyl, as defined herein.

The term "alkoxyiminoalkoxy," as used herein, refers to an alkoxyimino group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of alkoxyiminoalkoxy include, but are not limited to, 2-(methoxyimino)ethoxy, 2-(ethoxyimino)-1-propoxy, 3-(isopropoxyimino)-1-butoxy, and the like.

The term "alkoxyiminoalkyl," as used herein, refers to an alkoxyimino group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxyiminoalkyl include, but are not limited to, 2-(methoxyimino)ethyl, 2-(ethoxyimino)-1-propyl, 3-(isopropoxyimino)-1-butyl, and the like.

The term "alkyl," as used herein, refers to a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.

The term "alkylamino," as used herein, refers to an alkyl group, as defined herein,

appended to the parent molecular moiety through an amino group, as defined herein. Representative examples of alkylamino include, but are not limited to, methylamino, ethylamino, propylamino, and the like.

5 The term "alkylaminosulfonyl," as used herein, refers to an alkylamino group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkylaminosulfonyl include, but are not limited to, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, and the like.

10 The term "alkylcarbonyl," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, 1-oxopentyl, and the like.

15 The term "alkylcarbonylalkoxy," as used herein, refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of alkylcarbonylalkoxy include, but are not limited to, 2-oxopropoxy, 3,3-dimethyl-2-oxopropoxy, 3-oxobutoxy, 3-oxopentyl, and the like.

20 The term "alkylcarbonylalkyl," as used herein, refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkylcarbonylalkyl include, but are not limited to, 2-oxopropyl, 3,3-dimethyl-2-oxopropyl, 3-oxobutyl, 3-oxopentyl, and the like.

The term "alkylcarbonylamino," as used herein, refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an amino group, as defined herein. Representative examples of alkylcarbonylamino include, but are not limited to, acetilamino, 1-oxopropylamino, 2,2-dimethyl-1-oxopropylamino, and the like.

25 The term "alkylcarbonylaminoalkyl," as used herein, refers to an alkylcarbonylamino group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkylcarbonylaminoalkyl include, but are not limited to, acetilaminomethyl, 2-(1-oxopropylamino)ethyl, and the like.

The term "alkylcarbonyloxy," as used herein, refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy moiety, as defined herein. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, tert-butylcarbonyloxy, and the like.

5 The term "alkylene," denotes a divalent group derived from a straight or branched chain hydrocarbon of from 1 to 10 carbon atoms. Representative examples of alkylene include, but are not limited to, -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -CH₂CH(CH₃)CH₂-, and the like.

10 The term "alkylimino," as used herein, refers to R₈₁N= group, wherein R₈₁ is alkyl, as defined herein.

The term "alkylsulfinyl," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfinyl group, as defined herein. Representative examples of alkylsulfinyl include, but are not limited, methylsulfinyl, ethylsulfinyl, and the like.

15 The term "alkylsulfinylalkyl," as used herein, refers to an alkylsulfinyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkylsulfinylalkyl include, but are not limited, methylsulfinylmethyl, ethylsulfinylmethyl, and the like

20 The term "alkylsulfonyl," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkylsulfonyl include, but are not limited, methylsulfonyl, ethylsulfonyl, and the like.

25 The term "alkylsulfonylalkyl," as used herein, refers to an alkylsulfonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkylsulfonylalkyl include, but are not limited, methylsulfonylmethyl, 2-(ethylsulfonyl)ethyl, and the like.

The term "alkylsulfonylamino," as used herein, refers to an alkylsulfonyl group, as defined herein, appended to the parent molecular moiety through an amino group, as defined herein. Representative examples of alkylsulfonylamino include, but are not

limited, methylsulfonylamino, ethylsulfonylamino, and the like.

The term "alkylthio," as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a thio moiety, as defined herein.

Representative examples of alkylthio include, but are not limited, methylsulfanyl,

5 ethylsulfanyl, tert-butylsulfanyl, hexylsulfanyl, and the like.

The term "alkylthioalkyl," as used herein, refers to an alkylthio group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.

Representative examples of alkylthioalkyl include, but are not limited, methylsulfanylmethyl, 2-(ethylsulfanyl)ethyl, and the like.

10 The term "alkylthioalkylcarbonyl," as used herein, refers to an alkylthioalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylthioalkylcarbonyl include, but are not limited, methylsulfanylmethylcarbonyl, 2-(ethylsulfanyl)ethylcarbonyl, and the like.

15 The term "alkynyl," as used herein, refers to a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, 1-butynyl and the like.

20 The term "alkynylene," denotes a divalent group derived from a straight or branched chain hydrocarbon of from 2 to 10 carbon atoms containing at least one triple bond. Representative examples of alkynylene include, but are not limited to, $-C\equiv C-$, $-CH_2C\equiv C-$, $-CH(CH_3)CH_2C\equiv C-$, $-C\equiv CCH_2-$, $-C\equiv CCH(CH_3)CH_2-$, and the like.

The term "amino," as used herein, refers to a $-NH_2$ group.

25 The term "aminoalkoxy," as used herein, refers to an amino group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of aminoalkoxy include, but are not limited to, 2-aminomethoxy, 3-aminopropoxy, 4-amino-1-methylhexyloxy, and the like.

The term "aminoalkyl," as used herein, refers to an amino group, as defined herein,

appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of aminoalkyl include, but are not limited to, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-amino-1-methylhexyl, and the like.

5 The term "aminoalkylcarbonyl," as used herein, refers to an aminoalkyl group, as defined herein, appended to the parent molecular moiety through an carbonyl group, as defined herein. Representative examples of aminoalkylcarbonyl include, but are not limited to, 2-amino-1-oxoethyl (2-aminoacetyl), 3-amino-1-oxopropyl, and the like.

10 The term "aminoalkylcarbonyloxy," as used herein, refers to an aminoalkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy moiety, as defined herein. Representative examples of aminoalkylcarbonyloxy include, but are not limited to, 2-amino-1-oxoethyloxy (2-aminoacetoxo), 3-amino-1-oxopropoxy, and the like.

15 The term "aminoalkylcarbonyloxyalkoxy," as used herein, refers to an aminoalkylcarbonyloxy group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of aminoalkylcarbonyloxyalkoxy include, but are not limited to, 2-(2-amino-1-oxoethyloxy)ethoxy, 4-(3-amino-1-oxopropoxy)butoxy, 3-(3-amino-1-oxopropoxy)-3-methyl-1-butoxy, 3-(2-amino-1-oxoethyloxy)-3-methyl-1-butoxy and the like.

The term "aminocarbonyl," as used herein, refers to a $\text{H}_2\text{NC(O)-}$ group.

20 The term "aminocarbonylalkoxy," as used herein, refers to an aminocarbonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of aminocarbonylalkoxy include, but are not limited to, 2-(aminocarbonyl)ethoxy, 3-(aminocarbonyl)propoxy, and the like.

25 The term "aminocarbonylalkyl," as used herein, refers to an aminocarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of aminocarbonylalkyl include, but are not limited to, 2-(aminocarbonyl)ethyl, 3-(aminocarbonyl)propyl, and the like.

The term "aminosulfonyl," as used herein, refers to $\text{H}_2\text{NS(O)}_2\text{-}$ group.

The term "aryl," as used herein, refers to a monocyclic-ring system, or a bicyclic-

or a tricyclic- fused ring system wherein one or more of the fused rings are aromatic. Representative examples of aryl include, but are not limited to, azulenyl, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like.

The aryl groups of this invention can be substituted with 1, 2, or 3 substituents independently selected from alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkenyl, alkoxycarbonylalkyl, alkoxycarbonylalkylthio, alkyl, alkylamino, alkylaminosulfonyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonylamino, alkylcarbonyloxy, alkylimino, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkylthioalkylcarbonyl, alkynyl, amino, aminocarbonyl, aminocarbonylalkoxy, aminosulfonyl, aryl, arylalkoxy, arylalkyl, aryloxy, arylcarbonyl, carboxy, carboxyalkenyl, carboxyalkoxy, carboxyalkyl, cyano, cyanoalkoxy, cyanoalkyl, cycloalkyl, dialkylamino, dialkylaminosulfonyl, ethylenedioxy, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heterocyclic, heterocyclic alkoxy, heterocyclic alkyl, heterocyclic carbonyl, hydroxy, hydroxyalkoxy, hydroxyalkyl, methylenedioxy, mercapto, nitro, and sulfo. Representative examples of substituted aryl include, but are not limited to, 3-chlorophenyl, 3-fluorophenyl, 4-chlorophenyl, 4-fluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 3,4,-difluorophenyl, 4-methylsulfonylphenyl, 4-aminosulfonylphenyl, pentafluorophenyl, and the like.

The term "arylalkenyl," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkenyl group, as defined herein. Representative examples of arylalkenyl include, but are not limited to, 3-phenylpropen-2-yl, 3-phenylpropen-3-yl, 2-naphth-2-ylbuten-4-yl, and the like.

The term "arylalkoxy," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3-naphth-2-ylpropoxy, 5-phenylpentyloxy, and the like.

The term "arylalkoxycarbonyl," as used herein, refers to an arylalkoxy group, as

defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of arylalkoxycarbonyl include, but are not limited to, benzyloxycarbonyl, naphth-2-ylmethoxycarbonyl, and the like.

5 The term "arylalkyl," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-naphth-2-ylethyl, and the like.

The term "arylalkylthio," as used herein, refers to an arylalkyl group, as defined herein, appended to the parent molecular moiety through a thio moiety, as defined herein.
10 Representative examples of arylalkylthio include, but are not limited to, 2-phenylethylsulfanyl, 3-naphth-2-ylpropylsulfanyl, 5-phenylpentylsulfanyl and the like.

The term "arylalkynyl," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein. Representative examples of arylalkynyl include, but are not limited to, 3-phenylpropyn-2-yl, 3-phenylpropyn-3-yl, 2-naphth-2-ylbutyn-4-yl, and the like.
15

The term "arylcarbonyl," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of arylcarbonyl include, but are not limited to, benzoyl, naphthoyl, and the like.

20 The term "arylcarbonylalkyl," as used herein, refers to an arylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylcarbonylalkyl include, but are not limited to, 3-benzoylpropyl, 3-naphthoylpropyl, and the like.

The term "arylhaloalkyl," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through a haloalkyl group, as defined herein.
25 Representative examples of arylhaloalkyl include, but are not limited to, 1,1-difluoro-3-phenylpropyl, 1,1-dibromo-3-phenylpropyl, 1,1-difluoro-2-naphth-2-ylethyl, and the like.

The term "arylhydroxyalkyl," as used herein, refers to an aryl group, as defined herein, appended to the parent molecular moiety through a hydroxyalkyl group, as defined

herein. Representative examples of arylhydroxyalkyl include, but are not limited to, 1-hydroxy-3-phenylpropyl, 2-hydroxy-3-phenylpropyl, 1-hydroxy-2-naphth-2-ylethyl, and the like.

The term "aryloxy," as used herein, refers to an aryl group, as defined herein,
5 appended to the parent molecular moiety through an oxy moiety, as defined herein. Representative examples of aryloxy include, but are not limited to, phenoxy, naphthyloxy, 3-bromophenoxy, 4-chlorophenoxy, 4-methylphenoxy, 3,5-dimethoxyphenoxy, and the like.

The term "aryloxyalkyl," as used herein, refers to an aryloxy group, as defined
10 herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of aryloxyalkyl include, but are not limited to, 2-phenoxyethyl, 3-naphth-2-yloxypropyl, 3-bromophenoxyethyl, and the like.

The term "aryloxyhaloalkyl," as used herein, refers to an aryloxy group, as defined
15 herein, appended to the parent molecular moiety through a haloalkyl group, as defined herein. Representative examples of aryloxyhaloalkyl include, but are not limited to, 1,1-difluoro-3-(naphth-2-yloxy)propyl, 1,1-difluoro-3-(4-bromophenoxy)butyl, and the like.

The term "aryloxyhydroxyalkyl," as used herein, refers to an aryloxy group, as
defined herein, appended to the parent molecular moiety through a hydroxyalkyl group, as
defined herein. Representative examples of aryloxyhydroxyalkyl include, but are not
20 limited to, 1-hydroxy-3-(naphth-2-yloxy)propyl, 1-hydroxy-3-(4-bromophenoxy)butyl,
and the like.

The term "arylthio," as used herein, refers to an aryl group, as defined herein,
appended to the parent molecular moiety through a thio moiety, as defined herein.
Representative examples of arylthio include, but are not limited to, phenylsulfanyl,
25 naphth-2-ylsulfanyl, 5-phenylhexylsulfanyl, and the like.

The term "arylthioalkyl," as used herein, refers to an arylthio group, as defined
herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
Representative examples of arylthioalkyl include, but are not limited to,
phenylsulfanylmethyl, 2-naphth-2-ylsulfanylethyl, 5-phenylhexylsulfanylmethyl, and the

like.

The term "azido," as used herein, refers to a $-N_3$ group.

The term "carbonyl," as used herein, refers to a $-C(O)-$ group.

The term "carboxy," as used herein, refers to a $-CO_2H$ group.

5 The term "carboxyalkenyl," as used herein, refers to a carboxy group, as defined herein, appended to the parent molecular moiety through an alkenyl group, as defined herein. Representative examples of carboxyalkenyl include, but are not limited to, 3-carboxy-1-propenyl, 4-carboxy-1-butenyl, and the like.

10 The term "carboxyalkoxy," as used herein, refers to a carboxy group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of carboxyalkoxy include, but are not limited to, 3-carboxypropoxy, 4-carboxybutoxy, and the like.

15 The term "carboxyalkyl," as used herein, refers to a carboxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. The alkyl portion of carboxyalkyl may contain 1 or 2 hydroxy groups, as defined herein. Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl, 2-carboxyethyl, 1-hydroxy-3-carboxypropyl, 1,2-dihydroxy-3-carboxypropyl and the like.

20 The term "carboxyalkylcarbonyl," as used herein, refers to a carboxyalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of carboxyalkylcarbonyl include, but are not limited to, 2-carboxy-1-oxoethyl, 3-carboxy-2,3-dihydroxy-1-oxopropyl, 3-carboxy-1-oxopropyl, and the like.

25 The term "carboxyalkylcarbonyloxy," as used herein, refers to a carboxyalkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy moiety, as defined herein. Representative examples of carboxyalkylcarbonyloxy include, but are not limited to, 2-carboxy-1-oxoethoxy, 3-carboxy-2,3-dihydroxy-1-oxopropoxy, 3-carboxy-1-oxopropoxy, and the like.

 The term "carboxyalkylcarbonyloxyalkoxy," as used herein, refers to a carboxyalkylcarbonyloxy group, as defined herein, appended to the parent molecular

moiety through an alkoxy group, as defined herein. Representative examples of carboxyalkylcarbonyloxyalkoxy include, but are not limited to, 2-(2-carboxy-1-oxoethoxy)ethoxy, 3-(3-carboxy-2,3-dihydroxy-1-oxopropoxy)-3-methylbutoxy, 3-(3-carboxy-1-oxopropoxy)-2-methyl-1-propoxy, and the like.

5 The term "cyano," as used herein, refers to a -CN group.

 The term "cyanoalkoxy," as used herein, refers to a cyano group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of cyanoalkoxy include, but are not limited to, 2-cyanoethoxy, 3-cyanopropoxy, and the like.

10 The term "cyanoalkyl," as used herein, refers to a cyano group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of cyanoalkyl include, but are not limited to, cyanomethyl, 2-cyanoethyl, 3-cyanopropyl, and the like.

 The term "cycloalkenyl," as used herein, refers to a cyclalkyl group, as defined
15 herein, containing one double bond. Representative examples of cycloalkenyl include, but are not limited to, cyclopentenyl, cyclohexenyl, cycloheptenyl, and the like.

 The cycloalkenyl groups of this invention can be substituted with 1, 2, or 3 substituents selected from alkoxy, alkoxyalkoxy, alkoxycarbonyl, alkyl, alkylamino, alkylimino, alkylthio, amino, aminocarbonyl, aryl, arylalkyl, carboxy, cyano, cycloalkyl,
20 dialkylamino, formyl, halogen, haloalkyl, hydroxy, oxo, mercapto, and nitro.

 The term "cycloalkenylalkyl," as used herein, refers to cycloalkenyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of cycloalkenylalkyl include, but are not limited to, cyclopentenylmethyl, cyclohexenylmethyl, and the like.

25 The term "cycloalkyl," as used herein, refers to a saturated cyclic hydrocarbon group containing from 3 to 8 carbons. Representative examples of cycloalkyl include, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

 The cycloalkyl groups of this invention can be substituted with 1, 2, or 3 substituents selected from alkoxy, alkoxyalkoxy, alkoxycarbonyl, alkyl, alkylamino,

alkylimino, alkylthio, amino, aminocarbonyl, aryl, arylalkyl, carboxy, cyano, cycloalkyl, dialkylamino, formyl, halogen, haloalkyl, hydroxy, oxo, mercapto, and nitro.

The term "cycloalkylalkyl," as used herein, refers to cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.

5 Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, 4-cycloheptylbutyl, and the like.

The term "cycloalkylcarbonyl," as used herein, refers to cycloalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of cycloalkylcarbonyl include, but are not limited to, cyclopropylcarbonyl, 2-cyclobutylcarbonyl, cyclohexylcarbonyl, and the like.

The term "cycloalkylidene," as used herein, refers to cycloalkyl group, as defined herein, appended to the parent molecular moiety through a double bond. Representative examples of cycloalkylidene include, but are not limited to, cyclopropylidene, cyclohexylidene, and the like.

The term "cycloalkylidenealkyl," as used herein, refers to cycloalkylidene group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of cycloalkylidenealkyl include, but are not limited to, 2-cyclopropylideneethyl, 3-cyclohexylidenepropyl, and the like.

20 The term "dialkylamino," as used herein, refers to two independent alkyl groups, as defined herein, appended to the parent molecular moiety through an amino group. Representative examples of dialkylamino include, but are not limited to, diethylamino, dimethylamino, ethylmethylamino, and the like.

The term "dialkylaminosulfonyl," as used herein, refers to a dialkylamino group, as defined herein, appended to the parent molecular moiety through a sulfonyl group. Representative examples of dialkylaminosulfonyl include, but are not limited to, diethylaminosulfonyl, dimethylaminosulfonyl, ethylmethylaminosulfonyl, and the like.

The term "ethylenedioxy," as used herein, refers to a $-O(CH_2)_2O-$ group wherein the oxygen atoms of the ethylenedioxy group are attached to the parent molecular moiety

through one carbon atom forming a 5 membered ring or the oxygen atoms of the ethylenedioxy group are attached to the parent molecular moiety through two adjacent carbon atoms forming a six membered ring.

The term "formyl," as used herein, refers to a -C(O)H group.

5 The term "formylalkyl," as used herein, refers to a formyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of formylalkyl include, but are not limited to, formylmethyl, 2-formylethyl, and the like.

The term "halo" or "halogen," as used herein, refers to -Cl, -Br, -I or -F.

10 The term "haloalkenyl," as used herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkenyl group, as defined herein. Representative examples of haloalkenyl include, but are not limited to, 2,3,3-trifluoropropen-3-yl, 2,2-difluoroethenyl, and the like.

15 The term "haloalkenyloxy," as used herein, refers to a haloalkenyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein. Representative examples of haloalkenyloxy include, but are not limited to, 2,3,3-trifluoropropen-3-yloxy, 2,2-difluoroethenyloxy, and the like.

20 The term "haloalkoxy," as used herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, pentafluoroethoxy, and the like.

25 The term "haloalkoxyhydroxyalkyl," as used herein, refers to a haloalkoxy group, as defined herein, appended to the parent molecular moiety through a hydroxyalkyl group, as defined herein. Representative examples of haloalkoxyhydroxyalkyl include, but are not limited to, 4-(trifluoromethoxy)-1-hydroxybutyl, 4-(difluoromethoxy)-1-hydroxybutyl, and the like.

The term "haloalkyl," as used herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-

fluoroethyl, trifluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, and the like.

The term "haloalkynyl," as used herein, refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein. Representative examples of haloalkynyl include, but are not limited to, 4,4,4-trifluorobutyn-2-yl, 3,3-difluoropropyl-1-yl, and the like.

The term "heterocycle" or "heterocyclic," as used herein, refers to a monocyclic, bicyclic, or tricyclic ring system. Monocyclic ring systems are exemplified by any 3- or 4-membered ring containing a heteroatom independently selected from oxygen, nitrogen and sulfur; or a 5-, 6- or 7-membered ring containing one, two or three heteroatoms wherein the heteroatoms are independently selected from nitrogen, oxygen and sulfur. The 5-membered ring has from 0-2 double bonds and the 6- and 7-membered ring have from 0-3 double bonds. Representative examples of monocyclic ring systems include, but are not limited to, azetidiny, azepiny, aziridiny, diazepiny, 1,3-dioxolany, dioxany, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperaziny, piperidinyl, pyranyl, pyraziny, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, pyridaziny, pyrrolyl, pyrrolinyl, pyrrolidinyl, tetrahydrofurany, tetrahydrothiophenyl, tetraziny, tetrazolyl, thiadiazolyl, thiadiazolinyl, thiadiazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl, thiophenyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl, thiopyranyl, triaziny, triazolyl, trithianyl, and the like. Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or another monocyclic ring system. Representative examples of bicyclic ring systems include but are not limited to, for example, benzimidazolyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, benzofurany, benzopyranyl, benzothiopyranyl, benzodioxinyl, 1,3-benzodioxolyl, cinnolinyl, indazolyl, indolyl, indolinyl, indoliziny, naphthyridinyl, isobenzofurany, isobenzothiophenyl, isoindolyl, isoindolinyl, isoquinolyl, phthalaziny, pyranopyridyl, quinolyl, quinoliziny, quinoxaliny, quinazolinyl, tetrahydroisoquinolyl, tetrahydroquinolyl, thiopyranopyridyl, and the like.

Tricyclic rings systems are exemplified by any of the above bicyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or a monocyclic ring system. Representative examples of tricyclic ring systems include, but are not limited to, acridinyl, carbazolyl, carbolinyl, dibenzofuranyl, dibenzothiophenyl, naphthofuranyl, naphthothiophenyl, oxanthrenyl, phenazinyl, phenoxathiinyl, phenoxazinyl, phenothiazinyl, thianthrenyl, thioxanthenyl, xanthenyl, and the like.

The heterocyclic groups of this invention can be substituted with 1, 2, or 3 substituents independently selected from alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkenyl, alkoxycarbonylalkyl, alkoxycarbonylalkylthio, alkyl, alkylamino, alkylaminosulfonyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonylamino, alkylcarbonyloxy, alkylimino, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylsulfonylamino, alkylthio, alkylthioalkyl, alkylthioalkylcarbonyl, alkynyl, amino, aminocarbonyl, aminocarbonylalkoxy, aminosulfonyl, aryl, arylalkoxy, arylalkyl, aryloxy, arylcarbonyl, carboxy, carboxyalkenyl, carboxyalkoxy, carboxyalkyl, cyano, cyanoalkoxy, cyanoalkyl, cycloalkyl, dialkylamino, dialkylaminosulfonyl, ethylenedioxy, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heterocyclic, heterocyclic alkoxy, heterocyclic alkyl, heterocyclic carbonyl, hydroxy, hydroxyalkoxy, hydroxyalkyl, methylenedioxy, mercapto, nitro, and sulfo.

The term "heterocyclic alkoxy," as used herein, refers to a heterocyclic group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of heterocyclic alkoxy include, but are not limited to, 2-pyrid-3-ylethoxy, 3-quinolin-3-ylpropoxy, 5-pyrid-4-ylpentyloxy, and the like.

The term "heterocyclic alkyl," as used herein, refers to a heterocyclic, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heterocyclic alkyl include, but are not limited to, pyrid-3-ylmethyl, 2-pyrimidin-2-ylpropyl, and the like.

The term "heterocyclic alkylthio," as used herein, refers to a heterocyclic alkyl

group, as defined herein, appended to the parent molecular moiety through a thio moiety, as defined herein. Representative examples of heterocyclic alkylthio include, but are not limited to, 2-pyrid-3-ylethysulfanyl, 3-quinolin-3-ylpropysulfanyl, 5-pyrid-4-ylpentysulfanyl, and the like.

5 The term "heterocyclic carbonyl," as used herein, refers to a heterocyclic, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of heterocyclic carbonyl include, but are not limited to, pyrid-3-ylcarbonyl, quinolin-3-ylcarbonyl, sulfanylphen-2-ylcarbonyl, and the like.

10 The term "heterocyclic oxy," as used herein, refers to a heterocyclic group, as defined herein, appended to the parent molecular moiety through an oxy moiety, as defined herein. Representative examples of heterocyclic oxy include, but are not limited to, pyrid-3-yloxy, quinolin-3-yloxy, and the like.

 The term "heterocyclic oxyalkyl," as used herein, refers to a heterocyclic oxy
15 group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heterocyclic oxyalkyl include, but are not limited to, pyrid-3-yloxymethyl, 2-quinolin-3-yloxyethyl, and the like.

 The term "heterocyclic thio," as used herein, refers to a heterocyclic group, as defined herein, appended to the parent molecular moiety through a thio moiety, as defined
20 herein. Representative examples of heterocyclic thio include, but are not limited to, pyrid-3-ylsulfanyl, quinolin-3-ylsulfanyl, and the like.

 The term "heterocyclic thioalkyl," as used herein, refers to a heterocyclic thio group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heterocyclic thioalkyl include, but are not
25 limited to, pyrid-3-ylsulfanylmethyl, 2-quinolin-3-ylsulfanylethyl, and the like.

 The term "hydroxy," as used herein, refers to an -OH group.

 The term "hydroxyalkoxy," as used herein, refers to 1 or 2 hydroxy groups, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of hydroxyalkoxy include, but are not limited to,

hydroxymethoxy, 2-hydroxyethoxy, 2-hydroxy-2-methylethoxy, 3-hydroxy-1-propoxy, 4-hydroxy-1-butoxy, 3-hydroxy-3-methyl-1-butoxy, 2,3-dihydroxy-1-propoxy, and the like.

The term "hydroxyalkyl," as used herein, refers to 1 or 2 hydroxy groups, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-ethyl-4-hydroxyheptyl, 2,3-dihydroxypropyl, and the like.

The term "hydroxyimino," refers to a HON= group.

The term "hydroxyiminoalkoxy," as used herein, refers to a hydroxyimino group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of hydroxyiminoalkoxy include, but are not limited to, hydroxyiminomethoxy, 2-hydroxyiminoethoxy, 2-hydroxyiminopropoxy, and the like.

The term "hydroxyiminoalkyl," as used herein, refers to a hydroxyimino group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyiminoalkyl include, but are not limited to, hydroxyiminomethyl, 2-hydroxyiminoethyl, 2-hydroxyiminopropyl, and the like.

The term "imino," as used herein, refers to a HN= group.

The term "iminoalkoxy," as used herein, refers to an imino group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of iminoalkoxy include, but are not limited to, 2-iminoethoxy, 2-imino-1-propoxy, 3-imino-1-butoxy, and the like.

The term "iminoalkyl," as used herein, refers to an imino group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of iminoalkyl include, but are not limited to, 2-iminoethyl, 2-imino-1-propyl, 3-imino-1-butyl, and the like.

The term "mercapto," as used herein, refers to a -SH group.

The term "mercaptoalkoxy," as used herein, refers to a mercapto group, as defined

herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of mercaptoalkoxy include, but are not limited to, 2-mercaptoethoxy, 3-mercaptopropoxy, and the like.

5 The term "mercaptoalkyl," as used herein, refers to a mercapto group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of mercaptoalkyl include, but are not limited to, 2-mercaptoethyl, 3-mercaptopropyl, and the like.

10 The term "methylenedioxy," as used herein, refers to a $-\text{OCH}_2\text{O}-$ group wherein the oxygen atoms of the methylenedioxy are attached to the parent molecular moiety through two adjacent carbon atoms.

The term "nitro," as used herein, refers to a $-\text{NO}_2$ group.

The term "oxo," as used herein, refers to a $=\text{O}$ moiety.

The term "oxy," as used herein, refers to a $-\text{O}-$ moiety.

15 The term "phosphonato," as used herein, refers to a $(\text{R}_{34}\text{O})_2\text{P}(\text{O})\text{O}-$ group wherein R_{34} is selected from hydrogen and alkyl, as defined herein.

20 The term "phosphonatoalkoxy," refers to a phosphonato group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative example of phosphonatoalkoxy include, but are not limited to, 3-hydroxypropyl dihydrogen phosphate, 3-hydroxy-1,1-dimethylpropyl dihydrogen phosphate, and the like.

The term "sulfinyl," as used herein, refers to a $-\text{S}(\text{O})-$ group.

The term "sulfo," as used herein, refers to a $-\text{SO}_3\text{H}$ group.

The term "sulfonyl," as used herein, refers to a $-\text{S}(\text{O})_2-$ group.

The term "thio," as used herein, refers to a $-\text{S}-$ moiety.

25 The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate,

fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides; and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.

Basic addition salts can be prepared in situ during the final isolation and purification of the compounds of formula I, or separately by reacting a carboxylic acid function with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia, or an organic primary, secondary or tertiary amine. Such pharmaceutically acceptable salts include, but are not limited to, cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, aluminum salts and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Other representative organic amines useful for the formation of base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.

The term "pharmaceutically acceptable ester" as used herein refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanolic,

alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters includes formates, acetates, propionates, butyates, acrylates and ethylsuccinates.

The term "pharmaceutically acceptable prodrug" as used herein refers to those
5 prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term
10 "prodrug" refers to compounds that are rapidly transformed in vivo to provide the parent compound having the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press,
15 1987, both of which are incorporated herein by reference.

As used throughout this specification and the appended claims, the term metabolically cleavable group denotes a moiety which is readily cleaved in vivo from the compound bearing it, wherein said compound, after cleavage remains or becomes pharmacologically active. Metabolically cleavable groups form a class of groups reactive
20 with the carboxyl group of the compounds of this invention are well known to practitioners of the art. They include, but are not limited to groups such as, for example, alkylcarbonyl, such as acetyl, propionyl, butyryl, and the like; unsubstituted and substituted arylcarbonyl, such as benzoyl and substituted benzoyl; alkoxycarbonyl, such as ethoxycarbonyl; trialkylsilyl, such as trimethyl- and triethylsilyl; monoesters formed with
25 dicarboxylic acids, such as succinyl, and the like. Because of the ease with which the metabolically cleavable groups of the compounds of this invention are cleaved in vivo, the compounds bearing such groups act as pro-drugs of other prostaglandin biosynthesis inhibitors. The compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or

rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group.

Asymmetric centers may exist in the compounds of the present invention. The present invention contemplates the various stereoisomers and mixtures thereof. Individual stereoisomers of compounds of the present invention are made by synthesis from starting materials containing the chiral centers or by preparation of mixtures of enantiomeric products followed by separation as, for example, by conversion to a mixture of diastereomers followed by separation by recrystallization or chromatographic techniques, or by direct separation of the optical enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or are made by the methods detailed below and resolved by techniques well known in the organic chemical arts.

The present invention discloses pyridazinone compounds which are cyclooxygenase (COX) inhibitors and are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys.

Preferred compounds of the present invention include, but are not limited to,
2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(4-fluorophenyl)-5-methoxy-3(2H)-pyridazinone;
2-Benzyl-4-(4-fluorophenyl)-5-hydroxy-3(2H)-pyridazinone;
2-Benzyl-4-(4-fluorophenyl)-5-(trifluoromethylsulfonyloxy)-3(2H)-pyridazinone;
2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-Phenyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(Phenylpropargyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(Methyl-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
5 pyridazinone;

2-(3-Methyl-2-butenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2-Trifluoromethylbenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

10 2-(Cyclopropylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
15 pyridazinone;

2-(3-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(6-Fluoroquinolin-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

20 2-(Quinolin-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinethione

2-Benzyl-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
25 pyridazinone;

2-(3,3-Dichloro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Phenyl-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Carboxyphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(5-Methylthiazol-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(5-Chlorothiazol-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,3,3,4,4,4-Hexafluorobuten-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(2,4-Difluorophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(5-Chlorothiien-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(5-Methylthien-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(4-Diethylaminophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,3,4,5,6-Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(Phenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Chlorophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(Propargyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(4-Cyanophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(α -Methyl-4-fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Phenethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

- 2-Benzyl-4-(3-chloro-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-Benzyl-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(3-chloro-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 5 2-(4-Trifluoromethoxyphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(4-Trifluoromethylphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 10 2-[2-(Benzo[b]thien-3-yl)-2-oxoethyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3,3-Dimethyl-2-oxobutyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 15 2-(3-Thienylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(2-Benzo[b]thienylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 20 2,4-Bis(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-6-methyl-3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-6-methyl-3(2H)-pyridazinone;
- 2-Benzyl-4-(3,4-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 25 2-(2,2,2-Trifluoroethyl)-4-(4-n-propylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

10 2,4-Bis-(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2,2,2-Trifluoroethyl)-4-(3,4-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(2-propylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-cyclohexyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-cyclopentyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-propylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
5 pyridazinone;

2-Benzyl-4-(4-morpholino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,3,3-Trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2,4-Bis(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(2,2,2-Trifluoroethyl)-4-cyclopropylmethoxy-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-propen-1-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluoro- α -methylbenzyloxy)-5-[4-
15 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[4-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2,5-Bis[4-(methylsulfonyl)phenyl]-4-(4-fluorophenyl)-3(2H)-pyridazinone;

2-(3-Methyl-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
20 pyridazinone;

2-(2-Trifluoromethyl-4-nitrophenyl)-4-(4-fluorophenyl)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[3-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

25 2-[3-(Methylsulfonyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(5-Chloro-2-thienyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Trifluoromethylphenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-
5 3(2H)-pyridazinone;

2-(3-Fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-[2-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

10 2-(5-Nitro-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Benzothienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
15 pyridazinone;

2-(4-Fluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

20 2-(3-Bromophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,5-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
25 pyridazinone;

2-(4-Nitrobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Acetoxybenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Hydroxybenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Nitrobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3,4,4-Trifluoro-3-butenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2-Hexynyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3,3-Dichloro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-Cyclohexyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Cyclopentyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-Cyclobutyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Methyl-2-butenyl)-4-(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Cyclohexenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,3-Dihydro-1H-inden-2-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,3-Dihydro-1H-inden-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

- 3(2H)-pyridazinone;
2-(4-Tetrahydro-2H-pyran-4-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
2-(2-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
5 pyridazinone;
2-(2-Adamantyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
10 2-(1-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3,4-Difluorophenyl)-4-(4-fluoro-3-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(6-methyl-3-heptenyl)-5-[4-(methylsulfonyl)phenyl]-
15 3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(3-cyclopropylidenepropyl)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(5-methyl-3-hexenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
20 2-(3,4-Difluorophenyl)-4-(5-methylhexyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chloro-1-methyl-2E-propenyl)-4-(4-fluorophenyl)-5-[4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,3,3-Trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
25 3(2H)-pyridazinone;
2-(1,1,2-Trifluoro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;
2-(3,3-Difluoro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(α -Methyl-3-fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(1-Cyclohexenylmethyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

5 2-(α -Methyl-2,3,4-trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(α -Methyl-3,5-difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

10 2-(α -Methyl-3,4-difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(2,4,6-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,4,5-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

20 2-(2,3,4-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4,4,4-Trifluoro-3-methyl-2E-butenyl)-4-(4-fluorophenyl)-5-[4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Biphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

25 2-(4-Bromophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Nitrophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Phenoxyphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

- pyridazinone;
2-(4-t-Butylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
5 pyridazinone;
2-(3-Methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Vinylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
10 2-(2-Formylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(2-Nitrophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
15 pyridazinone;
2-(3-Bromophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
20 2-(5-Methyl-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Biphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3,5-Dimethylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
25 pyridazinone;
2-(3,4-Difluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chloro-4-fluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2-Thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Trifluoromethylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

5 2-[4-(1-Pyrrolyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(5-Chloro-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

10 2-(4-Methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(2-ethyl-1-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(3,5-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

20 2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Furyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Fluoro-4-methoxyphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

25 2-(2-Fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-[4-(Aminosulfonyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,5-Dichlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluoro-3-methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(4-Chloro-3-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; :

2-(4-Chloro-2-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; :

10 2-(1-Adamantylloxycarbonyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(4-Fluorophenyl)-4-(3-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-phenoxymethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(4-Fluorophenyl)-4-(t-butylthiomethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-methylpropylthiomethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone;

25 2-(4-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Bromophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,5-Difluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

5 2-(3-Chloro-4-fluorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[3-methyl-4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

10 2-(3-Chlorophenyl)-4-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(benzoyloxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(2,2,2-Trifluoroethyl)-4-(4-fluoro-3-methylphenyl)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3,5-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(3-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-trifluoromethylphenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

25 2-(2,2,2-Trifluoroethyl)-4-(2-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[3-(trifluoromethyl)phenyl]-5-[4-

- (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
5 2-(2,2,2-Trifluoroethyl)-4-(3,5-difluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
10 2-(2,2,2-Trifluoroethyl)-4-(2-propenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2-buten-2-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
15 2-(2,2,2-Trifluoroethyl)-4-(1-cyclohexenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
20 2-(2,2,2-Trifluoroethyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-Fluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-Fluorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
25 2-(4-Fluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-Fluorophenyl)-4-(phenylethynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-

- pyridazinone;
2-(3,4-Difluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3,4-Difluorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
5 pyridazinone;
2-(3,4-Difluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-vinyl-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(2-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
10 pyridazinone;
2-(3,4-Difluorophenyl)-4-(1-propynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3,4-Difluorophenyl)-4-t-butyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
15 2-(2,2,2-Trifluoroethyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chlorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(4-Fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
20 pyridazinone;
2-(3,4-Difluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chlorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
25 2-(4-Fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
2-(3-Chloro-4-fluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chloro-4-fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-Chloro-4-fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3,5-difluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3,4-Difluorophenyl)-4-(phenylethynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3,4-difluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-[4-Fluoro-3-(methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(4-fluorophenyl)-5-[4-(trifluoromethylsulfonyl)phenyl]-3(2H)-pyridazinone; :

2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-fluoro-5-trifluoromethylphenoxy)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(2,2,2-Trifluoroethyl)-4-(4-cyanophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-pyridyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

10 2-(2,2,2-Trifluoroethyl)-4-(4-n-propylphenoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[4-(methylsulfonyl)phenoxy]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-phenylphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(2,2,2-Trifluoroethyl)-4-[2-(methylthio)ethoxy]-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(phenylmethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(2-furylmethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[2-(3,4-dimethoxyphenyl)ethoxy]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[2-(4-morpholino)ethoxy]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2,2,2-Trifluoroethyl)-4-[2-(1-piperidinyloxy)ethoxy]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[4-(carboxamido)phenoxy]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(1-indanyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[4-(acetamido)phenoxy]-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
5 pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(1-methylcyclopropylmethoxy)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3,3-dimethylbutoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-chlorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
10 pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-bromophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(cyclopentylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
15 pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(1H-1,2,4-triazole-3-ylthio)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-phenylmethylthio-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenylthio)-5-[4-(methylsulfonyl)phenyl]-
20 3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(cyclohexylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-chloro-4-fluorophenylthio)-5-[4-
25 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2,2,2-trifluoroethylthio)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(tert-butylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

- 2-(2,2,2-Trifluoroethyl)-4-(4-acetamidophenylthio)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(2-propylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 5 2-(2,2,2-Trifluoroethyl)-4-(2-methylprop-1-ylthio)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-amino-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(3-methoxypropylamino)-5-[4-(methylsulfonyl)phenyl]-
10 3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(cyclopentylamino)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(cyclobutylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 15 2-(2,2,2-Trifluoroethyl)-4-(3,4-dimethoxyphenethylamino)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(cyclohexylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-[2-(1-piperidinyl)ethylamino]-5-[4-
20 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(2-tetrahydrofurfurylamino)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(cyclopropylmethylamino)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 25 2-(2,2,2-Trifluoroethyl)-4-(2,3-dihydro-1H-inden-1-ylamino)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(1-piperidinyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-(2,2,2-Trifluoroethyl)-4-(3-hydroxypropylamino)-5-[4-(methylsulfonyl)phenyl]-

- 3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-[3-(1H-imidazol-1-yl)propylamino]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2R-hydroxylpropylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
5 2-(2,2,2-Trifluoroethyl)-4-(2-cyanoethylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(4-cyanoanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
10 2-(2,2,2-Trifluoroethyl)-4-[3-methoxy-5-(trifluoromethyl)anilino]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-anilino-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2,5-dimethoxyphenylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
15 2-(2,2,2-Trifluoroethyl)-4-(3-fluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2,4-difluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
20 2-(2,2,2-Trifluoroethyl)-4-(2,3,5-trifluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(4-fluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(3-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
25 2-Benzyl-4-(2-benzofuranyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(5-chloro-2-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

- 2-Benzyl-4-(4-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(4-trifluoromethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-Benzyl-4-(2-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 5 2-Benzyl-4-(3,4-dimethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-Benzyl-4-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-Benzyl-4-(2-methoxypyrid-3-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
10 pyridazinone;
- 2-Benzyl-4-(3-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-Benzyl-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(tert-Butyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 15 2-(3-Chlorophenyl)-4-methoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 20 2-(3-Chlorophenyl)-4-(t-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-(3-Chlorophenyl)-4-(cyclohexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-(3-Chlorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
25 pyridazinone;
- 2-(3-Chlorophenyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
- 2-(3-Chlorophenyl)-4-(3-octyn-1-yloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

- 2-(3-Chlorophenyl)-4-[2-(dimethylamino)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-[2-methyl-1-(1-methylethyl)propoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 5 2-(3-Chlorophenyl)-4-(phenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-[3-(dimethylamino)phenoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 10 2-(3,4-Difluorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3,4-Difluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 15 2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3,4-Difluorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3,4-Difluorophenyl)-4-[2-(isopropoxy)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 20 2-(3,4-Difluorophenyl)-4-(3-methylpentylloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3,4-Difluorophenyl)-4-(4-methyl-3-penten-1-yloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 25 2-(3,4-Difluorophenyl)-4-[3-(methoxy)butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-(N-methylbenzylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; :
- 2-(4-Fluorophenyl)-4-(1-piperidiny)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Fluorophenyl)-4-(1-pyrrolidinyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(4-methylphenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

5 pyridazinone;

2-(3-Chlorophenyl)-4-(2-pyridylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(phenylmethylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

10 2-(3-Chlorophenyl)-4-(2-furylmethylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-[2-(methylpropyl)thio]-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(cyclopentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

15 pyridazinone;

2-(3-Chlorophenyl)-4-(2-methylpropyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(cyclopentylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

20 2-(3-Chlorophenyl)-4-(2-cyclopentylethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3-Chlorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(phenethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
5 pyridazinone;

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(benzyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

10 2-(4-Fluorophenyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(4-Fluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(Tetrahydro-2H-pyrano-2-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

20 2-(3-(4-Fluorophenyl)phenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[3-fluoro-4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(4-fluorobenzyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

5 2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(4-Fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2h)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(3-Chlorophenyl)-4-(phenethyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

20 2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

25 2-(4-Fluorophenyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(t-Butyl)-4-(3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-

5 3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

10 2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(aminosulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[3-fluoro-4-

15 (aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,3-Difluoro-2-propenyl)-4-(4-fluorophenyl)-5-[3-fluoro-4-

(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-[2-(2-propoxy)ethoxy]-5-[4-(aminosulfonyl)phenyl]-

3(2H)-pyridazinone;

20 2-(3,4-Difluorophenyl)-4-(4-methyl-3-pentenyl)-5-[4-(aminosulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-

25 3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Fluorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Fluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-Fluorophenyl)-4-cyclopropylmethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(2-cyclopropyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-cyclopropanemethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(2-cyclopropane-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(3-methyl-2-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(3-methyl-2-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(4-methyl-3-pentenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-methyl-3-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(4-methyl-3-pentenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-methyl-3-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(1,5-hexadienyl-3-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(5-methyl-2-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(2-ethyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-thioisopropyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(4-Fluorophenyl)-4-(3-methylthio-1-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-methyl-4-pentenyl-1-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3,4-Difluorophenyl)-4-(3-trifluoromethyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-ethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3,4-Difluorophenyl)-4-(4-methyl-2-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2-cyclopentyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3,4-Difluorophenyl)-4-(2-cyclopent-2-enyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2-Hydroxy-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2-Methoxy-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2-Methoxyimino-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[4-(aminosulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

5 pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

10 2-(2,3,3-Trifluoropropenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-

15 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-methoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,3,4,5,6-Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-

(dimethylamino)methylaminosulfonylphenyl]-3(2H)-pyridazinone;

20 2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-

(dimethylamino)methylaminosulfonylphenyl]-3(2H)-pyridazinone;

(4-Fluorophenyl)-5-[4-(methylselenonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

25 2-(4-Fluorophenyl)-4-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-

(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2-oxo-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,4-Difluorophenyl)-4-[2-(methoxyimino)-1-propoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 (S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

10 (R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3,4-Difluorophenyl)-4-(3-oxo-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-oxo-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-hydroxy-2-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(4-Fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(4-Fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-

- (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-Chlorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
5 2-(3-Chloro-4-fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-Chlorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
10 (S)-2-(4-Fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
(R)-2-(4-Fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
15 (S)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
(R)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
20 (R)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
25 (S)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
(R)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(R)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

5 (R)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(4-Fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3,4-Difluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)-phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

25 N-[[4-[2-(3,4-Difluorophenyl)-4-(2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide;

N-[[4-[2-(3,4-Difluorophenyl)-4-(2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]-sulfonyl]acetamide, sodium salt;

N-[[4-[2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-2H-pyridazin-3-on-5-

yl]phenyl)sulfonyl]acetamide;

N-[[4-[2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide, sodium salt;

5 N-[[4-[2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide;

N-[[4-[2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide, sodium salt;

N-[[4-[2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide;

10 N-[[4-[2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide, sodium salt;

N-[[4-[2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide;

15 N-[[4-[2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide, sodium salt;

N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide;

N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide, sodium salt;

20 N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide;

N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl)sulfonyl]acetamide, sodium salt;

25 2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Dichlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[(3-Trifluoromethyl)phenyl]-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Dichlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 (R,S)-2-(4-Fluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-Chloro-4-fluorophenyl)-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Dichlorophenyl)-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3,4-Dichlorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-[3-(Trifluoromethyl)phenyl]-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[3-(Trifluoromethyl)phenyl]-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[3-(Trifluoromethyl)phenyl]-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 (R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3,4-Difluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-

- (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(4-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
5 (S)-2-(3-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(3-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(3-bromophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
10 (S)-2-(3-trifluoromethylphenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(3-chloro-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
15 (S)-2-(3-fluoro-4-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(3,4-dichlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
20 (S)-2-(3-trifluoromethyl-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(3-bromo-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(R)-2-(3,4-Difluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
25 (R)-2-(4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(R)-2-(4-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 (R)-2-(3-bromophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3-trifluoromethylphenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 (R)-2-(3-chloro-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3-fluoro-4-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3,4-dichlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 (R)-2-(3-trifluoromethyl-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3-bromo-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3,4-Difluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-chlorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chlorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-bromophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-trifluoromethylphenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-chloro-4-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluoro-4-chlorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3,4-dichlorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-trifluoromethyl-4-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-bromo-4-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3,4-Difluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(4-chlorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chlorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3-bromophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-trifluoromethylphenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chloro-4-fluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

- (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-fluoro-4-chlorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-dichlorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
5 2-(4-fluoro-3-trifluoromethylphenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-bromo-4-fluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
10 2-(3,4-Difluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-fluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-chlorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
15 2-(3-fluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-chlorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
20 2-(3-bromophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-trifluoromethylphenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-chloro-4-fluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
25 2-(3-fluoro-4-chlorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluoro-3-trifluoromethylphenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-bromo-4-fluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3,4-Difluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(4-chlorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chlorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3-bromophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-trifluoromethylphenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3-chloro-4-fluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluoro-4-chlorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-dichlorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(4-fluoro-3-trifluoromethylphenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-bromo-4-fluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}-

- 3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 2-(4-fluorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 2-(4-chlorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 5 2-(3-fluorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 2-(3-chlorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 10 2-(3-bromophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 2-(3-trifluoromethylphenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 15 2-(3-chloro-4-fluorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 2-(3-fluoro-4-chlorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 20 2-(3,4-dichlorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 2-(3-trifluoromethyl-4-fluorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 25 2-(3-bromo-4-fluorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 3-({2-(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-

pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-trifluoromethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-chloro-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-fluoro-4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3,4-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-trifluoromethyl-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-bromo-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

2-(tert-Butyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(tert-Butyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(tert-butyl)-4-[3-{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; and

3-({2-(tert-butyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate; or pharmaceutically acceptable salts or prodrugs thereof.

5

Preparation of Compounds of the Invention

Abbreviations


As used throughout this specification and the appended claims, the following abbreviations have been used:


ACD for acid citrate dextrose, CAP for carrageenan induced air pouch prostaglandin, CIP
10 for rat carrageenan pleural inflammation model, COX-2 for cyclooxygenase-2, CPE for
carrageenan induced paw edema in rats, DBAD for di-t-butylazodicarboxylate, DEAD for
diethyl azodicarboxylate, DIAD for diisopropylazodicarboxylate, DMAP for 4-
(dimethylamino)pyridine, DME for 1,2-dimethoxyethane, DMF for N,N-
dimethylformamide, DMSO for dimethyl sulfoxide, DMSO for dimethyl sulfoxide, EDTA
15 for ethylenediaminetetraacetic acid, EIA for enzyme immunoassay, FAB for fast atom
bombardment, GI for gastrointestinal, HMDS, lithium or Li HMDS for lithium 1,1,1,3,3,3-
hexamethyldisilazide, HWPX for Human Whole Platelet Cyclooxygenase-1, MCPBA for
meta-chloroperoxybenzoic acid, NSAIDs for non-steroidal anti-inflammatory drugs, PEG
400 for polyethyleneglycol, PGE₂ for prostaglandin E₂, PGHS for prostaglandin
20 endoperoxide H synthase, RHUCX1 for recombinant human cyclooxygenase-1, RHUCX2
for recombinant human cyclooxygenase-2, r-hu Cox1 for recombinant human Cox-1, TEA
for triethylamine, TFA for trifluoroacetic acid, and THF for tetrahydrofuran and WISH for
human amnionic whole cell cyclooxygenase-2. The following examples illustrate the
process of the invention, without limitation.

25

The compounds of the invention may be prepared by a variety of synthetic routes. Representative procedures are outlined in Schemes 1-10, below.


Scheme 1





A general route to the compounds of the invention having Formula III, where the aryl group at the 5-position on the pyridazinone ring is substituted with a sulfonyl group is described in Scheme 1. Dichloro-3(2H)-pyridazinone can be treated with benzyl chloride and potassium carbonate in methanol to provide 2-benzyl-4-chloro-5-methoxy-3(2H)-pyridazinone. 2-Benzyl-4-chloro-5-methoxy-3(2H)-pyridazinone can be treated with a boronic acid such as 4-fluorobenzeneboronic acid (shown) and a palladium catalyst and the methoxy group can be hydrolyzed with 48% hydrobromic acid to provide the 5-hydroxypyridazinone compound. The 5-hydroxypyridazinone product can be treated with triflic anhydride followed by substitution on the pyridazinone ring using 4-methylthiobenzeneboronic acid to provide the methyl thioether compound. The methyl thioether compound which can be treated with peracetic acid in acetic acid and methylene chloride to provide the methyl sulfone. The benzyl group can be removed using aluminum bromide or another suitable Lewis acid. The R group can be added using an appropriate alkylating agent and base.

Scheme 2




An alternative route to the compounds of the present invention having Formula III is described in Scheme 2. 4-Bromothiobenzene or another suitable thioether can be treated with a trialkoxyborate, such as trimethoxyborate or triisopropylborate to provide 4-(methylthio)benzeneboronic acid. The boronic acid can be treated with 2-benzyl-4,5-dibromo-3(2H)-pyridazinone using tetrakis(triphenylphosphine)palladium (0) in

dimethoxyethane and then coupled with a second boronic acid such as 4-fluorobenzeneboronic acid (shown) in the presence of a palladium catalyst to provide the thioether. The methyl thioether compound can be treated with meta-chloroperoxybenzoic acid (MCPBA) in methylene chloride to provide the methyl sulfone.

5

Scheme 3




15

An alternative route to the compounds of the present invention having Formula III


is described in Scheme 3. (4-Thiomethylphenyl)dimethylthioacetone acetal, mono-S-oxide can be prepared by reaction of 4-thiomethylbenzaldehyde (Y is CH₃S) with methyl(methylsulfinylmethyl)sulfide and sodium hydroxide. The thioacetone acetal and methyl 4-fluorophenylacetate or suitable ester (X is fluorine) can be treated with a strong base such as sodium hexamethyldisilazide in THF to provide the butyrate ester. The dithioacetone ketene can be directly cyclized to the N-unsubstituted pyridazinone using hydrazine and a salt. The pyridazinone can be then be alkylated using an appropriate alkylating agent and a base.

10

Scheme 4




15




In an alternate route, shown in Scheme 4, the thioacetal ketene (X=F and Y=CH₃S) can be treated with perchloric acid to provide an ester-aldehyde as a mixture of diastereomers. The oxidation products can be treated with hydrazine and then oxidized with peroxyacetic acid to provide the sulfonyl dihydropyridazinone (Y=CH₃SO₂). The dihydropyridazinone can be dehydrogenated to form the pyridazinone by treatment with reagents such as bromine in acetic acid. The R group may be added via substitution using an appropriate alkylating agent and base.

Scheme 5



The preparation of the 5-hydroxy-2(5H)-furanones can be accomplished by the application of methodologies published in a variety of sources, including: J. Med. Chem., 1987, 30, 239-249 and WO 96/36623, hereby completely incorporated by reference. These 5-hydroxy-2(5H)-furanones can be converted to 6-substituted-4,5-diaryl-3(2H)pyridazinones as described in Scheme 5.

Scheme 6



10

A general route to the compounds of the invention having Formula III, where the aryl group at the 5-position on the pyridazinone ring is substituted with a para-sulfonyl group is described in Scheme 6. A mucohalo acid, such as mucobromic or mucochloric acid, can be treated with an hydrazine having the desired R group to provide the dihalopyridazinone compound, 6A. The dihalo-compound can be treated with an alcohol

in the presence of a base, such as sodium or potassium hydride, to provide an alkoxide 6B where R^{97} is selected from alkyl, aryl, arylalkyl, heterocyclic, and heterocyclic alkyl. (If the alkoxy group is to be removed at a later time then methanol is the preferred alcohol.)

The alkoxy-halide can be treated with methylthiophenylboronic acid to provide the

5 alkoxy-pyridazinone 6C. The alkoxy group can be converted to a hydrocarbyl group by

treatment with a Grignard reagent to provide thioether 6D where R^{96} is alkyl. The

thioether 6D can be oxidized with an oxidizing agent, such as peracetic acid, meta-chloroperoxybenzoic acid and the like, to form the sulfinyl compound 6G, or the

methylsulfone compound 6E. The methylsulfinyl compound, 6G, can be treated with

10 trifluoroacetic anhydride and NaOH/MeOH followed by addition of chlorine gas and then

ammonia hydroxide to provide the aminosulfonyl compound, 6H. Alternatively, the


methylsulfonyl compound, 6E, can be treated with a diazodicarboxylate, such as DBAD,


DIAD, DEAD and the like, and a disilazane anion, such as lithium HMDS and the like,

followed by treatment with sodium acetate and hydroxylamine-O-sulphonic acid in water

15 to provide the aminosulfonyl compound, 6H.


Scheme 7





Methylsulfonyl alkoxy pyridazinones and aminosulfonyl alkoxy pyridazinones can
5 be prepared as described in Scheme 7. Alkoxy-pyridazinone, 6C, from Scheme 6, can be
oxidized using peracetic acid to provide methyl sulfone, 7A. Methyl sulfone alkoxy
pyridazinone, 7A, can be treated as described in Scheme 6 to provide aminosulfonyl
alkoxy pyridazinone, 7B. Alternatively, alkoxy-pyridazinone 6C, from Scheme 6, can be
10 oxidized with one equivalent of meta-chloroperoxybenzoic acid or one equivalent of
hydroxy(tosyloxy)iodobenzene to provide the methylsulfinyl alkoxy pyridazinone, 7C.
Methylsulfinyl alkoxy pyridazinone, 7C, can be treated as described in Scheme 6 to
provide aminosulfonyl alkoxy pyridazinone, 7B.

Scheme 8




5 Pyridazinones of general formula 8D and 8E, wherein R^{80} is hydroxyalkyl, and A and B are selected from alkenyl, alkyl, haloalkyl, and halogen, can be prepared as described in Scheme 8. Pyridazinones of general formula 8A can be treated with diols and a base such as sodium hydride or potassium hydride in THF to selectively provide 4-substituted pyridazinones of general formula 8B. 4-Substituted pyridazinones of general

10 formula 8B can be treated with 4-(methylthio)phenylboronic acid, a base such as potassium carbonate, and a palladium catalyst such as dichlorobis(triphenylphosphine)palladium(II) in ethanol to provide methylthio compounds of general formula 8C. Methylthio compounds of general formula 8C can be oxidized with meta-chloroperoxybenzoic acid or peracetic acid to provide methylsulfones of general

15 formula 8D. Methylsulfones of general formula 8D can be processed as described in Scheme 6 to provide aminosulfonyl compounds of general formula 8E. Alternatively, methylthio compounds of general formula 8C can be oxidized to the sulfoxide and then processed as described in Scheme 6 to provide aminosulfonyl compounds of general

formula 8E.


Scheme 9



Preparation of compounds of the invention having Formula III, where the group at the 4-position on the pyridazinone ring is a substituted alkyl or alkenyl group is described in Scheme 9. Pyridazinone 9A can be treated with a halogenating reagent, such as NBS and peroxide, to provide bromo compound 9B. The bromo compound can be reacted with an alcohol and a weak base, such as sodium or potassium carbonate, to provide 4-alkyl-ether, 9C where R^{95} is alkyl. Alternatively, bromo compound 9B can be treated with a thio compound in the presence of a base, such as silver carbonate, to provide 4-alkyl-thioether, 9D where R^{94} is alkyl. Alternatively, bromo compound 9B can be treated with an amine

and a weak base, such as sodium or potassium carbonate to provide 4-alkylaminoalkyl compound 9E where R^{93} is alkyl.

Scheme 10



A general route to the compounds of the present invention having Formula III, where the group at the 4-position on the pyridazinone ring can be readily substituted is illustrated in Scheme 10. Alkoxide, 10A, where R^{97} is methyl, can be treated with a base, such as sodium or potassium hydroxide, to provide 4-hydroxy-pyridazinone, 10B. The alcohol can be treated with p-toluenesulfonyl chloride to provide tosyloxy compound, 10C. The tosyloxy compound can be readily substituted with a compound $R^{92}Z$ that can undergo a S_NAr reaction. Examples of these compounds are alcohols, thiols, amines or hydrocarbyl anions.

Compounds of the present invention include, but are not intended to be limited to, the following Examples:

Example 1

4-(Methylthio)benzeneboronic acid

A stirred solution of 4-bromothioanisole (5.0 g, 0.0246 mol) in anhydrous tetrahydrofuran (THF) was chilled to -78 °C under a nitrogen atmosphere. A 2.5 M solution of n-butyl lithium (12 mL, 0.030 mol) in hexanes was added dropwise to the chilled solution. When the addition was complete, the reaction mixture was stirred at -78 °C for about 45 minutes. Trimethylborate (8.5 mL, 0.0748) was introduced via syringe. The reaction mixture was then allowed to warm to room temperature overnight. The room temperature solution was treated successively with 10% aqueous sodium hydroxide solution (50 mL) and water (33.5 mL) and stirred at room temperature for 1 hour. The reaction mixture was lowered to about pH=4-5 using 10% aqueous citric acid and the THF was removed under reduced pressure. The aqueous residue was saturated with sodium chloride and extracted with ethyl acetate. The organic extract was dried over MgSO₄ and filtered. The filtrate was concentrated under reduced pressure to provide a white solid which was washed with hexanes to provide the product as a white solid (yield: 1.5 g; 36%). mp 170 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.47 (s, 3H), 7.20 (d, J=8 Hz, 2H), 7.71 (d, J=8 Hz, 2H), 7.96 (br s, 2H).

Example 2

2-Benzyl-4,5-dibromo-3(2H)-pyridazinone

Benzyl bromide (0.59 mL, 0.005 mol) was added to a stirred solution of 4,5-dibromo-3(2H)-pyridazinone (1.27 g, 0.005 mol) and potassium carbonate (0.76 g, 0.0055 mol) in 20 mL of anhydrous dimethylformamide (DMF). The solution was stirred overnight at room temperature, and partitioned between aqueous citric acid and ethyl acetate. The aqueous layer was extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over MgSO₄ and filtered. The filtrate was concentrated under reduced pressure to provide a beige solid, which was purified by column chromatography (silica gel, 9:1 hexanes/ethyl acetate). The product was obtained as a white solid (yield: 1.32 g, 76.7%). mp 95-96 °C. ¹H NMR (300 MHz, CDCl₃) δ 5.31 (s, 2H), 7.29-7.37 (m, 3H), 7.41-7.47 (m, 2H), 7.79 (s, 1H). MS (DCI/NH₃) m/z 345 (M+H)⁺. IR (KBr) 1645 cm⁻¹.

Example 3

2-Benzyl-4-bromo-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

A solution of the boronic acid (0.318 g, 0. mol), from Example 1, the
5 dibromopyridazinone (0.975 g, 0. mol), prepared according to the method of Example 2,
and tetrakis(triphenylphosphine)palladium (0) (0.16 g, 0.0142 mol), in dimethoxyethane
(30 mL) was prepared. A 2 M aqueous solution of sodium carbonate (2.83 mL, 0. mol)
was added to the dimethoxyethane solution and the mixture was heated at reflux. After 16
hours, a chromatographic (TLC) check (9:1 hexanes/ethyl acetate) indicated that both
10 starting materials were still present and a fresh aliquot of palladium catalyst was added.
The reaction mixture was stirred at reflux for an additional 5 hours, allowed to cool to
room temperature and stand over the weekend. The volatile materials were removed under
reduced pressure and the residue was partitioned between water and ethyl acetate. The
aqueous layer was extracted with ethyl acetate. The combined organic extracts were
15 washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated under
reduced pressure to provide an oil which was purified by column chromatography (silica
gel, 95:5 hexanes/ethyl acetate). Fractions containing the desired product were combined
and concentrated under reduced pressure. This material was rechromatographed (95:5
hexanes/ethyl acetate) to furnish 0.200 g of a beige solid. The solid was crystallized from
20 ether/hexanes to provide white crystals (yield: 110 mg, 15%) mp 115-118 °C. ^1H NMR
(300 MHz, CDCl_3) δ 2.53 (s, 3H), 5.40 (s, 2H), 7.30-7.42 (m, 7 H), 7.49-7.54 (m, 2H),
7.65 (s, 1H). MS (DCI/ NH_3) m/z 387 (M+H) $^+$.

Example 4

2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

25 A solution of the product from Example 3, (0.100 g, 0. mol), 4-
fluorobenzeneboronic acid (0.072 g, 0. mol), tetrakis(triphenylphosphine)palladium (0)
(0.015 g, 0. mol), and a 2 M aqueous solution of sodium carbonate (0.64 mL, 0. mol) in 30
mL of dimethoxyethane (DME) was stirred at reflux for 16 hours. A fresh aliquot of

palladium catalyst was added with an additional equivalent of the boronic acid. The reaction was maintained at reflux for 24 hours. The volatile materials were removed under reduced pressure and the residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgSO_4 , and filtered. The filtrate was adsorbed onto silica gel. The silica gel/product was placed at the top of a column of silica gel and the product eluted with 93:7 hexanes/ethyl acetate. Fractions containing product were combined and concentrated under reduced pressure. The residue was purified further by a second column chromatography (silica gel, 95:5 hexanes/ethyl acetate). Fractions containing product were concentrated under reduced pressure to provide a viscous oil (yield: 0.028 g, 27%). ^1H NMR (300 MHz, CDCl_3) δ 2.46 (s, 3H), 5.39 (s, 2H), 6.95 (t, $J=9$ Hz, 2H), 6.99 (d, $J=9$ Hz, 2H), 7.11 (d, $J=9$ Hz, 2H), 7.16-7.23 (m, 2H), 7.30-7.40 (m, 3H), 7.52-7.57 (m, 2H), 7.86 (s, 1H). MS (DCI/ NH_3) m/z 403 ($\text{M}+\text{H}$) $^+$.

Example 5

2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of meta-chloroperoxybenzoic acid (MPCBA) (0.039 g, 0.00013 mol) in dichloromethane (5 mL) was added dropwise to a stirred solution of the sulfide (0.027 g, 0. mol), from Example 4, in chilled (0 °C) dichloromethane (10 mL). After 5 minutes, TLC (1:1 hexanes/ethyl acetate) indicated that the starting sulfide had been consumed. The reaction was quenched with aqueous sodium sulfite. The organic layer was washed twice with aqueous sodium hydroxide and once with brine. The dichloromethane solution was dried over MgSO_4 , and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 7:3 hexanes/ethyl acetate) to provide the desired sulfone product. Further elution with 100% ethyl acetate removed the sulfoxide from the column. The sulfoxide product was re-subjected to the MCA oxidant (0.04 g, 1 hour, 0 °C) and worked-up as described above. The residue obtained was combined with the sulfone from the first column and the mixture was purified by column chromatography (silica gel, 7:3 hexanes/ethyl acetate). Fractions containing

product were combined and concentrated under reduced pressure. The residue was crystallized from ether/hexanes to provide the product as white crystals (yield: 13 mg, 44.6%). mp 101-103 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 5.40 (s, 2H), 6.95 (t, J=9 Hz, 2H), 7.12-7.20 (m, 2H), 7.28-7.41 (m, 3H), 7.31 (d, J=9 Hz, 2H), 7.58-7.53 (m, 2H), 7.84 (s, 1H), 7.87 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 435 (M+H)⁺. MS (F, high res.) calculated: m/z 435.1179 (M+H)⁺, found: m/z 435.1184 (M+H)⁺.

Example 6

2-Benzyl-4-(4-fluorophenyl)-5-methoxy-3(2H)-pyridazinone

To a mixture of 2-benzyl-5-methoxy-4-bromo-3(2H)-pyridazinone, prepared according to the method of (S. Cho et al. described in J. Het. Chem., (1996), 33, 1579-1582), (2.94 g; 10 mmol), 4-fluorobenzeneboronic acid (1.54 g; 11 mmol), and CsF (3.04 g; 22 mmol) in 25 mL of anhydrous DME, under N₂, was added Pd(Ph₃P)₄ (347 mg 0.3 mmol). After addition, the mixture was heated at reflux for at 100 °C, for 18 hours. The mixture was concentrated in vacuo and the residue partitioned between ethyl acetate and water. The acetate layer was washed with brine, dried over MgSO₄ and concentrated in vacuo. The solid residue was suspended in ethyl ether-hexanes and filtered to provide a solid product (yield: 3.1 g; about 100%; > 95% purity). ¹H NMR (300 MHz, CDCl₃) δ 3.90 (s, 3H), 5.36 (s, 2H), 7.09 (t, J=9 Hz, 2H), 7.31 (m, 3H), 7.50 (m, 4H), 7.91 (s, 1H). MS (DCI/NH₃) m/z 311 (M+H)⁺, 328 (M+NH₄)⁺.

Example 7

2-Benzyl-4-(4-fluorophenyl)-5-hydroxy-3(2H)-pyridazinone

The product from Example 6 (1.24 g; 4 mmol) in 20 mL of acetic acid was treated with aqueous 48% HBr (25 mL). The mixture was heated at reflux for about 5 to about 8 hours (TLC analysis). The mixture was concentrated in vacuo. The product was dissolved in ethyl acetate, washed with 10% bicarbonate, brine and concentrated in vacuo. The residue was treated with diethyl ether-hexanes (2:1) and the solid was filtered to provide an almost pure product (yield: 1.16 g; 98%). ¹H NMR (300 MHz, DMSO-d₆) δ 5.24 (2H),

7.21 (m, 2H), 7.30 (m, 5H), 7.55 (m, 2H), 7.85 (s, 1H), 11.31 (br s, 1H). MS (DCI/NH₃) m/z 296 (M+H)⁺, 314 (M+NH₄)⁺.

Example 8

2-Benzyl-4-(4-fluorophenyl)-5-(trifluoromethylsulfonyloxy)-3(2H)-pyridazinone

A solution of the product from Example 7, (89 mg, 0.3 mmol) in 2.5 mL of anhydrous pyridine under a N₂ atmosphere and maintained at 0 °C was treated with triflic anhydride (Tf₂O; 0.06 mL; 0.32 mmol) dropwise. The resulting mixture was stirred at 0 °C for 5 minutes and at room temperature for 16 hours. (The pyridine and Tf₂O should be pure for good results. Occasionally an additional amount of Tf₂O is necessary to force the reaction to completion.) The mixture was then poured to a cold solution of citric acid and extracted with ethyl acetate to obtain an almost pure product (yield: 127 mg, about 99%). ¹H NMR (300 MHz, DMSO-d₆) δ 5.34 (s, 2H), 7.35 (m, 7H), 7.60 (m, 2H), 8.48 (s, 1H). MS (DCI/NH₃) m/z 429 (M+H)⁺, 446 (M+NH₄)⁺.

Example 9

2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

A mixture of the product from Example 8 (154 mg, 0.36 mmol), 4-(methylthio)benzeneboronic acid (67 mg, 0.4 mmol), Et₃N (0.11 mmol; 0.8 mmol) and Pd(Ph₃P)₄ (30 mg, 0.025 mmol) in 15 mL of toluene was heated at reflux, about 100 °C for about 45 minutes. The mixture was concentrated in vacuo and the residue purified by column chromatography (hexanes-ethyl acetate 3:1) to provide the title compound (yield: 98 mg, 68%). ¹H NMR (300 MHz, CDCl₃) δ 2.47 (s, 3H), 5.38 (s, 2H), 6.98 (m, 4H), 7.12 (m, 2H), 7.20 (m, 2H), 7.35 (m, 3H), 7.54 (m, 2H), 7.86 (s, 1H). MS (DCI/NH₃) m/z 403 (M+H)⁺, 420 (M+NH₄)⁺.

Example 10

2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a solution of the product from Example 9 (140 mg, 0.348 mmol), in 10 mL of CH_2Cl_2 , at 0 °C was added peracetic acid (CH_3COOOH ; 0.5 mL; 30%). The mixture was stirred at 0 °C for 90 minutes. The dichloromethane was then removed in vacuo. The residue was dissolved in ethyl acetate, washed with 10% NaHCO_3 , and brine. The ethyl acetate was removed under reduced pressure. The residue was chromatographed (silica gel, CH_2Cl_2 -diethyl ether 19:1) to provide the title compound (yield: 130 mg, 86%). ^1H NMR (300 MHz, CDCl_3) δ 3.04 (s, 3H), 5.40 (s, 2H), 6.95 (m, 2H), 7.16 (m, 2H), 7.33 (m, 5H), 7.55 (m, 2H), 7.86 (m, 3H). MS (DCI/ NH_3) m/z 434 ($\text{M}+\text{H}$) $^+$, 452 ($\text{M}+\text{NH}_4$) $^+$.

Example 11

4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A mixture of the product from Example 10 (37 mg, 0.085 mmol) and AlBr_3 (70 mg, 0.26 mmol) in 10 mL of toluene was heated at reflux, about 80 °C for about 15 minutes and cooled to 0 °C. The cooled mixture was treated with 1N HCl and extracted with ethyl acetate. The acetate layer was washed with water, brine and concentrated in vacuo. Purification of the residue on silica gel column (ethyl acetate as an eluent) provided the title compound (yield: 22 mg, 76%). ^1H NMR (300 MHz, CDCl_3) δ 3.07 (s, 3H), 7.00 (t, $J=9$ Hz, 2H), 7.20 (m, 2H), 7.56 (d, $J=9$ Hz, 2H), 7.86 (s, 1H), 7.91 (d, $J=9$ Hz, 2H), 10.94 (br s, 1H). MS (DCI/ NH_3) m/z 345 ($\text{M}+\text{H}$) $^+$, 362 ($\text{M}+\text{NH}_4$) $^+$.

Example 12

2-Phenyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 12A

2-Phenyl-4-chloro-5-methoxy-3(2H)-pyridazinone

The title compound was prepared according to the method of (S. Cho et al. described in J. Het. Chem., (1996), 33, 1579-1582), starting with the N-phenyl-dichloropyridazinone. A mixture of 2-phenyl-4,5-dichloro-3(2H)-pyridazinone (1 g, 4.1 mmol) and finely powdered, anhydrous K_2CO_3 (580 mg, 4.2 mmol) in 50 mL of methanol

was heated at reflux for 5 hours and concentrated in vacuo. The residue was partitioned between water and ethyl acetate. The acetate layer was washed with water, and brine to provide 2-phenyl-4-chloro-5-methoxy-3(2H)-pyridazinone (yield: 920 mg, 95%). ¹H NMR (300 MHz, DMSO-d₆) δ 4.15 (s, 3H), 7.50 (m, 5H), 8.43 (s, 1H). MS (DCI/NH₃) m/z 237 (M+H)⁺, 254 (M+NH₄)⁺.

Example 12B

2-Phenyl-4-(4-fluorophenyl)-5-methoxy-3(2H)-pyridazinone

The 2-phenyl-4-chloro-5-methoxy-3(2H)-pyridazinone product was coupled with 4-fluorophenylboronic acid according to the method of Example 6 to provide 2-phenyl-4-(4-fluorophenyl)-5-methoxy-3(2H)-pyridazinone (yield: 1.1 g; 96%). ¹H NMR (300 MHz, CDCl₃) δ 4.00 (s, 3H), 7.10 (t, J=9 Hz, 2H), 7.45 (m, 3H), 7.60 (m, 4H), 8.06 (s, 1H). MS (DCI/NH₃) m/z 297 (M+H)⁺.

Example 12C

2-Phenyl-4-(4-fluorophenyl)-5-hydroxy-3(2H)-pyridazinone

The 2-phenyl-4-(4-fluorophenyl)-5-methoxy-3(2H)-pyridazinone product was treated with 48% HBr according to the method of Example 7 to furnish 2-phenyl-4-(4-fluorophenyl)-5-hydroxy-3(2H)-pyridazinone (yield: 957 mg, 92%). MS (DCI/NH₃) m/z 283 (M+H)⁺, 300 (M+NH₄)⁺.

Example 12D

2-Phenyl-4-(4-fluorophenyl)-5-trifluoromethanesulfonyloxy-3(2H)-pyridazinone

The 2-phenyl-4-(4-fluorophenyl)-5-hydroxy-3(2H)-pyridazinone product was sulfonylated according to the method of Example 8 to furnish 2-phenyl-4-(4-fluorophenyl)-5-trifluoromethanesulfonyloxy-3(2H)-pyridazinone (yield: 1.35 g; 96%) MS (DCI/NH₃) m/z 415 (M+H)⁺, 432 (M+NH₄)⁺.

Example 12E

2-Phenyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The 2-phenyl-4-(4-fluorophenyl)-5-trifluoromethanesulfonyloxy-3(2H)-pyridazinone was coupled with 4-(methylthio)phenylboronic acid as in Example 9 to provide 2-phenyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 915 mg, 92%) which was immediately oxidized with peracetic acid as in Example 9 to provide the title compound after column chromatography (silica gel, 1:1 hexanes-ethyl acetate) and crystallization from diethyl ether-hexanes (yield: 288 mg, 69%). mp 219-220 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), 7.15 (t, J=9 Hz, 2H), 7.30 (m, 2H), 7.46 (m, 1H), 7.56 (m, 4H), 7.64 (m, 2H), 7.90 (d, J=9 Hz, 2H), 8.24 (s, 1H). MS (DCI/NH₃) m/z 421 (M+H)⁺, 438 (M+NH₄)⁺.

Example 134-Fluorophenylacetic acid, methyl ester

A catalytic amount (0.5 mL) of concentrated sulfuric acid was added to a solution of 4-fluorophenylacetic acid (30.8 g, 0.20 mol) in 500 mL of methanol. The solution was stirred at reflux for 4 hours. The volatile materials were removed under reduced pressure to furnish a colorless oil which was dissolved in ether/ethyl acetate and washed with 2 N aqueous Na₂CO₃, brine, dried over MgSO₄, and filtered. The filtrate was concentrated under reduced pressure to provide an oil which was dried overnight under high vacuum (yield: 33.6 g; 95%). ¹H NMR (300 MHz, CDCl₃) δ 3.59 (s, 2H), 3.65 (s, 3H), 7.01 (t, J=9 Hz, 2H), 7.20-7.28 (m, 2H). MS (DCI/NH₃) m/z 186 (M+NH₄)⁺.

Example 14[4-(Methylthio)phenyl]dimethylthio ketene acetal, mono-S-oxide

A mixture of methyl(methylsulfinylmethyl)sulfide (50 g, 0.40 mol), and finely powdered sodium hydroxide (3.12 g, 0.078 mol) was stirred at 70 °C for 4 hours. 4-(Methylthio)benzaldehyde (27.4 mL, 0.195 mol) was then added in one lot and the reaction mixture was stirred at 70 °C for an additional 4 hours. The mixture was cooled to room temperature and partitioned between 10% aqueous citric acid and dichloromethane.

The organic layer was dried over MgSO_4 and filtered. The filtrate was concentrated under reduced pressure to provide a brown oil. The oil was purified by column chromatography (7:3 hexanes/ethyl acetate) to provide a solid. The solid was crystallized from ether/hexanes (yield: 24.7 g; 72%). mp 52-53 °C. ^1H NMR (300 MHz, CDCl_3) δ 2.33 (s, 3H), 2.53 (s, 3H), 2.77 (s, 3H), 7.17 (d, $J=9$ Hz, 2H), 7.57 (s, 1H), 7.86 (d, $J=9$ Hz, 2H). MS (DCI/ NH_3) m/z 259 ($\text{M}+\text{H}$) $^+$ and m/z 276 ($\text{M}+\text{NH}_4$) $^+$.

Example 15

2-(4-Fluorophenyl)-3-[4-(methylthio)phenyl]-4-methylthio-4-methylsulfinyl-n-butyric acid, methyl ester

A solution of the ester product from Example 13, (16.24 g, 0.0966 mol) in 50 mL of THF was added dropwise to a stirred solution of 1.0 M sodium hexamethyldisilazide in THF (96.6 mL, 0.0966 mol), maintained at 0 °C, under an atmosphere of dry nitrogen. After 30 minutes, a solution of the ketene thioacetal, prepared according to the method of Example 14 (20.8 g, 0.0805 mol), in 50 mL of THF, was added dropwise to the reaction mixture maintained at 0 °C. After 4 hours, the reaction mixture was acidified with 10% aqueous citric acid. The aqueous layer was washed twice with ethyl acetate. The organic extracts were combined, washed with brine, dried over MgSO_4 and filtered. The filtrate was concentrated under reduced pressure to provide a brown oil which was purified by column chromatography (85:15 to 1:1 dichloromethane/ethyl acetate gradient). Several products having different R_f values and NMR spectra were isolated. These compounds had identical mass spectra. The mixture of compounds was carried on in the following reactions (yield: 22.4 g; 65%). MS (DCI/ NH_3) m/z 444 ($\text{M}+\text{NH}_4$) $^+$.

Example 16

2-(4-Fluorophenyl)-3-[4-(methylthio)phenyl]-3-formyl-n-propanoic acid, methyl ester

The mixture of compounds from Example 17, (9.0 g, 0.021 mol) were dissolved in acetonitrile (80 mL) and cooled to 0 °C. Perchloric acid (60%; 1.06 g, 0.006 mol) was added to the stirred solution. The reaction mixture was stirred at 0 °C for 8 hours, and

quenched with 2 N aqueous Na_2CO_3 . The acetonitrile was removed under reduced pressure and the resulting aqueous mixture was extracted with ethyl acetate. The organic solution was dried over MgSO_4 and filtered. The filtrate was concentrated under reduced pressure to give a yellow oil which was purified by column chromatography (silica gel, 7:3
5 hexanes/ethyl acetate). Fractions containing the highest Rf diastereomers from the product mixture were concentrated in vacuo and the residue was crystallized from methanol to furnish the title aldehyde-ester compound as white crystals (yield: 0.27 g, 4.0%).

mp = 112-113 °C. ^1H NMR (300 MHz, CDCl_3) δ 2.49 (s, 3H), 2.46 (s, 3H), 4.39 (s, 2H), 7.03 (t, J=9 Hz, 1H), 7.21 (d, J=9 Hz, 1H), 7.25 (d, J=9 Hz, 2H), 7.40-7.47 (m, 2H). MS
10 (DCI/ NH_3) m/z 333 ($\text{M}+\text{H}$) $^-$ and m/z 350 ($\text{M}+\text{NH}_4$) $^+$. Fractions containing lower Rf compounds from the product mixture were concentrated in vacuo and the residue was identified as the hydrate of the aldehyde-ester (yield: 2.6 g, 35.2%). ^1H NMR (300 MHz, CDCl_3) δ 2.44 & 2.46 (2 s, 3H), 3.56 & 3.48 (2 s, 3H), 3.55 & 3.76 (2 dd, J=6 Hz, J=6 Hz, 1H), 3.98 & 4.26 (2 d, J=12 Hz, 1H), 5.41 & 5.47 (2 d, J=6 Hz, 1H), 6.96 & 7.00 (t, J=9
15 Hz, 2H), 7.11-7.26 (m, 6H). MS (DCI/ NH_3) m/z 333 ($\text{M}+\text{H}$) $^+$ and m/z 350 ($\text{M}+\text{NH}_4$) $^+$.

The lowest Rf compound was identified as the hydroxy lactone formed when a hydroxy group from the hydrate displaces the methoxy group from the ester (yield: 1.1 g, 16.4%). ^1H NMR (300 MHz, CDCl_3) δ 2.45 (s, 3H), 3.54-3.71 (m, 1H), 3.98-4.21 (m, 1H), 4.61 (br s, 1H), 5.85-6.01 (m, 1H), 6.98 (t, J=9 Hz, 2H), 7.12-7.27 (m, 6H). MS
20 (DCI/ NH_3) m/z 336 ($\text{M}+\text{NH}_4$) $^+$.

Example 17

4-(4-Fluorophenyl)-5-[4-(methylthio)phenyl]-4,5-dihydro-3(2H)-pyridazinone

The aldehyde-ester, hydrate, and hydroxy lactone from Example 16 (0.10 g, 3
25 mmol), were dissolved in 100 mL of ethanol. This solution was treated with hydrazine monohydrate (0.15 mL, 30 mmol) and the resulting solution was stirred at reflux in a Soxhlet apparatus containing molecular sieves. After 18 hours, the reaction mixture was cooled and the volatile materials removed under reduced pressure. The residue was partitioned between ethyl acetate and aqueous HCl. The aqueous layer was washed twice

with ethyl acetate. The combined organic extracts were washed twice with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (4:1 hexanes/ethyl acetate) to obtain the title compound (yield: 50 mg, 53%). ^1H NMR (300 MHz, CDCl_3) δ 2.46 (s, 3H), 3.75 (d, J=12 Hz, 1H), 3.87 (d, J=12 Hz, 1H), 6.93-7.08 (m, 6H), 7.16 (d, J=9 Hz, 2H), 8.71 (s(br), 1H). MS (DCI/ NH_3) m/z 315 ($\text{M}+\text{H}$) $^+$ and m/z 332 ($\text{M}+\text{NH}_4$) $^+$.

Example 18

4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4,5-dihydro-3(2H)-pyridazinone

A solution of peracetic acid, 32% in acetic acid, (0.4 mL, 1.6 mmol) was added to a stirred solution of the sulfide from Example 17 (0.050 g, 0.16 mmol) in dichloromethane, and maintained at 0 °C. The reaction mixture was stirred for 5 hours at 0 °C then diluted with water. The organic layer was dried over MgSO_4 and filtered. The filtrate was concentrated under reduced pressure to provide an oil which solidified on trituration with ether (yield: 47 mg, 85%). ^1H NMR (300 MHz, CDCl_3) δ 3.05 (s, 3H), 3.77 (d, J=12 Hz, 1H), 4.05 (d, J=12 Hz, 1H), 6.95-7.08 (m, 4H), 7.28 (d, J=9 Hz, 2H), 7.90 (d, J=9 Hz, 2H), 8.75 (s, broad, 1H). MS (DCI/ NH_3) m/z 364 ($\text{M}+\text{NH}_4$) $^+$.

Example 19

4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The dihydropyridazinone product from Example 18 (47 mg, 0.136 mmol) was dissolved in acetic acid (25 mL). Bromine (0.025 mL, 0.16 mmol) was added to the solution and the reaction mixture was stirred at 95 °C for 20 minutes. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over MgSO_4 and filtered. The filtrate was concentrated under reduced pressure to provide a solid which was eluted through a short pad of silica gel with ethyl acetate. The title compound was crystallized from ethyl acetate/hexanes (yield: 35 mg, 75%). mp 255-256 °C ^1H NMR (300 MHz, CDCl_3) δ 3.07 (s, 3H), 6.98 (t, J=9 Hz, 2H), 7.16-7.23 (m, 2H), 7.35 (d, J=9

Hz, 2H), 7.86 (s, 1H), 7.91 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 345 (M+H)⁺ and m/z 362 (M+NH₄)⁺.

Example 20

5 2-(4-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of the nitrogen-unsubstituted pyridazinone product from Example 19 (160 mg, 0.465 mmol), K₂CO₃ (193 mg, 1.4 mmol), 4-fluorobenzylbromide (0.09 mL, 0.7 mmol) and NaI (catalytic) in 10 mL of anhydrous N,N-dimethylformamide (DMF) was stirred at room temperature for 18 hours. The reaction mixture was quenched with 2N
10 HCl, extracted with ethyl acetate (2 x 20 mL), washed with brine and water, dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by column chromatography (2:2:6 ethyl acetate/dichloromethane/pentanes). Crystallization from ether/pentanes provided white crystals (yield: 110 mg, 52%). mp 153-154 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.06 (s, 3H), 5.36 (s, 2H), 6.96 (t, J=8.4 Hz, 2H), 7.04 (t, J=8.7 Hz, 2H), 7.16 (dd, J=9.1 Hz, J=5.4 Hz, 2H), 7.31 (d, J=8.5 Hz, 2H), 7.54 (dd, J=8.8 Hz, 5.5
15 Hz, 2H), 7.84 (s, 1H), 7.87 (d, J=8.8 Hz, 2H). MS (DCI/NH₃) m/z 453 (M+H)⁺.

Example 21

20 2-(Phenylpropargyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting phenylpropargyl bromide for 4-fluorobenzyl bromide. mp 100-103 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.06 (s, 3H), 5.26 (s, 2H), 6.97 (t, J=9 Hz, 2H), 7.20 (dd, J=9 Hz, J=6 Hz, 2H), 7.31 (m, 3H), 7.34 (d, J=9 Hz, 2H), 7.48 (m, 2H), 7.89 (d, J=9 Hz, 2H), 7.9 (s, 1H). MS (DCI/NH₃) m/z 459 (M+H)⁺.

25

Example 22

2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2,4-difluorobenzyl bromide for 4-fluorobenzyl bromide. mp 179-182 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.06 (s, 3H), 5.45 (s, 2H), 6.87 (m, 2H), 6.96 (t, J=9 Hz, 2H), 7.17 (dd, J=9 Hz, J=6 Hz, 2H), 7.32 (d, J=9 Hz, 2H), 7.54 (m, 1H), 7.86 (s, 1H), 7.88 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 471 (M+H)⁺.

Example 23

2-(Methyl-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 3-chloro-2-methylpropene for 4-fluorobenzyl bromide. mp 140-142 °C. ¹H NMR (CDCl₃, 300 MHz) δ 1.86 (s, 3H), 3.08 (s, 3H), 4.83 (s, 2H), 4.94 (t, J=1 Hz, 1H), 5.05 (t, J=1 Hz, 1H), 6.98 (t, J=9 Hz, 2H), 7.21 (dd, J=9 Hz, J=6 Hz, 2H), 7.37 (d, J=9 Hz, 2H), 7.89 (s, 1H), 7.91 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 399 (M+H)⁺.

Example 24

2-(3-Methyl-2-butenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The desired compound was prepared according to the method of Example 20 substituting 4-bromo-2-methyl-2-butene for 4-fluorobenzyl bromide. mp 169-172 °C. ¹H NMR (CDCl₃, 300 MHz) δ 1.78 (s, 3H), 1.85 (s, 3H), 3.06 (s, 3H), 4.86 (d, J=7.5 Hz, 2H), 5.47 (t, J=7.5 Hz, 1H), 6.96 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, J=6 Hz, 2H), 7.33 (d, J=9 Hz, 2H), 7.84 (s, 1H), 7.88 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 413 (M+H)⁺.

Example 25

2-(2-Trifluoromethylbenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(trifluoromethyl)benzyl bromide for 4-fluorobenzyl bromide. mp 87-90 °C.

¹H NMR (CDCl₃, 300 MHz) δ 3.07 (s, 3H), 5.66 (s, 2H), 6.97 (t, J=9 Hz, 2H), 7.21 (dd, J=9 Hz, J=6 Hz, 2H), 7.26 (d, J=7.7 Hz 1H), 7.37 (d, J=9 Hz, 2H), 7.42 (t J=7.7 Hz, 1H), 7.53 (t, J=7.7 Hz, 1H), 7.73 (d J=7.7 Hz, 1H), 7.9 (s, 1H), 7.91 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 503 (M+H)⁺.

5

Example 26

2-(Cyclopropylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(bromomethyl)cyclopropane for 4-fluorobenzyl bromide. mp 118-121 °C. ¹H NMR (CDCl₃, 300 MHz) δ 0.45-0.52 (m, 2H), 0.54-0.63 (m, 2H), 1.40-1.52 (m, 1H), 3.07 (s, 3H), 4.07 (d, J=7 Hz, 2H), 6.97 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, J=6 Hz, 2H), 7.35 (d, J=9 Hz, 2H), 7.83 (s, 1H), 7.88 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 399 (M+H)⁺ and m/z 416 (M+NH₄)⁺.

15

Example 27

2-(2-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(bromomethyl)pyridine for 4-fluorobenzyl bromide. mp 182-184 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.07 (s, 3H), 5.56 (s, 2H), 6.95 (m, 2H), 7.17 (m, 2H), 7.26 (m, 1H), 7.35 (m, 2H), 7.46 (m, 1H), 7.71 (m, 1H), 7.90 (m, 3H), 8.63 (m, 1H). MS (DCI/NH₃) m/z 436 (M+H)⁺.

20

Example 28

2-(4-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 4-(bromomethyl)pyridine for 4-fluorobenzyl bromide. mp 153-156 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.07 (s, 3H), 5.40 (s, 2H), 6.97 (m, 2H), 7.17 (m, 2H), 7.34 (m, 2H), 7.42 (m, 2H), 7.90 (m, 3H), 8.63 (m, 2H). MS (DCI/NH₃) m/z 436 (M+H)⁺.

25

Example 292-(3-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 3-(bromomethyl)pyridine for 4-fluorobenzyl bromide. mp 160-161 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.07 (s, 3H), 5.43 (s, 2H), 6.97 (m, 2H), 7.15 (m, 2H), 7.34 (m, 4H), 7.35 (m, 2H), 7.87 (m, 2H), 7.97 (s, 1H), 8.60 (m, 1H), 8.81 (m, 1H). MS (DCI/NH₃) m/z 436 (M+H)⁺.

Example 302-(6-Fluoroquinolin-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(chloromethyl)-6-fluoroquinoline for 4-fluorobenzyl bromide. mp 116-119 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.07 (s, 3H), 5.73 (s, 2H), 6.96 (m, 2H), 7.18 (m, 2H), 7.34 (m, 4H), 7.35 (m, 2H), 7.46 (m, 2H), 7.58 (m, 3H), 7.90 (m, 3H), 8.12 (m, 2H). MS (DCI/NH₃) m/z 504 (M+H)⁺.

Example 312-(Quinolin-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(chloromethyl)-quinoline for 4-fluorobenzyl bromide. mp 97-100 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.06 (s, 3H), 5.75 (s, 2H), 6.95 (m, 2H), 7.19 (m, 2H), 7.35 (m, 2H), 7.55 (m, 2H), 7.73 (m, 1H), 7.82 (m, 1H), 7.90 (m, 3H), 8.15 (m, 2H). MS (DCI/NH₃) m/z 386 (M+H)⁺.

Example 322-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinethione

A mixture of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared according to the method of Example 5, (109 mg, 0.25 mmol) and Lawesson's reagent (202 mg, 0.5 mmol) in 15 mL of toluene was stirred at reflux for 48 hours. The mixture was concentrated in vacuo and the residue was chromatographed (silica gel, ethyl acetate) to provide the title compound (yield: 100 mg, 88%). mp 88-90 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.04 (s, 3H), 6.05 (s, 2H), 6.96 (m, 2H), 7.08 (m, 2H), 7.26 (m, 2H), 7.37 (m, 3H), 7.61 (m, 2H), 7.84 (d, J=9 Hz, 2H), 8.13 (s, 1H). MS (DCI/NH₃) m/z 451 (M+H)⁺.

Example 33

2-Benzyl-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

Example 33 was prepared using a similar procedure as that described in (M. De Vleeschauwer and J.V. Gauthier, Syn. Lett., (1997) 375).

Example 33A

2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone

A solution of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared according to the method of Example 4, (450 mg, 1.12 mmol) in CH₂Cl₂ (10 mL) was added dropwise to a suspension of hydroxy(tosyloxy)iodobenzene (439 mg, 1.12 mmol) in CH₂Cl₂ (15 mL) and the mixture was stirred until a clear solution was obtained (about 1 hour). The reaction mixture was then washed with water and dried with MgSO₄. Removal of solvent in vacuo provided the corresponding sulfoxide (yield: 485 mg, about 100%). ¹H NMR (300 MHz, CDCl₃) δ 2.72 (s, 3H), 5.40 (s, 2H), 6.90 (m, 2H), 7.15 (m, 3H), 7.33 (m, 3H), 7.57 (m, 3H), 7.71 (m, 1H), 7.86 (s, 1H). MS (DCI/NH₃) m/z 419 (M+H)⁺, 436 (M+NH₄)⁺.

Example 33B

2-benzyl-4-(4-fluorophenyl)-5-(acetoxymethylsulfonylphenyl)-3(2H)-pyridazinone

A suspension of the sulfoxide from Example 33A, (485 mg, 1.12 mmol) and AcONa (1.4 g) in 15 mL of Ac₂O was stirred at reflux for 2 hours and concentrated in vacuo. The residue was distilled twice with toluene, dissolved in 25 mL of CH₂Cl₂, cooled to 0 °C, and treated with CH₃CO₃H (1 mL). After 1 hour, the mixture was washed, successively, with saturated NaHCO₃ and brine. The solvent was removed in vacuo. The residue was chromatographed (silica gel, 1:1 hexanes-ethyl acetate) to provide the desired product, 2-benzyl-4-(4-fluorophenyl)-5-(acetoxymethylsulfonylphenyl)-3(2H)-pyridazinone (yield: 150 mg, 27%). MS (DCI/NH₃) m/z 493 (M+H)⁺.

Example 33C

2-Benzyl-4-(4-fluorophenyl)-5-[4-(sodiumsulfinat)phenyl]-3(2H)-pyridazinone

To a solution of the acetoxymethylsulfone from Example 33B (150 mg, 0.305 mmol), in 10 mL of THF and 5 mL of methanol at 0 °C, was added 1 N NaOH (0.305 mL, 0.305 mmol). The mixture was stirred at 0 °C for 1 hour. The mixture was concentrated in vacuo, the residual water was removed via an EtOH/toluene azeotrope followed by a toluene azeotrope. The residue was dried under high vacuum for 48 hours to provide the sodium sulfinat (yield: 140 mg, 96%). MS (DCI/NH₃) m/z 443 (M+H)⁺.

Example 33D

2-Benzyl-4-(4-fluorophenyl)-5-[4-(chlorosulfonyl)phenyl]-3(2H)-pyridazinone

The sodium sulfinat (about 0.31 mmol) in CH₂Cl₂ (10 mL) was treated at 0 °C with SOCl₂ (0.033 mL, 0.4 mmol) for 2 hours. The mixture was washed with brine, dried with MgSO₄ and concentrated in vacuo to provide the crude sulfonyl chloride (yield: 145 mg, about 100%). MS (DCI/NH₃) m/z 455 (M+H)⁺.

Example 33E

2-Benzyl-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The crude chloride prepared according to the method of Example 33D, in 10 mL of THF, was added to a solution of 50% NH₄OH, in 10 mL of THF, maintained at 0 °C. The

mixture was allowed to warm to room temperature over 3.5 hours. The THF was removed in vacuo and the product was extracted with ethyl acetate. The ethyl acetate was removed in vacuo and the residue was treated with diethyl ether-hexanes 2:1 to provide the sulfonamide (yield: 113 mg, 84%). mp 188-191 °C. ¹H NMR (300 MHz, DMSO-
5 d₆) δ 2.70 (dd, J=15 Hz, 2H), 5.36 (s, 2H), 7.13 (t, J=9 Hz, 2H), 7.22 (m, 2H), 7.40 (m, 7H), 7.73 (d, J=9 Hz, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 436 (M+H)⁺.

Example 34

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
10 pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-iodo-1,1,1-trifluoroethane for 4-fluorobenzyl bromide. mp 177-179 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.06 (s, 3H), 4.88 (q, J=9 Hz, 2H), 6.98 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, J=6 Hz, 2H), 7.35 (d, J=9 Hz, 2H), 7.89 (s, 1H), 7.91 (d, J=9 Hz, 2H). MS
15 (DCI/NH₃) m/z 427 (M+H)⁺ and m/z 444 (M+NH₄)⁺.

Example 35

2-(3,3-Dichloro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
20 pyridazinone

The title compound was prepared according to the method of Example 20, substituting 1,1,3-trichloropropene for 4-fluorobenzyl bromide. mp 150-152 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.06 (s, 3H), 4.98 (d, J=7 Hz, 2H), 6.25 (t, J=7 Hz, 1H), 6.98 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, J=6 Hz, 2H), 7.33 (d, J=9 Hz, 2H), 7.85 (s, 1H), 7.89 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 453 (M+H)⁺ and m/z 470 (M+NH₄)⁺.

Example 36

2-(3-Phenyl-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
25 pyridazinone

The title compound was prepared according to the method of Example 20, substituting cinnamyl bromide for 4-fluorobenzyl bromide. mp 165-167 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.06 (s, 3H), 5.01 (d, J=7 Hz, 2H), 6.48 (dt, J=15 Hz, 7 Hz, 1H), 6.79 (d, J=15 Hz, 1H), 6.97 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, J=6 Hz, 2H), 7.25-7.44 (m, 5H), 7.37 (d, J=9 Hz, 2H), 7.86 (s, 1H), 7.89 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 461 (M+H)⁺ and m/z 478 (M+NH₄)⁺.

Example 37

2-(4-Carboxyphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting methyl 4-(bromomethyl)benzoate for 4-fluorobenzyl bromide and hydrolysis of the resulting ester. mp 239-241 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.06 (s, 3H), 5.46 (s, 2H), 6.96 (t, J=9 Hz, 2H), 7.17 (dd, J=9 Hz, 6 Hz, 2H), 7.33 (d, J=9 Hz, 2H), 7.63 (d, J=9 Hz, 2H), 7.87 (s, 1H), 7.89 (d, J=9 Hz, 2H), 8.08 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 479 (M+H)⁺ and m/z 496 (M+NH₄)⁺.

Example 38

2-(5-Methylthiazol-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(bromomethyl)-5-methylthiazole for 4-fluorobenzyl bromide. mp 114-116 °C. ¹H NMR (d₆-DMSO, 300 MHz) δ 2.64 (s, 3H), 3.23 (s, 2H), 5.37 (s, 2H), 7.13 (m, 2H), 7.23 (m, 2H), 7.40 (s, 1H), 7.47 (d, J=8 Hz, 2H), 7.87 (d, J=8 Hz, 2H), 8.10 (s, 1H). MS (DCI/NH₃) m/z 356 (M+H)⁺.

Example 39

2-(5-Chlorothiazol-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(bromomethyl)-5-chlorothiazole for 4-fluorobenzyl bromide. mp 185-186 °C. ¹H NMR (d₆-DMSO, 300 MHz) δ 2.32 (s, 3H), 5.50 (s, 2H), 7.15 (m, 2H), 7.24 (m, 2H), 7.47 (m, 2H), 7.87 (m, 3H), 8.14 (s, 1H). MS (DCI/NH₃) m/z 476 (M+H)⁺ and m/z 493 (M+NH₄)⁺.

Example 40

2-(2,3,3,4,4,4-Hexafluorobuten-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2,2,3,3,4,4,4-heptafluoro-1-iodobutane for 4-fluorobenzyl bromide. Under the alkylation conditions, elimination of HF provided the unsaturated product. mp 167-169 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.07 (s, 3H), 7.00 (t, J=9 Hz, 2H), 7.17 (dd, J=9 Hz, 6 Hz, 2H), 7.33 (d, J=9 Hz, 2H), 7.68 (d, J=24 Hz, 1H), 7.93 (d, J=9 Hz, 2H), 8.01 (s, 1H). MS (DCI/NH₃) m/z 507 (M+H)⁺ and m/z 524 (M+NH₄)⁺.

Example 41

2-(2,4-Difluorophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-chloro-2',4'-difluoroacetophenone for 4-fluorobenzyl bromide. mp 191-192 °C. ¹H NMR (CDCl₃, 300 MHz) δ 3.08 (s, 3H), 5.57 (d, J=3 Hz, 2H), 6.94-7.07 (m, 2H), 6.96 (t, J=9 Hz, 2H), 7.39 (dd, J=9 Hz, 6 Hz, 2H), 7.91 (s, 1H), 7.91 (d, J=9 Hz, 2H), 8.03-8.12 (m, 1H). MS (DCI/NH₃) m/z 499 (M+H)⁺ and m/z 516 (M+NH₄)⁺.

Example 42

2-(5-Chlorothiophen-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(bromomethyl)-5-chlorothiophene for 4-fluorobenzyl bromide. mp 139-141 °C. ¹H NMR (d₆-DMSO, 300 MHz) δ 3.23 (s, 3H), 5.43 (s, 2H), 7.03 (d, J=4 Hz, 1H), 7.09-7.29 (m, 5H), 7.47 (d, J=8 Hz, 2H), 7.87 (d, J=8 Hz, 3H), 8.13 (s, 1H). MS (DCI/NH₃) m/z 474 (M+H)⁺ and m/z 492 (M+NH₄)⁺.

Example 43

2-(5-Methylthien-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-(bromomethyl)-5-methylthiophene for 4-fluorobenzyl bromide. mp 172-175 °C. ¹H NMR (d₆-DMSO, 300 MHz) δ 3.22 (s, 3H), 5.49 (s, 2H), 7.03 (m, 1H), 7.14 (m, 2H), 7.23 (m, 3H), 7.48 (m, 3H), 7.86 (m, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 441 (M+H)⁺ and m/z 458 (M+NH₄)⁺.

Example 44

2-(4-Diethylaminophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-chloro-4'-diethylaminoacetophenone for 4-fluorobenzyl bromide. mp 105-108 °C. ¹H NMR (CDCl₃, 300 MHz) δ 1.23 (t, J=7 Hz, 3H), 3.07 (s, 3H), 3.44 (q, J=7 Hz, 2H), 5.61 (s, 2H), 6.66 (d, J=9 Hz, 2H), 6.94 (t, J=9 Hz, 2H), 7.21 (dd, J=9 Hz, 6 Hz, 2H), 7.38 (d, J=9 Hz, 2H), 7.87-7.94 (m, 4H), 7.90 (s, 1H). MS (DCI/NH₃) m/z 534 (M+H)⁺.

Example 45

2-(2,3,4,5,6-Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2,3,4,5,6-pentafluorobenzyl bromide for 4-fluorobenzyl bromide. mp 115-116

°C. ¹H NMR (CDCl₃, 300 MHz) 3.06 (s, 3H), 5.50 (s, 2H), 6.96 (t, J=9 Hz, 2H), 7.17 (dd, J=9 Hz, 6 Hz, 2H), 7.33 (d, J=9 Hz, 2H), 7.82 (s, 1H), 7.89 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 525 (M+H)⁺ and m/z 542 (M+NH₄)⁺.

5

Example 46

2-(Phenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-bromoacetophenone for 4-fluorobenzyl bromide. mp 228-230 °C. ¹H NMR (CDCl₃, 300 MHz) 3.07 (s, 3H), 5.68 (s, 2H), 6.95 (t, J=9 Hz, 2H), 7.20 (dd, J=9 Hz, 6 Hz, 2H), 7.38 (d, J=9 Hz, 2H), 7.53 (t, J=7 Hz, 2H), 7.65 (t, J=7 Hz, 1H), 7.90 (d, J=9 Hz, 2H), 7.91 (s, 1H), 8.04 (d, J=7 Hz, 2H). MS (DCI/NH₃) m/z 463 (M+H)⁺ and m/z 480 (M+NH₄)⁺.

10

Example 47

2-(4-Chlorophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-bromo-4'-chloroacetophenone for 4-fluorobenzyl bromide. mp 186-188 °C. ¹H NMR (CDCl₃, 300 MHz) 3.07 (s, 3H), 5.63 (s, 2H), 6.95 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.38 (d, J=9 Hz, 2H), 7.51 (d, J=9 Hz, 2H), 7.65 (t, J=7 Hz, 1H), 7.90 (d, J=9 Hz, 2H), 7.91 (s, 1H), 7.98 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 497 (M+H)⁺ and m/z 514 (M+NH₄)⁺.

20

Example 48

2-(Propargyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting propargyl bromide for 4-fluorobenzyl bromide. mp 196-198 °C. ¹H NMR (CDCl₃, 300 MHz) 2.42 (t, J=3 Hz, 1H), 3.06 (s, 3H), 5.04 (d, J=3 Hz, 2H), 6.97 (t, J=9

25

Hz, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.34 (d, J=9 Hz, 2H), 7.90 (s, 1H), 7.91 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 383 (M+H)⁺ and m/z 400 (M+NH₄)⁺.

Example 49

2-(4-Cyanophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-bromo-4'-cyanoacetophenone for 4-fluorobenzyl bromide. mp 188-189 °C. ¹H NMR (CDCl₃, 300 MHz) 3.08 (s, 3H), 5.64 (s, 2H), 6.96 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.38 (d, J=9 Hz, 2H), 7.84 (d, J=9 Hz, 2H), 7.91 (d, J=9 Hz, 2H), 7.93 (s, 1H), 8.14 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 488 (M+H)⁺.

Example 50

2-(α -Methyl-4-fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 20, substituting α -methyl-4-fluorobenzyl bromide for 4-fluorobenzyl bromide. mp 162-164 °C. ^1H NMR (CDCl_3 , 300 MHz) 3.06 (s, 3H), 6.40 (t, $J=9$ Hz, 2H), 6.95 (t, $J=9$ Hz, 2H), 7.05 (t, $J=9$ Hz, 2H), 7.15 (dd, $J=9$ Hz and 6 Hz, 2H), 7.31 (d, $J=9$ Hz, 2H), 7.53 (dd, $J=9$ Hz and 6 Hz, 2H), 7.87 (d, $J=9$ Hz, 2H), 7.88 (s, 1H). MS (DCI/NH_3) m/z 467 ($\text{M}+\text{H}$) $^+$ and m/z 484 ($\text{M}+\text{NH}_4$) $^+$.

Example 51

2-Phenethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting (2-bromoethyl)benzene for 4-fluorobenzyl bromide. mp 170-171 °C. ¹H NMR (CDCl₃, 300 MHz) 3.07 (s, 3H), 3.20 (t, J=9 Hz, 2H), 4.28 (t, J=9 Hz, 2H), 6.98 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz and 6 Hz, 2H), 7.22-37 (m, 5 H). 7.34 (d, J=9 Hz, 2H), 7.83 (s, 1H), 7.89 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 449 (M+H)⁺ and m/z 466 (M+NH₄)⁺.

Example 522-Benzyl-4-(3-chloro-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method described in Examples
5 6-10 substituting 3-chloro-4-fluorobenzeneboronic acid for 4-fluorobenzeneboronic acid in
Example 6. mp 134-136 °C. ¹H NMR (CDCl₃, 300 MHz) 3.06 (s, 3H), 5.41 (s, 2H), 6.96-
7.02 (m, 2H), 7.29-7.41 (m, 3H), 7.33 (d, J=9 Hz, 2H), 7.51-7.56 (m, 2H), 7.85 (s, 1H),
7.91 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 469 (M+H)⁺ and m/z 486 (M+NH₄)⁺.

10

Example 532-Benzyl-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method described in Examples
6-10 except substituting 4-chlorobenzeneboronic acid for 4-fluorobenzeneboronic acid in
Example 6. mp 157-159 °C. ¹H NMR (CDCl₃, 300 MHz) 3.05 (s, 3H), 5.40 (s, 2H), 7.11
15 (d, J=9 Hz, 2H), 7.24 (d, J=9 Hz, 2H), 7.28-7.40 (m, 2H), 7.31 (d, J=9 Hz, 2H), 7.51-7.57
(m, 2H), 7.84 (s, 1H), 7.88 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 451 (M+H)⁺ and m/z 468
(M+NH₄)⁺.

Example 54

20 2-(2,2,2-Trifluoroethyl)-4-(3-chloro-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared by N-debenzylation of the product, prepared in
Example 52 according to the method of Example 11, followed by alkylation with 2-iodo-
1,1,1-trifluoroethane according to the method of Example 20. mp 165-166 °C. ¹H NMR
25 (CDCl₃, 300 MHz) 3.07 (s, 3H), 4.89 (q, J=9 Hz, 2H), 7.00-7.06 (m, 2H), 7.31-7.35 (m,
1H), 7.37 (d, J=9 Hz, 2H), 7.90 (s, 1H), 7.94 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 461
(M+H)⁺ and m/z 478 (M+NH₄)⁺.

Example 55

2-(4-Trifluoromethoxyphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-bromo-4'-trifluoromethoxyacetophenone for 4-fluorobenzyl bromide. mp
5 160-161 °C. ¹H NMR (CDCl₃, 300 MHz) 3.08 (s, 3H), 5.65 (s, 2H), 6.96 (t, J=9 Hz, 2H), 7.20 (dd, J=9 Hz, 6 Hz, 2H), 7.37 (d, J=9 Hz, 2H), 7.91 (d, J=9 Hz, 2H), 7.93 (s, 1H), 8.11 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 547 (M+H)⁺ and m/z 564 (M+NH₄)⁺.

Example 56

10 2-(4-Trifluoromethylphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 2-bromo-4'-trifluoromethylacetophenone for 4-fluorobenzyl bromide. mp
205-206 °C. ¹H NMR (CDCl₃, 300 MHz) 3.07 (s, 3H), 5.66 (s, 2H), 6.96 (t, J=9 Hz, 2H),
15 7.20 (dd, J=9 Hz, 6 Hz, 2H), 7.38 (d, J=9 Hz, 2H), 7.80 (d, J=9 Hz, 2H), 7.91 (d, J=9 Hz, 2H), 7.92 (s, 1H), 8.15 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 531 (M+H)⁺ and m/z 548 (M+NH₄)⁺.

Example 57

20 2-[2-(Benzo[b]thien-3-yl)-2-oxoethyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 3-chloroacetylbenzo[b]thiophene for 4-fluorobenzyl bromide. mp 183-184
°C. ¹H NMR (CDCl₃, 300 MHz) 3.08 (s, 3H), 5.68 (s, 2H), 6.96 (t, J=9 Hz, 2H), 7.21 (dd,
25 J=9 Hz, 6 Hz, 2H), 7.39 (d, J=9 Hz, 2H), 7.42-7.54 (m, 2H), 7.91 (d, J=9 Hz, 2H), 7.91 (d, J=7 Hz, 1H), 7.94 (s, 1H), 8.53 (s, 1H), 8.72 (d, J=7 Hz, 1H). MS (DCI/NH₃) m/z 519 (M+H)⁺.

Example 58

2-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared by N-debenzylation of the product, prepared in Example 53 according to the method of Example 12, followed by alkylation with 2-iodo-
5 1,1,1-trifluoroethane according to the method of Example 20. mp 55-57 °C. ¹H NMR (CDCl₃, 300 MHz) 3.07 (s, 3H), 4.88 (q, J=9 Hz, 2H), 7.13 (d, J=9 Hz, 2H), 7.26 (d, J=9 Hz, 2H), 7.36 (d, J=9 Hz, 2H), 7.89 (s, 1H), 7.92 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 443 (M+H)⁺ and m/z 460 (M+NH₄)⁺.

10

Example 59

2-(3,3-Dimethyl-2-oxobutyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 20, substituting 1-bromopinacolone for 4-fluorobenzyl bromide. mp 168-170 °C. ¹H NMR
15 (CDCl₃, 300 MHz) 1.31 (s, 9H), 3.06 (s, 3H), 5.21 (s, 2H), 6.95 (t, J=9 Hz, 2H), 7.17 (dd, J=9 Hz, 6 Hz, 2H), 7.35 (d, J=7 Hz, 2H), 7.86 (s, 1H) 7.89 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 443 (M+H)⁺ and m/z 460 (M+NH₄)⁺.

20

Example 60

2-(3-Thienylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 3-(chloromethyl)thiophene for 4-fluorobenzyl bromide. mp 169-172 °C. ¹H
NMR (300 MHz, DMSO d₆) δ 3.22 (s, 3H), 5.36 (s, 2H), 7.18 (m, 5H), 7.51 (m, 4H), 7.88
(m, 2H); 8.08 (s, 1H). MS (DCI/NH₃) m/z 441 (M+H)⁺ and m/z 458 (M+NH₄)⁺.

25

Example 61

2-(2-Benzo[b]thienylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 20 substituting 2-(chloromethyl)benzo[b]thiophene for 4-fluorobenzyl bromide. mp 93-96 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 5.64 (s, 2H), 6.97 (m, 2H), 7.18 (m, 2H), 7.33 (m, 5H), 7.78 (m, 2H), 7.86 (m, 3H). MS (DCI/NH₃) m/z 491 (M+H)⁺ and m/z 508 (M+NH₄)⁺.

Example 62

2,4-Bis(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A mixture of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (172 mg, 0.5 mmol), prepared according to the method of Example 10, Cu powder (32 mg), anhydrous K₂CO₃ (207 mg, 1.5 mmol) and 4-fluoriodobenzene (0.12 mL, 1 mmol) was prepared in 20 mL of pyridine. The solution was stirred at reflux for 14 hours. The mixture was then cooled to room temperature and partitioned between water and ethyl acetate. The ethyl acetate layer was washed with 10% citric acid, water, brine and concentrated in vacuo. Separation by column chromatography (silica gel, CH₂Cl₂-diethyl ether 15:1) provided 190 mg of crude product. Crystallization from CH₂Cl₂-diethyl ether-hexanes furnished the title compound (yield: 175 mg, 79.9%). mp 168-169 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.07 (s, 3H), 6.98 (t, J=9 Hz, 2H), 7.20 (m, 4H), 7.40 (d, J=9 Hz, 2H), 7.69 (m, 2H), 7.92 (d, J=9 Hz, 2H), 7.98 (s, 1H). MS (DCI/NH₃) m/z 439 (M+H)⁺, 456 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆F₂N₂O₃S.0.25 H₂O: C, 62.36; H, 3.75; N, 6.32. Found: C, 62.23; H, 3.55; N, 6.26.

Example 63

4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-6-methyl-3(2H)-pyridazinone

The 5-hydroxy-5-methyl-2(5H)-furanone prepared via above cited methods (454 mg, 1.25 mmol) was dissolved in n-butanol (10 mL) and treated with hydrazine hydrate (0.3 mL, 6.2 mmol) and stirred at reflux for 18 hours. On cooling, white crystals (224 mg, 50%) were obtained. mp 290 °C (dec.) ¹H NMR (300 MHz, d₆-DMSO) δ 1.99 (s, 3H), 3.10 (s, 3H), 7.05 (t, J=9 Hz, 2H), 7.15 (dd, J=6 Hz, J=9 Hz, 2H), 7.48 (d, J=9 Hz, 2H),

7.85 (d, J=9 Hz, 2H), 13.10 (br s, 1H). MS (DCI/NH₃) 376 (M+NH₄)⁺. Anal. calc. for C₁₈H₁₅N₂FSO₃ 0.25 H₂O: C, 59.57; H, 4.30; N, 7.71. Found: C, 59.28; H, 4.39; N, 8.39

Example 64

5 2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-6-methyl-3(2H)-pyridazinone

The product of Example 63 (100 mg, 0.28 mmol) was dissolved in anhydrous DMF (3 mL) and treated with 1,1,1-trifluoro-2-iodoethane (27.5 mL, 280 mmol) in presence of anhydrous sodium carbonate (130 mg, 1.2 mmol) at 50-60 °C for 2 hours.

10 The reaction mixture was partitioned between water and ethyl acetate to provide the desired compound as an amorphous solid (60 mg, 48%). ¹H NMR (300 MHz, CDCl₃) δ 2.10 (s, 3H), 3.10 (s, 3H), 4.85 (q, J=9 Hz, 2H), 6.90 (m, 2H), 7.10 (dd, J=6 Hz, J=9 Hz, 2H), 7.25 (m, 2H), 7.95 (d, J=9 Hz, 2H). MS (DCI/NH₃) 458 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₆N₂F₄SO₃: C, 54.54; H, 3.66; N, 6.36. Found: C, 54.41; H, 3.56; N, 6.35.

15

Example 65

2-Benzyl-4-(3,4-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared by coupling 3,4-dichlorophenylboronic acid with 2-benzyl-4-bromo-5-methoxy-3(2H)-pyridazinone (J. Het. Chem., (1996) 33, 1579-1582) according to the method of Example 6. This product was converted to the 5-hydroxy-derivative according to the method of Example 7. The 5-hydroxy compound was converted to the 5-trifluoromethylsulfonyloxy-derivative according to the method of Example 8. Coupling of 4-(methylthio)phenylboronic acid to the triflate according to the method of Example 9 provided the 5-[4-(methylthio)phenyl]-intermediate which was oxidized according to the method of Example 10 to provide the final product (yield: 780 mg, 84%). mp 161-163 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.22 (s, 3H), 5.35 (s, 2H), 7.08 (dd, J=9 Hz, 3 Hz, 1H), 7.32-7.44 (m, 5H), 7.47 (dd, J=9 Hz, 3 Hz, 3H), 7.48 (d, J=3 Hz, 1H), 7.90 (d, J=9 Hz, 2H), 8.13 (s, 1H). MS (DCI/NH₃) m/z 485 (M+H)⁺. Anal. calc. for C₂₄H₁₈Cl₂N₂O₃S: C, 59.38; H, 3.73; N, 5.77. Found: C, 59.28; H, 3.92; N, 5.42.

25

Example 662-(2,2,2-Trifluoroethyl)-4-(4-n-propylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound was prepared by coupling 4-(n-propyl)phenylboronic acid with 2-benzyl-4-bromo-5-methoxy-3(2H)-pyridazinone (J. Het. Chem., 1996, 33, 1579-1582) according to the method of Example 6. This product was converted to the 5-hydroxy derivative according to the method of Example 7. This product was converted to the 5-trifluoromethylsulfonyloxy-derivative according to the method of Example 8. Coupling of
10 4-(methylthio)phenylboronic acid to the triflate according to the method of Example 9 provided the 5-[4-(methylthio)phenyl]-intermediate which was oxidized according to the method of Example 10 to provide the final product (yield: 220 mg, 70%). mp 64-66 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.91 (t, J=7.5 Hz, 3H), 1.6 (h, J=7.5 Hz, 2H), 2.55 (q, J=7.5 Hz, 2H), 3.05 (s, 3H), 4.88 (q, J=9 Hz, 2H), 7.08 (s, 4H), 7.35 (d, J=9 Hz, 2H), 7.86 (d, J=9 Hz, 2H), 7.87 (s, 1H). MS (DCI/NH₃) m/z 451 (M+H)⁺. Anal. calc. for C₂₂H₂₁F₃N₂O₃S: C, 58.65; H, 4.69; N, 6.21. Found: C, 58.71; H, 4.72; N, 6.20.

Example 672-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

20 The title compound was prepared by first coupling 3-fluoro-4-chlorophenylboronic acid with 2-benzyl-4-chloro-5-methoxy-3(2H)-pyridazinone according to the method of Example 6. The product was converted to the 5-hydroxy compound according to the method of Example 7. This 5-hydroxy compound was converted to the 5-trifluoromethylsulfonyloxy-derivative according to the method of Example 8. Coupling of
25 4-(methylthio)phenylboronic acid to the triflate according to the method of Example 9 provided the 5-[4-(methylthio)phenyl]-intermediate which was oxidized according to the method of Example 10 to provide the final product (yield: 170 mg, 84%). mp 174-175 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.09 (s, 3H), 4.89 (q, J=9 Hz, 2H), 6.87 (dm, J=9 Hz, 1H),

7.09 (dd, J=9 Hz, 3 Hz, 1H), 7.30 (t, J=9 Hz, 1H), 7.39 (d, J=9 Hz, 2H), 7.91 (s, 1H), 7.95 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 461 (M+H)⁺. Anal. calc. for C₁₉H₁₃ClF₄N₂O₃S: C, 49.52; H, 2.84; N, 6.07. Found: C, 49.66; H, 2.70; N, 5.96.

5

Example 68

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 2-(2,2,2-trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone (680 mg, 1.53 mmol) in trifluoroacetic anhydride (30 mL) was stirred at room temperature for 1 hour. The excess solvent was evaporated in vacuo and the residue was treated with a deoxygenated 1N solution of methanol-NaOH (50 mL, 4:1) at 0 °C. The solution was stirred at room temperature for 2 hours and quenched with dilute HCl solution until acidic. The white suspension formed was concentrated in vacuo to evaporate the methanol. THF was added to the resulting suspension until a clear solution was obtained. Chlorine gas was slowly bubbled into the solution, maintained at 0 °C. After 10 minutes, nitrogen gas was bubbled into the solution for a few minutes to displace residual chlorine. Ammonium hydroxide solution (30%, 5 to 10 mL), at 0 °C, was slowly added to the solution (to consume all starting sulfonyl chloride) and stirred at room temperature for 5 minutes. The solution was partitioned between water and ethyl acetate. The organic layer was washed first with water, then brine, and dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo. The residue was purified by chromatography on silica gel (40:60 ethyl acetate/hexanes) to provide the title compound (yield: 500 mg, 75%). mp 193-195 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.82 (s, 2H), 4.88 (q, J=9 Hz, 2H), 6.98 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.30 (d, J=9 Hz, 2H), 7.88 (d, J=9 Hz, 2H), 7.90 (s, 1H). MS (DCI/NH₃) m/z 428 (M+H)⁺. Anal. calc. for C₁₈H₁₃F₄N₃O₃S: C, 50.58; H, 3.06; N, 9.83. Found: C, 51.04; H, 3.26; N, 9.63.

25

Example 69

2-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound from Example 77 was converted to the sulfonamide product according to the method of Example 68 (yield: 540 mg, 70%). mp 154-156 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.86 (s, 2H), 4.87 (q, J=9 Hz, 2H), 7.14 (d, J=9 Hz, 2H), 7.29 (d, J=9 Hz, 2H), 7.31 (d, J=9 Hz, 2H), 7.89 (d, J=9 Hz, 2H), 8.00 (s, 1H). MS (DCI/NH₃) m/z 444 (M+H)⁺. Anal. calc. for C₁₈H₁₃ClF₃N₃O₃S: C, 48.71; H, 2.95; N, 9.46. Found: C, 49.05; H, 3.01; N, 9.15.

Example 70

2-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The methyl sulfide intermediate prepared in Example 83C was oxidized with one equivalent of meta-chloroperoxybenzoic acid to provide the methylsulfoxide which was converted to the sulfonamide final product according to the method of Example 68 (yield: 396 mg, 60%). mp 158-160 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, J=6 Hz, 6H), 4.83 (q, J=7.5 Hz, 2H), 4.86 (s, 2H), 5.46 (p, J=6 Hz, 1H), 7.72 (d, J=9 Hz, 2H), 7.82 (s, 1H), 8.03 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 392 (M+H)⁺. Anal. calc. for C₁₅H₁₆F₃N₃O₄S: C, 46.03; H, 4.12; N, 10.73. Found: C, 46.08; H, 4.22; N, 10.52.

Example 71

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone

The methyl sulfide intermediate of Example 76 was oxidized with one equivalent of meta-chloroperoxybenzoic acid to provide the methylsulfoxide which was converted to the sulfonamide final product according to the method of Example 68 (yield: 180 mg, 37%). mp 150-152 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.71 (q, J=7.5 Hz, 2H), 4.72 (s, 2H), 6.88 (dd, J=9 Hz, 4.5 Hz, 2H), 7.0 (t, J=9 Hz, 2H), 7.73 (d, J=9 Hz, 2H), 7.98 (s, 1H), 8.05 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 444 (M+H)⁺. Anal. calc. for C₁₈H₁₃F₄N₃O₄S: C, 48.76; H, 2.95; N, 9.47. Found: C, 48.49; H, 2.8; N, 8.95.

Example 722,4-Bis-(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

5

Example 72A2-Fluorothioanisole

A deoxygenated solution of 2-fluorothiophenol (10 g, 78 mmol) in anhydrous DMF (10 mL) was treated with iodomethane (4.9 mL, 78 mmol) and potassium carbonate (10.8 g, 78 mmol). The reaction mixture was stirred at room temperature for 1 hour. A
10 thin layer chromatography (100% hexanes) sample indicated that the reaction had not gone to completion, so an additional equivalent of base and iodomethane were added and the reaction mixture was stirred overnight at room temperature. The reaction was acidified with 10% aqueous citric acid and extracted with hexanes (2 X 125 mL). The combined organic extracts were washed with brine, dried over MgSO₄, and filtered. The filtrate was
15 concentrated under reduced pressure to provide the desired compound as a pale yellow oil (yield: 6.68 g; 60%).

Example 72B2-Fluorothioanisole

20 An alternative method for preparing 2-fluorothioanisole begins with a solution of 1,2-difluorobenzene (0.79 mL, 8 mmol) in anhydrous DMF (50 mL) was treated with sodium thiomethoxide (0.59 g, 8 mmol). The reaction mixture was stirred at room temperature for 6 hours, and partitioned between hexanes and water. The organic layer was washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated
25 under reduced pressure to provide the desired compound (1.1 g, 100%) slightly contaminated with 1,2-bis(methylthio)benzene, a lower R_f material, which was removed by chromatography with 100% hexanes (0.9 g, 80%). ¹H NMR (300 MHz, CDCl₃) δ 2.46 (s, 3H), 6.98-7.19 (m, 3H) 2.26 (dt, J=9 Hz, 3 Hz, 1H).

Example 72C4-Bromo-2-fluorothioanisole

A solution of 2-fluorothioanisole (1.42 g, 10 mmol) and iron powder (0.03 g, 0.5 mmol) in dichloromethane (20 mL) was chilled to °C and treated dropwise with Bromine (0.5 mL, 10 mmol). Upon completion of the Bromine treatment, the reaction was sampled for TLC (100% hexanes). A new, higher R_f material was present but the reaction had not gone to completion so another equivalent of bromine was added along with a catalytic amount of aluminum chloride. The reaction mixture was stirred overnight at room temperature. Aqueous sodium sulfite was added to the reaction mixture and the organic layer was isolated, dried over MgSO₄, and filtered. The filtrate was filtered through a pad of silica gel to remove color then concentrated under reduced pressure to provide the product as a clear, colorless oil (yield: 1.3 g; 60%). ¹H NMR (300 MHz, DMSO-d₆) δ 2.48 (s, 3H), 7.31 (t, J=9 Hz, 1H), 7.43 (dd, J=9 Hz, 3 Hz, 1H) 7.54 (dd, J=9 Hz, 3 Hz, 1H).

Example 72D3-Fluoro-4-(methylthio)benzeneboronic acid

A solution of 4-bromo-2-fluorothioanisole (0.5 g, 22.6 mmol) in dry THF (20 mL) was chilled to -78 °C under a nitrogen atmosphere. The reaction mixture was treated with 1.6 M n-butyllithium in hexanes (1.7 mL, 27.1 mmol), and the mixture was warmed to -40°C where it was maintained for 0.5 hours. The reaction mixture was then chilled to -78°C and three equivalents of triisopropyl borate (1.56 mL, 67.8 mmol) were added. The reaction mixture was allowed to warm to room temperature and stirred for 1.5 hours. At this point, 10% aqueous KOH (200 mL, 360 mmol) was added and the mixture was stirred overnight at room temperature. The reaction mixture was then poured into an ice/concentrated HCl mixture with stirring to yield a white precipitate. This solid was dried in a vacuum oven (65 °C, 29 in Hg) overnight to provide the title compound (yield: 0.22 g; 52.4%). ¹H NMR (300 MHz, DMSO-d₆) δ 2.48 (s, 3H), 7.31 (t, J=9 Hz, 1H), 7.49 (dd, J=12 Hz, 1.5 Hz, 1H) 7.54 (dd, J=9 Hz, 1.5 Hz, 1H).

Example 72E2,4-Bis-(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-chloro-5-methoxy-3(2H)-pyridazinone (J. Het. Chem., 1996, 33, 1579-1582) was converted to the 5-hydroxy-analog according to the method of Example 7 and then to the 5-trifluoromethylsulfonyloxy-analog following the method of Example 8. Subsequent coupling to 3-fluoro-4-(methylthio)phenylboronic acid, according to the method of Example 9, provided 2-benzyl-4-chloro-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone. This intermediate was coupled in the 4-position with 4-fluorophenylboronic acid following the method of Example 6. This product was N-debenzylated according to the method of Example 11 and N-arylated with 4-fluoroiodobenzene according to the method of Example 62. The resulting sulfide was oxidized with one equivalent of meta-chloroperoxybenzoic acid to provide the methylsulfoxide which was converted to the sulfonamide final product according to the method of Example 68 (yield: 500 mg, 75%). mp 222-224 °C. ¹H NMR (300 MHz, CDCl₃) δ 5.06 (s, 2H), 7.01 (t, J=9 Hz, 2H), 7.06 (d, J=9 Hz, 2H), 7.10 (d, J=9 Hz, 2H), 7.18 (t, J=9 Hz, 2H), 7.69 (dd, J=9 Hz, 3 Hz, 2H), 7.88 (t, J=9 Hz, 1H), 7.95 (s, 1H). MS (DCI/NH₃) m/z 458 (M+H)⁺. Anal. calc. for C₂₂H₁₄F₃N₃O₃S: C, 57.76; H, 3.08; N, 9.18. Found: C, 57.5; H, 3.15; N, 8.8.

Example 732-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The methyl sulfide intermediate prepared in Example 67 was oxidized with one equivalent of meta-chloroperoxybenzoic acid, according to the method of Example 68 to provide the methyl sulfoxide. The methyl sulfoxide was converted to the sulfonamide product according to the method of Example 68 (yield: 1.5 g, 63%). mp 180-183 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 5.09 (q, J=9 Hz, 2H), 7.01 (dd, J=9 Hz, 3 Hz, 1H), 7.15 (dd, J=9 Hz, 3 Hz, 1H), 7.39 (dd, J=9 Hz, 3 Hz, 1H), 7.47 (dd, J=9 Hz, 3 Hz, 1H), 7.55 (t, J=9 Hz, 1H), 7.71 (t, J=9 Hz, 1H), 7.78 (s, 2H), 8.37 (s, 1H). MS (DCI/NH₃) m/z 480

(M+H)⁺. Anal. calc. for C₁₈H₁₁ClF₅N₃O₃S: C, 45.05; H, 2.31; N, 8.75. Found: C, 46.19; H, 3.02; N, 7.43.

Example 74

2-Benzyl-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-chloro-5-methoxy-3(2H)-pyridazinone (J. Het. Chem., 1996, 33, 1579-1582) was converted to the 5-hydroxy-analog according to the method of Example 7 and then to the 5-trifluoromethylsulfonyloxy-analog following the method of Example 8. Subsequent coupling to 4-(methylthio)phenylboronic acid according to the method of Example 9 provided 2-benzyl-4-chloro-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone. This 4-chloro-intermediate thus prepared was treated with 2-propanol (20 mL, 261 mmol) and potassium t-butoxide (110 mg, 0.98 mmol) at reflux for 45 minutes furnished 2-benzyl-4-(2-propoxy)-5-[4-(methylthio)pentyl]-3(2H)-pyridazinone. This methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 180 mg, 80%). mp 109-111 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.18 (d, J=6 Hz, 6H), 3.12 (s, 3H), 5.36 (s, 2H), 5.49 (h, J=6 Hz, 1H), 7.35 (m, 3H), 7.47 (dd, J=9 Hz, 3 Hz, 2H), 7.74 (d, J=9 Hz, 2H), 7.79 (s, 1H), 8.03 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 399 (M+H)⁺. Anal. calc. for C₂₁H₂₂N₂O₄S: C, 63.29; H, 5.56; N, 7.03. Found: C, 63.17; H, 5.57; N, 6.95.

Example 75

2-Benzyl-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 74 substituting 4-fluorophenol in place of 2-propanol (yield: 180 mg, 99%). mp 188-190 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 3H), 5.26 (s, 2H), 6.86 (dd, J=9 Hz, 6 Hz, 2H), 6.99 (t, J=9 Hz, 2H), 7.34 (m, 3H), 7.46 (dd, J=9 Hz, 3 Hz, 2H), 7.72 (d, J=9 Hz, 2H), 7.92 (s, 1H), 8.02 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 451 (M+H)⁺. Anal. calc. for C₂₄H₁₉FN₂O₄S: C, 63.98; H, 4.25; N, 6.21. Found: C, 63.74; H, 4.2; N, 6.12.

Example 762-(2,2,2-Trifluoroethyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 75 substituting 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 180 mg, 63%). mp 161-164 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.09 (s, 3H), 4.81 (q, J=9 Hz, 2H), 6.88 (dd, J=9 Hz, 4.5 Hz, 2H), 7.0 (t, J=9 Hz, 2H), 7.78 (d, J=9 Hz, 2H), 7.79 (s, 1H), 8.06 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 443 (M+H)⁺. Anal. calc. for C₁₉H₁₄F₄N₂O₄S: C, 51.58; H, 3.18; N, 6.33. Found: C, 51.8; H, 3.3; N, 6.22.

Example 772-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-chloro-5-methoxy-3(2H)-pyridazinone (J. Het. Chem., 1996, 33, 1579-1582) was converted to the 5-hydroxy-analog according to the method of Example 7 and then to the 5-trifluoromethylsulfonyloxy-analog according to the method of Example 8. Subsequent coupling to 4-(methylthio)phenylboronic acid, according to the method of Example 9, provided 2-benzyl-4-chloro-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone. This intermediate was coupled with 4-chlorophenylboronic acid according to the method of Example 6. This product was N-debenzylated according to the method of Example 11 and N-alkylated with 2-iodo-1,1,1-trifluoroethane according to the method of Example 20. The resulting sulfide was oxidized to the corresponding sulfoxide with one equivalent of meta-chloroperoxybenzoic acid, according to the method of Example 5 to provide the title compound (yield: 130 mg, 70%). mp 154-155 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.74 (s, 3H), 4.88 (q, J=9 Hz, 2H), 7.14 (d, J=9 Hz, 2H), 7.26 (d, J=9 Hz, 2H), 7.31 (d, J=9 Hz, 2H), 7.61 (d, J=9 Hz, 2H), 7.82 (s, 1H). MS (DCI/NH₃) m/z 427 (M+H)⁺. Anal. calc. for C₁₉H₁₄ClF₃N₂O₂S: C, 53.46; H, 3.3; N, 6.56. Found: C, 53.58; H, 3.34; N, 6.42.

Example 78

2-Benzyl-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared by oxidizing 2-benzyl-4-chloro-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, (prepared as an intermediate in Example 77) according to the method of Example 10 (yield: 180 mg, 83%). mp 166-167 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 3H), 5.41 (s, 2H), 7.37 (m, 3H), 7.53 (dd, J=9 Hz, 3 Hz, 2H), 7.68 (d, J=9 Hz, 2H), 7.74 (s, 1H), 8.08 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 375 (M+H)⁺. Anal. calc. for C₁₈H₁₅ClN₂O₃S: C, 57.67; H, 4.03; N, 7.47. Found: C, 57.43; H, 4.06; N, 7.35.

Example 79

2-(2,2,2-Trifluoroethyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-bromo-5-methoxy-3(2H)-pyridazinone (J. Het. Chem., 1996, 33, 1579-1582) was converted to the 5-hydroxy-analog according to the method of Example 7 and then to the 5-(trifluoromethyl)sulfonyloxy-analog according to the method of Example 8. Subsequent coupling to 4-(methylthio)phenylboronic acid, according to the method of Example 9, provided 2-benzyl-4-bromo-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone. This intermediate was coupled with 4-methylphenylboronic acid according to the method of Example 6. This product was N-debenzylated according to the method of Example 11 and N-alkylated with 2-iodo-1,1,1-trifluoroethane according to the method of Example 20. The resulting sulfide was oxidized to the title compound according to the method of Example 10 (yield: 210 mg, 98%). mp 154-156 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.33 (s, 3H), 3.07 (s, 3H), 4.89 (q, J=9 Hz, 2H), 7.08 (s, 4H), 7.37 (d, J=9 Hz, 2H), 7.88 (s, 1H), 7.89 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 423 (M+H)⁺. Anal. calc. for C₂₀H₁₇F₃N₂O₃S: C, 56.86; H, 4.05; N, 6.63. Found: C, 56.59; H, 4.11; N, 6.53.

Example 80

2-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-chloro-5-methoxy-3(2H)-pyridazinone (J. Het. Chem., 1996, 33, 1579-1582) was converted to the 5-hydroxy-analog according to the method of Example 7 and then to the 5-(trifluoromethyl)sulfonyloxy-analog according to the method of Example 8. Subsequent coupling to 4-(methylthio)phenylboronic acid, according to the method of Example 9, provided 2-benzyl-4-chloro-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone. This intermediate was coupled with 4-chloro-3-fluorophenylboronic acid according to the method of Example 6. This product was N-debenzylated according to the method of Example 11 and N-alkylated with 2-iodo-1,1,1-trifluoroethane according to the method of Example 20. The resulting sulfide was oxidized to the corresponding sulfoxide with one equivalent of meta-chloroperoxybenzoic acid to provide the methylsulfoxide which was converted to the sulfonamide final product according to the method of Example 68 (yield: 500 mg, 75%). mp 214-215 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.82 (s, 2H), 4.88 (q, J=9 Hz, 2H), 6.88 (m, 1H), 7.09 (dd, J=9 Hz, 3 Hz, 1H), 7.31 (d, J=9 Hz, 1H), 7.32 (d, J=9 Hz, 2H), 7.90 (s, 1H), 7.92 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 462 (M+H)⁺. Anal. calc. for C₁₈H₁₂F₄ClN₃O₃S: C, 46.81; H, 2.61; N, 9.09. Found: C, 46.79; H, 2.59; N, 8.86.

Example 81

2-(2,2,2-Trifluoroethyl)-4-(3,4-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product described in Example 65 was N-debenzylated according to the method of Example 11. The intermediate was N-alkylated according to the method of Example 20, substituting 2-iodo-1,1,1-trifluoroethane in place of 4-fluorobenzyl bromide to provide the title compound (yield: 165 mg, 55%). mp 197-198 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.09 (s, 3H), 4.88 (q, J=9 Hz, 2H), 6.98 (dd, J=9 Hz, 3 Hz, 1H), 7.37 (d, J=9 Hz, 4H), 7.91 (s, 1H), 7.95 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 477 (M+H)⁺. Anal. calc. for C₁₉H₁₃F₃Cl₂N₂O₃S: C, 47.81; H, 2.74; N, 5.86. Found: C, 47.94; H, 2.87; N, 5.83.

Example 822-Benzyl-4-(2-propylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4,5-dibromo-3(2H)-pyridazinone (2 g, 6 mmol) was reacted with 2-aminopropane (2 mL, 23.5 mmol) and potassium t-butoxide (910 mg, 6.6 mmol) in toluene (40 mL) at reflux for 18 hours to provide the 4-(2-propylamino) derivative after column chromatography (silica gel, 92:8 hexanes/ethyl acetate). The intermediate was coupled in the 5-position with 4-(methylthio)phenylboronic acid according to the method of Example 6. The methyl sulfide was oxidized, according to the method of Example 10, to provide the title compound (yield: 120 mg, 48%). mp 146-147 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.92 (d, J=6 Hz, 6H), 3.11 (m, 1H), 3.13 (s, 3H), 5.34 (s, 2H), 5.59 (m, 1H), 7.33 (m, 3H), 7.42 (s, 1H), 7.48 (dd, J=9 Hz, 3 Hz, 2H), 7.56 (d, J=9 Hz, 2H), 8.00 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 399 (M+H)⁺. Anal. calc. for C₂₁H₂₃N₃O₃S: C, 63.45; H, 5.83; N, 10.57. Found: C, 63.31; H, 5.87; N, 10.44.

15

Example 832-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinoneExample 83A2-(2,2,2-Trifluoroethyl)-4,5-dibromo-3(2H)-pyridazinone

A solution of mucobromic acid (10 g, 38.8 mmol) and trifluoroethyl hydrazine (70% in water, 4.88 mL, 38.8 mmol) in 100 mL of methanol was prepared and heated at reflux for 3 hours. The reaction mixture was concentrated in vacuo and partitioned between ethyl acetate and water. The ethyl acetate layer was dried over MgSO₄, filtered, passed through a silica gel pad, and concentrated in vacuo. The product was obtained as yellowish solid (yield: 8.8 g, 68%). ¹H NMR (300 MHz, CDCl₃) δ 4.78 (q, J=9 Hz, 2H), 7.87 (s, 1H). MS (DCI/NH₃) m/z 337 (M+H)⁺.

25

Example 83B2-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-bromo-3(2H)-pyridazinone

A solution of 2-(2,2,2-trifluoroethyl)-4,5-dibromo-3(2H)-pyridazinone (2 g, 6 mmol), isopropyl alcohol (3 mL) and sodium hydride (60% dispersed in oil, 290 mg, 7.2 mmol) in toluene (40 mL) was heated at reflux for 5 hours. The reaction mixture was partitioned between ethyl acetate and water. The ethyl acetate layer was filtered, and concentrated in vacuo. The residue was purified by chromatography (95:5 hexanes/ethyl acetate) to provide the product as a greenish oil (yield: 1.22 g, 65%). ¹H NMR (300 MHz, CDCl₃) δ 1.46 (d, J=7.5 Hz, 6H), 5.48 (h, J=6 Hz, 1H), 7.87 (s, 1H). MS (DCI/NH₃) m/z 316 (M+H)⁺.

Example 83C

2-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

A solution of 2-(2,2,2-trifluoroethyl)-4-(2-propoxy)-5-bromo-3(2H)-pyridazinone (1.2 g, 3.8 mmol), 4-(methylthio)phenylboronic acid (704 mg, 4.19 mmol), tetrakis(triphenylphosphine)palladium(0) (220 mg, 5% mmol) and cesium carbonate (2.72 g, 8.3 mmol) in 20 mL of ethylene glycol dimethyl ether was heated to reflux for 5 hours. The mixture was partitioned between ethyl acetate and water. The ethyl acetate layer was washed with water, brine, dried over MgSO₄ and concentrated in vacuo. The residue was purified by chromatography on silica gel (94:6 hexanes/ethyl acetate). The product was obtained as a greenish solid (yield: 1.1 g, 81%). ¹H NMR (300 MHz, CDCl₃) δ 1.19 (d, J=7.5 Hz, 6H), 2.55 (s, 3H), 4.83 (q, J=9 Hz, 2H), 5.28 (h, J=6 Hz, 1H), 7.32 (d, J=9 Hz, 2H), 7.52 (d, J=9 Hz, 2H), 7.85 (s, 1H). MS (DCI) m/z 359 (M+H)⁺.

Example 83D

2-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 10, substituting 2-(2,2,2-trifluoroethyl)-4-(2-propoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 220 mg, 100%). mp 152-153 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.2 (d, J=6 Hz, 6H), 3.13 (s, 3H), 4.84 (q, J=9 Hz, 2H), 5.49 (p, J=6 Hz, 1H), 7.78 (d, J=9 Hz, 2H), 7.82

(s, 1H), 8.05 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 391 (M+H)⁺. Anal. calc. for C₁₆H₁₇F₃N₂O₄S: C, 49.22; H, 4.38; N, 7.17. Found: C, 49.34; H, 4.25; N, 7.01.

Example 84

5 2-(2,2,2-Trifluoroethyl)-4-cyclohexyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 83, substituting cyclohexanol in place of 2-propanol (yield: 250 mg, 52%). mp 129-130 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.1-1.6 (m, 8H), 1.84 (m, 2H), 3.12 (s, 3H), 4.83 (q, J=9 Hz, 2H), 5.21 (h, J=4.5 Hz, 1H), 7.77 (s, 1H), 7.80 (d, J=9 Hz, 2H), 8.06 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 431 (M+H)⁺. Anal. calc. for C₁₉H₂₁F₃N₂O₄S: C, 53.01; H, 4.91; N, 6.50. Found: C, 52.96; H, 4.84; N, 6.45.

Example 85

15 2-(2,2,2-Trifluoroethyl)-4-cyclopentyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 83, substituting cyclopentanol in place of 2-propanol (yield: 250 mg, 52%). mp 148-150 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.35-1.55 (m, 4H), 1.68-1.75 (m, 4H), 3.12 (s, 3H), 4.83 (q, J=9 Hz, 2H), 5.89 (h, J=4.5 Hz, 1H), 7.75 (d, J=9 Hz, 2H), 7.83 (s, 1H), 8.04 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 417 (M+H)⁺. Anal. calc. for C₁₈H₁₉F₃N₂O₄S: C, 51.91; H, 4.59; N, 6.72. Found: C, 52.04; H, 4.50; N, 6.65.

Example 86

25 2-(2,2,2-Trifluoroethyl)-4-(2-propylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 86A

2-(2,2,2-Trifluoroethyl)-4-(2-propylamino)-5-bromo-3(2H)-pyridazinone

The title compound was prepared according method of the Example 83B, substituting 2-propylamine in place of 2-propanol (yield: 70%). MS (DCI/NH₃) m/z 315 (M+H)⁺.

5

Example 86B

2-(2,2,2-Trifluoroethyl)-4-(2-propylamino)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound was prepared according method of the Example 83C, substituting 2-(2,2,2-trifluoroethyl)-4-(2-propylamino)-5-bromo-3(2H)-pyridazinone in place of 2-(2,2,2-trifluoroethyl)-4-isopropoxy-5-bromo-3(2H)-pyridazinone (yield: 80%).
10 MS (DCI/NH₃) m/z 358 (M+H)⁺.

Example 86C

2-(2,2,2-Trifluoroethyl)-4-(2-propylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

15 The title compound was prepared according to the method of Example 10 , substituting 2-(2,2,2-Trifluoroethyl)-4-(2-propylamino)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 180 mg, 83%). mp 173-174 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.95 (d, J=6 Hz, 6H), 3.13 (s, 3H), 4.81 (q, J=9 Hz, 2H), 5.97 (s, 1H), 7.45 (s, 1H), 7.59 (d, J=9 Hz, 2H),
20 8.03 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 340 (M+H)⁺. Anal. calc. for C₁₆H₁₈F₃N₃O₄S: C, 49.35; H, 4.65; N, 10.79. Found: C, 49.29; H, 4.52; N, 10.65.

Example 87

2-Benzyl-4-(4-morpholino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

25 2-Benzyl-4,5-dichloro-3(2H)-pyridazinone, prepared following the procedure in Example 2, was reacted with morpholine following the procedure of Example 86 to provide the 4-morpholino-derivative. The morpholino intermediate was coupled at the 5-position with 4-(methylthio)phenylboronic acid according to the method of Example 6. The resulting methyl sulfide was oxidized to the title compound according to the method

of Example 10 (yield: 150 mg, 69%). mp 158-160 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.06 (t, J=4.5 Hz, 3H), 3.12 (s, 3H), 3.69 (t, J=4.5 Hz, 3H), 5.33 (s, 2H), 7.35 (m, 3H), 7.5 (m, 4H), 7.58 (s, 1H), 8.05 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 426 (M+H)⁺. Anal. calc. for C₂₂H₂₃N₃O₄S: C, 62.10; H, 5.44; N, 9.87. Found: C, 61.74; H, 5.47; N, 9.59.

Example 88

2-(2,3,3-Trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 88A

1-Methylsulfonyloxy-2,3,3-trifluoro-2-propene

2,3,3-Trifluoro-2-propen-1-ol was prepared as reported in (J. Org.Chem., (1989) 54, 5640-5642). The mesylate was obtained by reacting 2,3,3-trifluoro-2-propen-1-ol with mesyl chloride in diethyl ether. Standard workup provided the product, which was used without purification.

Example 88B

2-(2,3,3-Trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone.

4-(4-Fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone is prepared starting with the 2-benzyl-pyridazinone from Example 9 and debenzylating the compound according to the procedure of Example 11.

A mixture of 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (250 mg, 0.8 mmol), Cs₂CO₃ (650 mg, 2 mmol), and 3-methylsulfonyloxy-1,1,2-trifluoropropene (mesylate, 250 mg, 1.19 mmol) in ethyl acetate (30 mL) was stirred at 55 °C for 1.5 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried with MgSO₄ and filtered. The filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel

eluted with 15% ethyl acetate/hexanes, to provide the methyl sulfide, 2-(2,3,3-trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone as a greenish oil (yield: 175 mg, 53%).

Example 88C

2-(2,3,3-Trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone

The methyl sulfide, prepared above, was oxidized to the title compound according to the method of Example 10 (yield: 125 mg, 68%). mp 154-156 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.07 (s, 3H), 5.1 (ddd, J=21 Hz, 3 Hz, 1.5 Hz, 2H), 6.98 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.35 (d, J=9 Hz, 2H), 7.89 (s, 1H), 7.9 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 439 (M+H)⁺. Anal. calc. for C₂₀H₁₄F₄N₂O₃S: C, 54.79; H, 3.21; N, 6.38. Found: C, 54.52; H, 3.15; N, 6.21.

Example 89

2,4-Bis(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 68 substituting 2,4-bis(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone in place of 2-(2,2,2-trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone (yield: 118 mg, 43%). mp 213-216 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 7.15 (t, 2H), 7.27 (m, 2H), 7.4 (m, 6H), 7.7 (dd, 2H), 7.76 (d, J=9 Hz, 2H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 440 (M+H)⁺, 439.44 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₅FN₂O₃S₂: C, 60.13; H, 3.44; N, 9.56. Found: C, 59.94; H, 3.37; N, 9.46.

Example 90

2-(2,2,2-Trifluoroethyl)-4-cyclopropylmethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 90A

2-(2,2,2-Trifluoroethyl)-4-methoxy-5-bromo-3(2H)-pyridazinone

The title compound was prepared according method of the Example 83B, substituting methanol in place of isopropanol (yield: 78%). ¹H NMR (300 MHz, CDCl₃) δ 4.3 (s, 3H), 4.76 (q, J=9 Hz, 2H), 7.85 (s, 1H). MS (DCI/NH₃) m/z 288 (M+H)⁺.

5

Example 90B2-(2,2,2-Trifluoroethyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound was prepared according method of the Example 83C, substituting 2-(2,2,2-trifluoroethyl)-4-methoxy-5-bromo-3(2H)-pyridazinone in place of 2-(2,2,2-trifluoroethyl)-4-(2-propoxy)-5-bromo-3(2H)-pyridazinone (yield: 80%). ¹H NMR (300 MHz, CDCl₃) δ 2.54 (s, 3H), 4.11 (s, 3H), 4.82 (q, J=9 Hz, 2H), 7.33 (d, J=9 Hz, 2H), 7.48 (d, J=9 Hz, 2H), 7.84 (s, 1H). MS (DCI/NH₃) m/z 331 (M+H)⁺.

10

Example 90C2-(2,2,2-Trifluoroethyl)-4-hydroxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

15

A solution of 2-(2,2,2-Trifluoroethyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (2 g, 6.1 mmol) and hydrobromic acid (40% in water, 20 mL) in acetic acid (40 mL) was heated at reflux for 3 hours. The reaction mixture was cooled to room temperature and water (50 mL) was added. The crystals formed were filtered, washed with water and 5% ethyl acetate in hexanes, and dried to constant weight. The product was obtained as a white solid (yield: 1.75 g, 91%). ¹H NMR (300 MHz, CDCl₃) δ 2.54 (s, 3H), 4.82 (q, J=9 Hz, 2H), 7.47 (d, J=9 Hz, 2H), 7.65 (d, J=9 Hz, 2H), 7.73 (br s, 1H), 8.00 (s, 1H). MS (DCI) m/z 317 (M+H)⁺.

20

25

Example 90D2-(2,2,2-Trifluoroethyl)-4-cyclopropylmethoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

A solution of 2-(2,2,2-trifluoroethyl)-4-hydroxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (150 mg, 0.47 mmol), cyclopropyl methanol (43 mL, 0.52 mmol) and

triphenylphosphine (124 mg, 0.47 mmol) in freshly distilled THF was prepared and added dropwise to diethyl azodicarboxylate (75 mL, 0.52 mmol) at 0 °C. The mixture was allowed to warm to room temperature, stirred for 5 hours and concentrated in vacuo. The residue was purified by chromatography on silica gel (95:5 hexanes/ethyl acetate) to provide the product as a colorless oil (yield: 140 mg, 81%). ¹H NMR (300 MHz, CDCl₃) δ 0.22 (m, 2H), 0.48 (m, 2H), 1.6 (m, 1H), 2.53 (s, 3H), 4.26 (d, J=7.5 Hz, 2H), 4.72 (q, J=9 Hz, 2H), 7.32 (d, J=9 Hz, 2H), 7.55 (d, J=9 Hz, 2H), 7.87 (s, 1H). MS (DCI/NH₃) m/z 371 (M+H)⁺.

Example 90E

10 2-(2,2,2-Trifluoroethyl)-4-cyclopropylmethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of example 10, substituting 2-(2,2,2-trifluoroethyl)-4-cyclopropylmethoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 130 mg, 85%). mp 133-135 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.22 (m, 2H), 0.5 (m, 2H), 1.07 (m, 1H), 3.12 (s, 3H), 4.4 (d, J=9 Hz, 2H), 4.83 (q, J=9 Hz, 2H), 7.79 (s, 1H), 7.83 (d, J=9 Hz, 2H), 8.07 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 403 (M+H)⁺. Anal. calc. for C₁₇H₁₇F₃N₂O₄S: C, 50.74; H, 4.25; N, 6.96. Found: C, 50.56; H, 4.09; N, 6.88.

20

Example 91

2-(2,2,2-Trifluoroethyl)-4-(3-propen-1-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 90, substituting 2-propen-1-ol in place of cyclopropylmethanol (yield: 120 mg, 77%). mp 121-123 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 3H), 4.84 (q, J=12 Hz, 2H), 5.07 (d, J=6 Hz, 2H), 5.21 (dd, J=13.5 Hz, 1 Hz, 1H), 5.27 (dd, J=15 Hz, 1 Hz, 1H), 5.85 (m, 1H), 7.25 (d, J=9 Hz, 2H), 7.83 (s, 1H), 8.06 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 389 (M+H)⁺.

25

Anal. calc. for $C_{16}H_{15}F_3N_2O_4S$: C, 49.48; H, 3.89; N, 7.21. Found: C, 49.24; H, 3.77; N, 7.16.

Example 92

5 2-(2,2,2-Trifluoroethyl)-4-(4-fluoro- α -methylbenzyloxy)-5-[4-(methylsulfonyl)phenyl]-
 3(2H)-pyridazinone

The title compound was prepared according to the method of Example 90, substituting 4-fluoro- α -methylbenzyl alcohol in place of cyclopropylmethanol (yield: 155 mg, 76%). mp 133-135 °C. 1H NMR (300 MHz, $CDCl_3$) δ 1.57 (d, J=6 Hz, 3H), 3.13 (s, 3H), 4.75 (q, J=7.5 Hz, 1H), 4.87 (q, J=7.5 Hz, 1H), 6.34 (q, J=6 Hz, 1H), 6.83 (t, J=9 Hz, 2H), 6.98 (dd, J=9 Hz, 6 Hz, 2H), 7.59 (d, J=9 Hz), 7.70 (s, 1H), 8.03 (d, J=9 Hz, 2H). MS (DCI/ NH_3) m/z 471 (M+H) $^+$. Anal. calc. for $C_{21}H_{18}F_4N_2O_4S$: C, 53.61; H, 3.85; N, 5.95. Found: C, 53.54; H, 3.73; N, 5.86.

10

15 Example 93

2-[4-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
 pyridazinone

A solution of the product from Example 11, 4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (344 mg, 1.0 mmol), 4-bromothioanisole (812 mg, 4.0 mmol), and copper (70 mg, 1.1 mmol) in 20 mL of pyridine was stirred at reflux under a nitrogen atmosphere for 18 hours. After cooling to room temperature, the reaction mixture was diluted with a mixture of water and ethyl acetate. The two layers were filtered through Celite®, and separated. The organic layer was washed with 10% aqueous citric acid, with brine, dried over $MgSO_4$, and filtered. The filtrate was concentrated in vacuo and the residue purified by column chromatography (silica gel, 93:7 dichloromethane/ethyl acetate) to provide the title compound as a foam (yield: 380 mg, 81.5%). 1H NMR (300 MHz, $CDCl_3$) δ 2.55 (s, 3H), 3.05 (s, 3H), 6.98 (t, J=9 Hz, 2H), 7.22 (dd, J=9 Hz, 6 Hz, 2H), 7.38 (dd, J=8 Hz, 2 Hz, 4H), 7.64 (d, J=9 Hz, 2H), 7.91 (d,

20

25

J=9 Hz, 2H), 7.98 (s, 1H). MS (DCI/NH₃) m/z 467 (M+H)⁺. Anal. calc. for C₂₄H₁₉FN₂O₃S₂·0.5 H₂O: C, 60.63; H, 4.21; N, 5.90. Found: C, 60.72; H, 3.96; N, 5.70.

Example 94

5 2,5-Bis[4-(methylsulfonyl)phenyl]-4-(4-fluorophenyl)-3(2H)-pyridazinone

The title compound was prepared by oxidizing the product of Example 93, according to the method of Example 10 (yield: 156 mg, 78%). ¹H NMR (300 MHz, CDCl₃) δ 3.10 (s, 3H), 3.12 (s, 3H), 7.02 (m, 2H), 7.24 (m, 2H), 7.42 (br d, J=9 Hz, 2H), 7.94 (dd, J=9 Hz, 2 Hz, 2H), 8.02 (dd, J=9 Hz, 2 Hz, 2H), 8.10 (m, 3H). MS (DCI/NH₃)
10 m/z 499 (M+H)⁺, 516 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉FN₂O₃S₂·0.5 H₂O: C, 56.80; H, 3.94; N, 5.53. Found: C, 56.50; H, 3.88; N, 5.38.

Example 95

15 2-(3-Methyl-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 2-bromo-3-methylthiophene in place of 4-bromothioanisole (yield: 190 mg, 43%). mp 215-217 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.21 (s, 3H), 3.08 (s, 3H), 6.90 (d, J=9 Hz, 1H), 6.98 (t, J=9 Hz, 2H), 7.24 (dd, J=9 Hz, 6 Hz, 3H), 7.41 (d, J=9 Hz, 2H), 7.94 (d, J=9 Hz, 2H), 7.98 (s, 1H). MS (DCI/NH₃) m/z 441 (M+H)⁺, 458 (M+NH₄)⁺. Anal. calc. for C₂₂H₁₇FN₂O₃S₂·0.5 H₂O: C, 58.80; H, 4.01; N, 6.24. Found: C, 58.85; H, 3.78; N, 5.99.

Example 96

25 2-(2-Trifluoromethyl-4-nitrophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 2-bromo-5-nitrobenzotrifluoride in place of 4-bromothioanisole (yield: 390 mg, 73%). ¹H NMR (300 MHz, CDCl₃) δ 3.08 (s, 3H), 6.98 (t, J=9 Hz, 2H), 7.21 (dd, J=9 Hz, 6 Hz, 2H), 7.43 (d, J=9 Hz, 2H), 7.80 (d, J=9 Hz, 1H), 7.96 (d, J=9 Hz, 2H), 8.02 (s, 1H), 8.61 (dd, J=9

Hz, 3 Hz, 1H), 8.75 (d, J=3 Hz, 1H). MS (DCI/NH₃) m/z 534 (M+H)⁺, 551 (M+NH₄)⁺.
Anal. calc. for C₂₄H₁₅F₄N₃O₅S.0.75 H₂O: C, 52.70; H, 3.02; N, 7.69. Found: C, 52.42; H, 3.04; N, 6.82.

5

Example 97

2-[3-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 3-bromothioanisole in place of 4-bromothioanisole (yield: 355 mg, 76%). mp 196 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.55 (s, 3H), 3.08 (s, 3H), 6.99 (t, J=9 Hz, 2H), 7.23 (dd, J=9 Hz, 6 Hz, 2H), 7.28-7.33 (m, 1H), 7.37-7.49 (m, 2H), 7.40 (d, J=9 Hz, 2H), 7.58 (m, 1H), 7.92 (d, J=9 Hz, 2H), 7.99 (m, 1H). MS (DCI/NH₃) m/z 467 (M+H)⁺, 484 (M+NH₄)⁺.
Anal. calc. for C₂₄H₁₉FN₂O₃S₂: C, 61.80; H, 4.08; N, 6.01. Found: C, 61.56; H, 3.93; N, 5.86.

15

Example 98

2-[3-(Methylsulfonyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared by oxidizing the product of Example 97, according to the method of Example 10 (yield: 98 mg, 65.6%). mp 141-142 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), 3.35 (s, 3H), 7.18 (t, J=9 Hz, 2H), 7.32 (dd, J=9 Hz, 6 Hz, 2H), 7.52 (d, J=9 Hz, 2H), 7.83 (t, J=9 Hz, 1H), 7.95 (d, J=9 Hz, 2H), 8.05 (m, 1H), 8.25 (t, J=1.5 Hz, 1H), 8.33 (s, 1H). MS (DCI/NH₃) m/z 516 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉FN₂O₅S₂.H₂O: C, 55.81; H, 4.07; N, 5.43. Found: C, 56.24; H, 4.29; N, 5.10.

25

Example 99

2-(4-Fluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

4-(4-Chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone is prepared starting with the 2-benzylpyridazinone from Example 53 and debenzylating the compound according to the method of Example 11.

The title compound was prepared according to the method of Example 93, starting
5 with 4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 1-fluoro-4-iodobenzene in place of 4-bromothioanisole (yield: 245 mg, 54%). mp 195-197 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.08 (s, 3H), 7.19 (m, 4H), 7.25 (m, 2H), 7.41 (d, J=9 Hz, 2H), 7.70 (m, 2H), 7.95 (d, J=9 Hz, 2H), 8.01 (s, 1H). MS (DCI/NH₃) m/z 455
10 (M+H)⁺, 472 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆ClFN₂O₃S: C, 60.78; H, 3.52; N, 6.17. Found: C, 60.81; H, 3.53; N, 5.93.

Example 100

2-(5-Chloro-2-thienyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
15 pyridazinone

The title compound was prepared according to Example 93, substituting 4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 2-bromo-5-chlorothiophene in place of 4-bromothioanisole (yield: 150 mg, 45%). mp 249-
20 251 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 6.92 (d, J=9 Hz, 1H), 7.18 (d, J=9 Hz, 2H), 7.31 (d, J=9 Hz, 2H), 7.39 (d, J=9 Hz, 2H), 7.58 (d, J=6 Hz, 1H), 7.94 (d, J=9 Hz, 2 Hz, 2H), 8.04 (s, 1H). MS (DCI/NH₃) m/z 477 (M+H)⁺, 494 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₄Cl₂N₂O₃S₂·H₂O: C, 50.9; H, 3.03; N, 5.60. Found: C, 50.5; H, 2.79; N, 5.26.

Example 101

2-(3-Trifluoromethylphenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
25 pyridazinone

The title compound was prepared according to Example 93, starting with 4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 4-(4-

fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 3-iodobenzotrifluoride in place of 4-bromothioanisole (yield: 210 mg, 59.5%). mp 103-105 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.08 (s, 3H), 7.18 (d, J=9 Hz, 2H), 7.28 (d, J=9 Hz, 2H), 7.41 (d, J=9 Hz, 2H), 7.65 (m, 2H), 7.95 (m, 3H), 8.04 (m, 2H). MS (DCI/NH₃) m/z 505 (M+H)⁺, 525 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₆ClF₃N₂O₃S: C, 57.14; H, 3.17; N, 5.56. Found: C, 56.61; H, 3.28; N, 5.38.

Example 102

2-(3-Chloro-4-fluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, starting with 4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (described in Example 99) in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 1-bromo-3-chloro-4-fluorobenzene in place of 4-bromothioanisole (yield: 330 mg, 58.8%). mp 205 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.10 (s, 3H), 7.17 (d, J=9 Hz, 2H), 7.23-7.31 (m, 1H), 7.28 (d, J=9 Hz, 2H), 7.41 (d, J=9 Hz, 2H), 7.65 (ddd, J=9 Hz, 3 Hz, 1.5 Hz, 1H), 7.85 (dd, J=9 Hz, 3 Hz, 1H), 7.93 (d, J=9 Hz, 2H), 8.01 (s, 1H). MS (DCI/NH₃) m/z 489 (M+H)⁺, 508 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₅Cl₂N₂O₃S: C, 56.44; H, 3.17; N, 5.73. Found: C, 56.37; H, 3.19; N, 5.64.

Example 103

2-(3-Fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 1-fluoro-3-iodobenzene in place of 4-bromothioanisole (yield: 310 mg, 70.8%). mp 245-247 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.08 (s, 3H), 6.98 (t, J=9 Hz, 2H), 7.14 (m, 1H), 7.24 (dd, J=9 Hz, 6 Hz, 2H), 7.40 (m, 2H), 7.52 (m, 3H), 7.92 (d, J=9 Hz, 2H), 8.01 (s, 1H). MS (DCI/NH₃) m/z 439 (M+H)⁺, 456 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆F₂N₂O₃S.0.25 H₂O: C, 62.34; H, 3.67; N, 6.38. Found: C, 62.33; H, 3.68; N, 6.22.

Example 1042-[2-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 2-bromothioanisole in place of 4-bromothioanisole (yield: 280 mg, 60%). mp 206-208 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.49 (s, 3H), 3.08 (s, 3H), 6.95 (t, J=9 Hz, 2H), 7.25 (dd, J=9 Hz, 6 Hz, 2H), 7.29-7.51 (m, 4H), 7.43 (d, J=9 Hz, 2H), 7.92 (d, J=9 Hz, 3H), 8.01 (s, 1H), 7.98 (s, 1H). MS (DCI/NH₃) m/z 467 (M+H)⁺, 484 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉FN₂O₃S₂·H₂O: C, 59.50; H, 4.13; N, 5.79. Found: C, 59.62; H, 4.15; N, 5.52.

Example 1052-(5-Nitro-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 2-bromo-5-nitrothiophene in place of 4-bromothioanisole (yield: 330 mg, 70%). mp 252-253 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.06 (s, 3H), 7.05 (t, J=9 Hz, 2H), 7.25 (dd, J=9 Hz, 6 Hz, 2H), 7.40 (d, J=9 Hz, 2H), 7.71 (d, J=6 Hz, 1H), 7.95 (m, 3H), 8.14 (s, 1H). MS (DCI/NH₃) m/z 472 (M+H)⁺, 489 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₄FN₃O₅S₂·0.5 H₂O: C, 52.50; H, 3.02; N, 8.75. Found: C, 52.79; H, 3.18; N, 8.74.

Example 1062-(3,4-Difluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, starting with 4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 1-bromo-3,4-difluorobenzene in place of 4-bromothioanisole (yield: 310 mg, 65.7%). mp 187-188 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.09 (s, 3H), 7.18 (d, J=9 Hz, 2H), 7.29 (m, 3H), 7.41 (d, J=9 Hz, 2H), 7.52 (m, 1H), 7.65 (m, 1H), 7.92 (d, J=9 Hz, 2H), 8.01 (s, 1H).

MS (DCI/NH₃) m/z 473 (M+H)⁺, 490 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₅ClF₂N₂O₃S.0.5 H₂O: C, 57.38; H, 3.33; N, 5.82. Found: C, 57.44; H, 3.38; N, 5.52.

Example 107

5 2-(3-Benzothieryl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 3-bromobenzothiophene in place of 4-bromothioanisole (yield: 185 mg, 41%). mp 265-267 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.09 (s, 3H), 7.0 (t, J=9 Hz, 2H), 7.27 (dd, J=9 Hz, 6 Hz, 2H), 7.39-7.47 (m, 2H), 7.44 (d, J=9 Hz, 2H), 7.75-7.82 (m, 1H), 7.87-7.94 (m, 2H),
10 7.94 (d, J=9 Hz, 2H), 8.05 (s, 1H). MS (DCI/NH₃) m/z 477 (M+H)⁺, 494 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₇FN₂O₃S₂: C, 63.03; H, 3.57; N, 5.88. Found: C, 62.89; H, 3.55; N, 5.71.

Example 108

15 2-(4-Fluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 108A

4-(4-Fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

20 The title compound was prepared by treating 2-benzyl-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 75) with AlBr₃ in toluene according to the procedure in Example 11 (yield: 1.8 g, 95%).

Example 108B

25 2-(4-Fluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, starting with 4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 1-fluoro-4-iodobenzene in place of 4-bromothioanisole (yield: 60 mg, 53%). mp 83-85 °C.

¹H NMR (300 MHz, CDCl₃) δ 3.10 (s, 3H), 6.89-7.03 (m, 4H), 7.15 (t, J=9 Hz, 2H), 7.65 (dd, J=9 Hz, 6 Hz, 2H), 7.83 (d, J=6 Hz, 2H), 8.07 (d, J=9 Hz, 2H), 8.08 (s, 1H). MS (DCI/NH₃) m/z 455 (M+H)⁺, 472 (M+NH₄)⁺.

5

Example 109

2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 1-bromo-3,4-difluorobenzene in place of 4-bromothioanisole and 4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 108A) in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 185 mg, 39%). mp 178-180 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.11 (s, 3H), 6.89-7.04 (m, 4H), 7.45-7.52 (m, 1H), 7.45-7.52 (m, 1H), 7.61 (dt, J=6 Hz, 3 Hz, 1H), 7.82 (d, J=9 Hz, 2H), 8.07 (d, J=9 Hz, 2H), 8.08 (s, 1H). MS (DCI/NH₃) m/z 473 (M+H)⁺, 490 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₅F₃N₂O₄S.0.5 H₂O: C, 57.38; H, 3.33; N, 5.83. Found: C, 57.17; H, 3.13; N, 5.62.

15

Example 110

2-(3-Bromophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 1,3-dibromobenzene in place of 4-bromothioanisole and 4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 108A) in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 260 mg, 50.5%). mp 208-210 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.09 (s, 3H), 6.89-7.04 (m, 4H), 7.34 (t, J=9 Hz, 1H), 7.53 (br d, J=9 Hz, 1H), 7.64 (br d, J=9 Hz, 1H), 7.82 (d, J=9 Hz, 2H), 7.87 (t, J=1.5 Hz, 1H), 8.08 (d, J=9 Hz, 2H), 8.09 (s, 1H). MS (DCI/NH₃) m/z 517 (M+H)⁺, 534 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆BrFN₂O₄S: C, 53.7; H, 3.11; N, 5.45. Found: C, 53.46; H, 2.88; N, 5.18.

25

Example 1112-(3,5-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 1-bromo-3,4-difluorobenzene in place of 4-bromothioanisole and 4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 108A) in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 175 mg, 37%). mp 209-211 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.10 (s, 3H), 6.85 (tt, J=9 Hz, 3 Hz, 1H), 6.90-7.04 (m, 4H), 7.38 (dd, J=9 Hz, 3 Hz, 2H), 7.81 (d, J=9 Hz, 2H), 8.07 (d, J=9 Hz, 2H), 8.10 (s, 1H). MS (DCI/NH₃) m/z 473 (M+H)⁺, 490 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₃F₃N₂O₄S.H₂O: C, 58.47; H, 3.18; N, 5.94. Found: C, 58.31; H, 3.15; N, 5.82.

Example 1122-(3-Chlorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 93, substituting 1-bromo-3-chlorobenzene in place of 4-bromothioanisole and 4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 108A) in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 25 mg, 5.3%). mp 211-213 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.30 (s, 3H), 7.15 (d, J=9 Hz, 4H), 7.51-7.64 (m, 3H), 7.71-7.75 (m, 1H), 7.91 (d, J=9 Hz, 2H), 8.06 (d, J=9 Hz, 2H), 8.41 (s, 1H). MS (DCI/NH₃) m/z 471 (M+H)⁺, 488 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆ClFN₂O₄S.0.5 H₂O: C, 57.62; H, 3.44; N, 5.85. Found: C, 57.62; H, 3.52; N, 5.48.

Example 1132-(4-Nitrobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 4-nitrobenzyl bromide in place of 4-fluorobenzyl bromide (yield: 164 mg, 58.9%). mp 183-184 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 5.47 (s, 2H), 6.96 (t,

J=9 Hz, 2H), 7.16 (dd, J=9 Hz, 3 Hz, 2H), 7.32 (d, J=9 Hz, 2H), 7.70 (d, J=9 Hz, 2H), 7.87 (s, 1H), 7.88 (d, J=9 Hz, 2H), 8.22 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 480 (M+H)⁺, m/z 497 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈FN₃O₅S: C, 60.12; H, 3.78; N, 8.76. Found: C, 59.89; H, 3.83; N, 8.61.

5

Example 114

2-(4-Acetoxybenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 4-(chloromethyl)phenyl acetate in place of 4-fluorobenzyl bromide (yield: 220 mg, 76.9%). mp 172-174 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.30 (s, 3H), 3.05 (s, 3H), 5.38 (s, 2H), 6.95 (t, J=9 Hz, 2H), 7.06 (d, J=9 Hz, 2H), 7.16 (dd, J=9 Hz, 5 Hz, 2H), 7.31 (d, J=9 Hz, 2H), 7.60 (d, J=9 Hz, 2H), 7.81 (s, 1H), 7.87 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 510 (M+NH₄)⁺. Anal. calc. for C₂₆H₂₁FN₂O₅S: C, 63.40; H, 4.30; N, 5.69. Found: C, 63.28; H, 4.41; N, 5.39.

15

Example 115

2-(4-Hydroxybenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 2-(4-acetoxybenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (0.2 g, 4.06 mmol) (Example 114) in THF (20 mL) was treated with a solution of lithium hydroxide monohydrate (0.05 g, 1.22 mmol) in water (5 mL). Methanol (2 mL) was added to provide a homogeneous solution which was stirred at room temperature overnight. The reaction mixture was then acidified with 10% aqueous citric acid and extracted with ethyl acetate. The ethyl acetate layer was dried over MgSO₄ and filtered. The filtrate was concentrated in vacuo to provide a white foam which was purified by column chromatography (silica gel, 65:35 hexanes/ethyl acetate). Product fractions were combined and concentrated in vacuo. The residue was crystallized from ethyl acetate/hexanes (yield: 195 mg, 70%). mp 225-226 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 4.86 (s, 1H), 5.33 (s, 2H), 6.80 (d, J=8.5 Hz, 2H), 6.95

25

(t, J=9 Hz, 2H), 7.15 (dd, J=9 Hz, 5 Hz, 2H), 7.30 (d, J=8.5 Hz, 2H), 7.46 (d, J=8.5 Hz, 2H), 7.83 (s, 1H), 7.87 (d, J=8.5 Hz, 2H). MS (DCI/NH₃) m/z 451 (M+H)⁺. Anal. calc. for C₂₄H₁₉FN₂O₄S: C, 63.99; H, 4.25; N, 6.22. Found: C, 63.73; H, 4.16; N, 6.11.

5

Example 116

2-(3-Nitrobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 3-nitrobenzyl bromide in place of 4-fluorobenzyl bromide (yield: 195 mg, 70%). mp 156-157 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 5.48 (s, 2H), 6.96 (t, J=9 Hz, 2H), 7.16 (dd, J=9 Hz, 5 Hz, 2H), 7.33 (d, J=8.5 Hz, 2H), 7.54 (t, J=7 Hz, 1H), 7.88 (s, 1H), 7.90 (d, J=8.5 Hz, 2H), 8.19 (br d, J=7 Hz, 1H), 8.37 (t, J=1.7 Hz, 1H). MS (DCI/NH₃) m/z 480 (M+H)⁺, m/z 497 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈FN₃O₅S: C, 60.12; H, 3.78; N, 8.76. Found: C, 59.98; H, 3.73; N, 8.67.

15

Example 117

2-(3,4,4-Trifluoro-3-butenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 4-bromo-1,1,2-trifluoro-1-butene in place of 4-fluorobenzyl bromide (yield: 38 mg, 14.5%). mp 131-132 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.92 (br d, J=21.7 Hz, 2H), 3.06 (s, 3H), 4.47 (t, J=6.6 Hz, 2H), 6.98 (t, J=9 Hz, 2H), 7.17 (dd, J=9 Hz, 5 Hz, 2H), 7.35 (d, J=8.5 Hz, 2H), 7.85 (s, 1H), 7.89 (d, J=8.5 Hz, 2H). MS (DCI/NH₃) m/z 453 (M+H)⁺, m/z 470 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₆F₄N₂O₃S: C, 55.75; H, 3.56; N, 6.19. Found: C, 55.63; H, 3.62; N, 6.10.

25

Example 118

2-(2-Hexynyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 1-chloro-2-hexyne in place of 4-fluorobenzyl bromide (yield: 170 mg, 69%).

mp 79-80 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.99 (t, J=7.5 Hz, 3H), 1.56 (h, J=7.5 Hz, 2H), 2.21 (m, 2H), 3.06 (s, 3H), 5.01 (t, J=3 Hz, 2H), 6.96 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, 6 Hz, 2H), 7.34 (d, J=9 Hz, 2H), 7.88 (s, 1H), 7.89 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 425 (M+H)⁺. Anal. calc. for C₂₃H₂₁FN₂O₃S: C, 65.07; H, 4.98; N, 6.59. Found: C, 64.87; H, 4.90; N, 6.58.

Example 119

2-(3,3-Dichloro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting 1,1,3-trichloropropene in place of 4-fluorobenzyl bromide (yield: 1.15 g, 68%). mp 184-185 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 4.39 (d, J=7.5 Hz, 2H), 6.43 (t, J=7.5 Hz, 1H), 7.14 (t, J=9 Hz, 2H), 7.23 (dd, J=9 Hz, 6 Hz, 2H), 7.38 (d, J=9 Hz, 2H), 7.43 (s, 2H), 7.73 (d, J=9 Hz, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 454 (M+H)⁺. Anal. calc. for C₁₉H₁₄Cl₂F₄N₃O₃S: C, 50.23; H, 3.1; N, 9.24. Found: C, 50.28; H, 3.29; N, 9.19.

Example 120

2-Cyclohexyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20 substituting cyclohexyl bromide in place of 4-fluorobenzyl bromide (yield: 163 mg, 76%). mp 169-171 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.23 (m, 1H), 1.41 (m, 2H), 1.71 (m, 3H), 1.87 (m, 4H), 3.23 (s, 3H), 4.85 (m, 1H), 7.11 (m, 2H), 7.22 (m, 2H), 7.46 (d, J=9 Hz, 2H), 7.85 (d, J=9 Hz, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 427 (M+H)⁺ and m/z 444 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₃FN₂O₃S.0.5 H₂O: C, 63.43; H, 5.55; N, 6.43. Found: C, 63.25; H, 5.28; N, 6.28.

Example 121

2-Cyclopentyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting cyclopentyl bromide in place of 4-fluorobenzyl bromide (yield: 165 g, 80%). mp 191-193 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.67 (m, 2H), 1.85 (m, 4H), 2.05 (m, 2H), 3.23 (s, 3H), 5.36 (m, 1H), 7.12 (t, J=9 Hz, 2H), 7.22 (m, 2H), 7.45 (d, J=9 Hz, 2H), 7.85 (d, J=9 Hz, 2H), 8.13 (s, 1H). MS (DCI/NH₃) m/z 413 (M+H)⁺ and m/z 430 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁FN₂O₃·0.5 H₂O: C, 62.69; H, 5.26; N, 6.57. Found: C, 62.53; H, 4.93; N, 6.50.

Example 122

10 2-Cyclobutyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 20, substituting cyclobutyl bromide in place of 4-fluorobenzyl bromide (yield: 270 g, 68%). mp 202-203 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 1.85 (m, 2H), 2.32 (m, 2H), 2.50 (m, 2H), 5.40 (quintet, J=7 Hz, 1H), 7.11 (t, J=9 Hz, 2H), 7.21 (m, 2H), 7.47 (d, J=9 Hz, 2H), 7.86 (d, J=9 Hz, 2H), 8.16 (s, 1H). MS (DCI/NH₃) m/z 399 (M+H)⁺ and m/z 416 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₉FN₂O₃·0.75 H₂O: C, 61.22; H, 5.01; N, 6.80. Found: C, 61.19; H, 4.62; N, 6.73.

Example 123

20 2-(3-Methyl-2-butenyl)-4-(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone, prepared according to the method of Example 68, was N-debenzylated according to the method of Example 11. The intermediate was N-alkylated according to the method of Example 20, substituting 1-bromo-3-methyl-2-butene in place of 4-fluorobenzyl bromide, to provide the title compound (yield: 50 mg, 30%). mp 134-136 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.79 (s, 3H), 1.86 (s, 3H), 4.78 (s, 2H), 4.85 (d, J=7.5 Hz, 2H), 5.48 (t, J=6 Hz, 1H), 6.96 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, 6 Hz, 2H), 7.28 (d,

J=9 Hz, 2H), 7.83 (s, 1H), 7.85 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 414 (M+H)⁺. Anal. calc. for C₂₁H₂₀FN₃O₃S: C, 61; H, 4.87; N, 10.16. Found: C, 60.98; H, 4.66; N, 9.95.

Example 124

5 2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone, prepared according to the method of Example 68, was N-debenzylated according to the method of Example 11. The intermediate was N-alkylated according to the method of Example 20, substituting 2,4-difluorobenzylbromide in place of 4-fluorobenzyl bromide to provide the title compound (yield: 65 mg, 24%). mp 236-238 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.78 (s, 2H), 5.43 (s, 2H), 6.88 (m, 2H), 6.97 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, 6 Hz, 2H), 7.38 (d, J=9 Hz, 2H), 7.55 (m, 1H), 7.85 (s, 1H), 7.86 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 472 (M+H)⁺. Anal. calc. for C₂₃H₁₆F₃N₃O₃S: C, 58.59; H, 3.42; N, 8.91. Found: C, 58.44; H, 3.47; N, 8.72.

Example 125

20 2-(Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 2,3,4,5,6-pentafluorobenzyl bromide in place of 1-bromo-3-methyl-2-butene (yield: 105 mg, 35%). mp 201-203 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.8 (s, 2H), 5.5 (s, 2H), 6.98 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, 6 Hz, 2H), 7.28 (d, J=9 Hz, 2H), 7.32 (s, 1H), 7.37 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 526 (M+H)⁺. Anal. calc. for C₂₃H₁₃F₆N₃O₃S: C, 52.57; H, 2.49; N, 7.99. Found: C, 52.66; H, 2.68; N, 7.8.

Example 126

25 2-(3-Cyclohexenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 3-bromocyclohexene in place of 1-bromo-3-methyl-2-butene (yield: 30 mg, 10%). mp 206-208 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.75-1.85 (m, 3H), 2.1-2.3 (m, 3H), 4.8 (s, 2H), 5.75 (m, 2H), 6.1 (m, 1H), 6.97 (t, J=9 Hz, 2H), 7.20 (dd, J=9 Hz, 6 Hz, 2H), 7.28 (d, J=9 Hz, 2H), 7.86 (d, J=9 Hz, 2H), 7.90 (s, 1H). MS (DCI/NH₃) m/z 426 (M+H)⁺. Anal. calc. for C₂₂H₂₀FN₃O₃S: C, 62.10; H, 4.73; N, 9.87. Found: C, 61.27; H, 4.75; N, 9.56.

Example 127

2-(3,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 3,4-difluorobenzyl bromide in place of 1-bromo-3-methyl-2-butene and running the reaction in DMSO instead of DMF to prevent formation of byproducts (yield: 210 mg, 62%). mp 253-255 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 5.33 (s, 2H), 7.13 (t, J=9 Hz, 2H), 7.22 (dd, J=9 Hz, 6 Hz, 2H), 7.28 (m, 1H), 7.39 (d, J=9 Hz, 2H), 7.42 (s, 2H), 7.47 (m, 2H), 7.73 (d, J=9 Hz, 2H), 8.12 (s, 1H). MS (DCI/NH₃) m/z 472 (M+H)⁺. Anal. calc. for C₂₃H₁₆F₃N₃O₃S: C, 58.59; H, 3.42; N, 8.91. Found: C, 58.05; H, 3.55; N, 8.49.

Example 128

2-(2,3-Dihydro-1H-inden-2-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (172 mg, 0.5 mmol), prepared in Example 11, 2-indanol (67 mg, 0.5 mmol) and Ph₃P (262 mg, 1 mmol) in toluene (20 mL) and ethyl acetate (5 mL) was prepared and added dropwise a solution of DIAD (0.2 mL, 1 mmol) in toluene (10 mL). The mixture was stirred at room temperature for 6 hours and concentrated in vacuo. The residue was chromatographed (silica gel, 19:1 CH₂Cl₂-ethyl acetate) to provide 200 mg of product

(contaminated with reduced DIAD). A second column chromatography (hexanes-ethyl acetate 1:1) furnished the title product (yield: 170 mg, 74%). mp 97-100 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 3.22 (s, 3H), 3.32 (m, 2H), 3.44 (dd, J=9 Hz and 15 Hz, 2H), 5.83 (m, 1H), 7.25 (m, 4H), 7.34 (m, 4H), 7.46 (d, J=9 Hz, 2H), 7.85 (d, J=9 Hz, 2H), 8.06 (s, 1H). MS (DCI/NH₃) m/z 461 (M+H)⁺ and m/z 478 (M+NH₄)⁺.

Example 129

2-(2,3-Dihydro-1H-inden-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 128 substituting 1-indanol in place of 2-indanol (yield: 110 mg, 48%). mp 128-130 °C. ¹H NMR (DMSO-d₆, 300 MHz) δ 2.40 (m, 1H), 2.60 (m, 1H), 3.00 (m, 1H), 3.22 (s+m, 4H), 6.60 (dd, J=9 Hz, 6 Hz, 1H), 7.16 (m, 4H), 7.27 (m, 4H), 7.47 (d, J=9 Hz, 2H), 7.85 (d, J=9 Hz, 2H), 8.02 (s, 1H). MS (DCI/NH₃) m/z 461 (M+H)⁺ and m/z 478 (M+NH₄)⁺.

Example 130

2-(4-Tetrahydro-2H-pyran-4-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 128 substituting 4-tetrahydropyranol in place of 2-indanol (yield: 140 g, 65%). mp 230-231 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.75 (m, 2H), 1.93 (m, 2H), 3.14 (s, 3H), 3.46 (m, 2H), 3.93 (m, 2H); 5.02 (m, 1H), 7.05 (t, J=9 Hz, 2H), 7.15 (m, 2H), 7.40 (d, J=9 Hz, 2H), 7.80 (d, J=9 Hz, 2H), 8.08 (s, 1H). MS (APCI-) m/z 428 (M-H)⁻ and m/z 463 (M+Cl)⁻. Anal. calc. for C₂₂H₂₁FN₂O₄S.1.25 H₂O: C, 58.59; H, 5.25; N, 6.21. Found: C, 58.31; H, 4.75; N, 6.05.

Example 131

2-(2-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 128 substituting 2-methylcyclopentanol in place of 2-indanol (yield: 230 g, 86%). mp 180-181 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, J=7 Hz, 3H), 1.60 (m, 2H), 1.89 (m, 2H), 2.10 (m, 1H), 2.21 (m, 1H), 2.40 (m, 1H), 3.23 (s, 3H), 5.37 (q, J=7 Hz, 1H), 7.12 (t, J=9 Hz, 2H), 7.21 (m, 2H), 7.47 (d, J=9 Hz, 2H), 7.86 (d, J=9 Hz, 2H), 8.11 (s, 1H). MS (APCI+) m/z 427 (M+H)⁺ and (APCI-) m/z 461 (M+Cl)⁻. Anal. calc. for C₂₃H₂₃FN₂O₃S: C, 64.77; H, 5.43; N, 6.56. Found: C, 64.71; H, 5.34; N, 6.28.

Example 132

10 2-(2-Adamantyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 128 substituting 2-adamantanol in place of 2-indanol, (yield: 75 g, 25%). mp 195-197 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.60 (m, 2H), 1.77 (m, 2H), 1.94 (m, 6H), 2.35 (m, 4H), 3.23 (s, 3H), 4.83 (m, 1H), 7.11 (t, J=9 Hz, 2H), 7.22 (m, 2H), 7.47 (d, J=9 Hz, 2H), 7.87 (d, J=9 Hz, 2H), 8.11 (s, 1H). MS (APCI+) m/z 479 (M+H)⁺ and (APCI-) m/z 478 (M-H)⁻, m/z 513 (M+Cl)⁻. Anal. calc. for C₂₇H₂₇FN₂O₃S.0.25 H₂O: C, 67.13; H, 5.73; N, 5.79. Found: C, 67.06; H, 5.76; N, 5.06.

Example 133

20 2-(3-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 128 substituting 3-methylcyclopentanol in place of 2-indanol (yield: 155 g, 73%). mp 169-171 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.05 (dd, 2:1, 3H), 1.24 (m, 1H), 1.63 (m, 1H), 2.00 (m, 3H), 2.22 (m, 2H), 3.23 (s, 3H), 5.43 (m, 1H), 7.1 (t, J=9 Hz, 2H), 7.21 (m, 2H), 7.46 (d, J=9 Hz, 2H), 7.86 (d, J=9 Hz, 2H), 8.12 (two s, 2:1, 1H). MS (APCI+) m/z 27 (M+H)⁺ and (APCI-) m/z 426 (M-H)⁻, m/z 461 (M+Cl)⁻. Anal. calc. for C₂₇H₂₇FN₂O₃S.0.25 H₂O: C, 64.09; H, 5.49; N, 6.49. Found: C, 64.27; H, 5.62; N, 6.46.

Example 1342-(1-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (206 mg, 0.6 mmol), prepared according to the method of Example 11, 1-methyl-1-cyclopentanol (60 mg, 0.6 mmol), DMAP (18 mg, 0.12 mmol) and Ph_3P (262 mg, 1 mmol) in toluene (30 mL) in ethyl acetate (5 mL) was prepared and added dropwise to a solution of DIAD (0.2 mL, 1 mmol) in 10 mL of toluene. The mixture was stirred at room temperature for 6 hours and then concentrated in vacuo. The residue was chromatographed (silica gel, 19:1 CH_2Cl_2 -ethyl acetate) to provide 80 mg of product (contaminated with reduced DIAD). A second column chromatography (hexanes-ethyl acetate 1:1) furnished the title product, (yield: 50 mg, 19%). mp 107-110 °C. ^1H NMR (DMSO- d_6 , 300 MHz) δ 1.55 (s, 3H), 1.70 (m, 4H), 2.08 (m, 2H), 2.32 (m, 2H), 3.22 (s, 3H), 7.10 (t, J=9 Hz, 2H), 7.20 (m, 2H), 7.45 (d, J=9 Hz, 2H), 7.86 (d, J=9 Hz, 2H), 8.03 (s, 1H). MS (APCI+) m/z 427 (M+H) $^+$ and (APCI-) m/z 426 (M-H) $^-$, m/z 461 (M+Cl) $^-$.

Example 1352-(3,4-Difluorophenyl)-4-(4-fluoro-3-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.Exampel 135A5-Bromo-2-fluorostyrene.

A mixture of methyltriphenylphosphonium bromide (2.14 g, 6 mmol) and potassium t-butoxide (672 mg, 6 mmol) in 50 mL of THF was refluxed for 30 minutes under N_2 and then cooled to room temperature. 5-Bromo-2-fluorobenzaldehyde (1.02 g, 5 mmol) was added and the resulting mixture was refluxed for 2 hours (until the TLC showed the disappearance of starting aldehyde). The reaction was concentrated in vacuo and partitioned between water and ethyl acetate. The acetate layer was washed with water and brine. The solution was dried over MgSO_4 and concentrated in vacuo. The residue

was purified by chromatography (silica gel, 15:1 hexanes-diethyl ether) to provide 900 mg (90%) of 5-bromo-2-fluorostyrene.

Example 135B

5 2-(3,4-Difluorophenyl)-4-(4-fluoro-3-vinylphenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone.

The bromo-styrene compound, Example 135A, in 10 mL of THF was added dropwise to a heated mixture of magnesium turnings (120 mg, 5 mmol) and a few drops of 1,2-dibromoethane in THF (20 mL) at a rate to maintain a gentle reflux. The mixture was
10 refluxed for the next 30 minutes and cooled to room temperature. The Grignard reagent solution was cooled to -78 °C and added, dropwise, to a solution of 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (540 mg, 1.5 mmol) in THF (20 mL). The reaction mixture was allowed to warm to room temperature for 12 hours. Afterwards, a saturated solution of NH₄Cl was added and the mixture was
15 extracted with ethyl acetate to provide 320 mg of crude sulfide.

Example 135C

2-(3,4-Difluorophenyl)-4-(4-fluoro-3-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

20 The sulfide, Example 135B, was dissolved in CH₂Cl₂ (20 mL) and at 0 °C was treated with 30% CH₃CO₃H in CH₃CO₂H (0.5 mL). After 1.5 hours, 10% NaHCO₃ was added and the mixture extracted with CH₂Cl₂. The extract was concentrated in vacuo and the residue purified by chromatography (silica gel, 1:1 hexanes-ethyl acetate) to provide the title compound (yield: 270 mg, 37%). ¹H NMR (DMSO-d₆, 300 MHz) δ 3.22 (s, 3H),
25 5.37 (d, J=12 Hz, 1H), 5.65 (d, J=18 Hz, 1H), 6.77 (dd, J=12 Hz and 18 Hz, 1H), 7.15 (m, 2H), 7.57 (m, 5H), 7.90 (m, 3H), 8.28 (s, 1H). MS (APCI+) m/z 483 (M+H)⁺ and (APCI-) m/z 517 (M+Cl)⁻. Anal. calc. for C₂₅H₁₇F₃N₂O₃S.0.5 H₂O: C, 61.09; H, 3.69; N, 5.69. Found: C, 61.04; H, 3.71; N, 5.34.

Example 1362-(3,4-Difluorophenyl)-4-(6-methyl-3-heptenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A Grignard, prepared as described in Example 135, substituting 2-(2-bromoethyl)-1,3-dioxane (586 mg, 3 mmol) in place of 5-bromo-2-fluorostyrene, was added to a solution of 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (720 mg, 2 mmol) in THF (30 mL) at -78 °C. The mixture was left at room temperature for 14 hours, quenched with a saturated solution of NH₄Cl and extracted with ethyl acetate to obtain 900 mg of crude sulfide.

The intermediate sulfide product was dissolved in CH₂Cl₂ (10 mL) and treated at 0 °C with 33% solution of CH₃CO₃H in CH₃CO₂H (0.7 mL) for 1 hour. The mixture was concentrated in vacuo and the residue was partitioned between saturated NaHCO₃ and ethyl acetate. The acetate layer was dried over MgSO₄ and concentrated in vacuo to provide 950 mg of crude sulfonyl derivative.

The sulfonyl compound, prepared above, was dissolved in acetone (50 mL) and treated with 2 N HCl (10 mL). The resulting mixture was refluxed for 16 hours and concentrated in vacuo. The residue was extracted with ethyl acetate to provide 900 mg of 2-(3,4-difluorophenyl)-4-(2-formylethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (crude aldehyde, contaminated with some unreacted starting dioxane derivative).

A mixture of isoamyltriphenylphosphonium bromide (414 mg, 1 mmol) and potassium t-butoxide (112 mg, 1 mmol) in toluene (25 mL) was refluxed for 30 minutes and then cooled to room temperature. The crude aldehyde was added and the mixture was refluxed for 14 hours. The reaction mixture was then cooled to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate and was washed with water, 10% citric acid, brine, dried over MgSO₄ and concentrated in vacuo. Purification by column chromatography (silica gel, 1:1 hexanes-ethyl acetate) provided the title compound as an oil (yield: 120 mg, 13%). ¹H NMR (300 MHz, DMSO-d₆) δ 0.74 (d, J=7 Hz, 6H), 1.44 (m, 1H), 1.70 (t, J=7 Hz, 2H), 2.22 (m, 2H), 2.54 (m, 2H); 3.30 (s, 3H), 5.29

(m, 2H), 7.51 (m, 1H), 7.63 (m, 1H), 7.74 (d, J=9 Hz, 2H), 7.82 (m, 1H), 8.02 (s, 1H), 8.10 (d, J=9 Hz, 2H). MS (APCI+) m/z 473 (M+H)⁺ and (APCI-) m/z 471 (M-H)⁻, m/z 507 (M+Cl)⁻. Anal. calc. for C₂₃H₂₆F₂N₂O₃S: C, 63.54; H, 5.54; N, 5.92. Found: C, 63.74; H, 5.67; N, 5.58.

5

Example 137

2-(3,4-Difluorophenyl)-4-(3-cyclopropylidenepropyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 136 substituting cyclopropyltriphenylphosphonium bromide in place of isoamyltriphenylphosphonium bromide (yield: 55 mg, 12%). mp 128-129 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.81 (m, 2H), 0.97 (m, 2H), 2.34 (m, 2H), 2.65 (m, 2H), 3.32 (s, 3H), 5.64 (m, 1H), 7.52 (m, 1H), 7.63 (m, 1H), 7.73 (d, J=9 Hz, 2H), 7.81 (m, 1H), 8.02 (s, 1H), 8.10 (d, J=9 Hz, 2H). MS (APCI+) m/z 443 (M+H)⁺ and (APCI-) m/z 441 (M-H)⁻, m/z 477 (M+Cl)⁻. Anal. calc. for C₂₃H₂₀F₂N₂O₃S.0.5 H₂O: C, 61.18; H, 4.68; N, 6.20. Found: C, 61.48; H, 4.60; N, 6.02.

15

Example 138

2-(3,4-Difluorophenyl)-4-(5-methyl-3-hexenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

20

The title compound, an oil, was prepared according to the method of Example 136 substituting isobutyltriphenylphosphonium bromide in place of isoamyltriphenylphosphonium bromide (yield: 170 mg, 74%). ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, J=7 Hz, 6H), 2.22 (m, 3H), 2.54 (m, 2H), 3.32 (s, 3H), 5.12 (m, 2H), 7.52 (m, 1H), 7.60 (m, 1H), 7.72 (d, J=9 Hz, 2H), 7.80 (m, 1H), 8.02 (s, 1H), 8.10 (d, J=9 Hz, 2H). MS (APCI+) m/z 459 (M+H)⁺ and (APCI-) m/z 457 (M-H)⁻, m/z 493 (M+Cl)⁻. Anal. calc. for C₂₄H₂₄F₂N₂O₃S: C, 62.86; H, 5.27; N, 6.10. Found: C, 62.57; H, 5.32; N, 5.81.

25

Example 1392-(3,4-Difluorophenyl)-4-(5-methylhexyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound, an oil, was prepared according to the method of Example 135B, substituting 5-methylhexylmagnesium bromide for 3-fluoro-4-vinylphenylmagnesium bromide, (yield: 28 mg, 10%). ¹H NMR (300 MHz, DMSO-d₆) δ 0.77 (d, J=7 Hz, 6H), 0.88 (m, 1H), 1.03 (m, 2H), 1.20 (m, 1H), 1.46 (m, 5H), 3.32 (s, 3H), 7.52 (m, 1H), 7.62 (m, 1H), 7.75 (d, J=9 Hz, 2H), 7.82 (m, 1H), 8.02 (s, 1H), 8.11 (d, J=9 Hz, 2H). MS (APCI+) m/z 461 (M+H)⁺ and (APCI) m/z 459 (M-H)⁻, m/z 495 (M+Cl)⁻.

Example 1402-(3-Chloro-1-methyl-2E-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 1,3-dichloro-1-butene in place of 2,4-difluorobenzyl bromide (yield: 55 mg, 30%). mp 152-154 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.71 (dt, J=15 Hz, 7.5 Hz, 2H), 2.28 (d, J=1.5 Hz, 3H), 4.8 (s, 2H), 4.99 (d, J=1 Hz, 1H), 5.02 (d, J=1 Hz, 1H), 5.85 (td, J=4 Hz, 1 Hz, 1H), 6.98 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.28 (d, J=9 Hz, 2H), 7.86 (s, 1H), 7.87 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 434 (M+H)⁺. Anal. calc. for C₂₀H₁₇ClFN₃O₃S: C, 55.36; H, 3.94; N, 9.68. Found: C, 54.99; H, 3.83; N, 9.34.

Example 1412-(2,3,3-Trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 1-methylsulfonyloxy-2,3,3-trifluoro-2-propene (mesylate), prepared in Example 88, in place of 2,4-difluorobenzyl bromide (yield: 10 mg, 4%). mp 173-175 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.39 (s, 2H), 5.09 (ddd, J=26 Hz, J=3 Hz, J=1 Hz, 2H), 6.98

(t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, J=6 Hz, 2H), 7.29 (d, J=9 Hz, 2H), 7.78 (s, 1H), 7.78 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 440 (M+H)⁺, MS (F, high res.) m/z calc. for C₁₉H₁₄F₄N₃O₃S: 440.0692 (M+H)⁺. Found: 440.0695 (M+H)⁺, (0.7 ppm error).

5

Example 142

2-(1,1,2-Trifluoro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was isolated from the same reaction mixture (Example 141) that was used to prepare 2-(2,3,3-trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone (The title product is a result of an SN2' attack.) (yield: 50 mg, 20%). mp 230-232 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.7 (s, 2H), 5.28 (dd, J=15 Hz, 4.5 Hz, 1H), 5.39 (dd, J=45 Hz, 4.5 Hz, 1H), 6.98 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.31 (d, J=9 Hz, 2H), 7.9 (d, J=9 Hz, 2H), 7.92 (s, 1H), . MS (DCI/NH₃) m/z 440 (M+H)⁺. Anal. calc. for C₁₉H₁₃F₄N₃O₃S: C, 51.93; H, 2.98; N, 9.56. Found: C, 51.88; H, 3.01; N, 9.15.

15

Example 143

2-(3,3-Difluoro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124 , substituting 1,3-dibromo-1,1-difluoropropane in place of 2,4-difluorobenzyl bromide and employing 5 equivalents of potassium carbonate (yield: 220 mg, 65%). mp 191-194 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 4.77 (d, J=7.5 Hz, 2H), 4.95 (dtd, J=24 Hz, 7.5 Hz, 1 Hz, 1H), 7.12 (t, J=9 Hz, 2H), 7.23 (dd, J=9 Hz, 6 Hz, 2H), 7.49 (d, J=9 Hz, 2H), 7.50 (s, 2H), 7.74 (d, J=9 Hz, 2H), 8.1 (s, 1H). MS (DCI/NH₃) m/z 422 (M+H)⁺. Anal. calc. for C₁₉H₁₄F₃N₃O₃S: C, 54.15; H, 3.34; N, 9.97. Found: C, 53.88; H, 3.42; N, 9.76.

25

Example 144

2-(α -Methyl-3-fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124 , substituting 3-fluoro- α -methylbenzyl chloride in place of 2,4-difluorobenzyl bromide (yield: 220 mg, 65%). mp 192-194 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.76 (d, 6 Hz, 3H), 6.27 (q, J=7 Hz, 1H), 7.1 (t, J=9 Hz, 2H), 7.22 (dd, J=9 Hz, 6 Hz, 2H), 7.49 (d, J=9 Hz, 2H), 7.51 (s, 2H), 7.72 (d, J=9 Hz, 2H), 8.18 (s, 1H). MS (DCI/NH₃) m/z 468 (M+H)⁺. Anal. calc. for C₂₄H₁₉F₂N₃O₃S: C, 61.66; H, 4.09; N, 8.98. Found: C, 61.36; H, 3.96; N, 8.86.

Example 145

2-(1-Cyclohexenylmethyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124 , substituting 1-bromomethylcyclohexene in place of 2,4-difluorobenzyl bromide (yield: 70 mg, 28%). mp 192-193 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.55 (m, 4H), 1.98 (m, 4H), 4.64 (s, 2H), 5.53 (s, 1H), 7.12 (t, J=9 Hz, 2H), 7.22 (dd, J=9 Hz, 6 Hz, 2H), 7.39 (d, J=9 Hz, 2H), 7.39 (s, 2H), 7.72 (d, J=9 Hz, 2H), 8.07 (s, 1H). MS (DCI/NH₃) m/z 440 (M+H)⁺. Anal. calc. for C₂₃H₂₂FN₃O₃S: C, 62.85; H, 5.04; N, 9.56. Found: C, 62.47; H, 5.23; N, 9.14.

Example 146

2-(α -Methyl-2,3,4-trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124 , substituting 2,3,4-trifluoro- α -methylbenzyl chloride in place of 2,4-difluorobenzyl bromide (yield: 70 mg, 50%). mp 192-194 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.84 (d, J=6 Hz, 3H), 4.8 (s, 2H), 6.54 (q, J=7 Hz, 1H), 6.96 (t, J=9 Hz, 2H), 6.99 (m, 1H), 7.18 (dd, J=9 Hz, 6 Hz, 2H), 7.2 (m, 1H), 7.38 (d, J=9 Hz, 2H), 7.86 (d, J=9 Hz, 2H), 7.88 (s,

1H). MS (DCI/NH₃) m/z 504 (M+H)⁺. Anal. calc. for C₂₄H₁₇F₄N₃O₃S: C, 57.25; H, 3.4; N, 8.34. Found: C, 56.84; H, 3.52; N, 7.91.

Example 147

5 2-(α-Methyl-3,5-difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124 , substituting 3,5-difluoro-α-methylbenzyl chloride in place of 2,4-difluorobenzyl bromide (yield: 80 mg, 45%). mp 139-141 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.83 (d, J=6 Hz, 3H), 4.79 (s, 2H), 6.32 (q, J=7 Hz, 1H), 6.84 (m, 1H), 6.97 (t, J=9 Hz, 2H), 7.02 (dd, J=6 Hz, 1.5 Hz, 2H), 7.18 (dd, J=9 Hz, 6 Hz, 2H), 7.28 (d, J=9 Hz, 2H), 7.85 (s, 1H), 7.9 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 486 (M+H)⁺. Anal. calc. for C₂₄H₁₈F₃N₃O₃S: C, 59.37; H, 3.73; N, 8.65. Found: C, 59.00; H, 3.70; N, 8.35.

10

15 Example 148

2-(α-Methyl-3,4-difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 3,4-difluoro-α-methylbenzyl chloride in place of 2,4-difluorobenzyl bromide (yield: 200 mg, 58%). mp 214-215 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.82 (d, J=6 Hz, 3H), 4.7 (s, 2H), 6.35 (q, J=7 Hz, 1H), 6.96 (t, J=9 Hz, 2H), 7.16 (m, 4H), 7.28 (d, J=9 Hz, 2H), 7.37 (m, 1H), 7.84 (d, J=9 Hz, 2H), 7.90 (s, 1H). MS (DCI/NH₃) m/z 486 (M+H)⁺. Anal. calc. for C₂₄H₁₈F₃N₃O₃S: C, 59.37; H, 3.73; N, 8.65. Found: C, 59.13; H, 3.73; N, 8.54.

20

25

Example 149

2-(3-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124 , substituting 3-fluorobenzyl bromide in place of 2,4-difluorobenzyl bromide (yield: 160

mg, 61%). mp 220-222 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 5.37 (s, 2H), 7.12 (t, J=9 Hz, 2H), 7.22 (m, 5H), 7.39 (m, 5H), 7.73 (d, J=9 Hz, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 454 (M+H)⁺. Anal. calc. for C₂₃H₁₇F₂N₃O₃S: C, 60.92; H, 3.77; N, 9.26. Found: C, 61.06; H, 4.22; N, 8.88.

5

Example 150

2-(4-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 4-fluorobenzyl bromide in place of 2,4-difluorobenzyl bromide (yield: 85 mg, 34%). mp 237-239 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 5.32 (s, 2H), 7.12 (t, J=9 Hz, 2H), 7.22 (m, 4H), 7.38 (m, 4H), 7.47 (dd, J=9 Hz, 6 Hz, 2H), 7.72 (d, J=9 Hz, 2H), 8.10 (s, 1H). MS (DCI/NH₃) m/z 454 (M+H)⁺. Anal. calc. for C₂₃H₁₇F₂N₃O₃S: C, 60.92; H, 3.77; N, 9.26. Found: C, 60.61; H, 3.96; N, 8.74.

15

Example 151

2-(2,4,6-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 2,4,6-trifluorobenzyl bromide in place of 2,4-difluorobenzyl bromide (yield: 255 mg, 73%). mp 201-203 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 5.38 (s, 2H), 7.13 (t, J=9 Hz, 2H), 7.23 (m, 4H), 7.38 (d, J=9 Hz, 2H), 7.42 (s, 2H), 7.70 (d, J=9 Hz, 2H), 8.08 (s, 1H). MS (DCI/NH₃) m/z 490 (M+H)⁺. Anal. calc. for C₂₃H₁₅F₄N₃O₃S: C, 56.44; H, 3.08; N, 8.58. Found: C, 56.31; H, 3.09; N, 8.40.

25

Example 152

2-(2,4,5-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124, substituting 2,4,5-trifluorobenzyl bromide in place of 2,4-difluorobenzyl bromide (yield:

180 mg, 49%). mp 236-238 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 5.35 (s, 2H), 7.13 (t, J=9 Hz, 2H), 7.23 (dd, J=9 Hz, 6 Hz, 2H), 7.39 (d, J=9 Hz, 2H), 7.41 (s, 2H), 7.6 (m, 2H), 7.72 (d, J=9 Hz, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 490 (M+H)⁺. Anal. calc. for C₂₃H₁₅F₄N₃O₃S: C, 56.44; H, 3.08; N, 8.58. Found: C, 56.38; H, 3.28; N, 8.41.

5

Example 153

2-(2,3,4-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124 ,
10 substituting 2,3,4-trifluorobenzyl bromide in place of 2,4-difluorobenzyl bromide (yield: 220 mg, 63%). mp 218-220 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 5.40 (s, 2H), 7.13 (t, J=9 Hz, 2H), 7.22 (dd, J=9 Hz, 6 Hz, 2H), 7.34 (m, 2H), 7.39 (d, J=9 Hz, 2H), 7.42 (s, 2H), 7.73 (d, J=9 Hz, 2H), 8.12 (s, 1H). MS (DCI/NH₃) m/z 490 (M+H)⁺. Anal. calc. for C₂₃H₁₅F₄N₃O₃S: C, 56.44; H, 3.08; N, 8.58. Found: C, 56.32; H, 3.24; N, 8.31.

15

Example 154

2-(4,4,4-Trifluoro-3-methyl-2E-butenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 124,
20 substituting 1-bromo-3-methyl-4,4,4-trifluoro-2-butene in place of 2,4-difluorobenzyl bromide (yield: 160 mg, 48%). mp 155-157 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.00 (s, 3H), 4.8 (s, 2H), 4.96 (d, J=7.5 Hz, 2H), 6.33 (m, 1H), 6.99 (t, J=9 Hz, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.29 (d, J=9 Hz, 2H), 7.95 (s, 1H), 7.97 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 468 (M+H)⁺. Anal. calc. for C₂₁H₁₇F₄N₃O₃S: C, 53.96; H, 3.66; N, 8.98. Found: C, 53.84; H, 3.51; N, 8.77.

25

Example 155

2-(4-Biphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 4-bromobiphenyl in place of 4-iodo-1-fluorobenzene (yield: 0.275 g, 100%). mp 249-251 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.16 (m, 2H), 7.30 (m, 2H), 7.42 (m, 1H), 7.48-7.58 (m, 4H), 7.75 (m, 4H), 7.84 (m, 2H), 7.91 (m, 2H), 8.27 (s, 1H). MS (DCI/NH₃) m/z 497 (M+H)⁺, 514 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₁FN₂O₃S: C, 70.15; H, 4.26; N, 5.64. Found: C, 69.81; H, 4.42; N, 5.41.

Example 156

2-(4-Bromophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1,4-dibromobenzene in place of 4-iodo-1-fluorobenzene (yield: 0.337 g, 93%). ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.14 (m, 2H), 7.28 (m, 2H), 7.64 (m, 2H), 7.75 (m, 2H), 7.90 (m, 2H), 8.25 (s, 1H). MS (DCI/NH₃) m/z 499 (M+H)⁺, 518 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆BrFN₂O₃S.0.75 H₂O: C, 53.86; H, 3.43; N, 5.46. Found: C, 53.92; H, 3.16; N, 5.34.

Example 157

2-(4-Nitrophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1-iodo-4-nitrobenzene in place of 4-iodo-1-fluorobenzene (yield: 0.45 g, 100%). mp 110-116 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.17 (m, 2H), 7.32 (m, 2H), 7.53 (m, 2H), 7.91 (m, 2H), 8.03 (m, 2H), 8.34 (s, 1H), 8.40 (m, 2H). MS (DCI/NH₃) m/z 466 (M+H)⁺, 483 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆FN₃O₅S: C, 59.35; H, 3.46; N, 9.03. Found: C, 59.02; H, 3.62; N, 8.82.

Example 158

2-(4-Phenoxyphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 4-bromodiphenylether in place of 4-iodo-1-fluorobenzene (yield: 0.667 g, 22%). mp 118-125 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.12 (m, 5H), 7.15-7.33 (m, 4H), 7.46 (m, 2H), 7.52 (m, 2H), 7.65 (m, 2H), 7.90 (m, 2H), 8.23 (s, 1H). MS (DCI/NH₃) m/z 513 (M+H)⁺. Anal. calc. for C₂₅H₂₁FN₂O₄S.0.75 H₂O: C, 66.21; H, 4.31; N, 5.32. Found: C, 65.98; H, 4.25; N, 5.27.

Example 159

2-(4-t-Butylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1-bromo-4-t-butyl-benzene in place of 4-iodo-1-fluorobenzene. No product was observed. The solution was concentrated in vacuo. The resulting solid was dissolved in DMF (5 mL) and CuI (13.3 mg, 0.07 mmol) was added. The solution was allowed to reflux overnight. Upon completion, the mixture was poured into 10% citric acid and extracted with ethyl acetate. The organic layer was washed with water, dried over MgSO₄ and concentrated in vacuo. The crude solid was purified using flash chromatography (SiO₂), eluting with 5% diethyl ether/CH₂Cl₂ to provide the desired product (yield: 0.292 g, 84%). mp 132-136 °C. ¹H NMR (300 MHz, DMSO d₆) δ 1.34 (s, 9H), 3.24 (s, 3H), 7.14 (m, 2H), 7.29 (m, 2H), 7.54 (m, 6H), 7.90 (m, 2H), 8.23 (s, 1H). MS (DCI/NH₃) m/z 477 (M+H)⁺, 494 (M+NH₄)⁺. Anal. calc. for C₂₇H₂₅FN₂O₃S: C, 68.05; H, 5.29; N, 5.88. Found: C, 67.94; H, 5.31; N, 5.67.

Example 160

2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 4-bromo-1-chlorobenzene in place of 4-iodo-1-fluorobenzene (yield: 0.254 g, 83.5%). mp 214-216 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.24 (s, 3H), 7.16 (m, 2H), 7.29 (m, 2H), 7.52 (m, 2H), 7.61 (m, 2H), 7.71 (m, 2H), 7.91 (m, 2H), 8.26 (s, 1H). MS

(DCI/NH₃) m/z 455 (M+H)⁺, 472 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆ClFN₂O₃S : C, 60.73; H, 3.55; N, 6.16. Found: C, 60.45, H, 3.41; N, 6.05.

Example 161

5 2-(3-Methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3-bromotoluene in place of 4-iodo-1-fluorobenzene (yield: 0.262 g, 83%). mp 213-216 °C. ¹H NMR (300 MHz, DMSO d₆) δ 2.39 (s, 3H), 3.24 (s, 3H), 7.14 (m, 2H), 7.28 (m, 3H), 7.43 (m, 3H), 7.53 (m, 2H), 7.80 (m, 2H), 8.22 (s, 1H). MS (DCI/NH₃) m/z 10 435 (M+H)⁺, 452 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉FN₂O₃S : C, 66.35; H, 4.41; N, 6.45. Found: C, 66.00, H, 4.16; N, 6.23.

Example 162

15 2-(3-Vinylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3-bromostyrene in place of 4-iodo-1-fluorobenzene (yield: 0.202 g, 62%). mp 182-183 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.25 (s, 3H), 5.35 (d, J=12 Hz, 1H), 5.92 (d, J=15 Hz, 1H), 6.82 (m, 1H), 7.15 (m, 2H), 7.30 (m, 2H), 7.50-7.60 (m, 4H), 7.74 (m, 1H), 7.91 (m, 2H), 8.24 (s, 1H). MS (DCI/NH₃) m/z 447 (M+H)⁺, 464 (M+NH₄)⁺. Anal. 20 calc. for C₂₅H₁₉FN₂O₃S.0.50 H₂O: C, 65.92; H, 4.42; N, 6.14. Found: C, 65.86; H, 4.40; N, 6.07.

Example 163

25 2-(2-Formylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title was prepared according to the method of Example 62 substituting 2-bromobenzaldehyde in place of 4-iodo-1-fluorobenzene (yield: 0.196 g, 60%). mp 234-236 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.15 (m, 2H), 7.27 (m, 2H), 7.54 (m, 2H), 7.64-7.75 (m, 2H), 7.86-7.95 (m, 3H), 8.01 (m, 1H), 8.29 (s, 1H), 10.02 (s, 1H).

MS (DCI/NH₃) m/z 449 (M+H)⁺. Anal. calc. for C₂₄H₁₇FN₂O₄S.0.50 H₂O: C, 63.01; H, 3.96; N, 6.12. Found: 63.04; H, 3.82; N, 5.88.

Example 164

5 2-(2-Nitrophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1-bromo-2-nitrobenzene in place of 4-iodo-1-fluorobenzene (yield: 0.307 g, 90.8%). mp 236-239 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.12-7.27 (m, 4H), 7.56 (m, 2H), 7.7-8.01 (m, 5H), 8.18 (m, 1H), 8.35 (s, 1H). MS (DCI/NH₃) m/z 466 (M+H)⁺, 483 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆FN₃O₅S.0.25 H₂O: C, 58.78; H, 3.53; N, 8.94. Found: C, 58.63; H, 3.54; N, 8.88.

Example 165

15 2-(3-Chlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1-bromo-3-chlorobenzene in place of 4-iodo-1-fluorobenzene (yield: 0.255 g, 77%). mp 232-235 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.23 (s, 3H), 7.14 (m, 2H), 7.29 (m, 2H), 7.49-7.58 (m, 4H), 7.66 (m, 1H), 7.79 (m, 1H), 7.90 (m, 2H), 8.25 (s, 1H). MS (DCI/NH₃) m/z 455 (M+H)⁺, 472 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆ClFN₂O₃S: C, 60.73; H, 3.55; N, 6.16. Found: C, 60.40; H, 3.43; N, 5.98.

Example 166

25 2-(3-Bromophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1,3 dibromobenzene in place of 4-iodo-1-fluorobenzene (yield: 0.216 g, 60%). mp 210-212 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.23 (s, 3H), 7.15 (m, 2H), 7.29 (m, 2H), 7.48-7.55 (m, 3H), 7.69 (m, 2H), 7.90 (m, 3H), 8.26 (s, 1H). MS (DCI/NH₃) m/z 499 (M+H)⁺, 519 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆BrFN₂O₃S: C, 55.32; H, 3.23; N, 5.61. Found: C, 55.12; H, 3.12; N, 5.51.

Example 1672-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 4-bromobenzonitrile in place of 4-iodo-1-fluorobenzene (yield: 0.349 g, 100%). mp 273-278 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.11-7.21 (m, 2H), 7.25-7.35 (m, 2H), 7.52 (m, 2H), 7.88-7.96 (m, 4H), 8.04 (m, 2H), 8.31 (s, 1H). MS (DCI/NH₃) m/z 445 (M+H)⁺. Anal. calc. for C₂₄H₁₆FN₃O₃S: C, 64.71; H, 3.62; N, 9.43. Found: C, 64.50; H, 3.53; N, 9.35.

Example 1682-(5-Methyl-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 2-bromo-5-methylthiophene in place of 4-iodo-1-fluorobenzene (yield: 0.200 g, 62%). mp 219-224 °C. ¹H NMR (300 MHz, DMSO d₆) δ 2.45 (s, 3H), 3.23 (s, 3H), 6.80 (m, 1H), 7.17 (m, 2H), 7.29 (m, 2H), 7.52 (m, 3H), 7.89 (m, 2H), 8.33 (s, 1H). MS (DCI/NH₃) m/z 441 (M+H)⁺, 458 (M+NH₄)⁺. Anal. calc. for C₂₂H₁₇FN₂O₃S₂: C, 59.99; H, 3.89; N, 6.36. Found: C, 59.90; H, 3.91; N, 6.26.

Example 1692-(3-Biphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3-bromobiphenyl in place of 4-iodo-1-fluorobenzene (yield: 0.28 g, 78%). mp 126-134 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.15 (m, 2H), 7.31 (m, 2H), 7.37-7.45 (m, 1H), 7.51 (m, 4H), 7.64 (m, 2H), 7.68-7.79 (m, 3H), 7.92 (m, 3H), 8.27 (s, 1H). MS (DCI/NH₃) m/z 497 (M+H)⁺, 514 (M+NH₄)⁺. Anal. calc. for C₂₉H₂₁FN₂O₃S: C, 70.15; H, 4.26; N, 5.64. Found: C, 69.91; H, 4.33; N, 5.74.

Example 1702-(3,5-Dimethylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 5-bromo-m-xylene in place of 4-iodo-1-fluorobenzene (yield: 0.152 g, 46.5%). mp 130-134 °C. ¹H NMR (300 MHz, DMSO d₆) δ 2.34 (s, 6H), 3.23 (s, 3H), 7.07-7.12 (m, 2H), 7.15 (m, 1H), 7.21-7.32 (m, 4H), 7.52 (m, 2H), 7.90 (m, 2H), 8.29 (s, 1H). MS (DCI/NH₃) m/z 449 (M+H)⁺, 466 (M+NH₄)⁺. Anal. calc. for C₂₅H₂₁FN₂O₃S : C, 66.95; H, 4.72; N, 6.25. Found: C, 66.81; H, 4.57; N, 6.07.

Example 1712-(3,4-Difluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

4-(4-Fluorophenylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 11, starting with 2-benzyl-4-(4-fluorophenylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.3319 g, 83%).

The title compound was prepared according to the method of Example 62 substituting 4-(4-fluorophenylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 1-bromo-3,4-difluorobenzene in place of 4-iodo-1-fluorobenzene (yield: 0.085 g, 54%). mp 157-159 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.30 (s, 3H), 3.88 (bs, 2H), 7.04 (m, 4H), 7.49-7.66 (m, 2H), 7.70 (m, 2H), 7.81 (m, 1H), 8.12 (s, 1H). MS (DCI/NH₃) m/z 471 (M+H)⁺, 488 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₇F₃N₂O₃S.0.25 H₂O: C, 60.69; H, 3.71; N, 5.84. Found: C, 6.39; H, 3.76; N, 5.81.

Example 172

2-(3-Chloro-4-fluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 4-(4-fluorophenylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 4-bromo-2-chloro-1-fluorobenzene in place of 4-iodo-1-fluorobenzene (yield: 0.110 g, 74%). mp 153-156 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.30 (s, 3H), 3.89 (bs, 2H), 7.02-7.07 (m, 4H), 7.59 (m, 1H), 7.65-7.72 (m, 4H), 8.07 (m, 2H), 8.12 (s, 1H). MS (DCI/NH₃) m/z 487 (M+H)⁺, 504 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₇ClF₂N₂O₃S·0.25 H₂O: C, 58.65; H, 3.58; N, 5.64. Found: C, 58.41; H, 3.56; N, 5.36.

Example 173

2-(2-Thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 2-bromothiophene in place of 1-bromo-4-fluorobenzene (yield: 98 mg, 40%). mp 215-217 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), 7.18 (m, J=9 Hz, 3H), 7.29 (m, 2H), 7.42 (d, 2H), 7.75 (d, 1H), 7.93 (d, J=9 Hz), 8.4 (s, 1H). MS (DCI/NH₃) m/z 427 (M+H)⁺, 444 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₃FN₂O₃S₂: C, 59.14; H, 3.54; N, 6.57.

Example 174

2-(4-Trifluoromethylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1-bromo-4-trifluoromethylbenzene in place of 1-bromo-4-fluorobenzene (yield: 185 mg, 64%). mp 171-173 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), 7.18 (t, 2H), 7.29 (m, 2H), 7.52 (d, J=9 Hz, 2H), 7.91 (d, J=9 Hz, 2H), 7.93 (s, 4H), 8.32 (s, 1H). MS (DCI/NH₃) m/z 489 (M+H)⁺, 506 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₆F₄N₂O₃S: C, 59.02; H, 3.3; N, 5.74. Found: C, 58.75; H, 3.35; N, 5.69.

Example 1752-[4-(1-Pyrrolyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1-(4-iodophenyl)pyrrole in place of 1-bromo-4-fluorobenzene (yield: 140 mg, 50%). mp 229-231 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), 6.3 (t, 2H), 7.18 (t, 2H), 7.29 (m, 2H), 7.46 (t, 2H) 7.53 (d, J=9 Hz 2H), 7.75 (s, 4H), 7.91 (d, J=9 Hz, 2H), 8.27 (s, 1H). MS (DCI/NH₃) m/z 486 (M+H)⁺, 504 (M+NH₄)⁺. Anal. calc. for C₂₇H₂₀FN₃O₃S.0.5 H₂O: C, 66.79; H, 4.15; N, 8.65. Found: C, 65.21; H, 4.29; N, 8.12.

Example 1762-(5-Chloro-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 2-bromo-5-chlorothiophene in place of 1-bromo-4-fluorobenzene (yield: 225 mg, 93%). mp 190-192 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.38 (s, 3H), δ 3.25 (s, 3H), 7.15 (t, 2H), 7.29 (m, 4H), 7.5 (D, 4H) 7.91 (d, J=9 Hz, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 435 (M+H)⁺, 452 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉ClF N₂O₃S: C, 66.35; H, 4.41; N, 6.45. Found: C, 66.15; H, 4.37; N, 6.3.

Example 1772-(4-Methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1-bromo-4-methylbenzene in place of 1-bromo-4-fluorobenzene (yield: 79 mg, 31%). mp 190-192 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.38 (s, 3H), δ 3.25 (s, 3H), 7.15 (t, 2H), 7.29 (m, 4H), 7.5 (D, 4H) 7.91 (d, J=9 Hz, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 435 (M+H)⁺, 452 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉F N₂O₃S: C, 66.35; H, 4.41; N, 6.45. Found: C, 66.15; H, 4.37; N, 6.3.

Example 1782-(4-Fluorophenyl)-4-(2-ethyl-1-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a solution of 2-ethyl-1-hexanol (65 mg, 0.5 mmol) in THF (15 mL) at room temperature was added NaH (60% oil suspension) (20 mg, 0.5 mmol) and after 10 minutes 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (193 mg, 0.5 mmol) was added. The resulting mixture was stirred at room temperature for the next 2 hours. The mixture was quenched with 10% citric acid and extracted with ethyl acetate. The extract was washed with water, brine, dried with MgSO_4 , and purified by chromatography (silica gel, 2:1 hexanes-ethyl acetate) to provide the desired product (yield: 140 mg, 60%). mp 120-122 °C. ^1H NMR (300 MHz, DMSO-d_6) δ 0.75 (m, 6H), 1.1 (m, 6H), 1.20 (quintet, $J=7$ Hz, 2H), 1.44 (m, 1H), 3.27 (s, 3H), 4.30 (d, $J=6$ Hz, 2H), 7.37 (t, $J=9$ Hz, 2H), 7.65 (m, 2H), 7.89 (d, $J=9$ Hz, 2H), 8.06 (d, $J=9$ Hz, 2H), 8.18 (s, 1H). MS (APCI+) m/z 473 ($\text{M}+\text{H}$) $^+$; (APCI-) m/z 507 ($\text{M}+\text{Cl}$) $^-$. Anal. calc. for $\text{C}_{25}\text{H}_{29}\text{FN}_2\text{O}_4\text{S}\cdot 0.5 \text{H}_2\text{O}$: C, 62.35; H, 6.27; N, 5.87. Found: C, 62.22; H, 6.14; N, 6.22.

Example 1792-(3-Thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3-bromothiophene in place of 1-bromo-4-fluorobenzene (yield: 225 mg, 93%). mp 200-202 °C. ^1H NMR (300 MHz, DMSO-d_6) δ 3.25 (s, 3H), 7.15 (t, 2H), 7.29 (m, 2H), 7.5 (d, $J=9$ Hz, 2H), 7.6 (M, 1H) 7.66 (dd, 1H), 7.91 (d, $J=9$ Hz, 2H), 8.13 (dd, 1H), 8.25 (s, 1H). MS (DCI/ NH_3) m/z 427 ($\text{M}+\text{H}$) $^+$, 444 ($\text{M}+\text{NH}_4$) $^+$. Anal. calc. for $\text{C}_{21}\text{H}_{13}\text{FN}_2\text{O}_3\text{S}_2$: C, 55.07; H, 4.07; N, 6.11. Found: C, 54.63; H, 3.47; N, 6.01.

Example 1802-(3,5-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3,5-difluorobromobenzene in place of 1-bromo-4-fluorobenzene (yield: 250 mg, 96%). mp 166-168 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), δ 7.15 (t, 2H), 7.27 (m, 2H), 7.4 (m, 1H), 7.41 (m, 2H), 7.51 (d, J=9 Hz, 4H), 7.9 (d, J=9 Hz, 2H), 8.3 (s, 1H). MS (DCI/NH₃) m/z 457 (M+H)⁺, 474 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₃F₃N₂O₃S: C, 60.13; H, 3.31; N, 6.14. Found: C, 60.49; H, 3.31; N, 6.03.

Example 181

2-(2,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 2,4-difluorobromobenzene in place of 1-bromo-4-fluorobenzene (yield: 40 mg, 15%). mp 245-247 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.23 (s, 3H), δ 7.15 (t, 2H), 7.3 (t, 2H), 7.54 (m, 2H), 7.57 (m, 2H), 7.75 (m, 1H), 7.9 (d, J=9 Hz, 2H), 8.27 (s, 1H). MS (DCI/NH₃) m/z 457 (M+H)⁺, 474 (M+NH₄)⁺. Anal. calc. for C₂₈H₁₅F₃N₂O₃S: C, 60.52; H, 3.31; N, 6.03.

Example 182

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3,4-difluorobromobenzene in place of 1-bromo-4-fluorobenzene (yield: 170 mg, 70%). mp 109-110 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.23 (s, 3H), δ 7.15 (t, 2H), 7.3 (t, 2H), 7.25 (m, 2H), 7.59 (m, 4H), 7.83 (m, 1H), 7.9 (d, J=9 Hz, 2H), 8.27 (s, 1H). MS (DCI/NH₃) m/z 457 (M+H)⁺, 474 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₃F₃N₃O₃S: C, 60.52; H, 3.31; N, 6.14. Found 60.60; H, 3.48; N, 5.89

Example 183

2-(3-Furyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3-bromofuran in place of 1-bromo-4-fluorobenzene (yield: 175 mg, 73%). mp 239-242 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), 7.09 (d, 1H), 7.15 (t, 2H), 7.29 (m, 2H), 7.5 (d, J=9 Hz, 2H), 7.8 (t, 1H), 7.91 (d, J=9 Hz, 2H), 8.3 (s, 1H), 8.58 (s, 1H). MS (DCI/NH₃) m/z 411 (M+H)⁺, 428 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₅F N₂O₄S.0.5 H₂O: C, 61.46; H, 3.68; N, 6.83. Found: C, 59.91; H, 3.54; N, 6.54.

Example 184

2-(3-Fluoro-4-methoxyphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3-fluoro-4-methoxybromobenzene in place of 1-bromo-4-fluorobenzene (yield: 230 mg, 85%). mp 97-101 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), 3.9 (s, 3H), 7.16 (d, 1H), 7.29 (m, 3H), 7.5 (m, 4H), 7.91 (d, J=9 Hz, 2H), 8.23 (s, 1H). MS (DCI/NH₃) m/z 469 (M+H)⁺, 491 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈F₂N₂O₄S.0.5 H₂O: C, 61.53; H, 3.87; N, 5.98. Found: C, 61.18; H, 4.01; N, 5.58.

Example 185

2-(2-Fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 2-fluorobromobenzene in place of 1-bromo-4-fluorobenzene (yield: 195 mg, 75%). mp 96-103 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.23 (s, 3H), δ 7.15 (t, 2H), 7.3 (m, 3H), 7.55 (m, 5H), 7.9 (d, J=9 Hz, 2H), 8.27 (s, 1H). MS (ESI) m/z 437 (M-H)⁺. Anal. calc. for C₂₃H₁₆F₂N₂O₃S: C, 63.01; H, 3.68; N, 6.39. Found: C, 62.91; H, 4.06; N, 5.99.

Example 186

2-[4-(Aminosulfonyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 4-aminosulfonyl-1-bromobenzene in place of 1-bromo-4-fluorobenzene. mp 213-216 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), 7.15 (t, 2H), 7.29 (m, 2H), 7.53 (s, 2H) 7.55 (s, 1H), 7.7 (dd, 2H) 7.91 (t, 4H), 7.98 (d, 2H), 8.3 (s, 1H). MS (DCI/NH₃) m/z 499 (M+H)⁺, 517 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₈FN₃O₅S₂·0.5 H₂O: C, 55.30; H, 3.63; N, 8.41. Found: C, 54.4; H, 3.79; N, 7.78.

Example 187

2-(3-Chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3-chloro-4-fluoro-1-bromobenzene in place of 1-bromo-4-fluorobenzene (yield: 320 mg, 78%). mp 155-157 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.23 (s, 3H), δ 7.15 (t, 2H), 7.3 (t, 2H), 7.25 (m, 2H), 7.53 (d, J=9 Hz, 2H), 7.59 (t, 1H), 7.73 (m, 1H), 7.9 (d, J=9 Hz, 2H) 7.96 (m, 1H), 8.27 (s, 1H). MS (DCI/NH₃) m/z 473 (M+H)⁺, 490 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₅ClF₂N₂O₃S: C, 58.42; H, 3.2; N, 5.92. Found 58.23; H, 2.87; N, 5.70

Example 188

2-(3,5-Dichlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 3,5-dichlorobenzene in place of 1-bromo-4-fluorobenzene (yield: 360 mg, 78%). mp 289-294 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.25 (s, 3H), δ 7.15 (t, 2H), 7.27 (m, 2H), 7.51 (d, J=9 Hz, 4H), 7.75 (t, 1H), 7.83 (d, 2H), 7.9 (d, J=9 Hz, 2H), 8.3 (s, 1H). MS (DCI/NH₃) m/z 490 (M+H)⁺, 507 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₅Cl₂FN₂O₃S·0.5 H₂O: C, 56.45; H, 3.09; N, 5.72. Found: C, 55.36; H, 3.00; N, 5.50.

Example 189

2-(4-Fluoro-3-methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62 substituting 1-bromo-4-fluoro-3-methylbenzene in place of 1-bromo-4-fluorobenzene (yield: 275 mg, 71%). mp 168-170 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.3 (s, 3H), δ 3.25 (s, 3H), 7.15 (t, 2H), 7.3 (m, 3H), 7.56 (m, 4H), 7.9 (d, 2H), 8.23 (s, 2H). MS (DCI/NH₃) m/z 453 (M+H)⁺, 471 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈F₂N₂O₃S: C, 63.71; H, 4.01; N, 6.01. Found: C, 63.53; H, 4.06; N, 5.92.

Example 190

2-(4-Chloro-3-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone:

The title compound was prepared according to the method of Example 62 substituting 4-bromo-1-chloro-2-fluorobenzene in place of 1-bromo-4-fluorobenzene (yield: 220 mg, 80%). mp 102-110 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.23 (s, 3H), 7.11-7.19 (m, 2H), 7.25-7.32 (m, 2H), 7.51 (d, J=5.6 Hz, 2H), 7.58-7.64 (m, 1H), 7.75-7.87 (m, 2H), 7.91 (d, J=5.6 Hz, 2H), 8.28 (s, 1H). MS (APCI+) m/z 473 (M+H)⁺.

Example 191

2-(4-Chloro-2-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone:

The title compound was prepared according to the method of Example 62 substituting 1-bromo-4-chloro-2-fluorobenzene in place of 1-bromo-4-fluorobenzene (yield: 65 mg 24%). mp 250-260 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.21 (s, 3H), 7.12-7.19 (m, 2H), 7.25-7.32 (m, 2H), 7.49-7.58 (m, 3H), 7.68-7.78 (m, 2H), 7.91 (d, J=8.7 Hz, 2H), 8.29 (s, 1H). MS (APCI+) m/z 473 (M+H)⁺. Anal. calc. for C₂₃H₁₅ClF₂N₂O₃S: C, 58.41; H, 3.19; N, 5.92. Found: C, 58.69; H, 3.45; N, 5.78.

Example 192

2-(1-Adamantyloxycarbonyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared according to the procedure of Example 11 (200 mg, 0.58 mmol) in CH₂Cl₂ (8 ml) was prepared and stirred. 1-Adamantylfluoroformate (172 mg, 0.87 mmol), dimethylaminopyridine (14 mg, 0.011 mmol) and triethylamine (0.12 ml, 0.87 mmol) were added. The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with CH₂Cl₂ (50 ml) and washed with 10% citric acid (50 ml), brine (50 ml) and dried over MgSO₄, and concentrated in vacuo. The resulting crude residue was purified using flash chromatography (SiO₂, eluting with 15:1 CH₂Cl₂:diethyl ether) to provide the desired product (yield: 55 mg, 18%). ¹H NMR (300 MHz, DMSO-d₆) δ 1.66 (bs, 6H), 2.25 (bd, 10H), 3.21 (s, 3H), 7.15 (t, 2H), 7.24 (m, 2H), 7.6 (dd, 2H), 7.88 (d, J=9 Hz, 2H), 8.15 (s, 1H). MS (ESI) m/z 521 (M-H)⁺. Anal. calc. for C₂₁H₁₅F N₂O₃S₂: C, 64.35; H, 5.20; N, 5.36.

Example 193

2-(2,2,2-Trifluoroethyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 193A

2-(2,2,2-Trifluoroethyl)-4,5-dichloro-3(2H)-pyridazinone

2,2,2-Trifluoroethylhydrazine (70% solution in water, 35.0 g, 0.307 mol) was treated with mucochloric acid (51.88 g, 0.307 mol) in ethanol (300 mL) and refluxed for 5 hours. The solvent was concentrated in vacuo. The crystals obtained were washed with water and air dried (yield: 50 g; 67.5%). ¹H NMR (300 MHz, CDCl₃) δ 4.8 (q, J=9 Hz, 2H), 7.85 (s, 1H). MS (DCI-NH₃) m/z 264 (M+NH₄)⁺.

Example 193B

2-(2,2,2-Trifluoroethyl)-4-chloro-5-hydroxy-3(2H)-pyridazinone

2-(2,2,2-Trifluoroethyl)-4,5-dichloro-3(2H)-pyridazinone (15.0 m 60.7 mmol), and potassium carbonate (10 g, 72.4 mmol.) were mixed with water (500 mL) and stirred at reflux for 6 hours. TLC (1:1:2 CH₂Cl₂/hexanes/ethyl acetate) indicated that all starting material was consumed.) The reaction mixture was cooled to room temperature. The pH of the reaction mixture was adjusted to about 4 with hydrochloric acid (15%). The product was extracted with ethyl acetate (700 mL). The organic phase was washed with brine, dried over anhydrous MgSO₄ and filtered. The filtrate was concentrated under reduced pressure. The hydroxy compound was obtained as a light brown solid (yield: 13.1 g, 94%). ¹H NMR (300 MHz, DMSO-d₆) δ 4.92 (q, J=9 Hz, 2H), 7.9 (s, 1H). MS (DCI/NH₃) m/z 229 (M+H)⁺.

Example 193C

2-(2,2,2-Trifluoroethyl)-4-chloro-5-(trifluoromethylsulfonyloxy)-3(2H)-pyridazinone

Anhydrous Na₂CO₃ (9.04 m, 85.32 mmol) was placed in a 500 mL round bottom flask and anhydrous CH₂Cl₂ (200 mL) was added. The reaction mixture was cooled to 0 °C under N₂. The halohydroxy pyridazinone prepared in Example 193B was dissolved in CH₂Cl₂ (100 mL) and added slowly to the flask and stirred overnight. The reaction slowly warmed to room temperature. (TLC (2: 1 hexanes/ethyl acetate) indicated completion of the reaction.) The reaction was quenched with H₂O. The organic phase containing the product was separated, washed with brine and dried over MgSO₄. The resulting filtrate was concentrated under reduced pressure. The crude product was isolated as deep red-brown residue. Purification using a silica gel column (30:70 ethyl acetate/pentanes) provided the title compound as a dark, reddish residue (14.3 m, 70%). ¹H NMR (300 MHz, CDCl₃) δ 4.85 (q, J=9 Hz, 2H), 7.9 (s, 1H). MS (DCI/NH₃) m/z 378 (M+NH₄)⁺.

Example 193D

2-(2,2,2-Trifluoroethyl)-4-chloro-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

A solution of the triflate prepared in Example 193C (1.56 g 4.3 mmol), 4-(methylthio)phenylboronic acid (870 mg, 5.16 mmol), tetrakis(triphenylphosphine)palladium(0) (250 mg, 5% mmol) and triethylamine (1.44 ml, 10.32 mmol) in toluene was heated at reflux for 1 hour. The mixture was partitioned between ethyl acetate and water. The ethyl acetate layer was washed with water, then brine, followed by drying over MgSO_4 and filtration. The filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica gel, 92:8 hexanes/ethyl acetate) to provide the coupled intermediate as a pale, greenish-yellow solid (yield: 500 mg, 35%). mp 130-139 °C. ^1H NMR (300 MHz, CDCl_3) δ 2.55 (s, 3H), 4.87 (q, J=9 Hz, 2H), 7.37 (d, J=9 Hz, 2H), 7.48 (d, J=9 Hz, 2H), 7.82 (s, 1H). MS (DCI/ NH_3) m/z 335 (M+H) $^+$.

Example 193E

2-(2,2,2-Trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 10, substituting the coupled intermediate prepared in Example 193D in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 440 mg, 81%). mp 221-222 °C. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 3.33 (s, 3H), 5.10 (q, J=9 Hz, 2H), 7.90 (d, J=9 Hz, 2H), 8.12 (d, J=9 Hz, 2H), 8.20 (s, 1H). MS (DCI/ NH_3) m/z 367 (M+H) $^+$.

X1E AH

Example 193F

2-(2,2,2-Trifluoroethyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Magnesium turnings (500 mg) were placed in a dry 250 mL round bottom flask. Anhydrous ether (20 mL) was added under N_2 at room temperature then fluorobenzyl bromide (3 mL) was added and stirred. The reaction was heated at 40 °C for 2 hours. All magnesium was consumed resulting in a pale brownish-yellow solution. The 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone prepared in

Example 193E was dissolved in dry THF (25 mL) and transferred to the Grignard solution. The mixture was heated for 3 hours. TLC (2:1 hexanes/ethyl acetate) indicated that the pyridazinone starting material was consumed.) The reaction was cooled to room temperature then quenched with a saturated NH_4Cl solution. The product was extracted with ethyl acetate (250 mL); and the organic layer was washed with saturated NH_4Cl , and brine. The ethyl acetate solution was dried over MgSO_4 and filtered. The filtrate was concentrated under reduced pressure. The product was isolated as an orange residue. Purification using a silica gel column (20:80 ethyl acetate/pentanes) provided the title compound as a pale yellow powder (yield: 140 mg, 28%). ^1H NMR (300 MHz, CDCl_3) δ 3.13 (s, 3H), 4.85 (m, 2H), 6.93 (m, 4H), 7.49 (d, $J=9$ Hz, 2H) 7.72 (s, 1H), 8.08 (d, $J=9$ Hz, 2H). MS (DCI/ NH_3) m/z 441 ($\text{M}+\text{H}$) $^+$. Anal. calc. for $\text{C}_{20}\text{H}_{16}\text{F}_4\text{N}_2\text{O}_3\text{S}\cdot 0.5\text{H}_2\text{O}$: C, 53.45; H, 3.81; N, 6.23. Found C, 53.45; H, 3.81; N, 6.23.

Example 194

2-(4-Fluorophenyl)-4-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 194A

2-(4-Fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone

Mucobromic acid (5.0 g, 19.4 mmol) dissolved in acetic acid (110 mL) was treated with 4-fluorophenyl hydrazine.HCl, and the heterogeneous mixture brought to reflux at a bath temperature of 115 °C for 15 hours. During the course of reaction, the mixture became a homogeneous deep red solution, and upon cooling to 23 °C, a crystalline precipitate formed. The solution was poured into ice water (1000 mL) and stirred for 20 minutes. The yellow/brown crystals were filtered off, washed with additional cold water, and dried in vacuo to provide 5.8 g (86%) of product. (J. Het. Chem., 1993, 30, 1501; Heterocycles 1985, 23, 2603) ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 7.31-7.41 (m, 2H), 7.57-7.64 (m, 2H), 8.29 (s, 1H). MS (DCI $^+$) m/z 347 ($\text{Br}_{79}\text{Br}_{79}\text{M}+\text{H}$) $^+$, m/z 349 ($\text{Br}_{79}\text{Br}_{81}\text{M}+\text{H}$) $^+$, m/z 364 ($\text{Br}_{79}\text{Br}_{79}\text{M}+\text{NH}_4$) $^+$, and m/z 366 ($\text{Br}_{79}\text{Br}_{81}\text{M}+\text{NH}_4$) $^+$.

Example 194B2-(4-Fluorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone

A 23 °C homogeneous solution of 2-(4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone (7.18 g, 20.6 mmol) prepared above in tetrahydrofuran (322 mL) was treated with methanol (0.843 mL, 20.8 mmol) and after 5 minutes with NaH (0.833 g, 20.8 mmol, 60% oil dispersion). The reaction exothermed for several minutes and then was continued for 8 hours at 23 °C (Note: several reactions have run to completion at this point). The reaction did not run to completion, and so the temperature was raised to reflux for 4 hours more. The reaction was still not completed. An additional 0.1 equivalent of NaOMe solution was prepared in a separate flask as above with the quantities: 32 mL of tetrahydrofuran, 0.084 mL of methanol, and 83 mg of 60% NaH oil dispersion. This NaOMe solution was added via syringe to the reaction mixture cooled to 23 °C, and then the temperature raised to reflux for 4 hours. The reaction was still not complete, and so another 0.1 equivalent NaOMe solution was prepared, added, and the reaction brought to reflux, as above. After this 4 hours, the reaction was completed. The mixture was cooled to 23 °C and diluted to 2000 mL with water. The yellow/white precipitate that formed was filtered off, washed with additional water, and concentrated in vacuo to provide 5.39 g (88%) of product. (J. Het. Chem., 1988, 25, 1757) ¹H NMR (300 MHz, DMSO-d₆) δ 4.13 (s, 3H), 7.30-7.40 (m, 2H), 7.56-7.62 (m, 2H), 8.22 (s, 1H). MS (APCI+) m/z 299 (⁷⁹Br M+H)⁺ and m/z 301 (⁸¹Br M+H)⁺.

Example 194C2-(4-Fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 6 starting with 2-(4-fluorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone in place of 2-benzyl-4-bromo-5-methoxy-3(2H)-pyridazinone and substituting 4-(methylthio)benzeneboronic acid in place of 4-fluorobenzeneboronic acid (yield: 70 mg, 61%). ¹H NMR (500 MHz, DMSO-d₆) δ 2.54 (s, 3H), 4.02 (s, 3H), 7.35 (dd, J=9.0, 9.0 Hz, 2H), 7.39 (d, J=8.5 Hz,

2H), 7.61 (d, J=8.5 Hz, 2H), 7.65 (dd, J=9.0, 5.0 Hz, 2H), 8.14 (s, 1H). MS (APCI+) m/z 343 (M+H)⁺.

Example 194D

5 2-(4-Fluorophenyl)-4-methyl-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 substituting methyl magnesium bromide in place of cyclohexylmagnesium chloride (yield: 0.83 g, 87%). ¹H NMR (300 MHz, CDCl₃) δ 2.25 (s, 3H), 2.55 (s, 3H), 7.17 (dd, J=8.8, 8.8 Hz, 2H), 7.31 (d, J=8.7 Hz, 2H), 7.38 (d, J=8.7 Hz, 2H), 7.61-7.68 (m, 2H), 7.82 (s, 1H). MS (APCI+) m/z 327 (M+H)⁺.

10

Example 194E

2-(4-Fluorophenyl)-4-methyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 10 substituting 2-(4-fluorophenyl)-4-methyl-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 473 mg, 86%). ¹H NMR (300 MHz, CDCl₃) δ 2.24 (s, 3H), 3.14 (s, 3H), 7.19 (dd, J=8.8, 8.8 Hz, 2H), 7.61 (d, J=8.4 Hz, 2H), 7.63-7.69 (m, 2H), 7.80 (s, 1H), 8.12 (d, J=8.4 Hz, 2H). MS (APCI+) m/z 359 (M+H)⁺ and m/z 376 (M+NH₄)⁺.

15

20

Example 194F

2-(4-Fluorophenyl)-4-bromomethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a heterogeneous, refluxing solution of 2-(4-fluorophenyl)-4-methyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (590 mg, 1.65 mmol) and carbon tetrachloride (24 mL) was quickly added N-bromosuccinimide (yield: 308 mg, 1.73 mmol) followed by benzoyl peroxide (12 mg, 0.05 mmol). After 1 hour the reaction had only run to near 50% completion. Additional benzoyl peroxide (12 mg, 0.05 mmol) was added, and the reaction checked after another 1 hour. The reaction was still not complete, and so more benzoyl peroxide (4 mg, 0.017 mmol) was added. After 30 minutes, the reaction was

25

completed. The mixture was cooled to 23 °C and diluted with ethyl acetate. The acetate solution was washed with saturated NaHCO₃, water, and brine. The solution was dried over MgSO₄, filtered, and concentrated in vacuo. The residue was chromatographed (flash silica gel, ethyl acetate/hexanes gradient 1:1 to 4:1) to provide the product (yield: 530 mg, 74%). ¹H NMR (300 MHz, CDCl₃) δ 3.16 (s, 3H), 4.34 (s, 2H), 7.20 (dd, J=8.8, 8.8 Hz, 2H), 7.67-7.74 (m, 2H), 7.82 (d, J=8.7 Hz, 2H), 7.86 (s, 1H), 8.17 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 437 (M+H)⁺.

Example 194G

2-(4-Fluorophenyl)-4-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a homogeneous solution of 2-(4-fluorophenyl)-4-bromomethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, Example 194F, (107 mg, 0.246 mmol) and 4-fluorophenol (30.3 mg, 0.270 mmol) dissolved in acetone (4 mL) was added powdered K₂CO₃ (37.3 mg, 0.270 mmol). The mixture was stirred at 23 °C for 2 hours, filtered through a bed of Celite®, and concentrated in vacuo. The residue was chromatographed (flash silica gel, ethyl acetate/hexanes 3:2) to provide the product (yield: 83 mg, 72%). mp 65-80 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 3H), 4.94 (s, 2H), 6.78-6.86 (m, 2H), 6.91-7.00 (m, 2H), 7.15-7.24 (m, 2H), 7.65-7.72 (m, 2H), 7.74 (d, J=8.7 Hz, 2H), 7.93 (s, 1H), 8.08 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 469 (M+H)⁺. Anal. calc. for C₂₄H₁₈F₂N₂O₄S: C, 61.53; H, 3.87; N, 5.97. Found: C, 61.22; H, 3.63; N, 5.64.

Example 195

2-(4-Fluorophenyl)-4-(3-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 194G substituting 3-fluorophenol in place of 4-fluorophenol (yield: 94 mg, 88%). mp 142-144 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 3H), 4.98 (s, 2H), 6.49-6.56 (m, 1H), 6.60-6.73 (m, 2H), 7.15-7.25 (m, 3H), 7.65-7.75 (m, 4H), 7.93 (s, 1H), 8.07 (d, J=8.7 Hz, 2H). MS

(APCI+) m/z 469 (M+H)⁺. Anal. calc. for C₂₄H₁₈F₂N₂O₄S: C, 61.53; H, 3.87; N, 5.97.

Found: C, 61.20; H, 3.92; N, 5.86.

Example 196

5 2-(4-Fluorophenyl)-4-phenoxyethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 294G substituting phenol in place of 4-fluorophenol (yield: 67 g, 93%). mp 42-75 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.28 (s, 3H), 4.92 (s, 2H), 6.83-6.90 (m, 2H), 6.91-6.99 (m, 1H), 7.22-7.30 (m, 2H), 7.35-7.44 (m, 2H), 7.66-7.73 (m, 2H), 7.81-7.88 (m, 2H), 8.02-8.08 (m, 10 2H), 8.21 (s, 1H). MS (APCI+) m/z 451 (M+H)⁺.

Example 197

2-(4-Fluorophenyl)-4-(t-butylthiomethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

15 A 0 °C solution of the 2-(4-fluorophenyl)-4-bromomethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone prepared in Example 194F (92.5 mg, 0.212 mmol) in acetone (2.5 mL) was treated with NaI (35 mg, 0.233 mmol), and after 5 minutes, the cooling bath was removed and the reaction warmed to 23 °C. After 30 minutes, conversion to the 2-(4-fluorophenyl)-4-iodomethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone was complete (thin layer chromatography, ethyl acetate/hexanes 4:1). 20 The NaBr and residual NaI were filtered off through a pad of Celite®. Additional acetone (2 mL) was added along with 2-methyl-2-propanethiol (20.5 mg, 0.227 mmol), and the solution cooled to 0 °C before addition of Ag₂CO₃ (63 mg, 0.227 mmol). After 5 minutes, the cooling bath was removed and the solution warmed to 23 °C for 5 hours. The reaction mixture was filtered through Celite® and concentrated in vacuo. The residue was 25 chromatographed (flash silica gel, ethyl acetate/hexanes gradient 1:1 to 3:2) to provide the product (yield: 57 mg, 60%). mp 50-70 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.34 (s, 9H), 3.14 (s, 3H), 3.65 (s, 2H), 7.13-7.21 (m, 2H), 7.63-7.70 (m, 2H), 7.79 (s, 1H), 7.84 (d,

J=8.7 Hz, 2H), 8.13 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 447 (M+H)⁺. Anal. calc. for C₂₂H₂₃FN₂O₃S₂: C, 59.17; H, 5.19; N, 6.27. Found: C, 59.48; H, 5.36; N, 5.90.

Example 198

5 2-(4-Fluorophenyl)-4-(2-methylpropylthiomethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 197 substituting 2-methyl-1-propanethiol in place of 2-methyl-2-propanethiol (yield: 66 mg, 70%). mp 45-60 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.95 (d, J=6.6 Hz, 6H), 1.67-1.82 (m, 10 1H), 2.62 (d, J=6.6 Hz, 2H), 3.15 (s, 3H), 3.61 (s, 2H), 7.19 (dd, J=8.2, 8.2 Hz, 2H), 7.62-7.71 (m, 2H), 7.75 (d, J=8.4 Hz, 2H), 7.79 (s, 1H), 8.13 (d, J=8.4 Hz, 2H). MS (APCI+) m/z 447 (M+H)⁺. Anal. calc. for C₂₂H₂₃FN₂O₃S₂: C, 59.17; H, 5.19; N, 6.27. Found: C, 59.35; H, 5.25; N, 6.05.

15 Example 199

2-(4-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound was prepared by the following sequence of reactions. Mucobromic acid and 4-fluorophenylhydrazine hydrochloride were reacted to provide 2-(4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone following the procedure in Example 20 194A.

The dibromo intermediate was reacted according to the procedure described in Example 194B, substituting isopropanol in place of methanol, to selectively react at the 4-position and provide 2-(4-fluorophenyl)-4-(2-propoxy)-5-bromo-3(2H)-pyridazinone.

The 5-bromo-compound was coupled to 4-(methylthio)phenylboronic acid according to the method of Example 6 to provide the title compound (yield: 435 mg, 25 53.9%). mp 135-137 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, J=6 Hz, 6H), 2.55 (s, 3H), 5.26 (sept, J=6 Hz, 1H), 7.17 (t, J=9 Hz, 2H), 7.34 (d, J=9 Hz, 2H), 7.57 (d, J=9 Hz, 2H), 7.58-7.66 (m, 2H), 7.95 (s, 1H). MS (DCI/NH₃) m/z 371 (M+H)⁺.

Example 2002-(4-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The methyl sulfide compound prepared in Example 199 was oxidized according to the method of Example 10 to provide the title compound (yield: 240 mg, 92%). mp 160-162 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.30 (d, J=6 Hz, 6H), 3.41 (s, 3H), 5.41 (m, 1H), 7.48 (t, J=9 Hz, 2H), 7.77 (dd, J=9 Hz, 6 Hz, 2H), 8.05 (d, J=9 Hz, 2H), 8.19 (d, J=9 Hz, 2H), 8.31 (s, 1H). MS (DCI/NH₃) m/z 403 (M+H)⁺, 420 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₉FN₂O₄S: C, 59.70; H, 4.73; N, 6.97. Found: C, 59.40; H, 4.86; N, 6.69.

Example 2012-(3-Chlorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3-Chlorophenyl)-4-(2-propoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 199, substituting 3-chlorophenylhydrazine hydrochloride in place of 4-fluorophenylhydrazine hydrochloride, in the first step. The resulting methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 260 mg, 80%). mp 134-136 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.24 (d, J=6 Hz, 6H), 3.13 (s, 3H), 5.48 (sept, J=6 Hz, 1H), 7.37-7.48 (m, 2H), 7.59 (dt, J=7 Hz, 1.5 Hz, 1H), 7.70 (br s, 1H), 7.84 (d, J=9 Hz, 2H), 7.93 (s, 1H), 8.06 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 419 (M+H)⁺, 436 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₉ClN₂O₄S: C, 57.42; H, 4.55; N, 6.70. Found: C, 57.08; H, 4.59; N, 6.44.

Example 2022-(3-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The methyl sulfide intermediate was prepared according to the method of Example 199, substituting 3-fluorophenylhydrazine hydrochloride in place of 4-fluorophenylhydrazine hydrochloride in the first step. The resulting methyl sulfide compound was oxidized according to the method of Example 10 to provide the title compound (yield: 290 mg, 72%). mp 110-112 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.31 (d,

J=6 Hz, 6H), 3.11 (s, 3H), 5.47 (sept, J=6 Hz, 1H), 7.09-7.18 (m, 1H), 7.41-7.52 (m, 3H), 7.83 (d, J=9 Hz, 2H), 7.93 (s, 1H), 8.08 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 403 (M+H)⁺, 447 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₉FN₂O₄S: C, 59.70; H, 4.73; N, 6.97. Found: C, 59.54; H, 4.87; N, 6.70.

5

Example 203

2-(3-Bromophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The methyl sulfide intermediate was prepared according to the method of Example 199, substituting 3-bromophenylhydrazine hydrochloride in place of
10 4-fluorophenylhydrazine hydrochloride. The resulting methyl sulfide compound was oxidized according to the method of Example 10 to provide the title compound (yield: 75 mg, 77.6%). mp 130-132 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.23 (d, J=6 Hz, 6H), 3.15 (s, 3H), 5.48 (sept, J=6 Hz, 1H), 7.38 (t, J=9 Hz, 1H), 7.55 (br d, J=7 Hz, 1H), 7.65 (br d, J=7 Hz, 1H), 7.79-7.87 (m, 1H), 7.83 (d, J=9 Hz, 2H), 8.13 (s, 1H), 8.06 (d, J=9 Hz, 2H).
15 MS (DCI/NH₃) m/z 465 (M+H)⁺, 480 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₉BrN₂O₄S: C, 51.84; H, 4.10; N, 6.05. Found: C, 51.95; H, 4.18; N, 5.74.

Example 204

2-(2,5-Difluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

20 2-(2,5-Difluorophenyl)-4-(2-propoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 199, substituting 2,5-difluorophenylhydrazine hydrochloride in place of 4-fluorophenylhydrazine hydrochloride.

The resulting methyl sulfide compound was oxidized according to the method of
25 Example 10 to provide the title compound (yield: 390 mg, 90%). mp 161-164 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.23 (d, J=6 Hz, 6H), 3.12 (s, 3H), 5.55 (sept, J=6 Hz, 1H), 7.12-7.29 (m, 3H), 7.82 (d, J=9 Hz, 2H), 7.92 (s, 1H), 8.07 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 421 (M+H)⁺, 438 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₈F₂N₂O₄S.0.5 H₂O: C, 55.94; H, 4.31; N, 6.53. Found: C, 55.86; H, 4.19; N, 6.38.

Example 2052-(3-Chloro-4-fluorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone

5 The title compound was prepared by the following sequence of reactions.
Mucobromic acid and 3-chloro-4-fluorophenylhydrazine hydrochloride were reacted to
provide 2-(3-chloro-4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone according to the
method of Example 194A.

10 The intermediate was selectively reacted at the 4-position with isobutanol and base
to provide 2-(4-fluorophenyl)-4-[1-(2-methylpropoxy)]-5-bromo-3(2H)-pyridazinone
according to the method of Example 194B

15 The 5-bromo-compound was coupled to 3-fluoro-4-(methylthio)phenylboronic acid
prepared in Example 194C according to the method of Example 6 to produce the
intermediate methyl sulfide. The sulfide compound was oxidized to the title methyl
sulfone according to the method of Example 10 (yield: 810 mg, 83.8%). mp 142-144 °C.
1H NMR (300 MHz, CDCl₃) δ 0.90 (d, J=6 Hz, 6H), 1.95 (sept, J=6 Hz, 1H), 3.30 (s, 3H),
4.37 (d, J=6 Hz, 2H), 7.26 (t, J=9 Hz, 1H), 7.52-7.61 (m, 3H), 7.75 (dd, J=9 Hz, 3 Hz, 1H),
7.89 (s, 1H), 8.10 (t, J=9 Hz, 1H). MS (DCI/NH₃) m/z 469 (M+H)⁺, 486 (M+NH₄)⁺.

Example 2062-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[3-methyl-4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinoneExample 206A2-Methylthioanisole

25 A solution of 2-bromothioanisole (10.53 g, 52 mmol) in tetrahydrofuran (173 mL)
was prepared and cooled to -78 °C. n-BuLi (21.8 mL, 54.5 mmol, 2.5 M solution in
hexanes) was slowly added along the interior wall of the reaction vessel. The resultant
light yellow solution was stirred for 30 minutes before methyl iodide (8.10 g, 57.1 mmol)

diluted with tetrahydrofuran (6 mL) was slowly added along the interior wall of the reaction vessel. The mixture was stirred for another 30 minutes at -78 °C. The cooling bath was removed, and the mixture stirred for 1 hour. The solution was cooled to 0 °C and a saturated aqueous NH₄Cl solution added. The resultant solution was extracted several times with ethyl acetate, and the combined acetate layers washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo. The residue was chromatographed (flash silica gel, ethyl acetate/hexanes 1:19) to provide the product (yield: 6.74 g, 94%). ¹H NMR (300 MHz, CDCl₃) δ 2.34 (s, 3H), 2.46 (s, 3H), 7.02-7.09 (m, 1H), 7.12-7.22 (m, 3H).

Example 206B

4-Bromo-2-methylthioanisole.

To a 0 °C solution of 2-methylthioanisole (0.50 g, 3.57 mmol) in methylene chloride (40 mL) was added powdered Fe (20 mg, 0.36 mmol) followed by dropwise addition of bromine (0.58 g, 3.54 mmol). After 30 minutes, the starting material had been consumed (thin layer chromatography, hexanes). The excess bromine was quenched by adding a solution of NaHSO₃ and stirring for several minutes. The methylene chloride layer was separated, and the aqueous phase extracted with additional methylene chloride. The combined methylene chloride solution was dried over MgSO₄, filtered, and concentrated in vacuo. The resultant oil was chromatographed (flash silica gel, ethyl acetate/hexanes 1:49) to provide the product (yield: 0.74 g, 96%). ¹H NMR (300 MHz, CDCl₃) δ 2.30 (s, 3H), 2.45 (s, 3H), 7.00 (d, J=8.4 Hz, 1H), 7.27-7.33 (m, 2H).

Example 206C

3-Methyl-4-(methylthio)benzeneboronic acid.

3-Methyl-4-(methylthio)benzeneboronic acid was prepared according to the method of Example 1, substituting 4-bromo-2-(methylthio)anisole in place of 4-bromothioanisole (yield: 5.3 g, 67%). mp 208-210 . ¹H NMR 2.28 (s, 3H), 2.46 (s, 3H), 7.20 (d, J=8.4 Hz, 1H), 7.62 (s, 1H), 7.70 (d, J=8.4 Hz, 1H).

Example 206D2-(3,4-Difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 194A,
5 substituting 3,4-difluorophenyl hydrazine-HCl in place of 4-fluorophenyl hydrazine-HCl
(yield: 39 g, 78%). ¹H NMR (300 MHz, DMSO-d₆) δ 7.45 (m, 1H), 7.61 (m, 1H), 7.75
(m, 1H), 8.30 (s, 1H). MS (DCI/NH₃) m/z 382 (M+NH₄)⁺.

Example 206E

10 2-(3,4-Difluorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 194B,
substituting 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone in place of 2-(4-
fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone (yield: 15 mg, 88%). ¹H NMR (300 MHz,
DMSO-d₆) δ 4.14 (s, 3H), 7.45 (m, 1H), 7.60 (m, 1H), 7.74 (m, 1H), 8.24 (s, 1H). MS
15 (DCI/NH₃) m/z 317 (M+H)⁺ and m/z 334 (M+NH₄)⁺.

Example 206F

2-(3,4-Difluorophenyl)-4-methoxy-5-[3-methyl-4-(methylthio)phenyl]-3(2H)-
pyridazinone.

20 The title compound was prepared according to the method of Example 6 starting
with 2-(3,4-difluorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone in place of 2-benzyl-
4-bromo-5-methoxy-3(2H)-pyridazinone and substituting 3-methyl-4-
(methylthio)benzeneboronic acid in place of 4-fluorobenzeneboronic acid (yield: 2.0 g,
85%). ¹H NMR (300 MHz, CDCl₃) δ 2.39 (s, 3H), 2.53 (s, 3H), 4.11 (s, 3H), 7.22-7.32 (m,
25 2H), 7.34 (s, 1H), 7.42-7.50 (m, 2H), 7.55-7.64 (m, 1H), 7.92 (s, 1H). MS (APCI+) m/z
375 (M+H)⁺.

Example 206G

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[3-methyl-4-(methylthio)phenyl]-3(2H)-pyridazinone.

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[3-methyl-4-(methylthio)phenyl]-3(2H)-pyridazinone, was prepared according to the method of Example 228, starting with
5 2-(3,4-difluorophenyl)-4-methoxy-5-[3-methyl-4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting 4-fluorophenyl magnesium bromide in place of cyclohexylmagnesium chloride (yield: 330 mg, 56%). ¹H NMR (300 MHz, CDCl₃) δ 2.24 (s, 3H), 2.47 (s, 3H), 6.90-7.03 (m, 6H), 7.22-7.31 (m, 2H), 7.49-7.54 (m, 1H), 7.60-7.68 (m, 1H), 8.02 (s, 1H).
10 MS (APCI+) m/z 439 (M+H)⁺.

Example 206H

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[3-methyl-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

15 The title compound was prepared according to the method of Example 10, substituting 2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-[3-methyl-4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 251 mg, 82%) mp 80-100 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.59 (s, 3H), 3.25 (s, 3H), 7.13-7.34 (m, 5H), 7.45 (s, 1H), 7.52-7.69 (m, 2H), 7.81
20 (d, J=8.4 Hz, 1H), 7.81-7.90 (m, 1H), 8.27 (s, 1H). MS (APCI+) m/z 471 (M+H)⁺ and m/z 488 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₇F₃N₂O₃S: C, 61.27; H, 3.64; N, 5.95. Found: C, 61.53; H, 3.92; N, 5.67.

Example 207

25 2-(3-Chlorophenyl)-4-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 207A

2-(3-Chlorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 194A, substituting 3-chlorophenyl hydrazine-HCl in place of 4-fluorophenyl hydrazine-HCl (yield: 24.8 g, 88%). ¹H NMR (300 MHz, DMSO-d₆) δ 7.53-7.57 (m, 3H), 7.67-7.70 (m, 1H), 8.29 (s, 1H). MS (DCI/NH₃) m/z 365 (M+H)⁺ and m/z 382 (M+NH₄)⁺.

5

Example 207B

2-(3-Chlorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 194B, substituting 2-(3-chlorophenyl)-4,5-dibromo-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone (yield: 12.4 g, 95%). ¹H NMR (300 MHz, DMSO-d₆) δ 4.21 (s, 3H), 7.58-7.62 (m, 3H), 7.73-7.76 (m, 1H), 8.28 (s, 1H). MS (DCI/NH₃) m/z 317 (M+H)⁺ and m/z 334 (M+NH₄)⁺.

10

Example 207C

2-(3-Chlorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone.

15

The title compound was prepared according to the method of Example 6 starting with 2-(3-chlorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone in place of 2-benzyl-4-bromo-5-methoxy-3(2H)-pyridazinone and substituting 4-(methylthio)benzeneboronic acid in place of 4-fluorobenzeneboronic acid (yield: 3.3 g, 68%). ¹H NMR (300 MHz, DMSO-d₆) δ 2.54 (s, 3H), 4.03 (s, 3H), 7.40 (d, J=9.0 Hz, 2H), 7.50-7.64 (m, 5H), 7.73-7.77 (m, 1H), 8.18 (s, 1H). MS (DCI/NH₃) m/z 359 (M+H)⁺.

20

Example 207D

2-(3-Chlorophenyl)-4-methyl-5-[3-methyl-4-(methylthio)phenyl]-3(2H)-pyridazinone.

25

2-(3-Chlorophenyl)-4-(4-fluorophenyl)-5-[3-methyl-4-(methylthio)phenyl]-3(2H)-pyridazinone, was prepared according to the method of Example 228, starting with 2-(3-chlorophenyl)-4-methoxy-5-[3-methyl-4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting 4-fluorophenyl magnesium bromide in place of cyclohexylmagnesium

chloride (yield: 180 mg, 94%). ¹H NMR (300 MHz, CDCl₃) δ 2.25 (s, 3H), 2.56 (s, 3H), 7.28-7.45 (m, 6H), 7.58-7.63 (m, 1H), 7.71-7.74 (m, 1H), 7.82 (s, 1H). MS (APCI+) m/z 343 (M+H)⁺ and m/z 360 (M+NH₄)⁺.

5

Example 207E2-(3-Chlorophenyl)-4-methyl-5-[4-(methylsulfonylphenyl)]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 10, substituting 2-(3-chlorophenyl)-4-methyl-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone for 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 125 mg, 67%). mp 164-168. ¹H NMR (300 MHz, CDCl₃) δ 2.23 (s, 3H), 3.13 (s, 3H), 7.37-7.46 (m, 2H), 7.61 (m, 3H), 7.71-7.74 (m, 1H), 7.81 (s, 1H), 8.13 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 343 (M+H)⁺ and m/z 360 (M+NH₄)⁺.

10

Example 207F2-(3-Chlorophenyl)-4-bromomethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3-Chlorophenyl)-4-bromomethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 194F, substituting 2-(3-chlorophenyl)-4-methyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 90 mg, 99%). ¹H NMR (300 MHz, CDCl₃) δ 3.13 (s, 3H), 4.33 (s, 2H), 7.40-7.47 (m, 2H), 7.66 (ddd, J=2.4, 2.4, 7.2 Hz, 1H), 7.76-7.78 (m, 1H), 7.81 (d, J=8.7 Hz, 2H), 7.86 (s, 1H), 8.17 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 453 (M+H)⁺ and m/z 470 (M+NH₄)⁺.

20

Example 207G2-(3-Chlorophenyl)-4-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

25

The title compound was prepared according to the method of Example 194G, substituting 2-(3-chlorophenyl)-4-bromomethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-bromomethyl-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone (yield: 30 mg, 31%). mp 50-80 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.11 (s, 3H), 4.94 (s, 2H), 6.78-6.85 (m, 2H), 6.91-6.99 (m, 2H), 7.39-7.48 (m, 2H), 7.64 (ddd, J=7.5, 1.9, 1.9 Hz, 1H), 7.71-7.77 (m, 3H), 7.93 (s, 1H), 8.08 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 485 (M+H)⁺.

5

Example 208

2-(3-Chlorophenyl)-4-(benzoyloxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 207 substituting benzoic acid in place of 4-fluorophenol (yield: 33 mg, 34%). mp 50-70 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.00 (s, 3H), 5.36 (s, 2H), 7.36-7.48 (m, 4H), 7.52-7.59 (m, 1H), 7.61-7.68 (m, 3H), 7.75-7.78 (m, 1H), 7.83-7.88 (m, 2H), 7.89 (s, 1H), 8.02 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 495 (M+H)⁺.

15

Example 209

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 193, substituting 1-bromo-3-methylbutane in place of 4-fluorobenzyl bromide (yield: 80 mg, 19%). ¹H NMR (300 MHz, CDCl₃) δ 0.81 (d, J=7.5 Hz, 6H), 1.3-1.6 (m, 3H), 2.52 (m, 2H), 3.14 (3 H, s), 4.85 (q, J=9 Hz, 2H), 7.55 (d, J=9 Hz, 2H), 7.67 (s, 1H), 8.1 (d, J=9 Hz, 2H). MS (DCI/NH₃), m/z 403 (M+H)⁺. Anal. calc. for C₁₈H₂₁F₃N₂O₃S.0.25 H₂O: C, 53.12; H, 5.32; N, 6.88. Found C, 52.90; H, 5.14; N, 6.43.

25

Example 210

2-(2,2,2-Trifluoroethyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 210A

4-fluoro-3-methylbenzeneboronic acid:

5-Bromo-2-fluorotoluene (6 g, 31.7 mmol) was dissolved in dry THF (50 mL) and cooled to -78 °C under N₂. n-BuLi (14 mL, 2.5M solution in THF) was added slowly using a dry syringe. Cloudiness appeared. The reaction was stirred for 40 minutes at -78 °C.

5 Triisopropyl borate (22 mL, 95 mmol) was slowly added while stirring. The reaction was allowed to warm to room temperature. Stirring continued for an additional 2 hours. A pale yellow, cloudy solution formed. (TLC (1:2 ethyl acetate /hexanes)) indicated disappearance of the starting material. The reaction was quenched by adding 10% aqueous NaOH (200 mL). After stirring for 45 minutes, 10% citric acid solution (300 mL) was added until, pH ~5.0. The product was extracted with ethyl acetate (500 mL). The organic phase was washed with brine and dried over MgSO₄, and filtered. The filtrate was concentrated under reduced pressure to provide an off white solid (yield: 4.1 g, 84%).

Example 210B

15 2-(2,2,2-trifluoroethyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The boronic acid (231 mg, 1.5 mmol), prepared in example 210A, 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (500 mg, 1.36 mmol), tetrakis-(triphenylphosphine)-palladium(0) (47 mg, 0.041 mmol), and CsF (413 mg, 2.72 mmol) were stirred at reflux in DME (20 mL) under N₂ for 5 hours. TLC (1:1 hexanes/ethyl acetate) indicated that all the starting material was consumed. Volatiles were removed in vacuo. The residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo. An off white powder was obtained (yield: 275 mg, 46%). mp 88-91 °C; ¹H NMR (300 MHz, CDCl₃, a mixture of rotamers) δ 2.2, 2.25 (2d, J=1.5 Hz, 3H) 3.05, 3.09 (2 s, 3H) 4.78-4.92 (m, 2H) 6.61-6.8 (m, 1H) 6.82-6.98 (m, 1H) 7.35 (d, J=9 Hz, 1H) 7.78 (d, J=9 Hz, 1H) 7.86-8.09 (m, 4H). MS (DCI/NH₃), m/z 441 (M+H)⁺. Anal. calc. for C₂₀H₁₆F₄N₂O₃S.0.5 H₂O: C, 53.45; H, 3.81; N, 6.23. Found C, 53.17; H, 3.65; N, 5.88.

Example 2112-(2,2,2-Trifluoroethyl)-4-(3,5-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 2-(2,2,2-Trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (150 mg, 0.409 mmol) (Example 193E) was dissolved in anhydrous DME (8 mL) and heated to reflux with 3,5-dichlorobenzeneboronic acid in presence of CsF (150 mg, 0.98 mmol) and tetrakis(triphenylphosphine)-palladium (17.38 mg, 0.015 mmol) for 6 hours. After cooling to room temperature the reaction mixture was diluted with water and
10 extracted with ethyl acetate (100 mL). The organic layer was washed with brine, dried over MgSO₄, and evaporated in vacuo. The compound was purified on a silica gel column, eluting with 30% ethyl acetate in pentanes, to provide the title compound (yield: 110 mg, 58%). ¹H NMR (300 MHz, CDCl₃) δ 3.08 (s, 3H), 4.88 (q, J=9 Hz, 2H), 7.06 (d, J=1.5 Hz, 9 Hz, 2H), 7.31 (t, J=1.5 Hz, 1H), 7.36 (d, J=9 Hz, 2H), 7.94 (s, 1H), 7.96 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 496 (M+NH₄)⁺. Anal. calc. for C₁₉H₁₃Cl₂F₃N₂O₃S: C, 47.81; H, 2.75; N, 5.87. Found: C, 47.77; H, 2.75; N, 5.65

Example 2122-(2,2,2-Trifluoroethyl)-4-(3-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

20 The title compound was prepared according to the method of Example 211, substituting 3-ethoxyphenylboronic acid for 3,5-dichlorobenzeneboronic acid (yield: 155 mg, 86%). ¹H NMR (300 MHz, CDCl₃) δ 1.42 (t, J=7.5 Hz, 3H), 3.06 (s, 3H), 3.90 (q, J=7.5 Hz, 2H), 4.88 (q, J=9 Hz, 2H), 6.65 (d, J=7.5 Hz, 1H), 6.75 (t, J=1.5 Hz, 1H), 6.85
25 (dd, J=1.5 Hz, 9 Hz, 1H), 7.15 (t, J=9 Hz, 1H), 7.38 (d, J=9 Hz, 2H), 7.88 (d, J=9 Hz, 2H), 7.90 (s, 1H). MS (DCI/NH₃) m/z 470 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₉Cl₂F₃N₂O₄S: C, 55.75; H, 4.23; N, 6.19. Found: C, 55.62; H, 4.30; N, 5.99

Example 213

2-(2,2,2-Trifluoroethyl)-4-(4-trifluoromethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 211, substituting 4-(trifluoromethyl)benzeneboronic acid in place of 3,5-dichlorobenzeneboronic acid (yield: 85 mg, 44%). ¹H NMR (300 MHz, CDCl₃) δ 3.08 (s, 3H), 4.90 (q, J=9 Hz, 2H), 7.35 (t, J=9 Hz, 4H), 7.58 (d, J=9 Hz, 2H), 7.90 (d, J=9 Hz, 3H). MS (DCI/NH₃) m/z 494 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₄F₆N₂O₃S: C, 50.42; H, 2.96; N, 5.88. Found: C, 50.20; H, 3.02; N, 5.70

Example 214

2-(2,2,2-Trifluoroethyl)-4-(3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 211, substituting 3-nitrobenzeneboronic acid in place of 3,5-dichlorobenzeneboronic acid (yield: 40 mg, 22%). ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 4.92 (q, J=9 Hz, 2H), 7.36 (d, J=9 Hz, 2H), 7.45-7.60 (m, 2H), 7.91 (d, J=9 Hz, 2H), 7.95 (s, 1H), 8.05 (m, 1H), 8.15-8.21 (m, 1H). MS (DCI/NH₃) m/z 471 (M+NH₄)⁺. Anal. calc. for C₁₉H₁₄Cl₂F₃N₃O₅S.0.5 EtOAc: C, 50.70; H, 3.64; N, 8.44. Found: C, 50.61; H, 3.58; N, 8.53

Example 215

2-(2,2,2-Trifluoroethyl)-4-(2-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 211, substituting 2-methylbenzeneboronic acid in place of 3,5-dichlorobenzeneboronic acid (yield: 45 mg, 27%). ¹H NMR (300 MHz, CDCl₃) δ 2.05, 2.12 (2s, 3H), 3.01 (s, 3H), 4.75-5.05 (m, 2H), 6.88 (d, J=9 Hz, 1H), 7.03-7.25 (m, 3H), 7.31 (d, J=9 Hz, 2H), 7.85 (d, J=9 Hz, 2H), 7.95 (s, 1H). MS (DCI/NH₃) m/z 440 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₇F₃N₂O₃S: C, 55.10; H, 4.27; N, 6.42. Found: C, 55.17; H, 4.18; N, 6.10

Example 2162-(2,2,2-Trifluoroethyl)-4-(4-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound was prepared according to the method of Example 211, substituting 4-vinylbenzeneboronic acid in place of 3,5-dichlorobenzeneboronic acid (yield: 56 mg, 32%). ¹H NMR (300 MHz, CDCl₃) δ 3.06, 3.08 (2s, 3H), 4.78-4.95 (m, 2H), 5.30 (t, J=6 Hz, 1H), 5.65, 5.75(2d, J=18 Hz, 1H), 6.58-6.92 (m, 1H), 7.1-7.4 (m, 6H), 7.75-8.08 (m, 3H). MS (DCI/NH₃) m/z 452 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₇F₃N₂O₃S: C, 58.06; H, 3.94; N, 6.45. Found: C, 57.82; H, 4.01; N, 6.09

Example 2172-(2,2,2-Trifluoroethyl)-4-[3-(trifluoromethyl)phenyl]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

15 The title compound was prepared according to the method of Example 211, substituting 3-trifluoromethylbenzeneboronic acid in place of 3,5-dichlorobenzeneboronic acid (yield: 120 mg, 63%). ¹H NMR (300 MHz, CDCl₃) δ 3.03, 3.08 (2s, 3H), 4.75-4.98 (m, 2H), 7.30-7.60 (m, 6H), 7.75-8.10 (m, 3H). MS (DCI/NH₃) m/z 494 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₄F₆N₂O₃S: C, 50.42; H, 2.96; N, 5.88. Found: C, 50.38; H, 2.97; N, 5.74

Example 2182-(2,2,2-Trifluoroethyl)-4-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

25 The title compound was prepared according to the method of Example 211, substituting 3-fluoro-4-methoxybenzeneboronic acid in place of 3,5-dichlorobenzeneboronic acid (yield: 32 mg, 18%). ¹H NMR (300 MHz, CDCl₃) δ 3.05, 3.09 (2s, 3H), 3.85, 3.87 (2s, 3H), 4.78-4.90 (m, 2H), 6.60-7.10 (m, 3H), 7.30-8.15 (m,

5H). MS (DCI/NH₃) m/z 474 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₆F₄N₂O₄S.0.5 H₂O: C, 51.61; H, 3.68; N, 6.01. Found: C, 51.52; H, 3.65; N, 5.93

Example 219

5 2-(2,2,2-Trifluoroethyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 211 substituting 3-fluoro-4-methylbenzeneboronic acid in place of 3,5-dichlorobenzeneboronic acid (yield: 58 mg, 33%). ¹H NMR (300 MHz, CDCl₃) δ 2.21, 2.25 (2d, J=1.5 Hz, 3H), 3.50, 3.55 (2s, 3H), 4.75-4.95 (m, 2H), 6.56-7.15 (m, 3H), 7.30-8.10 (m, 5H). MS
10 (DCI/NH₃) m/z 458 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₆F₄N₂O₃S.0.5 H₂O: C, 53.45; H, 3.81; N, 6.23. Found: C, 53.14; H, 3.80; N, 5.97

Example 220

15 2-(2,2,2-Trifluoroethyl)-4-(3,5-difluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 211, substituting 3,5-difluoro-4-methoxybenzeneboronic acid in place of 3,5-dichlorobenzeneboronic acid. ¹H NMR (300 MHz, CDCl₃) δ 2.9, 3.1 (2s, 3H), 3.92, 4.01
20 (2s, 3H), 4.78-4.95 (m, 2H), 6.25-6.80 (m, 1H), 7.30-7.5 (m, 2H), 7.7-8.15 (m, 4H). MS (DCI/NH₃) m/z 492 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₅F₃N₂O₄S: C, 50.64; H, 3.19; N, 5.90. Found: C, 50.542; H, 3.41; N, 5.67

Example 221

25 2-(2,2,2-Trifluoroethyl)-4-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

6-Bromophthalide (300 mg, 1.40 mmol, Teppema et al Recl. Trav. Chim. Pays-Bays, (1923) 42, 47) and hexamethylditin (326 μL, 1.55 mmol) were dissolved in toluene (5 mL), degassed with a nitrogen stream for 5 minutes, treated with (Ph₃P)₄Pd (79 mg) and

heated at reflux for 1 hour. The reaction was cooled and directly purified by chromatography on a Biotage 40S column (pretreated with hexanes-TEA 400:1 then rinsed with hexanes) eluted with 4:1 hexanes-ethyl acetate. The product fractions were combined and evaporated to provide 6-(trimethyltin)phthalide (yield: 362 mg, 87%).

5 The tin reagent (180 mg, 0.61 mmol), prepared above, and 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 193E, (223 mg, 0.61 mmol) were dissolved in dry toluene (10 mL), degassed with an nitrogen stream for 5 minutes, treated with $(\text{Ph}_3\text{P})_4\text{Pd}$ (34 mg) and heated at reflux for 1 day. The reaction was cooled and directly purified by chromatography on a Biotage 40S column
10 eluted with 4:1 hexanes-ethyl acetate. The product fractions were combined and evaporated to provide the title compound along with the 4-(1,3-dihydro-1-oxo-6-isobenzofuranyl)-isomer in a 9:1 ratio. Further manipulations to attempt to remove the minor isomer (ie chromatography, recrystallization from ethyl acetate-hexanes) failed (yield: 176 mg, 62%). mp 237-239 °C. ^1H NMR (300 MHz, CDCl_3) δ 3.07 (s, 3H), 4.91
15 (q, J=8 Hz, 2H), 5.30 (s, 2 H, major isomer), 5.33 (s, 2 H, minor isomer), 7.20 (dd, J=1 Hz, 7 Hz, 1H), 7.36 (d, J=8 Hz, 2H), 7.52 (s, 1H), 7.79 (d, J=7 Hz, 1H), 7.92 (d, J=8 Hz, 2H), 7.96 (s, 1H). MS (DCI/ NH_3) m/z 482 ($\text{M}+\text{NH}_4$) $^+$. Anal. calc. for $\text{C}_{21}\text{H}_{15}\text{F}_3\text{N}_2\text{O}_5\text{S}$: C, 54.31; H, 3.26; N, 6.03. Found: C, 54.15; H, 3.12; N, 5.76.

20 Example 222

2-(2,2,2-Trifluoroethyl)-4-(2-propenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A suspension of 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (200 mg, 0.546 mmol), prepared according to the method of Example 193E, in THF (27 mL) was cooled to -78 °C. A solution of isopropenylmagnesium
25 bromide (2.8 mL, 0.5 M in THF, Aldrich) was added. The reaction was warmed to room temperature and stirred for 30 minutes. The reaction was quenched at 0 °C by the addition of saturated ammonium chloride solution and partitioned between ethyl acetate and additional ammonium chloride solution. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to provide a reddish

brown solid. The crude material was dissolved in methylene chloride and adsorbed onto silica gel (2 g). Solvent was removed under reduced pressure, the adsorbed silica gel layered over an Extract-Clean Cartridge® (Alltech, packing: 5 g silica gel) and the cartridge eluted with a hexanes/acetone step gradient consisting of 40 mL of the following mixtures: hexanes, 8:1 hexanes/acetone, 4:1, 2:1, and 1:1. Fractions containing desired product were combined, concentrated, and further purified using HPLC (Technikrom Kromasil 60-5sil column, 20 mm x 25 cm). The column was eluted with a linear gradient consisting of 30% ethyl acetate/hexanes to 100% ethyl acetate at 10 mL/min over 50 minutes. Fractions containing the title product were combined and concentrated under reduced pressure to provide a pale yellow solid (yield: 99.3 mg, 49%). mp 192-195 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.03 (d, J=17.4 Hz, 2H), 7.76 (s, 1H), 7.55 (d, 2H, J=17.4 Hz), 5.23 (br s, 1H), 4.84 (m, 3H), 3.11 (s, 3H), 1.98 (s, 3H). MS (DCI/NH₃) m/z 373 (M+H)⁺, m/z 390 (M+NH₄)⁺. Anal. calc. for C₁₆H₁₅F₃N₂O₃S: C, 51.61; H, 4.06; N, 7.52. Found: C, 51.72; H, 4.24; N, 7.35.

Example 223

2-(2,2,2-Trifluoroethyl)-4-(2-buten-2-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 222 substituting 1-methyl-1-propenylmagnesium bromide in place of isopropenylmagnesium bromide to provide a mixture of geometric isomers (~3:1 ratio) as an off-white solid (yield: 44.8 mg, 21%). mp 175-180 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.03 (d, J=18.0 Hz, 1.5H), 8.01 (d, J=18.0 Hz, 0.5H), 7.29 (s, 0.75H), 7.28 (s, 0.25H), 7.56 (d, J=17.4 Hz, 1.5H), 7.51 (d, J=17.4 Hz, 0.5H), 5.55 (m, 0.75H), 5.33 (m, 0.25H), 5.86 (q, J=17.4 Hz, 2H), 3.12 (s, 2.25H), 3.11 (s, 0.75H), 2.88 (m, 2H), 2.85 (m, 1H), 1.27 (m, 3H). MS (DCI/NH₃) m/z 387 (M+H)⁺, m/z 404 (M+NH₄)⁺, m/z 421 (M+2NH₄-H)⁺. Anal. calc. for C₁₇H₁₇F₃N₂O₃S: C, 52.85; H, 4.43; N, 7.25. Found: C, 53.16; H, 4.68; N, 6.92.

Example 224

2-(2,2,2-Trifluoroethyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

Example 224A

5 3-Fluorobenzyl magnesium bromide.

3-Fluorobenzyl bromide (613 μ L, 5 mmol), followed by dibromoethane (10 μ L), was added dropwise to an oven-dried flask containing small pieces of magnesium ribbon (134 mg, 5.5 mmol) and diethyl ether (12 mL). Gas evolution was noted followed by gentle reflux of the ether. The reaction was stirred until gas evolution ceased and most of
10 the magnesium had dissolved. The resulting pale yellow solution of 3-fluorobenzylmagnesium bromide was used directly in the next reaction.

Example 224B

15 2-(2,2,2-Trifluoroethyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone.

A suspension of 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (200 mg, 0.546 mmol), prepared according to the method of Example 193E, in THF (10 mL) was cooled to 0 °C. A solution of 3-fluorobenzyl magnesium bromide (4.0 mL, ~0.42 M in diethyl ether), prepared above was added. The reaction was
20 stirred at 0 °C for 3 hours, quenched by the addition of saturated ammonium chloride solution, and partitioned, between ethyl acetate and additional ammonium chloride solution. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to provide a yellow oil. The crude material was dissolved in methylene chloride and adsorbed onto silica gel (2 g). Solvent was removed
25 under reduced pressure, the silica gel with the product adsorbed was layered over an Extract-Clean Cartridge® (Alltech, packing: 10 g silica gel) and the cartridge eluted with a hexanes/acetone step gradient consisting of 60 mL of each of the following mixtures: hexanes, 8:1 hexanes/acetone, 4:1, 2:1, and 1:1. Fractions containing desired product were combined, concentrated, and further purified using HPLC (Technikrom Kromasil 60-5 sil

silica column, 20 mm x 25 cm). The column was eluted with a linear gradient consisting of 30% ethyl acetate/hexanes to 100% ethyl acetate at 10 mL/min. for 50 minutes.

Fractions containing the title product were combined and concentrated under reduced pressure to provide a pale yellow solid (yield: 130.9 mg, 54%). mp 58-62 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.07 (d, J=18.0 Hz, 2H), 7.73 (s, 1H), 7.47 (d, J=17.4 Hz, 2H), 7.18 (m, 1H), 6.88 (m, 1H), 6.76 (br d, J=15.6 Hz, 1H), 6.68 (br d, J=18.6 Hz, 1H), 4.86 (q, J=17.4 Hz, 2H), 3.93 (s, 2H), 3.12 (s, 3H). MS (DCI/NH₃) m/z 441 (M+H)⁺, m/z 458 (M+NH₄)⁺, m/z 475 (M+2NH₄-H)⁺. Anal. calc. for C₂₀H₁₆F₄N₂O₃S: C, 54.54; H, 3.66; N, 6.36. Found: C, 54.52; H, 3.81; N, 6.17.

Example 225

2-(2,2,2-Trifluoroethyl)-4-(1-cyclohexenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 225A

1-Cyclohexenyltriflate.

n-Butyllithium (2.5M in hexanes, 2.20 mL, 5.50 mmol) was added to a solution of diisopropylamine (0.77 mL, 5.50 mmol) in THF (20 mL) at -78 °C. The resulting pale yellow solution was warmed to 0 °C for 30 minutes then was cooled to -78 °C.

Cyclohexanone (0.52 mL, 5.0 mmol) was added and the nearly colorless solution was warmed to 0 °C for 1 hour. N-Phenyltrifluoromethanesulfonimide (1.79 g, 5.5 mmol) was added as a solid. The solution was stirred at room temperature for 12 hours. The reaction mixture was then partitioned between diethyl ether and saturated sodium bicarbonate solution. The ether layer was washed with water then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography (20:1 hexanes/ethyl acetate) to provide the triflate as a pale yellow oil (yield: 0.73 g, 64%).

Example 225B

1-Cyclohexenyltrimethyltin.

A solution of 1-cyclohexenyltriflate (412 mg, 1.79 mmol), prepared according to the method of Example 225A, and LiCl (380 mg, 8.95 mmol) in THF (9 mL) was deoxygenated by bubbling a stream of N₂ through the solution. Hexamethylditin (339 μ L, 1.61 mmol) and tetrakis(triphenylphosphine)palladium(0) (414 mg, 0.36 mmol) were added and the reaction heated at reflux for 12 hours. The reaction was cooled to room temperature and partitioned between diethyl ether and saturated sodium bicarbonate solution. The ether layer was washed with water then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was dissolved in hexanes (1 mL) and loaded onto an Extract-Clean Cartridge® (Alltech, packing: 10 g silica gel) which had been wetted with 10% triethylamine in hexanes. The cartridge was eluted with hexanes and fractions containing the triflate combined and concentrated under reduced pressure to provide 1-cyclohexenyltrimethyltin as a clear oil (yield: 150 mg, 34%).

Example 225C2-(2,2,2-Trifluoroethyl)-4-(1-cyclohexenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

A solution of 1-cyclohexenyltrimethyltin (150 mg, 0.61 mmol), prepared according to the method of Example 225B, and 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (172 mg, 0.47 mmol), prepared according to the method of Example 193E, in anhydrous N-methylpyrrolidinone (1 mL) was deoxygenated with nitrogen. Dichlorobis(triphenylphosphine) palladium(II) (6.6 mg, 0.009 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (7.7 mg, 0.009 mmol) were added and the reaction heated at 80 °C for 16 hours. The reaction mixture was cooled to room temperature and partitioned between diethyl ether and water. The ether was washed with two additional portions water then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was dissolved in acetone and adsorbed onto silica gel (1 g). Solvent was removed under

reduced pressure, the adsorbed silica gel layered over an Extract-Clean Cartridge® (Alltech, packing: 10 g silica gel) and the cartridge eluted with a hexanes/acetone step gradient consisting of the following mixtures: hexanes (60 mL), 8:1 hexanes/acetone (80 mL), 4:1 hexanes/acetone (150 mL). Fractions containing desired product were combined, concentrated, and further purified using HPLC (Technikrom Kromasil 60-5 sil silica column, 20 mm x 25 cm). The column was eluted with a linear gradient consisting of 30% ethyl acetate/hexanes to 100% ethyl acetate at 10 mL/min. over 50 minutes. Fractions containing the title product were combined and concentrated under reduced pressure to provide a pale yellow foam (yield: 95.0 mg, 49%). mp 75-81 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.02 (d, J=17.4 Hz, 2H), 7.76 (s, 1H), 7.55 (d, J=17.4 Hz, 2H), 5.51 (br s, 1H), 4.83 (br q, J=16.2 Hz, 3H), 3.11 (s, 3H), 2.18 (br, 2H), 1.96 (br, 2H), 1.70-1.50 (m, 4H). MS (DCI/NH₃) m/z 413 (M+H)⁺, m/z 430 (M+NH₄)⁺, m/z 447 (M+2NH₄-H)⁺. Anal. calc. for C₁₉H₁₉F₃N₂O₃S: C, 55.33; H, 4.64; N, 6.79. Found: C, 55.53; H, 4.71; N, 6.55.

Example 226

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

Example 226A

3-Fluoro-4-(methylthio)benzeneboronic acid.

3-Fluoro-4-(methylthio)benzeneboronic acid was prepared according to the method of Example 1, substituting 4-bromo-2-fluorothioanisole in place of 4-bromothioanisole.

Example 226B

2-Benzyl-4-methoxy-5-bromo-3(2H)-pyridazinone

2-Benzyl-4-methoxy-5-bromo-3(2H)-pyridazinone is prepared according to the method of Example 83B starting with 2-benzyl-4,5-dibromo-3(2H)-pyridazinone, in place of 2-(2,2,2-trifluoroethyl)-4,5-dibromo-3(2H)-pyridazinone and substituting methanol in place of isopropanol.

Example 226C2-Benzyl-4-methoxy-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone

3-Fluoro-4-(methylthio)benzeneboronic acid and 2-benzyl-4-methoxy-5-bromo-
3(2H)-pyridazinone were coupled according to the method of Example 83C to provide 2-
5 benzyl-4-methoxy-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone as a yellow
solid (yield: 4.98 g, 91%). ¹H NMR (300 MHz, CDCl₃) δ 7.76 (s, 1H), 7.47 (m, 2H),
7.39-7.21 (m, 7H), 5.34 (s, 2H), 4.13 (s, 3H), 2.51 (s, 3H). MS (DCI/NH₃) m/z 357
(M+H)⁺, m/z 374 (M+NH₄)⁺.

10

Example 226D3-Methylbutylmagnesium bromide

An oven-dried flask containing small pieces of magnesium ribbon (134 mg, 5.5
mmol) was charged with diethyl ether (12 mL). 1-Bromo-3-methylbutane (600 μ L, 5
15 mmol) was added dropwise, followed by dibromoethane (10 μ L). The reaction required
heating at gentle reflux before gas evolution was observed. The reaction was refluxed for
3 hours and cooled to room temperature. The pale gray solution of
3-methylbutylmagnesium bromide was used in the next reaction.

20

Example 226E2-Benzyl-4-(3-methylbutyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone

A solution of 2-benzyl-4-methoxy-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-
pyridazinone (500 mg, 1.40 mmol), prepared according to the method of Example 226C,
in THF (20 mL) was cooled to -78 °C. 3-Methylbutylmagnesium bromide (5 mL, 1.96
25 mmol), prepared in Example 226D, was added, dropwise. Upon completion of the
addition, the reaction mixture was placed in an ice bath. After 2.5 hours, the reaction was
quenched by adding saturated ammonium chloride solution. The crude reaction mixture
was partitioned between ethyl acetate and additional ammonium chloride solution. The
organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated

under reduced pressure to provide a yellow oil (yield: 550 mg, 99%). ¹H NMR (300 MHz, CDCl₃) δ 7.67 (s, 1H), 7.49 (m, 2H), 7.39-7.25 (m, 4H), 7.02 (m, 2H), 5.35 (s, 2H), 2.57-2.49 (m, 2H), 2.52 (s, 3H), 1.62-1.36 (m, 3H), 0.83 (d, 6H, J=12.0 Hz). MS (DCI/NH₃) m/z 397 (M+H)⁺, m/z 414 (M+NH₄)⁺. MS (DCI/NH₃) m/z 397 (M+H)⁺, m/z 414 (M+NH₄)⁺.

Example 226F

4-(3-Methylbutyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone.

2-Benzyl-4-(3-methylbutyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone (550 mg, 1.39 mmol), prepared in Example 226E, was debenzylated according to the method of Example 11 to provide 4-(3-methylbutyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone as a pale yellow solid (yield: 375 mg, 88%). ¹H NMR (300 MHz, CDCl₃) δ 7.65 (s, 1H), 7.34 (dd, 1H, J=16.2, 16.2 Hz), 7.11-6.98 (m, 2H), 2.60-2.50 (m, 2H), 2.54 (s, 3H), 1.65-1.37 (m, 3H), 0.83 (d, 6H, J=12.0 Hz). MS (DCI/NH₃) m/z 307 (M+H)⁺, m/z 324 (M+NH₄)⁺. MS (DCI/NH₃) m/z 307 (M+H)⁺, m/z 324 (M+NH₄)⁺.

Example 226G

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone.

4-(3-Methylbutyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone (375 mg, 1.23 mmol), prepared in Example 226F, was alkylated according to the method of Example 20 to provide 2-(2,2,2-trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone as a clear oil (yield: 331 mg, 69%). ¹H NMR (300 MHz, CDCl₃) δ 7.67 (s, 1H), 7.34 (dd, 1H, J=16.8, 16.8 Hz), 7.11-6.98 (m, 2H), 4.82 (dd, 2H, J=17.4, 17.4 Hz), 2.60-2.51 (m, 2H), 2.53 (s, 3H), 1.61-1.32 (m, 3H), 0.85 (d, 6H, J=12.0 Hz). MS (DCI/NH₃) m/z 389 (M+H)⁺, m/z 406 (M+NH₄)⁺. MS (DCI/NH₃) m/z 389 (M+H)⁺, m/z 406 (M+NH₄)⁺.

Example 226H

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone.

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone (331 mg, 0.85 mmol), prepared in Example 226G, was oxidized according to the method of Example 5 using only one equivalent of MCA to provide 2-(2,2,2-trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone as an off-white solid (yield: 240 mg, 69%). ¹H NMR (300 MHz, CDCl₃) δ 8.02 (dd, 1H, J=15.0, 15.0 Hz), 7.67 (s, 1H), 7.37 (dd, 1H, J=17.4, 3.0 Hz), 7.11 (dd, 1H, J=18.6, 3.0 Hz), 4.84 (dd, 2H, J=17.4, 17.4 Hz), 2.91 (s, 3H), 2.53 (m, 2H), 1.60-1.35 (m, 3H), 0.57 (d, 6H, J=12.0 Hz). MS (DCI/NH₃) m/z 405 (M+H)⁺, m/z 422 (M+NH₄)⁺. MS (DCI/NH₃) m/z 405 (M+H)⁺, m/z 422 (M+NH₄)⁺.

Example 226I

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone (240 mg, 0.594 mmol), prepared in Example 226H, was converted to the sulfonamide according to the procedure of Example 68 to provide the title compound as a white solid (yield: 109 mg, 44%). mp 153-156 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.07 (dd, J=15.0, 15.0 Hz, 1H), 7.74 (s, 1H), 7.27-7.19 (m, 2H), 5.14 (br s, 2H), 4.83 (q, J=18.0 Hz, 2H), 2.52 (m, 2H), 1.55 (m, 1H), 1.41 (m, 2H), 0.85 (d, J=12.6 Hz, 6H). MS (ESI (-)) m/z 420 (M-H)⁻. Anal. calc. for C₁₇H₁₉F₄N₃O₃S: C, 48.45; H, 4.54; N, 9.97. Found: C, 48.24; H, 4.56; N, 9.80.

Example 227

2-(2,2,2-Trifluoroethyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared by adding 1.0 M benzylmagnesium chloride in ether (0.53 mL, 0.53 mmol) to a THF (20 mL) solution of 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (150 mg, 0.41 mmol), prepared

according to the method of Example 193E, at 0 °C, then allowing the mixture to warm to room temperature over 2 hours. After an aqueous work-up, the crude material was purified by column chromatography (silica gel, 65:35 hexanes/ethyl acetate) and crystallized from ethyl acetate/hexanes to provide white, crystalline product (yield: 74 mg, 43%). mp 112-114 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 3H), 3.94 (s, 2H), 4.85 (q, J=12 Hz, 2H), 6.99 (dd, J=7.5 Hz, 3 Hz, 2H), 7.2 (m, 3H), 7.48 (d, J=9 Hz, 2H), 7.72 (s, 1H), 8.06 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 423 (M+H)⁺. Anal. calc. for C₂₀H₁₇F₃N₂O₃S: C, 56.86; H, 4.05; N, 6.63. Found: C, 56.60; H, 4.13; N, 6.57.

Example 228

2-(4-Fluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in Example 194C, (200 mg, 0.51 mmol) in THF (8 ml) was cooled to -78 °C and treated with cyclohexylmagnesium chloride, 2 M solution in ether (0.31 ml, 0.7 mmol). The reaction mixture was stirred at -78 °C for 2 hours and then was warmed up to room temperature by removing the cooling bath. Stirred at room temperature for 2 hours water (50 ml) was added to the reaction mixture and extracted with ethyl acetate (50 ml). The organic layer was dried over MgSO₄ and concentrated in vacuo. The resulting methyl sulfide compound was purified by flash chromatography (SiO₂, eluting with 9:1 hexanes:ethyl acetate) to provide the desired product (yield: 128 mg, 69%). MS (DCI/NH₃) m/z 395 (M+H)⁺, 412 (M+NH₄)⁺.

The methyl sulfide compound, prepared above, (122 mg, 0.3 mmol) in CH₂Cl₂ (10 ml) at 0 °C, was treated with CH₃CO₃H (0.3 ml, 1 mmol). The reaction was complete in 2 hours. The reaction mixture was diluted with CH₂Cl₂ and washed with saturated NaHCO₃ and brine respectively. The resulting crude residue was purified by flash chromatography (SiO₂, eluting with 1:1 hexanes:ethyl acetate) to provide the desired product (yield: 110 mg, 93%). mp 231-233 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.1 (m, 3H), 1.6 (m, 6H), 2.15 (m, 2H), 7.35 (t, 2H), 7.65 (m, 2H), 7.73 (dd, 2H) 7.93 (s, 1H), 8.1 (d, 2H). MS

(DCI/NH₃) m/z 427 (M+H)⁺, 444 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₃FN₂O₃S.0.75 H₂O: C, 64.77; H, 5.44; N, 6.57. Found: C, 62.86; H, 5.53; N, 5.78.

Example 229

5 2-(4-Fluorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , substituting p-tolylmagnesium bromide in place of cyclohexylmagnesium chloride (yield: 90 mg, 39%). mp 242-244 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.25 (s, 3H), δ 3.25 (s, 3H), 7.1 (t, 4H), 7.35 (t, 2H). 7.5 (d, J=9 Hz, 2H), 7.7 (dd, 2H) 7.9 (d, J=9 Hz, 2H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 435 (M+H)⁺, 452 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉FN₂O₃S.0.5 H₂O: C, 66.34; H, 4.41; N, 6.45. Found: C, 64.61; H, 4.57; N, 6.10.

Example 230

15 2-(4-Fluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , substituting benzylmagnesium bromide in place of cyclohexylmagnesium chloride (yield: 179 mg, 81%). mp 180-182 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.3 (s, 3H), 7.0 (d, 2H), 7.2 (m, 3H), 7.35 (t, 2H), 7.65 (m, 2H), 7.72 (d, 2H) 8.05 (m, 3H). MS (DCI/NH₃) m/z 435 (M+H)⁺, 452 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉FN₂O₃S.0.5 H₂O: C, 66.34; H, 4.41; N, 6.45. Found: C, 66.48; H, 4.17; N, 6.36.

Example 231

25 2-(4-Fluorophenyl)-4-(phenylethynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , substituting phenylacetylene magnesium bromide in place of cyclohexylmagnesium chloride (yield: 150 mg, 55.5%). mp 203-204 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.3 (s, 3H), 7.4 (m, 8H), 7.7 (m, 2H), 8.16 (m, 4H) ; 8.35 (s, 1H). MS (DCI/NH₃) m/z 435 (M+H)⁺, 452 (M+NH₄)⁺. Anal. calc. for C₂₅H₁₇FN₂O₃S: C, 67.56; H, 3.86; N, 6.30. Found: C, 67.63; H, 3.86; N, 6.30.

Example 2322-(3,4-Difluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 ,
5 starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-
pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-
pyridazinone (yield: 245 mg, 80%). mp 80-83 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.1
(m, 3H), 1.6 (m, 6H), 2.15 (m, 2H), 7.5 (m, 1H), 7.6 (m, 2H), 7.7 (d, 2H), 7.78 (m, 2H),
7.93 (s, 1H), 8.1 (d, 2H). MS (DCI/NH₃) m/z 445 (M+H)⁺, 462 (M+NH₄)⁺. Anal. calc. for
10 C₂₃H₂₂F₂N₂O₃S: C, 62.15; H, 4.99; N, 6.30. Found: C, 62.65; H, 5.25; N, 5.97.

Example 2332-(3,4-Difluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 ,
15 starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-
pyridazinone in place of 2-(4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-
pyridazinone and substituting benzylmagnesium bromide in place of
cyclohexylmagnesium chloride (yield 206 mg, 66%). mp 166-168 °C. ¹H NMR (300
MHz, DMSO-d₆) δ 3.3 (s, 3H), 3.9 (s, 2H), 7.0 (d, 2H), 7.2 (m, 3H), 7.6 (m, 2H), 7.72 (d,
20 2H), 7.8 (d, 1H), 8.05 (d, 2H), 8.12 (s, 1H). MS (DCI/NH₃) m/z 453 (M+H)⁺, 470
(M+NH₄)⁺. Anal. calc. for C₂₄H₁₉F₂N₂O₃S: C, 63.71; H, 4.01; N, 6.19. Found: C, 63.53;
H, 4.33; N, 5.76.

Example 234

25 2-(3,4-Difluorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 228 ,
starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-
pyridazinone in place of 2-(4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-

pyridazinone and substituting p-tolylmagnesium bromide in place of cyclohexylmagnesium chloride (yield: 140 mg, 56%) . mp 190-192 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.28 (s, 2H), δ 3.25 (s, 3H), 7.1 (s, 4H), 7.5 (m, 4H), 7.89 (m, 3H), 8.05 (d, 2H), 8.23 (s, 1H). MS (DCI/NH₃) m/z 453 (M+H)⁺, 470 (M+NH₄)⁺. Anal. calc. for C₂₄F₂H₁₈N₂O₃S: C, 63.71; H, 4.01; N, 6.19. Found: C, 63.69; H, 4.29; N, 5.96.

Example 235

2-(3,4-Difluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting 4-fluoro-3-methylbenzenemagnesium bromide in place of cyclohexylmagnesium chloride (yield: 180 mg, 72.5%) . mp 166-168 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.15 (s, 3H), δ 3.25 (s, 3H), 7.01 (m, 2H), 7.25 (d, 1H), 7.6 (m, 4H), 7.9 (m, 3H), 8.26 (s, 2H). MS (DCI/NH₃) m/z 471 (M+H)⁺, 488 (M+NH₄)⁺. Anal. calc. for C₂₄F₃H₁₇N₂O₃S: C, 61.27; H, 3.64; N, 5.95. Found: C, 61.47; H, 3.84; N, 5.67.

Example 236

2-(3,4-Difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-vinyl-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting vinyl magnesium bromide in place of cyclohexylmagnesium chloride (yield: 85 mg, 31.8%). ¹H NMR (300 MHz, DMSO-d₆) δ 2.15 (s, 3H), δ 3.3 (s, 3H), 5.7 (dd, 1H), 6.4 (dd, 1H), 6.7 (dd, 1H), 7.01 (m, 2H), 7.5 (m, 1H), 7.65 (m, 1H), 7.8 (m, 3H), 8.1 (s, 3H). MS (DCI/NH₃) m/z 389 (M+H)⁺, 406 (M+NH₄)⁺.

Example 237

2-(3,4-Difluorophenyl)-4-(2-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting 2-thienylmagnesium bromide in place of cyclohexylmagnesium chloride (yield: 66 mg, 28%). mp 189-191 °C ¹H NMR (300 MHz, DMSO-d₆) δ 3.3 (s, 3H), 6.95 (m, 2H), 7.55 (m, 1H), 7.7 (m, 5H), 7.85 (m, 1H), 8.03 (d, J=9 Hz, 2H), 8.13 (s, 1H). MS (DCI/NH₃) m/z 445 (M+H)⁺, 462 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₄F₂N₂O₃S₂: C, 56.75; H, 3.17; N, 6.30. Found: C, 56.92, H, 3.92, N, 5.79.

Example 2382-(3,4-Difluorophenyl)-4-(1-propynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting methylacetylenemagnesium bromide in place of cyclohexylmagnesium chloride (yield: 65 mg, 24%). mp 149-150 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.1 (s, 3H), 3.3 (s, 3H), 7.51 (m, 1H), 7.65 (m, 1H), 7.8 (m, 1H), 8.1 (m, 4H); 8.3 (s, 1H). MS (DCI/NH₃) m/z 463(M+H)⁺, 480 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₄F₂N₂O₃S.0.25 H₂O: C, 59.94; H, 3.52; N, 7.00. Found: C, 59.49; H, 3.63; N, 6.34.

Example 2392-(3,4-Difluorophenyl)-4-t-butyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting t-butylmagnesium bromide in place of cyclohexylmagnesium chloride (yield: 60 mg, 24%). mp 158-161 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.21, (s, 9H), 3.3 (s, 3H), 7.51 (m, 1H), 7.45 (m, 1H), 7.75 (m, 4H),

8.02 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 419 (M+H)⁺, 436 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₀F₂N₂O₃S: C, 60.27; H, 4.82; N, 6.69. Found: C, 60.15; H, 5.10; N, 6.39

Example 240

5 2-(2,2,2-Trifluoroethyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , starting with 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in Example 193D, in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, (yield: 120 mg, 53%). mp 215-218 °C. ¹H
10 NMR (300 MHz, CDCl₃) δ 1.1 (tt, J=9 Hz, J=4.5 Hz, 2H), 1.25 (tt, J=9 Hz, 4.5 Hz, 1H), 1.49 (d, J=12 Hz, 2H), 1.63 (d, J=12 Hz, 1H), 1.75 (dt, J=12 Hz, 3 Hz, 2H), 2.21 (qd, J=9 Hz, 4.5 Hz, 2H), 2.51 (tt, J=12 Hz, 3 Hz, 1H), 3.17 (s, 3H), 4.83 (q, J=12 Hz, 2H), 7.49 (d, J=9 Hz, 2H), 7.6 (s, 1H), 8.09 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 415 (M+H)⁺. Anal. calc. for C₁₉H₂₁F₃N₂O₃S: C, 55.06; H, 5.1; N, 6.75. Found: C, 55.08; H, 5.10; N, 6.70.

15

Example 241

2-(3-Chlorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3-Chlorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228 , starting with 2-(3-chlorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in
20 Example 207C, and substituting 3-fluorobenzylmagnesium chloride in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide compound was oxidized according to the method of Example 10 to provide the title compound (yield: 180 mg, 55%). mp 142-143 °C. ¹H NMR (300
25 MHz, CDCl₃) δ 3.14 (s, 3H), 3.98 (s, 2H), 6.75 (br d, J=9 Hz, 1H), 6.82 (br d, J=9 Hz, 1H), 6.88 (br t, J=9 Hz, 1H), 7.15-7.23 (m, 1H), 7.37-7.47 (m, 2H), 7.54 (d, J=9 Hz, 2H), 7.63 (dt, J=9 Hz, 2 Hz, 1H), 7.75 (t, J=2 Hz, 1H), 7.82 (s, 1H), 8.10 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 469 (M+H)⁺, 486 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈ClF₂N₂O₃S.0.5 H₂O: C, 60.38; H, 3.88; N, 5.87. Found: C, 60.62; H, 3.89; N, 5.82.

Example 2422-(4-Fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone2-(4-Fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylthio)phenyl]-3(2H)-

5 pyridazinone was prepared according to the method of Example 228, starting with 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in Example 194C, and substituting 3-fluorobenzylmagnesium chloride in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide compound was oxidized according to the method of Example 10, to provide the title compound (yield: 450 mg, 66.8%). mp 176-178 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.14 (s, 3H), 3.95 (s, 2H), 6.75 (br d, J=9 Hz, 1H), 6.82 (br d, J=9 Hz, 1H), 6.88 (br t, J=9 Hz, 1H), 7.14-7.23 (m, 3H), 7.54 (d, J=9 Hz, 2H), 7.67 (dd, J=9 Hz, 6 Hz, 2H), 7.81 (s, 1H), 8.10 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 516 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉F₂N₂O₃S.H₂O: C, 61.28; H, 4.04; N, 5.96. Found: C, 61.24; H, 4.09; N, 5.77.

Example 2432-(3,4-Difluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

20 2-(3,4-Difluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228, starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, and substituting 3-fluorobenzylmagnesium chloride in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

25 The methyl sulfide compound was oxidized according to the method of Example 10 to provide the title compound (yield: 390 mg, 68%). mp 161-163 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.14 (s, 3H), 3.95 (s, 2H), 6.74 (br d, J=9 Hz, 1H), 6.82 (br d, J=9 Hz, 1H), 6.89 (br t, J=9 Hz, 1H), 7.15-7.33 (m, 2H), 7.48-7.57 (m, 1H), 7.53 (d, J=9 Hz, 2H), 7.59-7.67 (m, 1H), 7.83 (s, 1H), 8.10 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 471 (M+H)⁺,

Found: C, 60.08; H, 3.81; N, 5.54.

5 2-(3-Chlorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The methyl sulfide compound was oxidized according to the method of Example 10 to provide the title compound (yield: 620 mg, 57%). mp 228-230 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.20 (s, 3H), 3.06 (s, 3H), 6.83-6.93 (m, 2H), 7.19 (br d, J=9 Hz, 1H), 7.37-7.47 (m, 2H), 7.40 (d, J=9 Hz, 2H), 7.65 (dt, J=7 Hz, 3 Hz, 1H), 7.68 (t, J=3 Hz, 1H), 7.91 (d, J=9 Hz, 2H), 7.98 (s, 1H). MS (DCI/NH₃) m/z 469 (M+H)⁺, 486 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈ClFN₂O₃S: C, 61.54; H, 3.85; N, 5.99. Found: C, 61.39; H, 3.84; N, 5.82.

25 2-(4-Fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228, starting with 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in Example 194C, and substituting 4-fluoro-3-methylphenylmagnesium bromide in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

226

MHz, CDCl₃) δ 2.01 (s, 3H), 3.07 (s, 3H), 6.87 (m, 2H), 7.21 (m, 3H), 7.41 (d, J=9 Hz, 2H), 7.68 (m, 2H), 7.92 (d, J=9 Hz, 2H), 7.97 (s, 1H). MS (DCI/NH₃) m/z 453 (M+H)⁺, 470 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈F₂N₂O₃S.0.5 H₂O: C, 62.47; H, 3.90; N, 6.08. Found: C, 62.11; H, 4.11; N, 5.81.

5

Example 246

2-(3-Chloro-4-fluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

10

Example 246A

2-(3-Chloro-4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

The title compound is prepared according to the method of Example 194A, substituting 3-chloro-4-fluorophenyl hydrazine·HCl in place of 4-fluorophenyl hydrazine·HCl (yield: 9.1 g, 9%). ¹H NMR (300 MHz, CDCl₃) 7.22 (d, J=9 Hz, 1H), 7.53-7.58 (m, 1H), 7.73 (dd, J=9 Hz, 3 Hz, 1H), 7.94 (s, 1H). MS (DCI/NH₃) m/z 383 (M+H)⁺, 400 (M+NH₄)⁺

15

Example 246B

2-(3-Chloro-4-fluorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone.

The title compound is prepared according to the method of Example 194B, substituting 2-(3-chloro-4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone (yield: 5.6 g, 84%). ¹H NMR (300 MHz, CDCl₃) 4.32 (s, 3H), 7.22-7.30 (m, 1H), 7.45-7.55 (m, 1H), 7.64-7.74 (m, 1H), 7.94 (d, J=9 Hz, 1H). MS (DCI/NH₃) m/z 335 (M+H)⁺, 352 (M+NH₄)⁺.

20

Example 246C

2-(3-Chloro-4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone.

The title compound is prepared according to the method of Example 6 starting with 2-(3-chloro-4-fluorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone in place of 2-benzyl-

5-methoxy-4-bromo-3(2H)-pyridazinone and substituting 4-(methylthio)benzeneboronic acid in place of 4-fluorobenzeneboronic acid (yield: 3.2 g, 63%). ¹H NMR (300 MHz, CDCl₃) δ 2.53 (s, 3H), 4.13 (s, 3H), 7.25 (t, J=9 Hz, 1H), 7.35 (d, J=9 Hz, 2H), 7.52 (d, J=9 Hz, 2H), 7.55-7.64 (m, 1H), 7.78 (dd, J=9 Hz, 3 Hz, 1H), 7.93 (s, 2H). MS (DCI/NH₃) m/z 377 (M+H)⁺, 394 (M+NH₄)⁺.

Example 246D

2-(3-Chloro-4-fluorophenyl)-4-cyclohexyl-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound is prepared starting with 2-(3-chloro-4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone by treatment of the methoxy-sulfide compound with cyclohexylmagnesium chloride according to the method of Example 228 to provide the cyclohexyl sulfide compound.

Example 246E

2-(3-Chloro-4-fluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

The methyl sulfide compound was oxidized according to the method of Example 10 to provide the title compound (yield: 150 mg, 53%). mp 180-181 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.02-1.36 (m, 2H), 1.49-1.68 (m, 4H), 1.75 (br d, J=12 Hz, 2H), 2.28 (dq, J=12 Hz, 3 Hz, 2H), 2.57 (tt, J=12 Hz, 3 Hz, 1H), 3.17 (s, 3H), 7.25 (t, J=9 Hz, 1H), 7.53 (d, J=9 Hz, 1H), 7.53-7.61 (m, 2H), 7.69 (s, 1H), 7.78 (dd, J=9 Hz, 3 Hz, 1H), 8.12 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 461 (M+H)⁺, 478 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₂ClFN₂O₃S: C, 60.01; H, 4.78; N, 6.09. Found: C, 59.85; H, 4.97; N, 5.79.

Example 247

2-(3-Chloro-4-fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3-Chloro-4-fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228, starting with 2-(3-chloro-4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in Example 246C, and substituting 4-fluoro-3-methylphenylmagnesium bromide in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 118 mg, 53.7%). mp 207-208 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.21 (br s, 3H), 3.08 (s, 3H), 6.81-6.93 (m, 2H), 7.15-7.30 (m, 2H), 7.41 (d, J=9 Hz, 2H), 7.60-7.68 (m, 1H), 7.85 (dd, J=9 Hz, 3 Hz, 1H), 7.93 (d, J=9 Hz, 2H), 7.99 (s, 1H). MS (DCI/NH₃) m/z 487 (M+H)⁺, 504 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₇ClF₂N₂O₃S.0.25 H₂O: C, 58.75; H, 3.52; N, 5.72. Found: C, 58.74; H, 3.60; N, 5.32.

Example 248

2-(3-Chloro-4-fluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3-Chloro-4-fluorophenyl)-4-benzyl-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228, starting with 2-(3-chloro-4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in Example 246C, and substituting benzylmagnesium chloride in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 110 mg, 38.4%). mp 164-166 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.11 (s, 3H), 3.99 (s, 2H), 7.01-7.06 (m, 2H), 7.17-7.28 (m, 4H), 7.53 (d, J=9 Hz, 2H), 7.59-7.66 (m, 1H), 7.81 (s, 1H), 7.82 (dd, J=6 Hz, 3 Hz, 1H), 8.09 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 473 (M+H)⁺, 490 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈ClFN₂O₃S: C, 61.54; H, 3.85; N, 5.99. Found: C, 61.40; H, 3.82; N, 5.54.

Example 249

2-(3-Chloro-4-fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3-Chloro-4-fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228, starting with 2-(3-chloro-4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone,
5 prepared in Example 246C, and substituting 3-fluorobenzylmagnesium chloride in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 33 mg, 15%). mp 101-103 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.15 (s, 3H), 3.95 (s, 2H), 6.73 (br d, J=9 Hz, 1H), 6.81 (br d, J=9 Hz, 1H), 6.88 (br t, J=9 Hz, 1H), 7.15-7.28 (m, 2H), 7.51 (d, J=9 Hz, 2H), 7.53 (ddd, J=9 Hz, 3 Hz, 1.5 Hz, 1H), 7.83 (dd, J=6 Hz, 3 Hz, 1H), 7.83 (s, 1H), 8.10 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 487 (M+H)⁺, 504 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₇ClF₂N₂O₃S: C, 58.75; H, 3.52; N, 5.62. Found: C, 58.50; H, 3.65; N, 5.29.

Example 250

2-(4-Fluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(4-Fluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228, starting with 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in
20 Example 194C, and substituting 3-fluoro-4-methylphenylmagnesium bromide in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 540 mg, 73%). mp 245-248 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.22 (br s, 3H), 3.05 (s, 3H), 6.83 (dd, J=9 Hz, 1.5 Hz, 1H), 6.96 (dd, J=9 Hz, 1.5 Hz, 1H), 7.06 (t, J=9 Hz, 1H), 7.18 (t, J=9 Hz, 2H), 7.41 (d, J=9 Hz, 2H), 7.65-7.72 (m, 2H), 7.91 (d, J=9 Hz, 2H), 7.95 (s, 1H). MS (DCI/NH₃) m/z 452 (M+H)⁺, 470 (M+NH₄)⁺.

Anal. calc. for $C_{24}H_{18}F_2N_2O_3S$: C, 63.86; H, 3.99; N, 6.21. Found: C, 63.49; H, 4.13; N, 5.98.

Example 251

5 2-(3-Chloro-4-fluorophenyl)-4-(3,5-difluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3-Chloro-4-fluorophenyl)-4-(3,5-difluoro-4-methoxyphenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228, starting with 2-(3-chloro-4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in Example 246C, and substituting 3,5-difluoro-4-methoxyphenylmagnesium bromide in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 590 mg, 65.7%). mp 195-197 °C. 1H NMR (300 MHz, $CDCl_3$) δ 3.10 (s, 3H), 4.12 (s, 3H), 6.81 (br d, J=9 Hz, 2H), 7.27 (t, J=9 Hz, 1H), 7.43 (d, J=9 Hz, 2H), 7.60-7.67 (m, 1H), 7.83 (br d, J=9 Hz, 1H), 7.98 (d, J=9 Hz, 2H), 7.98 (s, 1H). MS (DCI/ NH_3) m/z 487 (M+H) $^+$, 504 (M+ NH_4) $^+$. Anal. calc. for $C_{24}H_{16}ClF_2N_2O_3S \cdot 0.5 H_2O$: C, 54.44; H, 3.12; N, 5.30. Found: C, 54.50; H, 3.12; N, 5.15.

20 Example 252

2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 228, starting with 2-(3-chloro-4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, prepared in Example 246C, and substituting 1-(3-methylbutyl)magnesium bromide in place of cyclohexylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 425 mg, 54.4%). mp 102-104 °C. 1H NMR (300 MHz,

CDCl₃) δ 0.85 (d, J=9 Hz, 6H), 1.41-1.62 (m, 1H), 2.50-2.63 (m, 2H), 3.30 (s, 3H), 7.22-7.38 (m, 3H), 7.57-7.64 (m, 1H), 7.72 (br s, 1H), 7.80 (br d, J=6 Hz, 1H), 8.15 (t, J=9 Hz, 1H). MS (DCI/NH₃) m/z 467 (M+H)⁺, 484 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁ClF₂N₂O₃S: C, 56.65; H, 4.51; N, 6.01. Found: C, 56.25; H, 4.49; N, 6.06.

5

Example 253

2-(4-Fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The sulfide from Example 242, 2-(4-fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, was oxidized to the methyl sulfoxide with one equivalent of meta-chloroperoxybenzoic acid according to the procedure in Example 69B to provide the sulfinyl compound.

The sulfoxide was converted to the title sulfonamide according to the method of Example 68 (yield: 120 mg, 31%). mp 199-202 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.92 (s, 2H), 6.85 (br t, J=9 Hz, 2H), 6.99 (br t, J=9 Hz, 1H), 7.26 (q, J=7 Hz, 1H), 7.35 (t, J=9 Hz, 2H), 7.50 (s, 2H), 7.62-7.71 (m, 4H), 7.95 (d, J=9 Hz, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 454 (M+H)⁺, 471 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₇F₂N₃O₃S: C, 60.86; H, 3.75; N, 9.27. Found: C, 60.99; H, 3.76; N, 9.02.

15

Example 254

2-(3,4-Difluorophenyl)-4-(phenylethynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228, starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 245 mg, 80%) and substituting phenylethynylmagnesium bromide in place of cyclohexylmagnesium chloride (yield: 195 mg, 61%). mp 211-213 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 7.46 (m, 5H), 7.65 (m, 2H), 8.18 (t, 4H); 8.4 (s, 1H). MS (DCI/NH₃) m/z 463(M+H)⁺, 480 (M+NH₄)⁺. Anal. calc. for C₂₅H₁₆F₂N₂O₃S: C, 64.56; H, 3.49; N, 6.06. Found: C, 64.49; H, 3.68; N, 5.86.

25

Example 2552-(3,4-Difluorophenyl)-4-(3,4-difluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 3,4-Difluorobenzyl bromide (0.1 ml, 0.8 mmol) in ether (10 ml) was treated with magnesium turnings (19.4 mg, 0.81 mmol) and the reaction mixture was refluxed for 1 hour. The reaction mixture was cooled and added to a solution of 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (0.25 g, 0.7 mmol) in THF (10 ml) at -78 °C. The reaction mixture was stirred at room temperature for 18 hours. Water
10 (50 ml) was added to the reaction mixture and extracted with ethyl acetate (50 ml). The organic layer was dried over MgSO₄ and concentrated in vacuo. The resulting crude residue was purified by flash chromatography (SiO₂, eluting with 9:1 hexanes:ethyl acetate) to provide 120 mg of desired product and some starting material.

 The methylthio compound (120 mg, 0.3 mmol) from above in CH₂Cl₂ (10 ml) at 0
15 °C, was treated with CH₃CO₃H (0.3 ml, 1 mmol). The reaction was complete in 2 hours. The reaction mixture was diluted with CH₂Cl₂ and washed with saturated NaHCO₃ and brine respectively. The resulting crude residue was purified by flash chromatography (SiO₂, eluting with 1:1 hexanes:ethyl acetate) to provide the desired product (yield: 44 mg, 13%). mp 177-179 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.3 (s, 3H), 3.9 (s, 2H),
20 6.85 (m, 1H), 7.15 (m, 1H), 7.25 (m, 2H), 7.6 (m, 7H), 8.15 (m, 3H). MS (DCI/NH₃) m/z 489 (M+H)⁺, 506 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₆F₄N₂O₃S.0.25 H₂O: C, 59.01; H, 3.30; N, 5.74. Found: C, 58.16; H, 3.56; N, 4.51.

Example 256

25 2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

 The title compound was prepared according to the method of Example 228, starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-

pyridazinone (yield: 245 mg, 80%) and substituting 1-bromo-3-methylbutane in place of cyclohexylmagnesium chloride (yield: 198 mg, 48%). mp 55-58 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, 6H), 1.4, (m, 3H), 2.48 (m, 2H), 3.3 (s, 3H), 7.51 (m, 1H), 7.65 (m, 1H), 7.75 (d, J=9 Hz, 2H), 7.81 (m, 1H) 8.05 (s, 1H), 8.12 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 433 (M+H)⁺, 450 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₂F₂N₂O₃S.0.25 H₂O: C, 61.10; H, 5.13; N, 6.48. Found: C, 61.09; H, 5.23; N, 6.36.

Example 257

2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 starting with 2-(3-chloro-4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone from Example 246C in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting 1-bromo-3-methylbutane in place of cyclohexylmagnesium chloride (yield: 256 mg, 88%). mp 55-58 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, 6H), 1.4, (m, 3H), 2.48 (m, 2H), 3.3 (s, 3H), 7.62 (m, 2H), 7.75 (d, 2H), 7.93 (dd, 1H), 8.05 (s, 1H), 8.12 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 449 (M+H)⁺, 466 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₂FN₂O₃SCl.0.25 H₂O: C, 58.86; H, 4.94; N, 6.24. Found: C, 59.23; H, 5.12; N, 6.00.

Example 258

2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228, procedure starting with 2-(3,4-difluorophenyl)-4-methoxy-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting 1-bromo-3-methylbutane in place of cyclohexylmagnesium chloride (yield: 100 mg, 20%). mp 119-121 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, 6H), 1.4, (m, 3H), 2.48 (m, 2H), 3.4 (s,

3H), 7.51 (m, 1H), 7.8 (m, 2H), 7.81 (m, 2H). MS (DCI/NH₃) m/z 451 (M+H)⁺, 468 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁F₃N₂O₃S: C, 58.66; H, 4.7; N, 6.22.

Example 259

5 2-[4-Fluoro-3-(methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
 3(2H)-pyridazinone

To a stirred solution of 2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (315 mg, 0.69 mmol), Example 182, in DMF (10 ml) at room temperature was treated with sodium thiomethoxide (51 mg, 0.7 mmol).
10 The reaction mixture was stirred at room temperature for 3.15 hours. The reaction was poured into water (75 ml) and extracted into ethyl acetate. The organic layer was washed two times with brine, dried over MgSO₄, and concentrated in vacuo. The resulting crude residue was purified using flash chromatography (SiO₂, eluting with (15:1 CH₂Cl₂:diethyl ether) to provide the desired product (yield: 30 mg, 8%). mp 105-107 °C. ¹H NMR (300
15 MHz, DMSO-d₆) δ 2.55 (s, 3H), 3.23 (s, 3H), δ 7.15 (m, 2H), 7.3 (m, 2H), 7.55 (m, 5H), 7.9 (d, 2H), 8.25 (s, 1H). MS (DCI/NH₃) m/z 485 (M+H)⁺, 502 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈F₂N₂O₃S₂: C, 59.49; H, 3.74; N, 5.78.

Example 260

20 2-Benzyl-4-(4-fluorophenyl)-5-[4-(trifluoromethylsulfonyl)phenyl]-3(2H)-pyridazinone:

Example 260A

2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared starting with 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and oxidizing the sulfide according to the
25 procedure in example 69B

Example 260B

Bis(4-(5-(2-benzyl-4-(4-fluorophenyl)-3(2H)-pyridazinone)phenyl)disulfide:

A heterogeneous solution of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone (1.0 g, 2.39 mmol) in trifluoroacetic anhydride (10 mL, 70.8 mmol) was rapidly stirred at reflux for 2 hours with a bath temperature of 40-43 °C. The reaction solution was cooled to 23 °C, concentrated in vacuo, and azeotroped with toluene (2 x 5-7 mL). The resultant yellow/orange oil was cooled to 0 °C, and methanol/triethylamine (1:1, 6 mL) was slowly added, along the interior wall of the reaction vessel with rapid stirring. The bright red-orange solution was stirred for 10 minutes at 0 °C, the cooling bath removed, and the reaction mixture stirred an additional 1.5 hours warming to 23 °C. The mixture was cooled back to 0 °C, and a saturated NH₄Cl solution (200 mL) slowly added followed by enough aqueous 1 M HCl to adjust the solution to pH 1-2. The cooling bath was removed and the solution stirred overnight. The mixture was extracted with ethyl acetate. The ethyl acetate solution was washed with water and brine, and concentrated in vacuo. The resultant yellow/brown oil (0.89 g) was a mixture of predominantly the mono-sulfide and desired di-sulfide. Subsequent rapid stirring of a portion of the crude reaction mixture (360 mg) in benzene (100 mL) with I₂ (648 mg, 2.55 mmol) at 23 °C for 30 minutes completed the conversion of the mono-sulfide to the di-sulfide. (Chem. Pharm. Bull., 1992, 40, 2842) The mixture was treated with a 0.1 M Na₂S₂O₃ solution to consume the excess I₂. This solution was extracted with ethyl acetate, and the ethyl acetate layers dried over MgSO₄, filtered, and concentrated in vacuo. The residue was dissolved in CH₂Cl₂/hexanes and concentrated in vacuo to provide the of product (yield: 347 mg, 90% for partial conversion). ¹H NMR (300 MHz, CDCl₃) δ 5.38 (s, 4H), 6.91 (dd, J=8.8, 8.8 Hz, 4H), 7.02 (d, J=8.7 Hz, 4H), 7.11-7.20 (m, 4H), 7.28-7.39 (m, 10H), 7.54 (dd, J=6.9, 1.5 Hz, 4H), 7.83 (s, 2H).

Example 260C

2-Benzyl-4-(4-fluorophenyl)-5-[4-(trifluoromethylthio)phenyl]-3(2H)-pyridazinone:

A rapidly stirred mixture of bis[4-{5-[2-benzyl-4-(4-fluorophenyl)-3(2H)-pyridazinone]}-phenyl]-disulfide (140 mg, 0.181 mmol), potassium trifluoroacetate (55 mg, 0.361 mmol), and sulfolane (1.5 mL) was immersed in a 180 °C pre-heated oil bath.

The oil bath was heated to increase the temperature to 210 °C, and the reaction flask was promptly removed from the oil bath after 10 minutes from the point of first immersion. During the course of the reaction, the mixture changed from colorless and heterogeneous to deep, blood red and homogeneous. After cooling to 23 °C, the mixture was diluted with ethyl acetate and washed with aqueous 1 M HCl, water, and brine. The ethyl acetate solution was dried over MgSO₄, filtered and concentrated in vacuo. The residue was chromatographed (flash silica gel, ethyl acetate/hexanes 1:4) to provide the product (yield: 17 mg, 41%). (Tetrahedron Lett., 1996, 37, 9057) ¹H NMR (300 MHz, CDCl₃) δ 5.41 (s, 2H), 6.94 (dd, J=8.2, 8.2 Hz, 2H), 7.11-7.20 (m, 4H), 7.31-7.42 (m, 3H), 7.52-7.61 (m, 4H), 7.86 (s, 1H). MS (APCI+) m/z 457 (M+H)⁺ and m/z 474 (M+NH₄)⁺.

Example 260D

2-Benzyl-4-(4-fluorophenyl)-5-[4-(trifluoromethylsulfonyl)phenyl]-3(2H)-pyridazinone:

A solution of 2-benzyl-4-(4-fluorophenyl)-5-[4-(trifluoromethylthio)phenyl]-3(2H)-pyridazinone (100 mg, 0.219 mmol), 3-chloroperoxybenzoic acid (380 mg, 1.3 mmol, 57-86%), and methylene chloride (5 mL) was brought to reflux at a bath temperature of 55 °C. After 1.75 hours, 3.5 hours, 5 hours, and 6 hours, the reaction was not complete and additional 3-chloroperoxybenzoic acid (380 mg, 1.3 mmol, 57-86%) was added each time. With the reaction completed after 7.75 hours, the mixture was cooled to 23 °C and concentrated in vacuo. The residue was diluted with ethyl acetate and carefully shaken with a NaHSO₃ solution, 3 times, for several minutes to consume the excess 3-chloroperoxybenzoic acid. The ethyl acetate solution was subsequently washed with a saturated Na₂CO₃ solution (3x), water, and brine and dried over MgSO₄, filtered, and concentrated in vacuo. The residue was chromatographed (flash silica gel, ethyl acetate/methylene chloride/hexanes 1:2:7) to provide of product (yield: 93 mg, 87%). (J. Med. Chem., 1990, 33, 2569) mp 80-115 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 5.36 (s, 2H), 7.11 (dd, J=9.0, 9.0 Hz, 2H), 7.18-7.26 (m, 2H), 7.29-7.46 (m, 5H), 7.66 (d, J=8.7 Hz, 2H), 8.10 (d, J=8.7 Hz, 2H), 8.18 (s, 1H). MS (APCI+) m/z 489 (M+H)⁺ and m/z 506

(M+NH₄)⁺. Anal. calc. for C₂₄H₁₆F₄N₂O₃S: C, 59.02; H, 3.30; N, 5.74. Found: C, 59.30; H, 3.48; N, 5.59.

Example 261

5 2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

2-(2,2,2-Trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (150 mg, 0.41 mmol), prepared in Example 193E, and neopentyl alcohol (43 mg, 0.49 mmol) were dissolved in DMF (2 mL) and NaH (25 mg, 0.62 mmol, 60% in mineral oil) was added with shaking and left overnight. The reaction mixture was carefully quenched with saturated NH_4Cl solution, diluted with ethyl acetate and extracted with 1 N HCl, twice, then water, 3 times, and then dried over MgSO_4 . After filtration of the drying agent and concentration of the filtrate in vacuo, the residue was purified by chromatography on silica gel (Biotage 40S) eluted with 2:1 hexanes-ethyl acetate. The product fractions were combined and evaporated to provide the title compound (yield: 137 mg, 76%). mp 145-146 °C. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 0.76 (s, 9H), 3.28 (s, 3H), 4.06 (s, 2H), 5.02 (q, $J=9$ Hz, 2H), 7.88 (d, $J=8$ Hz, 2H), 8.04 (d, $J=8$ Hz, 2H), 8.13 (s, 1H). MS (DCI/ NH_3) m/z 419 ($\text{M}+\text{H}$) $^+$, 436 ($\text{M}+\text{NH}_4$) $^+$. Anal. calc. for $\text{C}_{18}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_4\text{S}$: C, 51.67; H, 5.06; N, 6.69. Found: C, 51.47; H, 5.12; N, 6.48.

Example 262

2-(2,2,2-Trifluoroethyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 261, substituting 4-methoxyphenol in place of neopentyl alcohol (yield: 130 mg, 54%). mp 194-195 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.24 (s, 3H), 3.26 (s, 3H), 5.00 (q, J=9 Hz, 2H), 6.88 (d, J=8 Hz, 2H), 7.09 (d, J=8 Hz, 2H), 7.37 (d, J=8 Hz, 2H), 8.03 (d, J=8 Hz, 2H), 8.33 (s, 1H). MS (ESI-) m/z 439 (M-H)⁻. Anal. calc. for C₁₉H₁₇F₃N₂O₄S: C, 54.79; H, 3.91; N, 6.39. Found: C, 55.04; H, 4.00; N, 6.11.

Example 2632-(2,2,2-Trifluoroethyl)-4-(2-fluoro-5-trifluoromethylphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound was prepared according to the method of Example 261, substituting 2-fluoro-5-trifluoromethylphenol in place of neopentyl alcohol (yield: 155 mg, 89%). mp 133-135 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.28 (s, 3H), 5.03 (q, J=9 Hz, 2H), 7.10-7.53 (m, 2H), 7.72 (dd, J=1 Hz, 7 Hz 1H), 7.92 (d, J=8 Hz, 2H), 8.07 (d, J=8 Hz, 2H), 8.38 (s, 1H). MS (DCI/NH₃) m/z 528 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₃F₇N₂O₄S: C, 47.66; H, 3.09; N, 5.05. Found: C, 47.68; H, 2.95; N, 5.16.

10

Example 2642-(2,2,2-Trifluoroethyl)-4-(4-cyanophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

15 The title compound was prepared according to the method of Example 261, substituting 4-cyanophenol in place of neopentyl alcohol (yield: 109 mg, 71%). mp 179-181 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.26 (s, 3H), 5.02 (q, J=9 Hz, 2H), 7.25 (d, J=9 Hz, 2H), 7.81 (d, J=9 Hz, 2H), 7.86 (d, J=8 Hz, 2H), 8.03 (d, J=8 Hz, 2H), 8.37 (s, 1H). MS (DCI/NH₃) m/z 467 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₄F₃N₃O₄S: C, 53.45; H, 3.14; N, 9.35. Found: C, 53.19; H, 3.01; N, 9.09.

20

Example 2652-(2,2,2-Trifluoroethyl)-4-(3-pyridyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

25 The title compound was prepared according to the method of Example 261, substituting 3-hydroxypyridine in place of neopentyl alcohol (yield: 120 mg, 69%). mp 191-193 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.26 (s, 3H), 5.01 (q, J=9 Hz, 2H), 7.36 (dd, J=3 Hz, 8 Hz, 1H), 7.55 (ddd, J=1 Hz, 3 Hz, 8 Hz, 1H), 7.88 (d, J=8 Hz, 2H), 8.04 (d, J=8 Hz, 2H), 8.31 (dd, J=1 Hz, 5 Hz, 1H), 8.36 (s, 1H), 8.38 (d, J=3 Hz, 1H). MS

(DCI/NH₃) m/z 426 (M+H)⁺, 443 (M+NH₄)⁺. Anal. calc. for C₁₈H₁₄F₃N₃O₄S: C, 50.82; H, 3.32; N, 9.88. Found: C, 50.95; H, 3.57; N, 9.71.

Example 266

5 2-(2,2,2-Trifluoroethyl)-4-(4-n-propylphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 261, substituting 4-(n-propyl)phenol in place of neopentyl alcohol (yield: 147 mg, 77%). mp 152-153 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.87 (t, J=7 Hz, 3H), 1.54 (h, J=7 Hz, 2H), 3.25 (s, 3H), 5.00 (q, J=9 Hz, 2H), 6.88 (d, J=9 Hz, 2H), 7.09 (d, J=9 Hz, 2H), 7.87 (d, J=8 Hz, 2H), 8.02 (d, J=8 Hz, 2H), 8.32 (s, 1H). MS (DCI/NH₃) m/z 484 (M+H)⁺. Anal. calc. for C₂₇H₂₇F₃N₂O₄S: C, 56.33; H, 4.54; N, 6.01. Found: C, 56.23; H, 4.75; N, 5.79.

Example 267

15 2-(2,2,2-Trifluoroethyl)-4-[4-(methylsulfonyl)phenoxy]-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 4-(methylsulfonyl)phenol in place of neopentyl alcohol (yield: 115 mg, 56%). mp 212-213 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 3.21 (s, 3H), 3.27 (s, 3H), 5.03 (q, J=9 Hz, 2H), 7.31 (d, J=9 Hz, 2H), 7.83-7.89 (m, 4H), 8.04 (d, J=8 Hz, 2H), 8.40 (s, 1H). MS (DCI/NH₃) *m/z* 520 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₇F₃N₂O₆S₂: C, 47.81; H, 3.41; N, 5.58. Found: C, 47.92; H, 3.18; N, 5.52.

Example 268

25 2-(2,2,2-Trifluoroethyl)-4-(4-phenylphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 261, substituting 4-phenylphenol in place of neopentyl alcohol (yield: 105 mg, 51%). mp 163-165 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.26 (s, 3H), 5.02 (q, J=9 Hz, 2H), 7.10 (d, J=8

Hz, 2H), 7.33 (br t, J=7 Hz, 1H), 7.44 (t, J=7 Hz, 2H), 7.57-7.63 (m, 4H), 7.92 (d, J=8 Hz, 2H), 8.04 (d, J=8 Hz, 2H), 8.37 (s, 1H). MS (DCI/NH₃) m/z 518 (M+NH₄)⁺. Anal. calc. for C₂₅H₁₉F₃N₂O₄S: C, 60.00; H, 3.83; N, 5.60. Found: C, 60.18; H, 3.66; N, 5.52.

5

Example 2692-(2,2,2-Trifluoroethyl)-4-[2-(methylthio)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 2-(methylthio)ethanol in place of neopentyl alcohol (yield: 105 mg, 61%). mp 103-105 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.01 (s, 3H), 2.72 (t, J=7 Hz, 2H), 3.29 (s, 3H), 4.59 (t, J=7 Hz, 2H), 5.03 (q, J=9 Hz, 2H), 7.91 (d, J=8 Hz, 2H), 8.04 (d, J=8 Hz, 2H), 8.15 (s, 1H). MS (DCI/NH₃) m/z 423 (M+H)⁺, 440 (M+NH₄)⁺. Anal. calc. for C₁₆H₁₇F₃N₂O₄S₂: C, 45.49; H, 4.06; N, 6.33. Found: C, 45.83; H, 4.11; N, 6.42.

15

Example 2702-(2,2,2-Trifluoroethyl)-4-(phenylmethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting benzyl alcohol in place of neopentyl alcohol (yield: 137 mg, 76%). mp 121-123 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.28 (s, 3H), 5.06 (q, J=9 Hz, 2H), 5.48 (s, 2H), 7.20-7.25 (m, 2H), 7.27-7.81 (m, 3H), 7.76 (d, J=8 Hz, 2H), 7.98 (d, J=8 Hz, 2H), 8.12 (s, 1H). MS (DCI/NH₃) m/z 456 (M+H)⁺. Anal. calc. for C₂₀H₁₇F₃N₂O₄S: C, 54.79; H, 3.91; N, 6.39. Found: C, 55.10; H, 3.91; N, 6.13.

25

Example 2712-(2,2,2-Trifluoroethyl)-4-(2-furylmethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 2-(hydroxymethyl)furan in place of neopentyl alcohol (yield: 101 mg, 58%).

mp 113-115 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.28 (s, 3H), 5.07 (q, J=9 Hz, 2H), 5.52 (s, 2H), 6.41 (dd, J=2 Hz, 3 Hz, 1H), 6.45 (d, J=4 Hz, 1H), 7.62 (d, J=2 Hz, 1H), 7.69 (d, J=8 Hz, 2H), 7.97 (d, J=8 Hz, 2H), 8.13 (s, 1H). MS (DCI/NH₃) m/z 446 (M+NH₄)⁺. Anal. calc. for C₁₈H₁₅F₃N₂O₅S: C, 50.66; H, 3.80; N, 6.21. Found: C, 51.02; H, 3.71; N, 6.23.

Example 272

2-(2,2,2-Trifluoroethyl)-4-[2-(3,4-dimethoxyphenyl)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 2-(3,4-dimethoxyphenyl)ethanol in place of neopentyl alcohol (yield: 118 mg, 56%). mp 133-134 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.82 (t, J=7 Hz, 2H), 3.28 (s, 3H), 3.63 (s, 3H), 3.70 (s, 3H), 4.68 (t, J=7 Hz, 2H), 5.01 (q, J=9 Hz, 2H), 6.61 (dd, J=2 Hz, 8 Hz, 1H), 6.74 (d, J=2 Hz, 1H), 6.77 (d, J=8 Hz, 1H), 7.74 (d, J=8 Hz, 2H), 7.93 (d, J=8 Hz, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 530 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₃F₃N₂O₆S: C, 53.90; H, 4.52; N, 5.47. Found: C, 53.87; H, 4.48; N, 5.45.

Example 273

2-(2,2,2-Trifluoroethyl)-4-[2-(4-morpholino)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 4-(2-hydroxyethyl)morpholine in place of neopentyl alcohol (yield: 111 mg, 59%). mp 147-148 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.23 (m, 4H), 2.46 (t, J=5 Hz, 2H), 3.28 (s, 3H), 3.40 (m, 4H), 4.60 (t, J=5 Hz, 2H), 5.02 (q, J=8 Hz, 2H), 7.96 (d, J=8 Hz, 2H), 8.03 (d, J=8 Hz, 2H), 8.17 (s, 1H). MS (DCI/NH₃) m/z 462 (M+H)⁺. Anal. calc. for C₁₉H₂₂F₃N₃O₅S: C, 49.45; H, 4.81; N, 9.11. Found: C, 49.59; H, 4.80; N, 8.88.

Example 274

2-(2,2,2-Trifluoroethyl)-4-[2-(1-piperidinyl)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 1-(2-hydroxyethyl)piperidine in place of neopentyl alcohol (yield: 103 mg, 55%). mp 117-118 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.30 (br s, 6H), 2.20 (br s, 4H), 2.41 (t, J=4 Hz, 2H), 3.28 (s, 3H), 4.60 (t, J=5 Hz, 2H), 5.02 (q, J=9 Hz, 2H), 7.97 (d, J=8 Hz, 2H), 8.03 (d, J=8 Hz, 2H), 8.15 (s, 1H). MS (DCI/NH₃) m/z 460 (M+H)⁺. Anal. calc. for C₂₀H₂₄F₃N₃O₄S: C, 52.28; H, 5.26; N, 9.15. Found: C, 52.22; H, 5.08; N, 8.94.

Example 275

2-(2,2,2-Trifluoroethyl)-4-[4-(carboxamido)phenoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 4-hydroxybenzamide in place of neopentyl alcohol (yield: 50 mg, 26%). mp > 250 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.26 (s, 3H), 5.02 (q, J=8 Hz, 2H), 7.08 (d, J=9 Hz, 2H), 7.30 (s, 1H), 7.82 (d, J=9 Hz, 2H), 7.88 (d, J=8 Hz, 2H), 7.92 (s, 1H), 8.03 (d, J=8 Hz, 2H), 8.47 (s, 1H). MS (DCI/NH₃) m/z 468 (M+H)⁺, 485 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₆F₃N₃O₅S: C, 51.39; H, 3.45; N, 8.99. Found: C, 51.31; H, 3.28; N, 8.77.

Example 276

2-(2,2,2-Trifluoroethyl)-4-(1-indanyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 1-indanol in place of neopentyl alcohol (yield: 84 mg, 44%). mp 113-114 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.07-2.14 (m, 1H), 2.22-2.35 (m, 1H), 2.73 (dd, J=5 Hz, 7 Hz, 2H), 3.24 (s, 3H), 5.00-5.22 (m, 2H), 6.48 (dd, J=2 Hz, 6 Hz, 1H), 7.12-7.24 (m, 2H), 7.21-7.28 (m, 2H), 7.44 (d, J=8 Hz, 2H), 7.87 (d, J=8 Hz, 2H), 8.09 (s, 1H). MS (DCI/NH₃) m/z 482 (M+NH₄)⁺. Anal. calc. for C₂₂H₁₉F₃N₂O₄S: C, 57.19; H, 4.48; N, 5.80. Found: C, 57.36; H, 4.30; N, 5.78.

Example 2772-(2,2,2-Trifluoroethyl)-4-[4-(acetamido)phenoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound was prepared according to the method of Example 261, substituting 4-acetamidophenol in place of neopentyl alcohol (yield: 45 mg, 23%). mp 215-216 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.02 (s, 3H), 3.26 (s, 3H), 5.02 (q, J=8 Hz, 2H), 6.61-6.65 (m, 1H), 7.17-7.20 (m, 2H), 7.34 (br s, 1H), 7.88 (d, J=9 Hz, 2H), 8.03 (d, J=8 Hz, 2H), 8.36 (s, 1H), 9.97 (s, 1H). MS (DCI/NH₃) m/z 499 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₈F₃N₃O₅S: C, 52.39; H, 3.77; N, 8.73. Found: C, 52.57; H, 4.02; N, 8.37.

Example 2782-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

15 The title compound was prepared according to the method of Example 261, substituting 2-methylpropanol in place of neopentyl alcohol (yield: 111 mg, 50%). mp 108-110 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.77 (d, J=6.4 Hz, 6H), 1.52 (sept, J=6.4 Hz, 1H), 3.28 (s, 3H), 4.17 (d, J=6 Hz, 2H), 5.02 (q, J=9 Hz, 2H), 7.88 (d, J=9 Hz, 2H), 8.04 (d, J=9 Hz, 2H), 8.14 (s, 1H). MS (DCI/NH₃) m/z 405 (M+H)⁺, 422 (M+NH₄)⁺.
20 Anal. calc. for C₁₇H₁₉F₃N₂O₅S: C, 50.49; H, 4.74; N, 6.93. Found: C, 50.69; H, 4.89; N, 6.75.

Example 2792-(2,2,2-Trifluoroethyl)-4-(1-methylcyclopropylmethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

25 The title compound was prepared according to the method of Example 261, substituting 1-methylcyclopropanemethanol in place of neopentyl alcohol (yield: 360 mg, 75.5%). mp 98-99 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.35 (dt, J=40 Hz, 5 Hz, 4H), 0.91 (s, 3H), 3.11 (s, 3H), 4.32 (s, 2H), 4.82 (q, J=8.5 Hz, 2H), 7.80 (d, J=8.5 Hz, 2H), 7.84 (s,

1H), 8.06 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 417 (M+H)⁺, m/z 434 (M+NH₄)⁺. Anal. calc. for C₁₈H₁₉F₃N₂O₄S: C, 51.92; H, 4.60; N, 6.73. Found: C, 51.87; H, 4.72; N, 6.69.

Example 280

5 2-(2,2,2-Trifluoroethyl)-4-(3,3-dimethylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 261, substituting 3,3-dimethyl-1-butanol in place of neopentyl alcohol (yield: 270 mg, 67.4%). mp 83-85 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.88 (s, 9H), 1.56 (t, J=8 Hz, 2H), 4.60 (t, J=8 Hz, 2H), 4.83 (q, J=8.5 Hz, 2H), 7.73 (d, J=8.5 Hz, 2H), 7.81 (s, 1H), 8.05 (d, J=8.5 Hz, 2H). MS (DCI/NH₃) m/z 433 (M+H)⁺, m/z 450 (M+NH₄)⁺. Anal. calc. for C₁₉H₂₃F₃N₂O₄S: C, 52.77; H, 5.36; N, 6.48. Found: C, 52.95; H, 5.29; N, 6.35.

Example 281

15 2-(3,4-Difluorophenyl)-4-(4-chlorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A mixture of 2-benzyl-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (187 mg, 0.5 mmol), prepared in Example 78, p-chlorophenol (129 mg, 0.5 mmol) and NaH (60% oil suspension) (40 mg, 1 mmol) in THF (25 mL) was refluxed at 50 °C for 20 hours and then concentrated in vacuo. The residue was partitioned between water and ethyl acetate. The acetate layer was washed with brine, dried over MgSO₄ and concentrated in vacuo. The residue was chromatographed (silica gel, 1:1 hexanes-ethyl acetate) to provide 2-benzyl-4-(4-chlorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 200 mg, 82%).

25 The above derivative was dissolved in toluene (25 mL) and was treated with AlBr₃ (400 mg, 1.5 mmol) for 20 minutes at 80 °C. The mixture was cooled to room temperature and poured into ice-10% citric acid-ethyl acetate. The organic layer was separated, dried over MgSO₄ and concentrated in vacuo to provide crude desbenzyl derivative. This compound was immediately dissolved in pyridine (50 mL) and was treated with 3,4-

5 difluorobromobenzene (0.17 mL, 1.5 mmol), Cu (20 mg) and K_2CO_3 (100 mg, 1.5 mmol) at reflux for 16 hours. After the mixture was concentrated in vacuo, the residue was dissolved in ethyl acetate and was washed with water, 10% citric acid and brine. Purification by column chromatography (silica gel, 1:1 hexanes-ethyl acetate) provided the title compound (yield: 73 mg, 30%). mp 192-194 °C. 1H NMR (300 MHz, DMSO- d_6) δ 3.22 (s, 3H), 7.13 (m, 2H), 7.35 (m, 2H), 7.50 (m, 1H), 7.60 (m, 1H), 7.75 (m, 1H), 7.87 (d, J=9 Hz, 2H), 8.05 (d, J=9 Hz, 2H), 8.41 (s, 1H). MS (APCI+) m/z 488 (M+H) $^+$ and (APCI-) m/z 523 (M+Cl) $^-$.

10

Example 282

2-(3,4-Difluorophenyl)-4-(4-bromophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

15

The title compound was prepared according to the method of Example 281, substituting p-bromophenol in place of p-chlorophenol (yield: 54 mg, 20%). mp 196-199 °C. 1H NMR (300 MHz, DMSO- d_6) δ 3.25 (s, 3H), 7.09 (d, J=9 Hz, 2H), 7.47 (d, J=9 Hz, 2H), 7.52 (m, 1H), 7.62 (m, 1H), 7.78 (m, 1H), 7.89 (d, J=9 Hz, 2H), 8.05 (d, J=9 Hz, 2H), 8.41 (s, 1H). MS (APCI+) m/z 533 (M+H) $^+$ and (APCI-) m/z 569 (M+Cl) $^-$.

20

Example 283

2-(2,2,2-Trifluoroethyl)-4-(cyclopentylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

25

To a solution of NaH (26 mg, 1.1 mmol) in acetonitrile (3.0 mL), under nitrogen, was added cyclopentyl mercaptan (120 μ L, 1.1 mmol) dropwise via syringe. The resulting solution was flushed with nitrogen for a period of 20 minutes; after which 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 193E, (200 mg, 0.52 mmol) was added in one portion. The solution was stirred for an additional 20 minutes at which time, all the 4-bromo pyridazinone was consumed. The solution was analyzed by TLC (1:1, ethyl acetate-Hex). Water (5 mL) was carefully added and the reaction partitioned between ethyl acetate (125 mL) and saturated saline (50

mL). The organic layer is washed with saturated saline (50 mL), dried over MgSO_4 , and concentrated in vacuo. Silica gel chromatography (20% ethyl acetate-80% hexanes) provided a pale yellow solid (yield: 202 mg, 83.1%). mp 149-151 °C. ^1H NMR (300 MHz, CDCl_3) δ 1.40-1.34 (m, 2H), 1.62-1.54 (m, 4H), 1.93-1.88 (m, 2H), 3.13 (s, 3H), 4.40-4.35 (m, 1H), 4.85 (q, $J=8.2$ Hz, 2H), 7.58 (d, $J=8.5$ Hz, 2H), 7.66 (s, 1H), 8.06 (d, $J=8.4$ Hz, 2H). MS (DCI/ NH_3) m/z 432 ($\text{M}+\text{H}$) $^+$, ($\text{M}+\text{NH}_4$) $^+$. Anal. calc. for $\text{C}_{18}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_3\text{S}_2$: C, 49.99; H, 4.43; N, 6.48. Found: C, 50.15; H, 4.39; N, 6.45.

Example 284

10 2-(2,2,2-Trifluoroethyl)-4-(1H-1,2,4-triazole-3-ylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 283, substituting 1H-1,2,4-triazole-3-thiol in place of cyclopentyl mercaptan (yield: 164 mg, 93%). mp 197-200 °C. ^1H NMR (300 MHz, CDCl_3) δ 3.14 (s, 3H), 4.84 (q, $J=8.1$ Hz, 2H), 7.41 (s, 1H), 7.68 (d, $J=6.8$ Hz, 2H), 7.83 (s, 1H), 8.00 (d, $J=7.1$ Hz, 2H), 8.05 (s, 1H). MS (DCI/ NH_3) m/z 431 ($\text{M}+\text{H}$) $^+$, ($\text{M}+\text{NH}_4$) $^+$. Anal. calc. for $\text{C}_{15}\text{H}_{12}\text{F}_3\text{N}_2\text{O}_3\text{S}_2$: C, 41.76; H, 2.80; N, 16.23. Found: C, 41.68; H, 2.85; N, 15.99.

Example 285

20 2-(2,2,2-Trifluoroethyl)-4-phenylmethylthio-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 283, substituting benzyl mercaptan in place of cyclopentyl mercaptan (yield: 141 mg, 76%). mp 108-111 °C. ^1H NMR (300 MHz, CDCl_3) δ 3.01 (s, 3H), 4.38 (s, 2H), 4.87 (q, $J=8.1$ Hz, 2H), 7.10-7.06 (m, 2H), 7.22-7.20 (m, 5H), 7.59 (s, 1H), 7.95 (d, $J=8.5$ Hz, 2H). MS (DCI/ NH_3) m/z 454 ($\text{M}+\text{H}$) $^+$, ($\text{M}+\text{NH}_4$) $^+$. Anal. calc. for $\text{C}_{20}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_3\text{S}_2$, 0.75 EtOAc: C, 53.06; H, 4.45; N, 5.38. Found: C, 53.55; H, 4.16; N, 5.84.

Example 286

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 283 , substituting 4-fluorophenylmethyl mercaptan in place of cyclopentyl mercaptan (yield: 184 mg, 73.5%). mp 182-185 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.08 (s, 3H), 4.82 (q, J=8.5 Hz, 2H), 6.87-6.81 (m, 2H), 7.19-7.11 (m, 2H), 7.48 (d, J=9.0 Hz, 2H), 7.68 (s, 1H), 7.93 (d, J=8.5 Hz, 2H). MS (DCI/NH₃) m/z 458 (M+H)⁺, (M+NH₄)⁺. Anal. calc. for C₁₉H₁₄F₄N₂O₃S₂: C, 49.78; H, 3.08 ; N, 6.11. Found: C, 49.89 ; H, 3.18 ; N, 5.86

Example 287

2-(2,2,2-Trifluoroethyl)-4-(cyclohexylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 283 , substituting cyclohexyl mercaptan in place of cyclopentyl mercaptan (yield: 189 mg, 78%). mp 165-167 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.28-1.17 (m, 5H), 1.64-1.56 (m, 3H), 1.82-1.79 (m, 2H), 3.13 (s, 3H), 4.08-4.05 (m, 1H), 4.86 (q, J=8.5 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.67 (s, 1H), 8.06 (d, J=8.5 Hz, 2H). MS (DCI/NH₃) m/z 446 (M+H)⁺, (M+NH₄)⁺. Anal. calc. for C₁₉H₂₁F₃N₂O₃S₂: C, 51.11; H, 4.74 ; N, 6.27. Found: C, 51.39 ; H, 4.72 ; N, 5.91.

Example 288

2-(2,2,2-Trifluoroethyl)-4-(3-chloro-4-fluorophenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 283 , substituting 3-chloro-4-fluorothiophenol in place of cyclopentyl mercaptan (yield: 190 mg, 65%). mp 142-145 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.18 (s, 3H), 4.85 (q, J=8.4 Hz, 2H), 6.96 (ov. t, J=8.5 Hz, 1H), 7.14-7.10 (m, 1H), 7.18 (dd, J=2.1, 6.5 Hz, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.77 (s, 1H), 7.96 (d, J=8.0 Hz, 2H). MS (CI) m/z 493 (M+1)⁺, (M+NH₄)⁺.

Anal. calc. for $C_{19}H_{13}ClF_4N_2O_3S_2 \cdot 0.25 C_6H_6 \cdot H_2O$: C, 47.36 ; H, 2.92; N, 5.41. Found: C, 47.88 ; H, 2.95; N, 5.24.

Example 289

5 2-(2,2,2-Trifluoroethyl)-4-(2,2,2-trifluoroethylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 283, substituting 2,2,2-trifluoroethyl mercaptan in place of cyclopentyl mercaptan (yield: 175 mg, 66%). mp 155-158 °C. 1H NMR (300 MHz, $CDCl_3$) δ 3.14 (s, 3H), 3.98 (q, J=9.8 Hz, 2H), 4.86 (q, J=8.1 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.75 (s, 1H), 8.10 (d, J=8.4 Hz, 2H). MS (DCI/ NH_3) m/z 446 (M+H) $^+$, (M+ NH_4) $^+$. Anal. calc. for $C_{15}H_{12}F_6N_2O_3S_2$: C, 40.36 ; H, 2.71; N, 6.28. Found: C, 40.50; H, 2.72; N, 6.01.

Example 290

15 2-(2,2,2-Trifluoroethyl)-4-(tert-butylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 283, substituting tert-butyl mercaptan in place of cyclopentyl mercaptan (yield: 212 mg, 85%). mp 186-189 °C. 1H NMR (300 MHz, $CDCl_3$) δ 1.25 (s, 9H), 3.13 (s, 3H), 4.87 (q, J=8.1 Hz, 2H), 7.62 (d, J=8.5 Hz, 2H), 7.67 (s, 1H), 8.05 (d, J=8.1 Hz, 2H). MS (ESI) m/z 420 (M+H) $^+$, (M+Na) $^+$. Anal. calc. for $C_{17}H_{19}F_3N_2O_3S_2$: C, 48.56 ; H, 4.55; N, 6.66. Found: C, 50.15; H, 4.39; N, 6.45.

Example 291

25 2-(2,2,2-Trifluoroethyl)-4-(4-acetamidophenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 283, substituting 4-acetamidothiophenol in place of cyclopentyl mercaptan (yield: 100 mg, 37%). mp 191-193 °C. 1H NMR (300 MHz, $CDCl_3$) δ 2.16 (s, 3H), 3.08 (s, 3H), 4.83 (q,

J=8.2 Hz, 2H), 7.00 (d, J=8.8 Hz, 2H), 7.19 (d, J=8.8 Hz, 2H), 7.31 (d, J=8.1 Hz, 2H), 7.58 (s, 1H), 7.78 (d, J=8.1 Hz, 2H). MS (CI) m/z 497 (M+H)⁺, (M+NH₄)⁺. Anal. calc. for C₂₁H₁₈F₃N₃O₄S₂·0.25H₂O·0.25 C₆H₆: C, 52.83; H, 4.06; N, 7.70. Found: C, 52.97; H, 3.85; N, 7.65.

5

Example 292

2-(2,2,2-Trifluoroethyl)-4-(2-propylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 283 ,
10 substituting isopropyl mercaptan in place of cyclopentyl mercaptan (yield: 180 mg, 81%).
mp 165-167 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.17 (d, J=6.8 Hz, 6H), 3.13 (s, 3H), 4.33 (p, J=6.8 Hz, 1H), 4.86 (q, J=8.5 Hz, 2H), 6.59 (d, J=8.5 Hz, 2H), 7.68 (s, 1H), 8.07 (d, J=8.1 Hz, 2H). MS (DCI/NH₃) m/z 406 (M+H)⁺, (M+NH₄)⁺. Anal. calc. for C₁₆H₁₇F₃N₂O₃S₂·0.75H₂O: C, 45.76 ; H, 4.4; N, 6.67. Found: C, 45.91; H, 3.98; N, 6.46.

15

Example 293

2-(2,2,2-Trifluoroethyl)-4-(2-methylprop-1-ylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 283 ,
20 substituting 2-methyl-1-propyl mercaptan in place of cyclopentyl mercaptan (yield: 100 mg, 83%). mp 135-138 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.87 (d, J=6.4 Hz, 6H), 1.67-1.60 (m, 1H), 3.00 (d, J=6.7 Hz, 2H), 3.14 (s, 3H), 4.84 (q, J=8.5 Hz, 2H), 7.61 (d, J=8.4 Hz, 2H), 7.67 (s, 1H), 8.08 (d, J=8.5 Hz, 2H). MS (DCI/NH₃) m/z 420 (M+H)⁺, (M+NH₄)⁺. Anal. calc. for C₁₇H₁₉F₃N₂O₃S₂: C, 48.56 ; H, 4.55; N, 6.66. Found: C, 47.86;
25 H, 4.57; N, 6.51.

Example 294

2-(2,2,2-Trifluoroethyl)-4-amino-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(2,2,2-Trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared according to Example 193E, (500 mg, 1.36 mmol) was dissolved in DMF (10 mL) and treated with NaN₃ (100 mg, 1.5 mmol). After 2 hours at room temperature, the reaction was diluted with ethyl acetate and washed with water, 4 times, and dried over MgSO₄. After filtration of the drying agent and concentration of the filtrate in vacuo, the residue was purified by chromatography on silica gel (Biotage 40S) eluted with 2:1 hexanes-ethyl acetate. The product fractions were combined and evaporated to provide the azido intermediate, 2-(2,2,2-Trifluoroethyl)-4-azido-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 481 mg, 95%).

The 4-azido-compound above (39 mg, 0.105 mmol) was dissolved in THF (3 mL) and MeOH (2 mL) and treated with excess NaBH₄. After 15 minutes, the reaction was quenched with saturated NH₄Cl solution and the product was extracted into ethyl acetate. The organic layer was washed with water, 3 times, and dried over MgSO₄. Filtration of the drying agent and evaporation of the solvent provided the title compound (yield: 26 mg, 71%). mp > 260 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.26 (s, 3H), 4.93 (q, J=9 Hz, 2H), 6.71 (s, 2H), 7.72 (s, 1H), 7.76 (d, J=8 Hz, 2H), 8.02 (d, J=8 Hz, 2H). MS (ESI-) m/z 346 (M-H)⁻. Anal. calc. for C₁₃H₁₂F₃N₃O₃S: C, 44.96; H, 3.48; N, 12.10. Found: C, 44.59; H, 3.52; N, 11.93.

Example 295

2-(2,2,2-Trifluoroethyl)-4-(3-methoxypropylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (200 mg, 0.546 mmol), prepared according to the method of Example 193E, and 3-methoxypropylamine (145 mg, 1.64 mmol) in pyridine (4 mL) was heated at 100 °C for 16 hours. The reaction mixture was cooled to room temperature, mixed with silica gel (2 g), and the solvent removed under reduced pressure. The adsorbed silica gel was layered over an Extract-Clean Cartridge® (Alltech, packing: 10 g silica gel) and the cartridge eluted with a hexanes/acetone step gradient consisting of 60 mL of each of the

following mixtures: hexanes, 8:1 hexanes/acetone, 4:1, 2:1, and 1:1. Fractions containing desired product were combined, concentrated, and further purified using HPLC (Technikrom Kromasil 60-5 sil silica column, 20 mm x 25 cm). The column was eluted with a linear gradient consisting of 30% ethyl acetate/hexanes to 100% ethyl acetate at 10 mL/min over 50 minutes. Fractions containing product were combined and concentrated under reduced pressure to provide the product as off-white crystals (yield: 215 mg, 95%). mp 110-113 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.02 (d, J=18.0 Hz, 2H), 7.55 (d, 2H, J=18.0 Hz), 7.48 (s, 1H), 6.57 (br t, 1H, J=9.0 Hz), 4.81 (q, J=17.4 Hz, 2H), 3.33 (t, J=12.0 Hz, 2H), 3.28 (s, 3H), 3.12 (s, 3H), 2.76 (dt, J=12.0, 12.0 Hz, 2H), 1.65 (tt, J=12.0, 12.0 Hz, 2H). MS (DCI/NH₃) m/z 420 (M+H)⁺, m/z 437 [M+NH₄]⁺. Anal. calc. for C₁₇H₂₀F₃N₃O₄S: C, 48.68; H, 4.81; N, 10.02. Found: C, 48.74; H, 4.69; N, 9.84.

Example 296

2-(2,2,2-Trifluoroethyl)-4-(cyclopentylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting cyclopentylamine in place of 3-methoxypropylamine to provide brown crystals (yield: 195 mg, 86%). mp 134-139 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.03 (d, J=18.0 Hz, 2H), 7.56 (d, J=18.0 Hz, 2H), 7.45 (s, 1H), 6.12 (br d, J=16.8 Hz, 1H), 4.79 (q, J=17.4 Hz, 2H), 3.33 (br m, 1H), 3.12 (s, 3H), 1.64-1.23 (br m, 8H). MS (DCI/NH₃) m/z 416 (M+H)⁺, m/z 433 (M+NH₄)⁺. Anal. calc. for C₁₈H₂₀F₃N₃O₃S: C, 52.04; H, 4.85; N, 10.11. Found: C, 52.40; H, 4.93; N, 10.03.

Example 297

2-(2,2,2-Trifluoroethyl)-4-(cyclobutylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting cyclobutylamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 206 mg, 94%). mp 169-172 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.03 (d, J=17.4 Hz, 2H),

7.54 (d, J=17.4 Hz, 2H), 7.45 (s, 1H), 6.28 (br d, J=16.2 Hz, 1H), 4.81 (q, J=17.4 Hz, 2H), 3.42 (m, 1H), 3.13 (s, 3H), 1.79 (m, 4H), 1.64 (m, 1H), 1.39 (m, 1H). MS (DCI/NH₃) m/z 402 (M+H)⁺, m/z 419 (M+NH₄)⁺. Anal. calc. for C₁₇H₁₈F₃N₃O₃S.0.25 CH₃COCH₃: C, 51.25; H, 4.72; N, 10.10; found: C, 51.38; H, 4.68; N, 10.25.

5

Example 298

2-(2,2,2-Trifluoroethyl)-4-(3,4-dimethoxyphenethylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting 3,4-dimethoxyphenethylamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 206 mg, 94%). mp 163-165 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.02 (d, J=18.0 Hz, 2H), 7.52 (d, J=18.0 Hz, 2H), 7.45 (s, 1H), 6.75 (d, J=16.2 Hz, 1H), 6.50 (m, 2H), 6.16 (br d, J=11.4 Hz, 1H), 4.79 (q, J=17.4 Hz, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 3.11 (s, 3H), 2.91 (dt, J=12.6, 12.6 Hz, 2H), 2.60 (t, J=13.8 Hz, 2H). MS (DCI/NH₃) m/z 529 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₄F₃N₃O₅S: C, 54.01; H, 4.73; N, 8.21. Found: C, 54.30; H, 4.69; N, 8.16.

15

Example 299

2-(2,2,2-Trifluoroethyl)-4-(cyclohexylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

20

The product was prepared according to the method of Example 295, substituting cyclohexylamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 103 mg, 42%). ¹H NMR (300 MHz, CDCl₃) δ 8.04 (d, J=18.0 Hz, 2H), 7.58 (d, J=18.0 Hz, 2H), 7.44 (s, 1H), 6.06 (br d, J=18.6 Hz, 1H), 4.81 (q, J=18.0 Hz, 2H), 3.11 (s, 3H), 2.70 (m, 1H), 1.66-1.48 (m, 4H), 1.42 (m, 1H), 1.07 (m, 3H), 0.76 (m, 2H). MS (DCI/NH₃) m/z 430 (M+H)⁺, m/z 447 (M+NH₄)⁺. Anal. calc. for C₁₉H₂₂F₃N₃O₃S: C, 53.14; H, 5.16; N, 9.78. Found: C, 52.86; H, 5.06; N, 9.52.

25

Example 300

2-(2,2,2-Trifluoroethyl)-4-[2-(1-piperidinyl)ethylamino]-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting 2-(1-piperidinyl)ethylamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 210 mg, 84%). ¹H NMR (300 MHz, CDCl₃) δ 8.02 (d, J=18.0 Hz, 2H), 7.56 (d, J=18.0 Hz, 2H), 7.49 (s, 1H), 6.91 (br, 1H), 4.82 (q, J=18.0 Hz, 2H), 3.13 (s, 3H), 2.64 (br, 2H), 2.32 (br, 4H), 1.58 (br, 6H), 1.42 (br, 2H). MS (DCI/NH₃) m/z 459 (M+H)⁺. Anal. calc. for C₁₉H₂₂F₃N₃O₃S: C, 52.39; H, 5.50; N, 12.22. Found: C, 52.64; H, 5.59; N, 12.00.

Example 301

2-(2,2,2-Trifluoroethyl)-4-(2-tetrahydrofurfurylamino)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting tetrahydrofurfurylamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 150 mg, 64%). mp 128-129 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.03 (d, J=18.0 Hz, 2H), 7.56 (d, J=18.0 Hz, 2H), 7.47 (s, 1H), 6.48 (br t, J=9.0 Hz, 1H), 4.81 (q, J=18.0 Hz, 2H), 3.84 (m, 2H), 3.72 (m, 1H), 3.12 (s, 3H), 2.83 (m, 1H), 2.64 (m, 1H), 1.84 (m, 3H), 1.34 (m, 1H). MS (DCI/NH₃) m/z 432 (M+H)⁺, m/z 449 (M+NH₄)⁺. Anal. calc. for C₁₈H₂₀F₃N₃O₃S: C, 50.11; H, 4.67; N, 9.74. Found: C, 50.25; H, 4.68; N, 9.68.

Example 302

2-(2,2,2-Trifluoroethyl)-4-(cyclopropylmethylamino)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting cyclopropylmethylamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 130 mg, 59%). mp 145-146 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.01 (d, J=18.0 Hz, 2H), 7.53 (d, J=18.0 Hz, 2H), 7.48 (s, 1H), 6.20 (br, 1H), 4.82 (q, J=18.0 Hz, 2H), 3.12 (s, 3H), 2.45 (br d, J=13.2 Hz, 2H), 0.88 (m, 1H), 0.51 (m, 2H), 0.10 (m, 2H). MS

(DCI/NH₃) m/z 402 (M+H)⁺, m/z 419 (M+NH₄)⁺. Anal. calc. for C₁₇H₁₈F₃N₃O₃S: C, 50.87; H, 4.52; N, 10.47. Found: C, 51.00; H, 4.52; N, 10.44.

Example 303

5 2-(2,2,2-Trifluoroethyl)-4-(2,3-dihydro-1H-inden-1-ylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting 1-indanylamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 82 mg, 32%). mp 155-158 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.04 (d, J=18.0 Hz, 2H), 7.68 (d, J=18.0 Hz, 2H), 7.49 (s, 1H), 7.27-7.14 (m, 4H), 6.30 (br d, J=18.0 Hz, 1H), 4.81 (q, J=18.0 Hz, 2H), 4.57 (m, 1H), 3.09 (s, 3H), 2.89 (m, 1H), 2.60 (m, 1H), 1.85 (m, 1H), 1.68 (m, 1H). MS (ESI (-)) m/z 462 (M-H)⁻. Anal. calc. for C₂₂H₂₀F₃N₃O₃S: C, 57.01; H, 4.35; N, 9.07. Found: C, 57.30; H, 4.45; N, 8.86.

15 Example 304

2-(2,2,2-Trifluoroethyl)-4-(1-piperidinyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting piperidine in place of 3-methoxypropylamine to provide an off-white solid (yield: 180 mg, 79%). mp 160-161 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.04 (d, J=18.0 Hz, 2H), 7.58 (s, 1H), 7.46 (d, J=18.0 Hz, 2H), 4.80 (q, J=18.0 Hz, 2H), 3.13 (s, 3H), 2.96 (m, 4H), 1.65-1.52 (m, 6H). MS (DCI/NH₃) m/z 416 (M+H)⁺. Anal. calc. for C₁₈H₂₀F₃N₃O₃S.H₂O: C, 52.04; H, 4.85; N, 10.11. Found: C, 52.21; H, 5.02; N, 9.75.

25 Example 305

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxypropylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting 3-hydroxypropylamine in place of 3-methoxypropylamine to provide a white solid (yield:

109.6 mg, 50%). mp 152-154 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.02 (d, J=18.0 Hz, 2H), 7.56 (d, J=18.0 Hz, 2H), 7.48 (s, 1H), 6.48 (br, 1H), 4.79 (q, J=17.4 Hz, 2H), 3.63 (t, J=12.0 Hz, 2H), 3.12 (s, 3H), 2.81 (dt, J=12.0, 12.0 Hz, 2H), 1.65 (tt, J=12.0, 12.0 Hz, 2H). MS (DCI/NH₃) m/z 406 (M+H)⁺, m/z 423 (M+NH₄)⁺. Anal. calc. for C₁₆H₁₈F₃N₃O₄S: C, 47.41; H, 4.48; N, 10.37. Found: C, 47.53; H, 4.33; N, 10.27.

Example 306

2-(2,2,2-Trifluoroethyl)-4-[3-(1H-imidazol-1-yl)propylamino]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

10 The product was prepared according to the method of Example 295, substituting 1-(3-aminopropyl)imidazole in place of 3-methoxypropylamine. The reaction mixture was concentrated to dryness and the residue purified using RP-HPLC (Rainin Dynamax C-18 column, 60 Å pore size, 21.4 mm i.d.). The column was eluted with a linear gradient consisting of 20% acetonitrile (containing 0.1% TFA)/80% water (containing 0.1% TFA) 15 to 100% acetonitrile (containing 0.1% TFA) at 15 mL/min over 70 minutes. The peak corresponding to the title product was collected and lyophilized to provide a tan hygroscopic foam (yield: 70.2 mg, 28%). ¹H NMR (300 MHz, DMSO) δ 8.95 (br s, 1H), 7.97 (d, J=16.8 Hz, 2H), 7.66 (d, J=16.2 Hz, 2H), 7.61 (s, 1H), 7.58 (d, J=15.0 Hz, 2H), 6.99 (br t, 1H, J=13.2 Hz), 4.97 (dt, J=18.0, 18.0 Hz, 2H), 3.97 (t, J=13.2 Hz, 2H), 3.28 (s, 20 3H), 2.69 (m, 2H), 1.81 (tt, J=13.2, 13.2 Hz, 2H). MS (DCI/NH₃) m/z 456 (M+H)⁺. Anal. calc. for C₁₉H₂₀F₃N₅O₃S.1.4 CF₃COOH: C, 42.57; H, 3.51; N, 11.39. Found: C, 42.78; H, 3.58; N, 11.24.

Example 307

2-(2,2,2-Trifluoroethyl)-4-(2R-hydroxypropylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting (R)-(-)-2-propanolamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 109.6 mg, 50%). M.p. =140-142 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.04 (d,

J=18.0 Hz, 2H), 7.56 (d, J=18.0 Hz, 2H), 7.49 (s, 1H), 6.42 (br, 1H), 4.79 (m, 2H), 3.80 (m, 1H), 3.12 (s, 3H), 2.68 (m, 2H), 1.02 (d, J=12.0 Hz, 3H). MS (DCI/NH₃) m/z 406 (M+H)⁺, m/z 423 (M+NH₄)⁺. Anal. calc. for C₁₆H₁₈F₃N₃O₄S: C, 47.41; H, 4.48; N, 10.37. Found: C, 47.56; H, 4.41; N, 10.25.

5

Example 308

2-(2,2,2-Trifluoroethyl)-4-(2-cyanoethylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 295, substituting
10 2-cyanoethylamine in place of 3-methoxypropylamine to provide an off-white solid (yield: 27 mg, 12%). mp 172-174 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.09 (d, J=18.0 Hz, 2H), 7.63 (d, J=18.0 Hz, 2H), 7.51 (s, 1H), 6.08 (br t, 1H), 4.87 (q, J=18.0 Hz, 2H), 3.17 (dt, J=13.2, 13.2 Hz, 2H), 3.13 (s, 3H), 2.39 (t, J=13.2 Hz, 2H). MS (DCI/NH₃) m/z 418 (M+NH₄)⁺. Anal. calc. for C₁₆H₁₅F₃N₄O₃S: C, 48.00; H, 3.78; N, 13.99. Found: C, 48.28;
15 H, 3.77; N, 13.80.

Example 309

2-(2,2,2-Trifluoroethyl)-4-(4-cyanoanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A suspension of 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-
20 3(2H)-pyridazinone (300 mg, 0.820 mmol), prepared according to the method of Example 193E, 4-aminobenzonitrile (290 mg, 2.46 mmol), and silver oxide (760 mg, 3.28 mmol) in pyridine (1.5 mL) was stirred at 80 °C for 24 hours. The reaction was cooled to room temperature, adsorbed onto silica gel (2 g) and solvent removed under reduced pressure.
25 The adsorbed silica gel was layered over an Extract-Clean Cartridge® (Alltech, packing: 10 g silica gel) and the cartridge eluted with a hexanes/acetone step gradient consisting of 60 mL of each of the following mixtures: hexanes, 8:1 hexanes/acetone, 4:1, 2:1, and 1:1. Fractions containing desired product were combined, concentrated, and further purified using HPLC (Technikrom Kromasil 60-5sil column, 20 mm x 25 cm). The column was

eluted with a linear gradient consisting of 30% ethyl acetate/hexanes to 100% ethyl acetate at 10 mL/min over 50 minutes. Fractions containing product were combined and concentrated under reduced pressure to provide the product as a tan solid (yield: 149.9 mg, 41%). mp >230 °C. ¹H NMR (300 MHz, DMSO) δ 9.49 (s, 1H), 8.00 (s, 1H), 7.69 (d, J=17.4 Hz, 2H), 7.43 (d, J=16.8 Hz, 2H), 7.32 (d, J=18.0 Hz, 2H), 6.78 (d, J=18.0 Hz, 2H), 5.06 (q, J=18.0 Hz, 2H), 3.13 (s, 3H), 2.68 (m, 2H), 1.02 (d, J=12.0 Hz, 3H). MS (DCI/NH₃) m/z 466 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₃F₃N₄O₃S: C, 53.57; H, 3.37; N, 12.49. Found: C, 53.47; H, 3.49; N, 12.35.

Example 310

2-(2,2,2-Trifluoroethyl)-4-[3-methoxy-5-(trifluoromethyl)anilino]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 309, substituting 3-methoxy-5-(trifluoromethyl)aniline in place of 4-aminobenzonitrile to provide a brown solid (yield: 226.5 mg, 80%). mp 206-208 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.90 (s, 1H), 7.77 (s, 1H), 7.71 (d, J=18.0 Hz, 2H), 7.28 (d, J=17.4 Hz, 2H), 6.61 (br s, 1H), 6.46 (br s, 1H), 6.31 (br s, 1H), 4.90 (q, J=17.4 Hz, 2H), 3.72 (s, 3H), 2.94 (s, 3H). MS (DCI/NH₃) m/z 539 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₇F₆N₃O₄S: C, 48.37; H, 3.29; N, 8.06. Found: C, 48.60; H, 3.33; N, 7.94.

Example 311

2-(2,2,2-Trifluoroethyl)-4-anilino-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 309, substituting aniline in place of 4-aminobenzonitrile to provide a tan solid (yield: 90 mg, 53%). mp 154-156 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.89 (br s, 1H), 7.72 (s, 1H), 7.62 (d, J=18.0 Hz, 2H), 7.19 (d, J=18.0 Hz, 2H), 7.96-7.82 (m, 3H), 6.61 (d, J=14.4 Hz, 2H), 4.90 (q, J=18.0 Hz, 2H), 2.94 (s, 3H). MS (DCI/NH₃) m/z 424 (M+H)⁺, m/z 441 (M+NH₄)⁺. Anal. calc. for C₁₉H₁₆F₃N₃O₃S: C, 53.90; H, 3.81; N, 9.92. Found: C, 53.87; H, 3.73; N, 9.89.

Example 3122-(2,2,2-Trifluoroethyl)-4-(2,5-dimethoxyphenylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 309, substituting
5 2,5-dimethoxyaniline in place of 4-aminobenzonitrile to provide a tan solid (yield: 140
mg, 53%). mp 95-96 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.78 (br s, 1H), 7.72 (s, 1H), 7.63
(d, J=18.0 Hz, 2H), 7.18 (d, J=18.0 Hz, 2H), 6.54 (d, J=18.0 Hz, 1H), 6.38 (dd, J=6.0, 18.0
Hz, 1H), 4.89 (q, J=18.0 Hz, 2H), 3.73 (s, 3H), 3.47 (s, 3H), 2.96 (s, 3H). MS (DCI/NH₃)
m/z 484 (M+H)⁺, m/z 501 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₀F₃N₃O₅S: C, 52.17; H, 4.17;
10 N, 8.69. Found: C, 52.47; H, 4.17; N, 8.43.

Example 3132-(2,2,2-Trifluoroethyl)-4-(3-fluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 309, substituting 3-
15 fluoroaniline in place of 4-aminobenzonitrile to provide a tan solid (yield: 151.3 mg,
42%). mp 156-158 °C. ¹H NMR (300 MHz, DMSO) δ 9.18 (s, 1H), 7.91 (s, 1H), 7.62 (d,
J=17.4 Hz, 2H), 7.36 (d, J=17.4 Hz, 2H), 6.88 (dd, J=15.0, 15.0 Hz, 1H), 6.56 (m, 1H),
6.49 (m, 2H), 5.04 (q, J=18.0 Hz, 2H), 3.08 (s, 3H). MS (DCI/NH₃) m/z 442 (M+H)⁺, m/z
20 459 (M+NH₄)⁺, m/z 476 (M+2NH₄-H)⁺. Anal. calc. for C₁₉H₁₅F₄N₃O₃S.0.5 CH₃COCH₃: C,
52.33; H, 3.85; N, 8.93. Found: C, 52.51; H, 3.58; N, 8.81.

Example 3142-(2,2,2-Trifluoroethyl)-4-(2,4-difluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 309, substituting
25 2,4-difluoroaniline in place of 4-aminobenzonitrile to provide a tan solid (yield: 63.1 mg,
17%). mp 170-175 °C. ¹H NMR (300 MHz, DMSO) δ 9.00 (s, 1H), 7.80 (s, 1H), 7.57 (d,
J=17.4 Hz, 2H), 7.26 (d, J=17.4 Hz, 2H), 7.05 (m, 1H), 6.75 (m, 2H), 5.05 (q, J=18.0 Hz,

2H), 3.09 (s, 3H). MS (DCI/NH₃) m/z 460 (M+H)⁺, m/z 477 (M+NH₄)⁺. Anal. calc. for C₁₉H₁₄F₃N₃O₃S: C, 49.68; H, 3.07; N, 9.15; found: C, 50.00; H, 2.95; N, 9.10.

Example 315

5 2-(2,2,2-Trifluoroethyl)-4-(2,3,5-trifluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 309, substituting 2,3,5-trifluoroaniline in place of 4-aminobenzonitrile to provide a pale purple solid (yield: 85.3 mg, 22%). mp 190-194 °C. ¹H NMR (300 MHz, DMSO) δ 9.27 (s, 1H), 7.90 (s, 1H), 7.70 (d, J=17.4 Hz, 2H), 7.39 (d, J=17.4 Hz, 2H), 7.03 (m, 1H), 6.76 (m, 1H), 5.06 (q, J=18.0 Hz, 2H), 3.14 (s, 3H). MS (DCI/NH₃) m/z 495 (M+NH₄)⁺. Anal. calc. for C₁₉H₁₃F₆N₃O₃S: C, 47.80; H, 2.74; N, 8.80. Found: C, 47.51; H, 2.55; N, 8.63.

Example 316

15 2-(2,2,2-Trifluoroethyl)-4-(4-fluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The product was prepared according to the method of Example 309, substituting 4-fluoroaniline in place of 4-aminobenzonitrile to provide a tan solid (yield: 15.8 mg, 4%). mp 158-160 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.80 (br s, 1H), 7.69 (s, 1H), 7.65 (d, J=18.0 Hz, 2H), 7.18 (d, J=18.0 Hz, 2H), 6.63 (d, J=3.6 Hz, 2H), 6.61 (s, 2H), 4.89 (q, J=17.4 Hz, 2H), 2.96 (s, 3H). MS (DCI/NH₃) m/z 459 (M+NH₄)⁺. Anal. calc. for C₁₉H₁₃F₄N₃O₃S.1.25 H₂O: C, 49.19; H, 3.80; N, 9.05. Found: C, 59.57; H, 3.53; N, 8.70.

Example 317

25 2-Benzyl-4-(3-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone prepared in Example 78 (150 mg, 0.4 mmol), thiophene-3-boronic acid (66.5 mg, 0.52 mmol), CsF (145.8 mg, 0.96 mmol), and tetrakis-(triphenylphosphine)-palladium(0) (13.9 mg, 0.012 mmol) in DME (25 mL) were stirred at reflux for 6 hours TLC (1CH₂Cl₂:1 hexanes:1.5

ethyl acetate) indicated that all starting materials were consumed. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated under reduced pressure. The residue was purified using a silica gel column (0.5:2.5:0.5 CH_2Cl_2 /hexanes/ethyl acetate). A yellow powder was obtained (yield: 50 mg, 31%). ^1H NMR (300 MHz, CDCl_3) δ 3.09 (s, 3H), 5.41 (s, 2H), 6.72 (dd, $J=1.5$ Hz, 9 Hz, 1H), 7.13 (dd, $J=3$ Hz, 3 Hz, 1H), 7.3-7.45 (m, 5H), 7.5-7.6 (m, 3H), 7.78 (s, 1H), 7.92 (d, 9 Hz, 2H). MS (DCI/ NH_3) m/z 423 ($\text{M}+\text{H}$) $^+$. Anal. calc. for $\text{C}_{22}\text{H}_{18}\text{N}_2\text{O}_3\text{S}_2 \cdot 0.5 \text{H}_2\text{O}$: C, 6.23; H, 4.43; N, 6.49. Found C, 61.29; H, 4.40; N, 6.16.

Example 318

2-Benzyl-4-(2-benzofuranyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 317, substituting 2-benzofuranboronic acid for 3-thiopheneboronic acid (yield: 46 mg, 25%). ^1H NMR (300 MHz, CDCl_3) δ 3.13 (s, 3H), 5.5 (s, 2H), 6.85-6.92 (m, 1H), 7.15-7.25 (m, 3H), 7.3-7.42 (m, 3H), 7.45-7.7 (m, 5H), 7.79 (s, 1H) 8.0 (d, $J=9$ Hz, 2H), 8.08 (s, 1H). MS (DCI/ NH_3), m/z 457 ($\text{M}+\text{H}$) $^+$. Anal. calc. for $\text{C}_{26}\text{H}_{20}\text{N}_2\text{O}_4\text{S} \cdot \text{H}_2\text{O}$: C, 65.80; H, 4.67; N, 5.90. Found C, 65.44; H, 4.42; N, 6.14.

Example 319

2-Benzyl-4-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 221, substituting 2-benzyl-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 78, in place of 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 112 mg, 44%). mp > 250 $^\circ\text{C}$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 3.20 (s, 3H), 5.34 (s, 2H), 5.36 (s, 2H), 7.30-7.44 (m, 6H), 7.48 (d, $J=8$ Hz, 2H), 7.57 (s, 1H), 7.73 (d, $J=8$ Hz, 1H), 7.85 (d, $J=8$ Hz, 2H), 8.17 (s,

1H). MS (DCI/NH₃) m/z 473 (M+H)⁺, 490 (M+NH₄)⁺. Anal. calc. for C₂₆H₂₀N₂O₃S: C, 65.46; H, 4.33; N, 5.87. Found: C, 65.56; H, 4.48; N, 5.75.

Example 320

5 2-Benzyl-4-(5-chloro-2-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 317, substituting 5-chloro-2-thiopheneboronic acid in place of 3-thiopheneboronic acid (yield: 21 mg, 17%). ¹H NMR (300 MHz, CDCl₃) δ 3.15 (s, 3H), 5.45 (s, 2H), 6.51 (d, J=4.5 Hz, 1H), 6.7 (d, J=4.5 Hz, 1H), 7.3-7.4 (m, 3H), 7.5=7.6 (m, 4H), 7.6 (s, 1H), 8.05 (d, J=9 Hz, 2H). MS (DCI/NH₃), m/z 457 (M+H)⁺. Anal. calc. for C₁₈H₁₃ClN₂O₃S: C, 57.68; H, 4.03; N, 7.47. Found C, 57.61; H, 3.84; N, 7.14.

10

Example 321

15 2-Benzyl-4-(3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 317, substituting 3-nitrobenzeneboronic acid in place of 3-thiopheneboronic acid (yield: 20 mg, 11%). ¹H NMR (300 MHz, CDCl₃) δ 3.0 (s, 3H), 5.93 (s, 2H), 7.6-7.8 (m, 9H), 7.8 (t, J=4.5 Hz, 3H), 8.04 (s, 1H), 8.15 (m, 1H). MS (DCI/NH₃), m/z 462 (M+H)⁺. Anal. calc. for C₂₄H₁₉N₃O₅S · 0.75 H₂O: C, 60.68; H, 4.35; N, 8.84. Found C, 60.99; H, 3.97; N, 8.35.

20

Example 322

25 2-Benzyl-4-(4-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 317, substituting 4-vinylbenzeneboronic acid in place of 3-thiopheneboronic acid (yield: 40 mg, 23%). ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 5.28 (d, J=12 Hz, 1H), 5.41 (s, 2H), 5.74 (d, J=18 Hz, 1H), 6.65 (dd, J=12 Hz, 18 Hz, 1H), 7.1-7.6 (m, 11H), 7.83 (d, J=3 Hz, 2H), 7.85 (s, 1H). MS (DCI/NH₃), m/z 443 (M+H)⁺. Anal. calc. for C₂₆H₂₂N₂O₃S: C, 70.57; H, 5.01; N, 6.33. Found C, 70.34; H, 4.67; N, 5.97.

Example 3232-Benzyl-4-(4-trifluoromethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 317, substituting 4-(trifluoromethyl)benzeneboronic acid in place of 3-thiopheneboronic acid (yield: 101 mg, 52%). ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 5.42 (s, 2H), 7.3-7.5 (m, 8H), 7.55-7.6 m, 3H), 7.85 (s, 2H), 7.9 (s, 1H). MS (DCI/NH₃) m/z 485 (M+H)⁺. Anal. calc. for C₂₃H₁₉F₃N₂O₃S.0.25 H₂O: C, 61.40; H, 4.01; N, 5.72. Found C, 61.26; H, 4.01; N, 5.35.

Example 3242-Benzyl-4-(2-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 317, substituting 2-methoxybenzeneboronic acid in place of 3-thiopheneboronic acid (yield: 75 mg, 42%). ¹H NMR (300 MHz, CDCl₃) δ 3.01 (s, 3H), 3.5 (s, 3H), 5.40 (dd, J=12 Hz, 18 Hz, 2H), 6.76 (d, J=9 Hz, 1H), 6.85-6.95 (m, 1H), 7.09 (dd, J=1.5 Hz, 9 Hz, 1H), 7.26-7.41 (m, 6H), 7.55 (dd, J=1.5 Hz, 9 Hz, 2H), 7.82 (d, J=9 Hz, 3H). MS (DCI/NH₃) m/z 447 (M+H)⁺. Anal. calc. for C₂₃H₂₂N₂O₄S.0.5 H₂O: C, 65.91; H, 5.08; N, 6.14. Found C, 65.86; H, 5.08; N, 5.58.

Example 3252-Benzyl-4-(3,4-dimethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-Benzyl-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (150 mg, 0.4 mmol) prepared in Example 78 was dissolved in anhydrous DME (10 mL) and heated to reflux with 3,4-dimethylbenzeneboronic acid in presence of CsF (146 mg, 0.96 mmol) and tetrakis(triphenylphosphine)palladium (14 mg, 0.012 mmol) for 6 hours. After cooling to room temperature the reaction mixture was diluted with water and extracted with ethyl acetate (100 mL). The organic layer was washed with brine, dried over MgSO₄, and evaporated in vacuo. The compound was purified on a silica gel column, eluting with 30% ethyl acetate in pentanes, providing the desired compound (yield: 100 mg, 56%). ¹H NMR

(300 MHz, CDCl₃) δ 2.15, 2.20 (2s, 3H), 2.25, 2.30 (2s, 3H), 3.05, 3.08 (2s, 3H), 5.35, 5.40 (2s, 2H), 6.60-7.1 (m, 3H), 7.30-7.40 (m, 4H), 7.42-7.60 (m, 2H), 7.70-8.02 (m, 4H). MS (DCI/NH₃) m/z 445 (M+H)⁺. Anal. calc. for C₂₆H₂₄N₂O₃S.H₂O: C, 67.51; H, 5.66; N, 6.05. Found: C, 67.45; H, 5.56; N, 5.85.

5

Example 326

2-Benzyl-4-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 325 ,
10 substituting 3-fluoro-4-methoxybenzeneboronic acid in place of 3,4-dimethylbenzeneboronic acid (yield: 35 mg, 19%). ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 3.85 (s, 3H), 5.3, 5.4 (2s, 2H), 6.75-7.03 (m, 3H), 7.3-7.40 (m, 5H), 7.4-7.55 (dd, J=1.5 Hz; 7.5 Hz, 2H), 7.8-7.95 (m, 3H). MS (DCI/NH₃) m/z 465 (M+H)⁺. Anal. calc. for C₂₅H₂₁N₂O₄S.0.25 H₂O: C, 64.02; H, 4.62; N, 5.97. Found: C, 63.93; H, 4.54; N, 5.43

15

Example 327

2-Benzyl-4-(2-methoxypyrid-3-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 325 ,
substituting 2-methoxy-3-pyridylboronic acid in place of 3,4-dimethylbenzeneboronic acid
20 (yield: 35 mg, 19%). ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 3.58 (s, 3H), 5.4 (dd, J=15 Hz, 18 Hz; 2H), 6.88 (m, 1H), 7.28-7.40 (m, 5H), 7.5-7.6 (dd, J=1.5 Hz; 7.5 Hz, 3H), 7.82 (s, 1H), 7.85 (d, J=18 Hz, 2H), 8.15 (br s, 1H). MS (DCI/NH₃) m/z 448 (M+H)⁺. Anal. calc. for C₂₄H₂₁N₃O₄S: C, 64.42; H, 4.73; N, 9.39. Found: C, 64.17; H, 5.11; N, 9.04

25

Example 328

2-Benzyl-4-(3-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 325 ,
substituting 3-ethoxybenzeneboronic acid in place of 3,4-dimethylbenzeneboronic acid
(yield: 115 mg, 67%). ¹H NMR (300 MHz, CDCl₃) δ 1.31 (t, J=7.5 Hz, 3H), 3.05 (s, 3H),

3.89 (q, J=7.5 Hz, 2H), 5.14 (s, 2H), 6.65 (d, J=9 Hz, 1H), 6.72 (t, J=1.5 Hz, 1H), 6.8 (dd, J=1.5 Hz, 9 Hz, 1H), 7.15 (t, J=9 Hz, 1H), 7.3-7.4 (m, 5H), 7.5-7.6 (m, 2H), 7.85 (d, J=9 Hz, 3H). MS (DCI/NH₃) m/z 461 (M+H)⁺. Anal. calc. for C₂₆H₂₄N₂O₄S.0.5H₂O: C, 66.50; H, 5.36; N, 5.96. Found: C, 66.39; H, 5.02; N, 5.77

5

Example 329

2-Benzyl-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-(2H)-pyridazinone

Example 329A

10

2-Benzyl-4,5-dibromo-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 194A, substituting benzyl hydrazine hydrochloride in place of 4-fluorophenyl hydrazine hydrochloride (yield: 7.86 g, 60%). ¹H NMR (300 MHz, DMSO d₆) δ 5.27 (s, 2H), 7.26-7.41 (m, 5H), 8.19 (s, 1H). MS (DCI/NH₃) m/z 345 (M+H)⁺, 362 (M+H)⁺.

15

Example 329B

2-Benzyl-5-bromo-4-methoxy-3(2H)-pyridazinone

The title compound was prepared according to the method described in Example 194B, substituting 2-benzyl-4,5-dibromo-3(2H)-pyridazinone for 2-(4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone (yield: 2.877 g; 85%). ¹H NMR (300 MHz, DMSO-d₆) δ 4.14 (s, 3H), 5.23 (s, 2H), 7.26-7.38 (m, 5H), 8.11 (s, 1H). MS (DCI-NH₃) m/z 295 (M+H)⁺, 312 (M+NH₄)⁺.

20

Example 329C

25

2-Benzyl-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method described in Example 6, substituting 2-benzyl-4-methoxy-5-bromo-3(2H)-pyridazinone for 2-benzyl-4-methoxy-5-bromo-3(2H)-pyridazinone (yield: 3.705 g). ¹H NMR (300 MHz, DMSO-d₆) δ 2.52 (s,

3H), 3.99 (s, 3H), 5.28 (s, 2H), 7.26-7.41 (m, 7H), 7.55 (m, 2H), 8.02 (s, 1H). MS (DCI-NH₃) m/z 339 (M+H)⁺, 356 (M+NH₄)⁺.

Example 329D

5 2-Benzyl-4-(4-fluorobenzyl-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228, substituting 4-fluorobenzyl magnesium chloride in place of cyclohexylmagnesium chloride and 2-benzyl-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone was substituted in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone.

10

Example 329E

2-Benzyl-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-(2H)-pyridazinone

The sulfide compound, Example 329D, was oxidized to the methyl sulfonyl compound according to the method of Example 10. mp 186-189 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.27 (s, 3H), 3.83 (s, 2H), 5.31 (s, 2H), 6.94-7.05 (m, 4H), 7.27-7.40 (m, 5H), 7.67 (m, 2H), 7.94 (s, 1H), 8.03 (m, 2H). MS (DCI/NH₃) m/z 449 (M+H)⁺, 466 (M+NH₄)⁺. Anal. calc. for C₂₅H₂₁FN₂O₃S: C, 66.95; H, 4.72; N, 6.25. Found: C, 66.68; H, 4.75; N, 6.14.

15

20

Example 330

2-(tert-Butyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 330A

25 2-(tert-Butyl)-4,5-dichloro-3(2H)-pyridazinone

A solution of mucochloric acid (33.8 g, 200 mmol) and tert.-butylhydrazine hydrochloride (24.9 g, 200 mmol) in methanol (400 mL) was stirred at reflux overnight. Methanol was removed in vacuo and the residue was partitioned between ether and water. The organic layer was dried over MgSO₄ and filtered. The filtrate was concentrated in

vacuo and the residue was purified by column chromatography (silica gel, 100% hexanes). Product-containing fractions were combined and the title compound was crystallized from ether/hexanes (yield: 10.0 g, 22.6%). mp 63-64 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.65 (s, 9H), 7.73 (s, 1H). MS (DCI/NH₃) m/z 221 (M+H)⁺, 238 (M+NH₄)⁺.

5

Example 330B

2-(tert-Butyl)-4-(3-methylbutoxy)-5-chloro-3(2H)-pyridazinone

A stirred, room temperature solution of 3-methyl-1-butanol (0.5 mL, 4.52 mmol) in tetrahydrofuran (10 mL) was treated with a 60% oil suspension of sodium hydride (0.24 g, 5.88 mmol). After 5 minutes, hydrogen gas evolution had subsided, so the dichloro-
10 intermediate from Example 330A (1.0 g, 4.52 mmol) was added and the reaction mixture was stirred at room temperature for 20 hours. The reaction was quenched with 10% aqueous citric acid and extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo, and the
15 residue was purified by column chromatography (silica gel, 100% hexanes). The title compound was obtained as a pale yellow oil (yield: 0.7 g, 56.7%). ¹H NMR (300 MHz, CDCl₃) δ 0.95 (d, J=6 Hz, 6H), 1.63 (s, 9H), 1.64 (q, J=6 Hz, 2H), 1.85 (nonet, J=6 Hz, 1H), 4.49 (t, J=6 Hz, 2H), 7.64 (s, 1H). MS (DCI/NH₃) m/z 273 (M+H)⁺, 290 (M+NH₄)⁺.

20

Example 330C

2-(tert-Butyl)-4-(3-methylbutoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

A solution of the intermediate from Example 330B (700 mg, 2.57 mmol), 4-(methylthio)benzeneboronic acid (560 mg, 3.34 mmol), cesium carbonate (2.17 g, 6.67 mmol), and tetrakis(triphenylphosphine)palladium(0) (210 mg, 0.18 mmol) in
25 dimethoxyethane (40 mL) was heated at reflux for 5 hours. The heat source was then removed and the reaction mixture was stirred at room temperature for 64 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo to provide a brown oil. This oil was purified by column chromatography twice (silica gel, 97:3 hexanes/ethyl acetate, then 96:4 hexanes/ethyl acetate) to provide a semi-solid product

(yield: 270 mg, 29.2%). ¹H NMR (300 MHz, CDCl₃) δ 0.81 (d, J=6 Hz, 6H), 1.49 (q, J=6 Hz, 2H), 1.63 (nonet, J=6 Hz, 1H), 1.69 (s, 9H), 2.52 (s, 3H), 7.32 (d, J=9 Hz, 2H), 7.50 (d, J=9 Hz, 2H), 7.73 (s, 1H). MS (DCI) m/z 361 (M+H)⁺.

5

Example 330D

2-(tert-Butyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 10, substituting 2-(tert.-butyl)-4-(3-methylbutoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone for 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 188 mg, 63.9%). mp 138-139°C. ¹H NMR (300 MHz, CDCl₃) δ 0.81 (d, J=6 Hz, 2H), 1.48 (q, J=6 Hz, 2H), 1.48-1.68 (m, 1H), 1.69 (s, 9H), 3.10 (s, 3H), 4.38 (t, J=6 Hz, 2H), 7.71 (s, 1H), 7.74 (d, J=9 Hz, 2H), 8.03 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 393 (M+H)⁺. Anal. calc. for C₂₀H₂₈N₂O₄S: C, 61.20; H, 7.19; N, 7.14. Found: C, 61.13; H, 7.23; N, 6.89.

15

Example 331

2-(3-Chlorophenyl)-4-methoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 10, substituting 2-(3-chlorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (Example 207C) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 3.31 g, 96%). mp 112-114 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.31 (m, 3H), 4.10 (m, 3H), 7.52-7.65 (m, 3H), 7.75 (m, 1H), 7.90 (m, 2H), 8.07 (m, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 391 (M+H)⁺, 408 (M+NH₄)⁺. Anal. calc. for: C₁₈H₁₅ClN₂O₄S.0.25 H₂O: C, 54.68; H, 3.95; N, 7.08. Found: C, 54.59; H, 3.65; N, 6.98.

25

Example 332

2-(3-Chlorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A suspension of 2-(3-chlorophenyl)-4-(methoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (6.26 g, 16 mmol) in 5% NaOH (54 mL) dioxane (39.4 mL) was

heated at reflux and stirred for 1.5 hours. As the reaction proceeds, the solution becomes orange and homogeneous. The mixture was cooled and poured into 1N HCl, with constant stirring. The resulting white solid was filtered and rinsed with H₂O and left to dry overnight. The mostly dry product was taken up in CH₂Cl₂ and azeotroped with toluene to remove any remaining H₂O, to provide the desired product as a white solid (yield: 6.79 g, >100%). ¹H NMR (300 MHz, DMSO d₆) δ 2.27 (s, 3H), 7.51-7.62 (m, 2H), 7.68 (m, 1H), 7.79 (m, 1H), 8.03 (m, 4H), 8.24 (s, 1H). MS (DCI/NH₃) m/z 377 (M+H)⁺, 396 (M+NH₄)⁺.

10

Example 333

2-(3-Chlorophenyl)-4-tosyloxv-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a 0 °C solution of 2-(3-chlorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 332, (6.79 g, 16 mmol) in pyridine (160 mL) was added p-toluenesulfonyl chloride (3.06 g, 16 mmol). The solution was left to warm slowly to room temperature with stirring under nitrogen. After 2.5 hours, the mixture was poured into H₂O with constant stirring. The resulting off-white solid was filtered, rinsed with H₂O and dried to provide the desired product (yield: 6.26 g, 79%). mp 198-200 °C. ¹H NMR (300 MHz, DMSO d₆) δ 2.35 (s, 3H), 3.28 (s, 3H), 7.20 (m, 2H), 7.52-7.64 (M, 5H), 7.70 (m, 3H), 7.89 (m, 2H), 8.32 (s, 1H). MS APCI+ 531 (M+H)⁺, 548 (M+H₂O)⁺, APCI-493 (M+35)⁻. Anal. calc. for C₂₄H₁₉ClN₂O₆S₂: C, 54.29; H, 3.61; N, 5.28. Found: C, 54.55; H, 3.46; N, 5.57.

20

Example 334

2-(3-Chlorophenyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 2-(3-chlorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 332, in POCl₃ was heated to reflux for 3 hours while stirring under nitrogen. The mixture was cooled to room temperature and poured into ice with constant swirling. The resulting white solid was extracted with ethyl acetate. The combined organics were washed with H₂O, dried over MgSO₄, and concentrated to a solid.

25

The crude product was purified using flash chromatography (SiO₂, eluting with 1:1 ethyl acetate/hexanes) to provide the desired product (yield: 0.151 g, 29%). mp 203-204 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.29-3.36 (3H, obstructed by H₂O), 7.60 (m, 3H), 7.76 (m, 1H), 7.92 (m, 2H), 8.14 (m, 2H), 8.25 (s, 1H). MS (DCI/NH₃) m/z 395 (M+H)⁺, 412 (M+NH₄)⁺. Anal. calc. for C₁₇H₁₂Cl₂N₂O₃S: C, 51.66; H, 3.06; N, 7.09. Found: C, 51.67; H, 3.03; N, 6.93.

Example 335

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a stirred suspension of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 333, (0.175 g, 0.33 mmol) in THF (3.3 mL) was added isobutanol (0.03 mL, 0.33 mmol), and NaH (0.0132 g, 0.33 mmol). The resulting solution was stirred under nitrogen for 1 hour. The reaction was poured into H₂O and extracted with ethyl acetate. The combined organics were dried over MgSO₄ and concentrated in vacuo. The crude solid was purified using flash chromatography (SiO₂, 2:1 hexanes:ethyl acetate) to provide the desired product (yield: 0.1088 g 76%). mp 166-169 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.78 (d, J=6 Hz, 6H), 1.84 (m, 1H), 3.29 (s, 3H), 4.20 (d, J=6 Hz, 2H), 7.51-7.63 (m, 3H), 7.76 (m, 1H), 7.92 (m, 2H), 8.07 (m, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 433 (M+H)⁺, 450 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₁ClN₂O₄S: C, 57.07; H, 5.01; N, 6.33. Found: C, 57.06; H, 4.78; N, 6.13.

Example 336

2-(3-Chlorophenyl)-4-(t-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting t-butanol in place of isobutanol (yield: 0.093 g, 66%). mp 232-235 °C. ¹H NMR (300 MHz, DMSO d₆) δ 1.18 (s, 9H), 3.30 (s, 3H), 7.52-7.64 (m, 3H), 7.74 (m, 1H), 7.92 (m, 2H), 8.08 (m, 2H), 8.20 (s, 1H). MS (DCI/NH₃) m/z 433 (M+H)⁺, 450

(M+NH₄)⁺. Anal. calc. for C₂₁H₂₁ClN₂O₄S: C, 58.26; H, 4.89; N, 6.47. Found: C, 58.21; H, 4.88; N, 6.28.

Example 337

5 2-(3-Chlorophenyl)-4-(cyclohexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting cyclohexanol in place of isobutanol (yield: 0.139 g, 92%). semi-solid; ¹H NMR (300 MHz, CDCl₃) δ 1.09-1.50 (m, 6H), 1.57 (m, 2H), 1.88 (m, 2H), 3.13 (s, 3H), 5.19 (m, 1H), 7.38-7.48 (m, 2H), 7.59 (m, 1H), 7.70 (m, 1H), 7.83 (m, 2H), 7.92 (s, 1H), 10 8.07 (m, 2H). MS APCI+ 459 (M+H)⁺, 476 (M+H₂O)⁺, APCI-458 (M)⁻, 493 (M+35)⁻. Anal. calc. for C₂₃H₂₃ClN₂O₄S.0.25 H₂O: C, 59.60; H, 5.11; N, 6.04. Found: C, 59.48; H, 4.86; N, 5.88.

Example 338

15 2-(3-Chlorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting neopentyl alcohol in place of isobutanol (yield: 0.109 g, 74%). mp 151-153 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.78 (s, 9H), 3.29 (s, 3H), 4.10 (s, 2H), 7.52-7.64 (m, 3H), 7.76 (m, 1H), 7.92 (m, 2H), 8.07 (m, 2H), 8.20 (s, 1H). MS (DCI/NH₃) m/z 447 20 (M+H)⁺, 464 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₃ClN₂O₄S: C, 59.12; H, 5.19; N, 6.27. Found C, 59.40; H, 5.31; N, 5.99.

Example 339

25 2-(3-Chlorophenyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 3-methyl-1-butanol in place of isobutanol (yield: 0.229 g, 80.5%). mp 134-135 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.79 (d, J=6 Hz, 6H), 1.42-1.64 (m, 3H), 3.30 (s, 3H), 4.43 (t, J=6 Hz, 2H), 7.52-7.65 (m, 3H), 7.76 (m, 1H), 7.90 (m, 2H), 8.07 (m, 2H),

8.21 (s, 1H). MS (DCI/NH₃) m/z 447 (M+H)⁺, 464 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₃ClN₂O₄S: c, 59.12; H, 5.19; N, 6.27. Found: C, 58.91; H, 5.12; N, 6.01.

Example 340

5 2-(3-Chlorophenyl)-4-(3-octyn-1-yloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 3-octyn-1-ol in place of isobutanol (yield: 0.128 g, 77%). Oil. ¹H NMR (300 MHz, CDCl₃) δ 0.88 (m, 3H), 1.25-1.44 (m, 4H), 2.05 (m, 2H), 2.52 (m, 2H), 4.68 (t, J=6
10 Hz, 2H), 7.43 (m, 2H), 7.59 (m, 1H), 7.70 (m, 1H), 7.86 (m, 2H), 7.92 (s, 1H). MS (DCI/NH₃) m/z 485 (M+H)⁺. Anal. calc. for C₂₅H₂₅ClN₂O₄S: C, 61.94; H, 5.20; N, 5.78. Found: C, 61.82; H, 4.99; N, 5.57.

Example 341

15 2-(3-Chlorophenyl)-4-[2-(dimethylamino)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting N,N-(dimethyl)ethanolamine in place of isobutanol (yield: 0.111 g, 75%). mp 110-113 °C. ¹H NMR (300 MHz, DMSO d₆) δ 2.29 (bs, 6H), 2.68 (bs, 2H), 4.68 (t, J=5
20 Hz, 2H), 7.38-7.48 (m, 2H), 7.57 (m, 1H), 7.68 (m, 1H), 7.89 (m, 2H), 8.07 (m, 2H). MS (DCI/NH₃) m/z 448 (M+H)⁺. Anal. calc. for C₂₁H₂₂ClN₃O₄S.0.50 H₂O: C, 55.19; H, 5.07; N, 9.19. Found: C, 55.24; H, 4.97; N, 9.07.

Example 342

25 2-(3-Chlorophenyl)-4-[2-methyl-1-(1-methylethyl)propoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2,4-dimethyl-3-pentanol in place of isobutanol (yield: 0.075 g, 48%). Semi-solid; ¹H NMR (300 MHz, DMSO d₆) δ 0.79 (m, 12H), 1.78-1.92 (m, J=6 Hz, 2H), 3.29 (s,

3H), 5.40 (t, J=6 Hz, 1H). 7.57 (m, 3H), 7.72 (m, 1H), 7.91 (m, 2H), 8.07 (m, 2H), 8.17 (m, 1H). MS (DCI/NH₃) m/z 475 (M+H)⁺, 492 (M+NH₄)⁺. Anal. calc. for C₂₄H₂₇ClN₂O₄S (0.75 H₂O): C, 59.00; H, 5.88; N, 5.78. Found: C, 58.83; H, 5.74; N, 5.52.

5

Example 3432-(3-Chlorophenyl)-4-(phenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting phenol in place of isobutanol (yield: 0.053 g, 35%). mp 205-207 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.28 (s, 3H), 7.08 (m, 3H), 7.31 (m 2H), 7.50-7.64 (m, 3H), 7.73 (m, 1H), 7.90 (m, 2H), 8.05 (m, 2H), 8.40 (s, 1H). MS (DCI/NH₃) m/z 453 (M+H)⁺, 470 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₇ClN₂O₄S: C, 60.99; H, 3.78; N, 6.19. Found: C, 60.79; H, 3.65; N, 5.87.

10

Example 344

15 2-(3-Chlorophenyl)-4-[3-(dimethylamino)phenoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 3-(dimethylamino)phenol in place of isobutanol (yield: 0.057 g, 60%). mp 191-193; ¹H NMR (300 MHz, DMSO d₆) δ 2.85 (s, 6H), 3.27 (s, 3H), 6.36 (m, 3H), 7.05 (m, 1H), 7.51-7.63 (m, 3H), 7.72 (m, 1H), 7.90 (m, 2H), 8.05 (m, 2H), 8.39 (s, 1H). MS APCI+ 495 (M+H)⁺, APCI-, 495 (M)⁻, 590 (M+35)⁻. Anal. calc. for C₂₅H₂₂ClN₃O₄S: C, 60.54; H, 4.47; N, 8.47. Found: C, 60.04; H, 4.49; N, 8.26.

20

Example 345

25 2-(3-Chlorophenyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 4-methoxyphenol in place of isobutanol (yield: 0.080 g, 69%). mp 182-184 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.27 (s, 3H), 3.70 (s, 3H), 6.84 (m, 2H), 7.00 (m,

2H), 7.56 (m, 3H), 7.72 (m, 1H), 7.90 (m, 2H), 8.04 (m, 2H), 8.38 (s, 1H). MS (DCI/NH₃) m/z 483 (M+H)⁺, 500 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉ClN₂O₅S: C, 59.64; H, 3.97; N, 5.80. Found: C, 59.86; H, 3.94; N, 5.62.

5

Example 3462-(3,4-Difluorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 150 mg, 61%). mp 116-117 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.78 (d, 6H), 1.84, (m, 1H), 3.3 (s, 3H), 4.2 (d, 2H), 7.54 (m, 1H), 7.6 (m, 1H), 7.82 (m, 1H), 7.91 (d, 2H), 8.07 (d, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 435 (M+H)⁺, 452 (M+NH₄)⁺. Anal. calc. for C₂₁F₂H₂₀N₂O₄S: C, 58.06; H, 4.64; N, 6.45.

15

Example 3472-(3,4-Difluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 346 substituting 3-methyl-1-butanol in place of isobutanol (yield: 63 mg, 23%). mp 121-123 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.78 (d, 6H), 1.48, (m, 3H), 3.3 (s, 3H), 4.43 (t, 2H), 7.54 (m, 1H), 7.6 (m, 1H), 7.82 (m, 1H), 7.91 (d, J=9 Hz, 2H), 8.07 (d, J=9 Hz, 2H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 449 (M+H)⁺, 466 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₂F₂N₂O₄S: C, 58.92; H, 4.94; N, 6.25. Found, C, 59.22; H, 4.97; N, 6.07.

25

Example 3482-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 346, starting with 2-(3,4-difluorophenyl)-4-tosyloxy-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 4-fluorophenol in place of isobutanol mp 168-170 °C.

¹H NMR (300 MHz, DMSO-d₆) δ 3.39 (s, 3H), 7.15 (d, 4H), 7.51 (m, 1H), 7.6 (m, 1H) 7.75 (m, 3H), 7.97 (t, 1H); 8.4 (s, 1H). MS (DCI/NH₃) m/z 491 (M+H)⁺, 508 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₄F₄N₂O₄S: C, 56.33; H, 2.88; N, 5.71. Found, C, 56.07; H, 2.94; N, 5.33.

Example 349

2-(3,4-Difluorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 346 substituting neopentyl alcohol in place of isobutanol (yield: 1.18 g, 94%). mp 126-128 °C.

¹H NMR (300 MHz, DMSO-d₆) δ 0.78 (s, 9H), 3.3 (s, 3H), 4.1 (s, 2H), 7.51 (m, 1H), 7.6 (m, 1H), 7.82 (m, 1H), 7.91 (d, J=9 Hz, 2H), 8.07 (d, J=9 Hz, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 449 (M+H)⁺, 466 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₂F₂N₂O₄S: C, 58.92; H, 4.94; N, 6.25. Found: C, 59.03; H, 5.03; N, 6.18.

Example 350

2-(3,4-Difluorophenyl)-4-[2-(isopropoxy)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 346 substituting 2-(isopropoxy)ethanol in place of isobutanol (yield: 432 mg, 72%). mp 105-107 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.95 (d, 6H), 3.3 (s, 3H), 3.43 (m, 1H), 3.54 (m, 2H), 4.63 (m, 2H), 7.54 (m, 1H), 7.6 (m, 1H), 7.8 (m, 1H), 8.01 (m, 4H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 465 (M+H)⁺, 482 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₂F₂N₂O₅S: C, 56.89; H, 4.77; N, 6.03. Found, C, 57.03; H, 4.65; N, 5.83.

Example 3512-(3,4-Difluorophenyl)-4-(3-methylpentyl-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 346 substituting 3-methylpentyl-1-ol in place of isobutanol (yield: 400 mg, 80%). mp 100-102 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (m, 6H), 1.05 (m, 1H), 1.28 (m, 3H) 1.6 (m, 1H), 3.3 (s, 3H), 4.45 (m, 2H), 7.5 (m, 1H), 7.6 (m, 1H), 7.8 (m, 1H), 7.9 (d, J=9 Hz, 2H) 8.05 (d, J=9 Hz, 2H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 463 (M+H)⁺, 480 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₄F₂N₂O₄S: C, 59.73; H, 5.23; N, 6.06. Found, C, 59.78; H, 5.31; N, 6.00.

Example 3522-(3,4-Difluorophenyl)-4-(4-methyl-3-penten-1-yl-oxy)-5-[4-(methylsulfonyl)phenyl]-5-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 346 substituting 4-methyl-3-pentene-1-ol in place of isobutanol (yield: 405 mg, 67.8%). mp 88-90 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.5 (d, 6H), 2.27 (m, 2H) 3.3 (s, 3H), 4.43 (t, 2H), 4.95 (m, 1H), 7.5 (m, 1H), 7.6 (m, 1H), 7.8 (m, 1H), 7.9 (d, 2H), 8.06 (d, 2H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 461 (M+H)⁺, 478 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₂F₂N₂O₄S: C, 59.99; H, 4.82; N, 6.08. Found, C, 59.88; H, 4.76; N, 5.84.

Example 3532-(3,4-Difluorophenyl)-4-[3-(methoxy)butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 346 substituting 3-methoxybutyl-1-ol in place of isobutanol (yield: 350 mg, 68%). mp 99-101 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.97 (d, 3H), 1.7 (m, 2H), 3.05 (s, 3H), 3.2 (m, 1H) 3.3 (s, 3H), 4.45 (m, 2H), 7.54 (m, 1H), 7.6 (m, 1H), 7.8 (m, 1H), 7.9 (d, J=9 Hz, 2H) 8.01 (d, J=9 Hz, 2H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 465 (M+H)⁺, 482 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₂F₂N₂O₅S: C, 56.89; H, 4.77; N, 6.03. Found, C, 56.60; H, 4.83; N, 5.96.

Example 3542-(3-Chlorophenyl)-4-(N-methylbenzylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone:

5 To a rapidly stirred 0 °C mixture of N-methylbenzylamine (67.5 mg, 0.56 mmol) and tetrahydrofuran (3.7 mL) was slowly added dropwise an n-BuLi solution (0.235 mL, 0.59 mmol, 2.5 M in hexanes). The reaction mixture was stirred for 10 minutes at 0 °C and 1 hour at 23 °C. The solution was cooled to -78 °C, and a tetrahydrofuran (10-15 mL) solution of the 2-(3-chlorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-
10 pyridazinone (200 mg, 0.56 mmol) slowly added along the interior wall of the reaction vessel. This reaction mixture was stirred overnight, slowly warming to 23 °C as the cooling bath evaporated. The reaction was quenched with water and diluted with a large excess of ethyl acetate. The layers were separated, and the ethyl acetate layer washed with additional water and brine and dried over MgSO₄, filtered, and concentrated in vacuo. The
15 residue was chromatographed (flash silica gel, ethyl acetate/hexanes 1:9) to provide 2-(3-chlorophenyl)-4-(N-methyl benzylamino)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 145 mg, 58%).

The title compound was prepared according to the method of Example 10, substituting 2-(3-chlorophenyl)-4-(N-methylbenzylamino)-5-[4-(methylthio)phenyl]-
20 3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 143 mg, 95%). mp 60-85 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.46 (s, 3H), 3.09 (s, 3H), 4.63 (s, 2H), 7.19 (d, J=8.7 Hz, 2H), 7.24-7.29 (m, 2H), 7.32-7.48 (m, 5H), 7.60 (ddd, J=7.2, 1.8, 1.8 Hz, 1H), 7.67 (s, 1H), 7.70 (dd, J=1.8, 1.8 Hz, 1H), 7.91 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 480 (M+H)⁺.

25

Example 3552-(4-Fluorophenyl)-4-(1-piperidinyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a slightly heterogeneous solution of piperidine (99.7 mg, 1.17 mmol) and toluene (8 mL) cooled to -78 °C was slowly added dropwise an n-BuLi solution (0.235

mL, 0.59 mmol, 2.5 M in hexanes). After stirring at -78 °C for 10 minutes, the cooling bath was removed and the mixture stirred an additional 1 hour at 23 °C. The 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (400 mg, 1.17 mmol) was dissolved in portions in toluene (3 x 6-7 mL aliquots) with a heat gun and cooled to 0 °C prior to transfer via syringe to the lithium amide solution (cooled to -78 °C). The addition was made slowly along the interior wall of the reaction vessel. This reaction mixture was stirred overnight, slowly warming to 23 °C as the cooling bath evaporated. The reaction was quenched with water and diluted with a large excess of ethyl acetate. The layers were separated, and the ethyl acetate layer washed with additional water and brine and dried over MgSO₄, filtered, and concentrated in vacuo. The residue was chromatographed (flash silica gel, ethyl acetate/hexanes 1:2) to provide 440 mg (95%) of 2-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-4-piperidino-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 10, substituting 2-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-4-piperidino-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (yield: 165 mg, 98%). mp 80-100 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.59 (br s, 6H), 2.59 (br s, 4H), 3.14 (s, 3H), 7.17 (dd, J=8.7, 8.7 Hz, 2H), 7.51 (d, J=8.7 Hz, 2H), 7.55-7.62 (m, 2H), 7.68 (s, 1H), 8.06 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 428 (M+H)⁺. Powdered out in CH₂Cl₂/C₆H₁₄. Anal. calc. for C₂₂H₂₂FN₃O₃S.0.25C₆H₁₄: C, 62.85; H, 5.72; N, 9.35. Found: C, 62.46; H, 5.77; N, 9.13.

Example 356

2-(4-Fluorophenyl)-4-(1-pyrrolidinyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 355, substituting pyrrolidine for piperidine (yield: 107 mg, 82%). mp 192-195 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.71-1.80 (m, 4H), 3.13 (s, 3H), 3.40-3.49 (m, 4H), 7.16 (dd, J=8.7, 8.7 Hz, 2H), 7.47-7.60 (m, 5H), 7.99 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 414 (M+H)⁺. Anal. calc. for C₂₁H₂₀FN₃O₃S: C, 61.00; H, 4.87; N, 10.16. Found: C, 60.95; H, 4.94; N, 10.07.

Example 3572-(3-Chlorophenyl)-4-(4-methylphenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 To a stirred suspension of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 333, (0.0802 g, 0.15 mmol) in EtOH (1.5 mL) was added thiocresol (0.019 g, 0.15 mmol) and K_2CO_3 (0.0203 g, 0.15 mmol). The suspension was heated to 50 °C with stirring for 2.5 hours. The mixture was poured into H_2O with constant stirring. The resulting precipitate was filtered, rinsed
10 with H_2O and dried to provide the desired product (yield: 0.060 g, 83%). mp 178-178 °C. 1H NMR (300 MHz, $DMSO-d_6$) δ 2.19 (s, 3H), 3.23 (s, 3H), 6.95 (m, 2H), 7.08 (m, 2H), 7.52-7.66 (m, 3H), 7.72 (m, 1H), 7.88 (m, 2H), 8.08 (s, 1H). MS (DCI/ NH_3) m/z 483 ($M+H$)⁺, 500 ($M+NH_4$)⁺. Anal. calc. for: $C_{24}H_{19}ClN_2O_3S_2 \cdot 0.75 H_2O$: C, 58.05; H, 4.16; N, 5.64. Found: C, 57.99; H, 3.69; N, 5.76.

15

Example 3582-(3-Chlorophenyl)-4-(2-pyridylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 357, substituting 2-mercaptopyridine in place of thiocresol (yield: 0.061 g, 39%). mp 110-114
20 °C. 1H NMR (300 MHz, $DMSO-d_6$) δ 3.28 (s, 3H), 7.16 (m, 1H), 7.37 (m, 1H), 7.51-7.71 (m, 5H), 7.81 (m, 2H), 8.03 (m, 2H), 8.27 (s, 1H), 8.34 (m, 1H). MS (DCI/ NH_3) m/z 470 ($M+H$)⁺. Anal. calc. for $C_{22}H_{16}ClN_3O_3S_2 \cdot 0.50 H_2O$: C, 55.16; H, 3.57; N, 8.77. Found: C, 54.88; H, 3.19; N, 8.59.

25

Example 3592-(3-Chlorophenyl)-4-(phenylmethylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a stirred suspension of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 333, (0.175 g, 0.33

mmol) in THF (3.3 mL) was added benzyl mercaptan (0.04 mL, 0.33 mmol) and TEA (0.046 mL, 0.33 mmol). The resulting solution was stirred at room temperature under nitrogen for 1 hour. The mixture was poured into H₂O and extracted with ethyl acetate. The combined organics were dried over MgSO₄ and concentrated in vacuo. The resulting crude product was purified using flash chromatography (SiO₂, 2:1 hexanes:ethyl acetate) to provide the desired product (yield: 0.136 g 85%). mp 142-145 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.31 (s, 3H), 4.36 (s, 2H), 7.17 (m, 2H), 7.21-7.33 (m, 3H), 7.51 (m, 2H), 7.57-7.64 (m, 3H), 7.74 (m, 1H), 8.01 (m, 2H). MS (DCI/NH₃) m/z 483 (M+H)⁺, 500 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉ClN₂O₃S₂: C, 59.68; H, 3.96; N, 5.80. Found: C, 59.40; H, 4.11; N, 5.71.

Example 360

2-(3-Chlorophenyl)-4-(2-furylmethylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 359, substituting furfuryl mercaptan in place of benzyl mercaptan (yield: 0.162 g, 100%). mp 140-149 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.31 (s, 3H), 4.46 (s, 2H), 6.20 (m, 1H), 6.37 (m, 1H), 7.50-7.67 (m, 6H), 7.77 (m, 1H), 8.03 (m, 2H), 8.08 (s, 1H). MS (DCI/NH₃) m/z 473 (M+H)⁺, 490 (M+NH₄)⁺. Anal. calc. for C₂₂H₁₇ClN₂O₄S₂: C, 55.87; H, 3.62; N, 5.92. Found: C, 55.84; H, 3.61; N, 5.82.

Example 361

2-(3-Chlorophenyl)-4-[2-(methylpropyl)thio]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 359, substituting 2-methyl-1-propanethiol in place of benzyl mercaptan (yield: 0.134 g, 91%). Oil. ¹H NMR (300 MHz, DMSO d₆) δ 0.61 (d, J=6 Hz, 6H), 1.54-1.69 (m, 1H), 2.91 (d, J=6 Hz, 2H), 3.33 (s, 3H), 7.52-7.64 (m, 3H), 7.74 (m, 1H), 7.79 (m, 2H), 8.04 (m, 3H).

MS (DCI/NH₃) m/z 449 (M+H)⁺, 466 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₁ClN₂O₃S₂ (0.50 H₂O): C, 55.07; H, 4.84; N, 6.11. Found: C, 54.70; H, 4.64; N, 5.85.

Example 362

5 2-(3-Chlorophenyl)-4-(cyclopentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a -78 °C solution of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, prepared in Example 333, (0.175 g, 0.33 mmol) in THF (3.3 mL) was added cyclopentyl magnesium chloride (0.17 mL, 1.0 M in diethyl ether). The resulting solution was stirred under nitrogen less than 1 hour with
10 warming to room temperature. The reaction was poured into water and extracted with ethyl acetate. The combined organics were dried over MgSO₄ and concentrated in vacuo. The resulting crude product was purified using flash chromatography (SiO₂, 2:1 ethyl acetate:hexanes) to provide the desired product (yield: 0.1328 g, 94%). mp 155-157 °C.
15 ¹H NMR (300 MHz, DMSO d₆) δ 1.50 (m, 2H), 1.66 (m, 2H), 1.79 (m, 2H), 2.09 (m, 2H), 2.90 (m, J=8 Hz, 1H), 3.26-3.37 (3H, obstructed by H₂O), 7.49-7.63 (m, 3H), 7.71 (m, 3H), 7.97 (s, 1H), 8.10 (m, 2H). MS (DCI/NH₃) m/z 429 (M+H)⁺, 446 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁ClN₂O₃S: C, 61.60; H, 4.93; N, 6.53. Found: C, 61.48; H, 4.81; N, 6.22.

Example 363

20 2-(3-Chlorophenyl)-4-(2-methylpropyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound, an oil, was prepared according to the method of Example 362, substituting isobutyl magnesium chloride in place of cyclopentylmagnesium chloride, (yield: 0.132 g, 96%). ¹H NMR (300 MHz, CDCl₃) δ 0.77 (d, J=6 Hz, 6H), 2.08 (m, 1H), 2.54 (d, J=7 Hz, 2H), 7.36-7.46 (m, 2H), 7.56 (m, 2H), 7.62 (m, 1H), 7.73 (m, 2H), 8.11
25 (m, 2H). MS (DCI/NH₃) m/z 417 (M+H)⁺, 434 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₁ClN₂O₃S.0.50 H₂O: C, 59.21; H, 5.20; N, 6.57. Found: C, 59.27; H, 5.40; N, 6.12.

Example 364

2-(3-Chlorophenyl)-4-(cyclopentylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound, an oil, was prepared according to the method of Example 362, substituting cyclopentylmethyl magnesium bromide in place of cyclopentyl magnesium chloride (yield: 0.0579 g, 38%). ¹H NMR (300 MHz, DMSO d₆) δ 0.66 (m, 2H), 1.03 (m, 3H), 1.50 (m, 6H), 1.61 (m, 1H), 2.46 (m, 1H), 3.27-3.42 (3H, obstructed by H₂O), 7.50-7.66 (m, 3H), 7.75 (m, 3H), 7.99 (s, 1H), 8.10 (m, 2H). MS (DCI/NH₃) m/z 457 (M+H)⁺, 474 (M+NH₄)⁺. Anal. calc. for C₂₄H₂₅ClN₂O₃S: C, 63.08; H, 5.51; N, 6.13. Found: C, 63.08; H, 5.47; N, 6.04.

Example 365

2-(3-Chlorophenyl)-4-(2-cyclopentylethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 362, substituting cyclopentylethyl magnesium bromide in place of cyclopentyl magnesium chloride (yield: 0.165 g, 94%). ¹H NMR (300 MHz, DMSO d₆) δ 0.76 (m, 3H), 0.99-1.21 (m, 5H), 1.31-1.62 (m, 8H), 2.42-2.56 (1H, obstructed by DMSO), 3.25-3.34 (2H, obstructed by H₂O), 7.48-7.65 (m, 3H), 7.48-7.65 (m, 3H), 7.76 (m, 3H), 8.01 (s, 1H), 8.10 (m, 2H). MS (DCI/NH₃) m/z 471 (M+H)⁺, 488 (M+NH₄)⁺. Anal. calc. for C₂₅H₂₇ClN₂O₃S: C, 63.75; H, 5.78; N, 5.95. Found: C, 63.48; H, 5.70; N, 5.67.

Example 366

2-(3-Chlorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 362, substituting 3-methylbutyl magnesium bromide in place of cyclopentylmagnesium chloride (yield: 0.0221 g, 16%). mp 60-65 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.75 (d, J=7 Hz, 6H), 1.32-1.52 (m, 3H), 3.31 (s, 3H), 7.50-7.65 (m, 3H), 7.77 (m, 3H), 8.03 (s, 1H), 8.11 (m, 2H). MS (DCI/NH₃) m/z 431 (M+H)⁺, 448 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₃ClN₂O₃S.0.25 H₂O: C, 60.68; H, 5.43; N, 6.43. Found C, 60.29; H, 5.60; N, 6.17.

Example 3672-(3-Chlorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 362, substituting benzyl magnesium chloride in place of cyclopentylmagnesium chloride. mp 174-177 °C (yield: 25.9 g, 57%). ¹H NMR (300 MHz, DMSO d₆) δ 3.30 (s, 3H), 3.91 (bs, 2H), 7.02 (m, 2H), 7.12-7.25 (m, 3H), 7.51-7.64 (m, 3H), 7.72 (m, 3H), 8.07 (m, 2H), 8.12 (s, 1H). MS (DCI/NH₃) m/z 451 (M+H)⁺, 468 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉ClN₂O₃S: C, 63.92; H, 4.25; N, 6.21. Found: C, 63.69; H, 4.28; N, 6.02.

Example 3682-(3-Chlorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 362 substituting cyclohexylmagnesium chloride in place of cyclopentylmagnesium chloride (yield: 0.099 g, 68%). mp 85-90 °C. ¹H NMR (300 MHz, CDCl₃) δ 1.01-1.30 (m, 3H), 1.48-1.69 (m, 3H), 1.75 (m, 2H), 2.28 (m, 2H), 2.57 (m, 1H), 3.16 (s, 3H), 7.35-7.46 (m, 2H), 7.50-7.62 (m, 3H), 7.68 (m, 2H), 8.11 (m, 2H). MS (DCI/NH₃) m/z 443 (M+H)⁺, 460 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₃ClN₂O₃S (1.25 H₂O): C, 59.34; H, 5.52; N, 6.01. Found: C, 59.02; H, 5.24; N, 5.65.

Example 3692-(3-Chlorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 using the product from Example 207C and substituting 4-fluorobenzyl magnesium chloride in place of cyclohexyl magnesium chloride (yield: 0.1895 g, 41%). mp 183-185 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.25-3.36 (3H, obstructed by H₂O), 3.89 (bs, 2H), 6.97-7.09 (m, 4H), 7.50-7.64 (m, 3H), 7.71 (m, 3H), 8.06 (m, 2H), 8.11 (s, 1H). MS (DCI/NH₃) m/z 469 (M+H)⁺, 486 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈ClFN₂O₃S: C, 61.47; H, 3.87; N, 5.97. Found: C, 61.23; H, 3.84; N, 5.77.

Example 3702-(3-Chlorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 362 substituting p-tolylmagnesium bromide in place of cyclopentylmagnesium chloride (yield: 65 mg, 40.9%). mp 222-224 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.28 (s, 3H), 3.25 (s, 3H), 7.12 (t, 4H), 7.6 (m, 5H), 7.79 (t, 1H) 7.9 (d, J=9 Hz, 2H), 8.22 (s, 1H). MS (DCI/NH₃) m/z 451 (M+H)⁺, 468 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉ClN₂O₃S.0.25 H₂O: C, 63.92; H, 4.25; N, 6.21. Found: C, 62.99; H, 4.28; N, 5.85.

Example 3712-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 362, starting with 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 3-fluoro-4-methylphenylmagnesium bromide in place of cyclopentylmagnesium chloride to provide the methyl sulfide compound.

The methyl sulfide was oxidized according to the method of Example 10 to provide the title compound (yield: 265 mg, 85.4%). mp 204-206 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.25 (br s, 3H), 3.08 (s, 3H), 6.83 (dd, J=9 Hz, 1.5 Hz, 1H), 6.96 (dd, J=9 Hz, 1.5 Hz, 1H), 7.08 (t, J=9 Hz, 1H), 7.23-7.33 (m, 1H), 7.41 (d, J=9 Hz, 2H), 7.49-7.56 (m, 1H), 7.61-7.69 (m, 1H), 7.93 (d, J=9 Hz, 2H), 7.99 (s, 1H). MS (DCI/NH₃) m/z 471 (M+H)⁺, 488 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₇F₃N₂O₃S: C, 61.28; H, 3.62; N, 5.96. Found: C, 61.07; H, 3.95; N, 5.56.

Example 3722-(3-Chlorophenyl)-4-(phenethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228 , starting with 2-(3-chlorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting phenethyl magnesium chloride in place of cyclohexylmagnesium chloride then oxidizing by the method of Example 10 (yield: 0.100 g, 39%). mp 142-145 °C. ¹H NMR (300 MHz, DMSO d₆) δ 2.80 (m, 4H), 3.30 (s, 3H), 7.01 (m, 2H), 7.21 (m, 3H), 7.51-7.60 (m, 4H), 7.63 (m, 1H), 7.78 (m, 1H), 8.03 (m, 3H). MS (DCI/NH₃) m/z 465 (M+H)⁺, 482 (M+NH₄)⁺. Anal. calc. for C₂₅H₂₁ClN₂O₃S: C, 64.58; H, 4.55; N, 6.02. Found: C, 64.24; H, 4.50; N, 5.90.

Example 373

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 373A

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-bromo-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 194B, starting with 2-(3-chlorophenyl)-4,5-dibromo-3(2H)-pyridazinone (Example 207A) in place of 2-(4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone and substituting 2-methyl-1-propanol in place of methanol.

Example 373B

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 6, starting with 2-(3-chlorophenyl)-4-(2-methylpropoxy)-5-bromo-3(2H)-pyridazinone in place of 2-benzyl-4-bromo-5-methoxy-3(2H)-pyridazinone and substituting 3-fluoro-4-(methylthio)benzeneboronic acid (Example 72D) in place of 4-fluorobenzeneboronic acid.

Example 373C2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 373B was oxidized according to the method of Example 10 to provide the title compound (yield: 0.73 g, 100%). mp 180-183 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.82 (d, J=6 Hz, 2H), 3.30-3.39 (3H, obstructed by H₂O) 4.25 (d, J=6 Hz, 2H), 7.57 (m, 3H), 7.75 (m, 1H), 7.85 (m, 1H), 8.00 (m, 1H), 8.23 (s, 1H). MS (DCI/NH₃) m/z 451 (M+H)⁺, 468 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₀ClFN₂O₄S: C, 55.94; H, 4.47; N, 6.21. Found: C, 55.73; H, 4.58; N, 6.01.

Example 3742-(3-Chlorophenyl)-4-(benzyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a stirred solution of 2-(3-chlorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 332) (0.100 g, 0.28 mmol) in DMF (2.8 mL) was added benzyl chloride (0.32 mL, 0.28 mmol). The resulting solution was stirred with heating to 60 °C overnight. The solvent was removed in vacuo and the resulting residue partitioned between ethyl acetate and 10% citric acid. After extracting with ethyl acetate, the combined organics were dried over MgSO₄ and concentrated in vacuo. The crude product was purified using flash chromatography (SiO₂, 1:1 ethyl acetate:hexanes) to provide the desired product (yield: 0.096 g, 76%). mp 110-113 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.39 (s, 3H), 5.48 (s, 2H), 7.29 (m, 4H), 7.59-7.71 (m, 3H), 7.76 (m, 3H), 8.00 (m, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 467 (M+H)⁺, 484 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₉ClN₂O₄S: C, 61.73; H, 4.10; N, 6.00. Found: C, 62.00; H, 4.18; N, 5.93.

Example 3752-(4-Fluorophenyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

2-(4-Fluorophenyl)-4-methoxy-5-bromo-3(2H)-pyridazinone (Example 194B) was converted into 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-

pyridazinone according to the method of Example 194C followed by the oxidation method in Example 10. The methoxy compound was converted to the 2-(4-fluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, by treatment with NaOH according to the procedure of Example 332. The hydroxy compound was treated with p-toluenesulfonyl chloride according to the procedure of Example 333, to furnish 2-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-tosyloxy-3(2H)-pyridazinone.

The title compound was prepared according to the method of Example 335, , starting with 2-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-tosyloxy-3(2H)-pyridazinone in place of 2-(3-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-tosyloxy-3(2H)-pyridazinone substituting 3-methyl-1-butanol in place of isobutanol (yield: 0.3932 g, 94%). mp 117-120 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.79 (d, J=6 Hz, 6H), 1.41-1.59 (m, 3H), 3.30 (s, 3H), 4.42 (d, J=5 Hz, 2H), 7.36 (m, 2H), 7.65 (m, 2H), 7.90 (m, 2H), 8.06 (m, 2H), 8.18 (s, 1H). MS (DCI/NH₃) m/z 431 (M+H)⁺, 448 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₃FN₂O₄S: C, 61.38; H, 5.39; N, 6.51. Found: C, 61.42; H, 5.30; N, 6.40.

Example 376

2-(4-Fluorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-tosyloxy-3(2H)-pyridazinone (prepared as an intermediate in Example 375) in place of 2-(3-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-tosyloxy-3(2H)-pyridazinone (yield: 0.486 g, 100%). mp 121-128 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.78 (d, J=7 Hz, 6H), 1.84 (m, 1H), 3.30 (s, 3H), 4.20 (d, J=6 Hz, 2H), 7.37 (m, 2H), 7.66 (m, 2H), 7.92 (m, 2H), 8.07 (m, 2H), 8.19 (s, 1H). MS (DCI/NH₃) m/z 417 (M+H)⁺, 434 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₁FN₂O₄S.0.50 H₂O: C, 59.28; H, 5.21; N, 6.58. Found: C, 59.49; H, 4.97; N, 6.34.

Example 377

2-(4-Fluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 62, starting with 4-(4-fluorophenylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and reacting with 1-iodo-4-fluorobenzene (yield: 0.0881 g, 78%). mp 175-177 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.27-3.36 (3H, obstructed by H₂O), 3.88 (bs, 2H), 6.98-7.09 (m, 4H), 7.34 (m, 2H), 7.65 (m, 2H), 7.71 (m, 2H), 8.06 (m, 3H). MS (DCI/NH₃) m/z 453 (M+H)⁺, 470 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₈F₂N₂O₃S: C, 63.71; H, 4.01; N, 6.19. Found: C, 63.61; H, 4.26; N, 6.03.

Example 378

2-(4-Fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228, substituting 3-methylbutyl magnesium bromide in place of cyclohexylmagnesium chloride (yield: 0.325 g, 69%). mp 151-154 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.75 (d, J=7 Hz, 6H), 1.32-1.51 (m, 3H), 3.31 (s, 3H), 7.37 (m, 2H), 7.66 (m, 2H), 7.77 (m, 2H), 8.00 (s, 1H), 8.10 (m, 2H). MS (DCI/NH₃) m/z 415 (M+H)⁺, 432 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₃FN₂O₃S.0.50 H₂O: C, 62.39; H, 5.71; N, 6.61. Found: C, 62.04; H, 5.78; N, 6.46.

Example 379

2-(Tetrahydro-2H-pyrano-2-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To the solution of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone prepared according to Example 11 (172 mg, 0.5 mmol) and p-toluenesulfonic acid hydrate (19 mg, 0.1 mmol) in dioxane (10 mL) was added 2,3-dihydropyran (2 mL). The mixture was stirred at room temperature for 6 hours. The mixture was then poured into a solution of saturated NaHCO₃ and extracted with ethyl acetate. The ethyl acetate was concentrated in vacuo and the residue was chromatographed (silica gel, 1:1 hexanes-ethyl acetate) to provide the title compound (yield: 25 mg, 11%). ¹H NMR (DMSO-d₆, 300 MHz) δ 1.54 (m, 2H), 1.74 (m, 2H), 2.00 (m, 1H), 2.17 (m, 1H), 3.23 (s, 3H), 3.62 (m,

1H), 4.00 (m, 1H), 5.98 (m, 1H), 7.13 (7, J=9 Hz, 2H), 7.23 (m, 2H), 7.47 (d, J=9 Hz, 2H), 7.86 (d, J=9 Hz, 2H), 8.12 (s, 1H). MS (DCI/NH₃) m/z 429 (M+H)⁺.

Example 380

5 2-(3-(4-Fluorophenyl)phenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 4, starting with 2-(3-bromophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 166) in place of 2-benzyl-4-bromo-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting cesium fluoride for sodium carbonate (yield: 0.62g, 62%). mp 222-225 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.24 (s, 3H), 7.16 (m, 2H), 7.36 (m, 3H), 7.53 (m, 2H), 7.64 (m, 2H), 7.73-7.81 (m, 3H), 7.93 (m, 3H), 8.27 (s, 1H). MS (DCI/NH₃) m/z 515 (M+H)⁺, 532 (M+NH₄)⁺. Anal. calc. for C₂₉H₂₀F₂N₂O₃S.0.25 H₂O: C, 67.10; H, 3.98; N, 5.35. Found: C, 66.93; H, 3.99; N, 5.17.

15

Example 381

2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

20 2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone was prepared according to the method of Example 261, substituting 2-(2,2,2-trifluoroethyl)-4-chloro-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone in place of 2-(2,2,2-trifluoroethyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

25 The methyl sulfide was oxidized with one equivalent of meta-chloroperoxybenzoic acid to give the methyl sulfoxide. The sulfoxide was converted to the title compound according to the method of Example 68 (yield: 196 mg, 28%). mp 144-145 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.86 (s, 9H), 4.23 (s, 2H), 4.82 (q, J=8 Hz, 2H), 5.10 (s, 2H), 7.46 (s, 1H), 7.48 (br s, 1H), 7.79 (s, 1H), 8.03 (t, J=8 Hz, 1H). MS (DCI/NH₃) m/z 438 (M+H)⁺.

Anal. calc. for $C_{17}H_{19}F_4N_3O_4S$: C, 46.68; H, 4.38; N, 9.61. Found: C, 46.76; H, 4.30; N, 9.52.

Example 382

5 2-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-
 3(2H)-pyridazinone

The title compound was prepared according to the method of Example 68 substituting 2-(2,2,2-trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone in place of 2-(2,2,2-trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone (yield: 260 mg, 26%). mp 163-164 °C. 1H NMR (300 MHz, $CDCl_3$) δ 0.86 (d, $J=6.6$ Hz, 6H), 1.91 (septet, $J=6.6$ Hz, 1H), 4.34 (d, $J=6.6$ Hz, 2H), 5.11 (br s, 2H), 7.43-7.52 (m, 2H), 7.80 (s, 1H), 8.02 (t, $J=8$ Hz, 1H). MS (DCI/ NH_3) m/z 424 ($M+H$) $^+$, m/z 441 ($M+NH_4$) $^+$. Anal. calc. for $C_{16}H_{17}F_4N_3O_4S$: C, 45.39; H, 4.05; N, 9.92. Found: C, 59.89; H, 3.83; N, 8.61.

15

Example 383

2-Benzyl-4-(4-fluorobenzyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-benzyl-4-(4-fluorophenylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.5723 g 34%). mp 120-123 °C. 1H NMR (300 MHz, DMSO d_6) δ 3.83 (bs, 2H), 5.30 (bs, 2H), 6.95-7.06 (m, 4H), 7.28-7.40 (m, 5H), 7.48 (m, 2H), 7.60 (m, 2H), 7.91 (m, 2H), 7.95 (s, 1H). MS (DCI/ NH_3) m/z 450 ($M+H$) $^+$, 467 ($M+NH_4$) $^+$. Anal. calc. for $C_{24}H_{20}FN_3O_3S$: C, 64.13; H, 4.48; N, 9.35. Found: C, 63.76; H, 4.71; N, 9.02.

25

Example 384

2-Benzyl-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

To a solution of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (130 mg, 0.3 mmol) and di-*t*-butylazodicarboxylate (DBAD) (69 mg, 0.3 mmol) in THF (30 mL) at -78 °C was added dropwise a 1 N solution of lithium 1,1,1,3,3,3-hexamethyldisilazide (0.9 mL, 0.9 mmol) in THF

5 After addition, the reaction was stirred an additional 45 minutes at -78 °C (or until the TLC indicated a disappearance of starting material). The reaction was quenched with a saturated solution of NH₄Cl and extracted with ethyl acetate. The acetate extract was dried over MgSO₄ and concentrated in vacuo to obtain 220 mg of crude adduct.

The above adduct was dissolved in THF (30 mL) and was treated at room
10 temperature with 1 N NaOH (3 mL) for 5 hours. Sodium acetate (NaOAc.3 H₂O, 1.38 g, 10 mmol) was added followed by addition of hydroxylamine-O-sulfonic acid (1.13 g, 10 mmol) and H₂O (30 mL). The resulting mixture was stirred at room temperature for 18 hours and then extracted with ethyl acetate. The extract was washed with water, brine, dried over MgSO₄ and concentrated in vacuo. The residue was purified by
15 chromatography (silica gel, 1:1 hexanes-ethyl acetate) to provide the desired product (yield: 70 mg, 54%). mp 185-189 °C. ¹H NMR (DMSO-*d*₆, 300 MHz) δ 5.33 (s, 2H), 7.11 (m, 2H), 7.22 (m, 2H), 7.40 (m, 7H), 7.83 (d, J=9 Hz, 2H), 8.10 (s, 1H). MS (DCI/NH₃) *m/z* 436 (M+H)⁺. Anal. calc. for C₂₃H₁₈FN₃O₃S.0.75 H₂O: C, 61.65; H, 4.26; N, 9.04. Found: C, 61.67; H, 4.61; N, 8.66.

20

Example 385

2-(4-Fluorophenyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The product from Example 108 was converted to the title sulfonamide according to the method of Example 384, (yield: 65 mg, 28.8%). mp 227-229 °C. ¹H NMR (300
25 MHz, DMSO-*d*₆) δ 7.08-7.17 (m, 4H), 7.36 (t, J=3 Hz, 2H), 7.47 (br s, 2H), 7.61-7.69 (m, 2H), 7.83 (d, J=9 Hz, 2H), 7.93 (d, J=9 Hz, 2H), 8.40 (s, 1H). MS (DCI/NH₃) *m/z* 469 (M+H)⁺, 486 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₅F₂N₃O₄S: C, 58.02; H, 3.30; N, 9.24. Found: C, 57.84; H, 3.34; N, 9.01.

Example 3862-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The product from Example 371 was converted to the title sulfonamide according to the method of Example 384 (yield: 45 mg, 28%). mp 198-200 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 6.87 (dd, J=9 Hz, 3 Hz, 1H), 7.13 (dt, J=9 Hz, 3 Hz, 1H), 7.19 (t, J=7 Hz, 1H), 7.46 (d, J=9 Hz, 2H), 7.47 (br s, 2H), 7.52-7.69 (m, 2H), 7.79 (d, J=9 Hz, 2H), 7.82-7.89 (m, 1H), 8.25 (s, 1H). MS (DCI/NH₃) m/z 472 (M+H)⁺, 489 (M+NH₄)⁺.

Example 3872-(4-Fluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The product from Example 250 was converted to the title sulfonamide according to the method of Example 384 (yield: 185 mg, 46%). mp 187-188 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.22 (br s, 3H), 6.87 (dd, J=9 Hz, 3 Hz, 1H), 7.16 (q, J=9 Hz, 2H), 7.38 (t, J=9 Hz, 2H), 7.46 (br s, 2H), 7.47 (d, J=9 Hz, 2H), 7.67-7.73 (m, 2H), 7.77 (d, J=9 Hz, 2H), 8.22 (s, 1H). MS (DCI/NH₃) m/z 454 (M+H)⁺, 471 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₇F₂N₃O₃S.0.25 H₂O: C, 60.36; H, 3.87; N, 9.19. Found: C, 60.30; H, 4.26; N, 8.83.

Example 3882-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The product from Example 109 was converted to the title sulfonamide according to the method of Example 384 (yield: 110 mg, 45.7%). mp 224-226 °C. ¹H NMR (300 MHz, CDCl₃) δ 4.86 (br s, 2H), 6.89-7.03 (m, 4H), 7.19-7.30 (m, 1H), 7.45-7.52 (m, 1H), 7.56-7.66 (m, 1H), 7.79 (d, J=9 Hz, 2H), 8.04 (d, J=9 Hz, 1H), 8.08 (s, 1H). MS (DCI/NH₃) m/z 474 (M+H)⁺, 491 (M+NH₄)⁺. Anal. calc. for C₂₂H₁₄F₃N₃O₄S.0.25 H₂O: C, 55.32; H, 2.93; N, 8.80. Found: C, 55.26; H, 3.11; N, 8.58.

Example 3892-(3-Chloro-4-fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The product from Example 247 was converted to the title sulfonamide according to the method of Example 384 (yield: 230 mg, 38%). mp 243-245 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.17 (br s, 3H), 6.94-7.09 (m, 2H), 7.25 (dd, J=9 Hz, 3 Hz, 1H), 7.41-7.48 (m, 4H), 7.60 (t, J=9 Hz, 1H), 7.68-7.75 (m, 1H), 7.77 (d, J=9 Hz, 2H), 7.95 (dd, J=6 Hz, 3 Hz, 1H), 8.25 (s, 1H). MS (DCI/NH₃) m/z 469 (M+H)⁺, 486 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆ClF₂N₃O₃S: C, 56.67; H, 3.29; N, 8.63. Found: C, 56.81; H, 3.35; N, 8.95.

Example 3902-(4-Fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The methyl sulfone product of Example 245 was converted to the title sulfonamide according to the method of Example 384 (yield: 78 mg, 28.3%). mp 202-204 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.22 (s, 3H), 4.86 (s, 2H), 6.83-6.91 (m, 2H), 7.14-7.25 (m, 3H), 7.36 (d, J=9 Hz, 2H), 7.65-7.72 (m, 2H), 7.91 (d, J=9 Hz, 2H), 8.0 (s, 1H). MS (DCI/NH₃) m/z 454 (M+H)⁺, 471 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₇F₂N₃O₃S.0.25 H₂O: C, 60.36; H, 3.77; N, 9.19. Found: C, 60.24; H, 3.93; N, 9.25.

Example 3912-(3-Chlorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2h)-pyridazinone

The methyl sulfone product of Example 244 was converted to the title sulfonamide according to the method of Example 384 (yield: 125 mg, 39%). mp 187-188 °C. ¹H NMR (300 MHz, CDCl₃) δ 2.21 (s, 3H), 4.71 (s, 2H), 6.85-6.92 (m, 2H), 7.21 (d, J=9 Hz, 1H), 7.32-7.47 (m, 2H), 7.37 (d, J=9 Hz, 2H), 7.64 (dt, J=7 Hz, 3 Hz, 1H), 7.77 (br s, 1H), 7.91 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 470 (M+H)⁺, 487 (M+NH₄)⁺. Anal.

calc. for $C_{23}H_{17}ClFN_3O_3S \cdot 0.25 H_2O$: C, 58.32; H, 3.65; N, 8.88. Found: C, 58.27; H, 3.91; N, 8.62.

Example 392

5 2-(3-Chlorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(3-chlorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 366) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.0756 g, 16%). mp 167-170 °C. ¹H NMR (300 MHz, DMSO d_6) δ 0.78 (d, J=6 Hz, 6H), 1.47 (5H, obstructed by hexanes), 7.51-7.65 (m, 4H), 7.68 (m, 2H), 7.75 (m, 1H), 7.98 (m, 2H), 8.03 (s, 1H), 8.60 (bs, 1H). MS (DCI/NH₃) m/z 432 (M+H)⁺, 449 (M+NH₄)⁺. Anal. calc. for $C_{21}H_{22}ClN_3O_3S \cdot 0.25 H_2O$: C, 57.79; H, 5.19; N, 9.62. Found: C, 57.78; H, 5.02; N, 9.40.

15 Example 393

2-(3-Chlorophenyl)-4-(phenethyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(3-chlorophenyl)-4-(phenethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 372) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.075 g, 17%). semi-solid; ¹H NMR (300 MHz, DMSO d_6) δ 2.80 (m, 4H), 3.29-3.42 (3H, obstructed by H₂O), 6.96 (m, 2H), 7.14-7.28 (m, 3H), 7.46-7.68 (m, 7H), 7.78 (m, 1H), 7.92 (m, 2H), 8.01 (s, 1H). MS (DCI/NH₃) m/z 466 (M+H)⁺, 483 (M+NH₄)⁺. Anal. calc. for $C_{24}H_{20}ClN_3O_3S \cdot 0.25 H_2O$: C, 61.27; H, 4.39; N, 8.93. Found: 61.18; H, 4.68; N, 8.58.

25

Example 394

2-(3-Chlorophenyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(3-chlorophenyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone (Example 339) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.575 g, 18%). mp 137-139 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.81 (d, J=7 Hz, 6H), 1.49 (m, 2H), 1.57 (m, 1H), 4.42 (t, J=7 Hz, 2H), 7.44-7.65 (m, 5H), 7.76 (m, 1H), 7.84 (m, 2H), 7.94 (m, 2H), 8.20 (s, 1H). MS (DCI/NH₃) m/z 448 (M+H)⁺, 465 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₂ClN₃O₄S: C, 56.31; H, 4.95; N, 9.38. Found C, 56.02; H, 4.82; N, 9.31.

Example 395

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(3-chlorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 335) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.0458 g, 25%). mp 80-85 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.80 (d, J=6 Hz, 6H), 1.74-1.92 (m, 3H), 4.20 (d, J=6 Hz, 2H), 7.49-7.64 (m, 5H), 7.76 (m, 1H), 7.85 (m, 2H), 7.95 (m, 2H), 8.21 (m, 1H). MS (DCI/NH₃) m/z 434 (M+H)⁺, 451 (M+NH₄)⁺. Anal. calc. for C₂₀H₂₀ClN₃O₄S: C, 55.36; H, 4.65; N, 9.68. Found: C, 55.12; H, 4.58; N, 9.42.

Example 396

2-(4-Fluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 378) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (0.090 g 21%). mp 180-183 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.78 (d, J=6 Hz, 6H), 1.49 (m, 5H), 7.36 (m, 2H), 7.53 (m, 2H), 7.62-7.73 (m, 4H), 7.98 (m, 3H). MS (DCI/NH₃) m/z 416 (M+H)⁺, 433 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₂FN₃O₃S: C, 60.71; H, 5.34; N, 10.11. Found: C, 60.37; H, 5.36; N, 9.84.

Example 3972-(4-Fluorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(4-fluorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 376) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.024 g, 6%). mp 132-136 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.79 (d, J=6 Hz, 6H), 1.83 (m, 1H), 4.19 (d, J=6 Hz, 2H), 7.36 (m, 2H), 7.50 (m, 2H), 7.66 (m, 2H), 7.84 (m, 2H), 7.95 (m, 2H), 8.18 (s, 1H). MS (DCI/NH₃) m/z 418 (M+H)⁺, 435 (M+NH₄)⁺. Anal. calc. for C₂₀H₂₀FN₃O₄S: C, 57.54; H, 4.83; N, 10.07. Found C, 57.26; H, 5.00; N, 9.78.

Example 3982-(4-Fluorophenyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(4-fluorophenyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 375) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.051 g, 18%). Yellow oil. ¹H NMR (300 MHz, DMSO d₆) δ 0.80 (d, J=5 Hz, 6H), 1.47 (m, 3H), 4.42 (t, J=6 Hz, 2H), 7.37 (m, 2H), 7.50 (m, 1H), 7.65 (m, 2H), 7.83 (m, 2H), 7.93 (m, 2H), 8.18 (s, 1H), 8.60 (bs, 1H). MS (DCI/NH₃) m/z 432 (M+H)⁺, 449 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₂FN₃O₄S: C, 58.46; H, 5.14; N, 9.74. Found: C, 58.16; H, 5.21; N, 9.57.

Example 3992-(t-Butyl)-4-(3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

2-(t-Butyl)-4-(3-methyl-1-butoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone prepared in Example 330C was oxidized with one equivalent of meta-chloroperoxybenzoic acid to the corresponding methyl sulfoxide. The sulfoxide was converted to the title sulfonamide by the method of Example 68 (yield: 1.25 g, 54%). mp 153-155°C. ¹H

NMR (300 MHz, CDCl₃) δ 0.82 (d, J=6 Hz, 2H), 1.48 (q, J=6 Hz, 2H), 1.49-1.69 (m, 1H), 1.70 (s, 9H), 4.37 (t, J=6 Hz, 2H), 4.32 (s, 2H), 7.70 (d, J=9 Hz, 2H), 7.72 (s, 1H), 8.01 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 394 (M+H)⁺. Anal. calc. for C₁₉H₂₇N₃O₄S: C, 57.99; H, 6.91; N, 10.67. Found: C, 58.11; H, 6.71; N, 10.58.

5

Example 400

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to Example 384 substituting 2-(3,4-difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 182) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 950 mg, 54%). mp 177-181 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 7.15 (t, 2H), 7.29 (m, 2H), 7.43 (s, 1H), 7.45 (bs, 2H), 7.59 (m, 2H), 7.76 (d, J=9 Hz, 2H), 7.85 (m, 1H), 8.27 (s, 1H). MS (DCI/NH₃) m/z 458 (M+H)⁺, 475 (M+NH₄)⁺. Anal. calc. for C₂₂H₁₄F₃N₃O₃S: C, 57.77; H, 3.08; N, 9.19. Found, C, 57.22; H, 3.28; N, 8.99.

15

Example 401

2-(3-Chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(3-chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 380 mg, 47%). mp 208-210 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 7.15 (t, 2H), 7.27 (m, 2H), 7.43 (s, 1H), 7.45 (bs, 2H), 7.51 (d, J=9 Hz, 4H), 7.6 (t, 1H), 7.7 (m, 1H), 7.75 (d, J=9 Hz, 2H), 7.94 (dd, 1H), 8.25 (s, 1H). MS (DCI/NH₃) m/z 474 (M+H)⁺, 491 (M+NH₄)⁺. Anal. calc. for C₂₂H₁₄F₂ClN₃O₃S.0.5 H₂O: C, 55.76; H, 2.98; N, 8.87. Found: C, 56.05; H, 3.42; N, 8.65.

25

Example 402

2-(3,4-Difluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of procedure Example 384, substituting 2-(3,4-difluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 105 mg, 27%). mp 243-245 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.2 (s, 3H), 7.01 (m, 2H), 7.25 (m, 1H), 7.45 (s, 1H), 7.47 (bs, 2H), 7.6 (m, 2H), 7.77 (d, J=9 Hz, 2H), 7.85 (m, 1H), 8.26 (s, 2H). MS (DCI/NH₃) m/z 472 (M+H)⁺, 489 (M+NH₄)⁺. Anal. calc. for C₂₄H₁₇F₃N₂O₃S.0.5 H₂O: C, 58.59; H, 3.42; N, 8.91. Found: C, 57; H, 4.23; N, 8.89.

Example 403

2-(3,4-Difluorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(3,4-difluorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 35 mg, 42%). mp 169-171 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.78 (d, 6H), 1.84 (m, 1H), 4.2 (d, 2H), 7.54 (m, 3H), 7.6 (m, 1H), 7.82 (m, 3H), 7.91 (d, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 436 (M+H)⁺, 453 (M+NH₄)⁺. Anal. calc. for C₂₀H₁₉F₂N₃O₄S.0.25 H₂O: C, 55.17; H, 4.40; N, 9.65. Found: C, 54.19; H, 4.25; N, 9.35

Example 404

2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(3,4-difluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone (yield: 58 mg, 52%). mp 171-173 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, 6H), 1.4, (m, 3H), 2.48 (m, 2H), 3.3 (s, 3H), 7.51 (m, 1H), 7.65 (m, 1H), 7.75 (d, J=9 Hz, 2H), 7.81 (m, 1H) 8.05 (s, 1H), 8.12 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 434 (M+H)⁺, 451 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₁F₂N₃O₃S.0.25 H₂O: C, 58.19; H, 4.88; N, 9.69. Found: C, 57.69; H, 5.01; N, 9.18.

Example 405

2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384, substituting 2-(3-chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 102 mg, 61.8%). mp 154-156 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, 6H), 1.4, (m, 3H), 2.48 (m, 2H), 7.54 (s, 2H), 7.6 (m, 1H), 7.69 (m, 2H), 7.93 (dd, 1H), 8.05 (m, 2H). MS (DCI/NH₃) m/z 450 (M+H)⁺, 468 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₂FN₃O₃SCl.0.25 H₂O: C, 58.86; H, 4.94; N, 6.24. Found: C, 59.23; H, 5.12; N, 6.00.

Example 406

2-(3,4-Difluorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384 substituting 2-(3,4-difluorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 310 mg, 38%). mp 173-175 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.8 (s, 9H), 3.3 (s, 3H), 4.1 (s, 2H), 7.51 (m, 3H), 7.6 (m, 1H), 7.85 (m, 3H), 7.95 (d, J=9 Hz, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 450 (M+H)⁺, 467 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₁F₂N₃O₄S: C, 56.12; H, 4.71; N, 9.35. Found, C, 55.83; H, 4.73; N, 9.08.

Example 4072-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound was prepared according to the method of Example 384 substituting 2-(3,4-difluorophenyl)-4-(4-fluorophenoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 125 mg, 31%). mp 224-226 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 7.15 (d, 4H), 7.51 (m, 1H), 7.6 (m, 2H) 7.75 (m, 4H), 7.9
10 (t, 1H); 8.4 (s, 1H). MS (DCI/NH₃) m/z 492 (M+H)⁺, 509 (M+NH₄)⁺. Anal. calc. for C₂₂H₁₃F₄N₃O₄S: C, 53.77; H, 2.67; N, 8.55. Found.; C, 53.33; H, 2.84; N, 8.22

Example 4082-(3,3-Difluoro-2-propenyl)-4-(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

15 The intermediate, 2-benzyl-4-(4-fluorophenyl)-5-[3-fluoro-4-(methylthio)phenyl]-3(2H)-pyridazinone prepared according to the method of Example 72, was oxidized with one equivalent of meta-chloroperoxybenzoic acid to provide the methyl sulfoxide which was converted to the sulfonamide according to the method of Example 68. The
20 sulfonamide material was N-debenzylated according to the method of Example 11 and N-alkylated according to the method of Example 20, substituting 1,3-dibromo-1,1-difluoropropane in place of 4-fluorobenzyl bromide and employing 4 equivalents of potassium carbonate to provide the title compound (yield: 120 mg, 27%). mp 180-183 °C.
25 ¹H NMR (300 MHz, CDCl₃) δ 4.71 (dt, J=15 Hz, 7.5 Hz, 2H), 4.75 (d, J=7.5 Hz, 2H), 5.06 (s, 2H), 7.02 (m, 2H), 7.19 (dd, J=9 Hz, 6 Hz, 2H), 7.81 (s, 1H), 7.87 (t, J=7.5 Hz, 2H). MS (DCI/NH₃) m/z 440 (M+H)⁺. Anal. calc. for C₁₉H₁₃F₄N₃O₃S: C, 51.93; H, 2.98; N, 9.56. Found: C, 51.71; H, 3.15; N, 9.28.

Example 409

2-(3,4-Difluorophenyl)-4-[2-(2-propoxy)ethoxy]-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384 , substituting 2-(3,4-difluorophenyl)-4-[2-(2-propoxy)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 110 mg, 34%). mp 54-56 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.0 (d, 6H), 3.43 (m, 1H), 3.54 (m, 2H), 4.63 (m, 2H), 7.5 (m, 3H), 7.6 (m, 1H), 7.8 (m, 1H), 7.95 (m, 4H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 466 (M+H)⁺, 483 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₁F₂N₃O₅S: C, 54.19; H, 4.55; N, 9.03. Found, C, 54.29; H, 4.67; N, 8.95.

Example 410

2-(3,4-Difluorophenyl)-4-(4-methyl-3-pentenloxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384 substituting 2-(3,4-difluorophenyl)-4-(4-methyl-3-pentenloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone. mp 70-73 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.5 (d, 6H), 2.27 (m, 2H), 4.43 (t, 2H), 4.5 (m, 1H), 7.5 (m, 2H), 7.6 (m, 1H), 7.8 (m, 2H), 7.92 (d, J=2 H, 2H), 8.2 (s, 1H). MS (DCI/NH₃) m/z 462 (M+H)⁺, 479 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁F₂N₃O₄S: C, 57.26; H, 4.59; N, 9.11. Found, : C, 56.96; H, 4.70; N, 9.01.

Example 411

2-(3-Chlorophenyl)-4-(3-fluorophenoxy)-5-[4-(methysulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, , substituting 3-fluorophenol in place of isobutanol (yield: 0.034 g, 22%). mp 178-180 °C. ¹H NMR (300 MHz, DMSO d₆) δ 3.27 (s, 3H), 6.88-7.00 (m, 2H), 7.10 (m, 1H), 7.36 (m, 1H), 7.59 (m, 3H), 7.74 (m, 1H), 7.90 (m, 2H), 8.06 (m, 2H), 8.43 (s, 1H). MS (DCI/NH₃)

m/z 488 (M+H)⁺. Anal. calc. for C₂₃H₁₆ClFN₂O₄S.0.25 H₂O: C, 58.10; H, 3.49; N, 5.89. Found C, 58.04; H, 3.59; N, 5.80.

Example 412

5 2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 384 , substituting 2-(3-chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 0.019 g, 10%). mp 157-159 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.81 (d, J=6 Hz, 6H), 1.86 (m, 1H), 4.24 (d, J=6 Hz, 2H), 7.75 (m, 3H), 7.66 (m, 1H), 7.73 (m, 2H), 7.83 (m, 2H), 7.91 (m, 1H), 8.23 (s, 1H). Anal. calc. for C₂₁H₁₉ClFN₃O₄S: C, 53.16; H, 4.24; N, 9.30. Found: C, 53.02; H, 4.43; N, 9.10.

15 Example 413

2-(3-Chlorophenyl)-4-(4-methylpentyl)oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 4-methyl-1-pentanol in place of isobutanol (yield: 0.137 g, 90%). mp 139-140 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.74 (d, J=6 Hz, 6H), 1.03 (m, 2H), 1.39 (m, 1H), 1.54 (m, 2H), 3.29 (s, 3H), 4.40 (t, J=5 Hz, 2H), 7.51-7.60 (m, 3H), 7.75 (m, 1H), 7.90 (m, 2H), 8.07 (m, 2H), 8.20 (s, 1H). MS (DCI/NH₃) m/z 461 (M+H)⁺, 478 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₅ClN₂O₄S: C, 59.95; H, 5.97; N, 6.08. Found: C, 59.62; H, 5.63; N, 5.86.

25 Example 414

2-(4-Fluorophenyl)-4-(4-methylpentyl)oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, starting with 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in

place of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 4-methyl-1-pentanol in place of isobutanol (yield: 0.128 g, 85%). mp 123-125 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.74 (d, J=6 Hz, 6H), 1.03 (m, 2H), 1.39 (m, 1H), 1.54 (m, 2H), 3.28 (s, 3H), 4.39 (t, J=6 Hz, 2H), 7.37 (m, 2H), 7.66 (m, 2H), 7.91 (m, 2H), 8.07 (m, 2H), 8.18 (s, 1H). MS (DCI/NH₃) m/z 445 (M+H)⁺. Anal. calc. for C₂₃H₂₅FN₂O₄S: C, 62.14; H, 5.67; N, 6.30. Found: C, 62.28; H, 5.59; N, 6.25.

Example 415

2-(4-Fluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 332, substituting 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone for 2-(3-chlorophenyl)-4-methoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 2.022 g, 97%). ¹H NMR (300 MHz, DMSO d₆) δ 3.28 (s, 3H), 7.38 (m, 2H), 7.70 (m, 2H), 8.03 (m, 4H), 8.22 (s, 1H). MS (APCI-+Q1MS) 361 (M+H)⁺, (-Q1MS) 359 (M-H)⁻.

Example 416

2-(4-Fluorophenyl)-4-cyclopropylmethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting cyclopropylmethanol in place of isobutanol (yield: 0.117 g, 83%). mp 166-167 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.22 (m, 2H), 0.46 (m, 2H), 1.10 (m, 1H), 3.31 (s, 3H), 4.30 (d, J=7 Hz, 2H), 7.36 (m, 2H), 7.66 (m, 2H), 7.96 (m, 2H), 8.07 (m, 2H), 8.20 (s, 1H). MS (DCI/NH₃) m/z 415 (M+H)⁺, 432 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₅ClN₂O₄S: C, 60.86; H, 4.62; N, 6.76. Found: C, 60.76; H, 4.72; N, 6.61.

Example 417

2-(4-Fluorophenyl)-4-(2-cyclopropyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 2-cyclopropane ethanol in place of isobutanol (yield: 0.1472 g, 100%). mp 111-117 °C. ¹H NMR (300 MHz, DMSO d₆) δ -0.01 (m, 2H), 0.31 (m, 2H), 0.60 (m, 1H), 1.49 (q, J=6 Hz, 2H), 3.29 (s, 3H), 4.48 (t, J=6 Hz, 2H), 7.37 (m, 2H), 7.65 (m, 2H), 7.91 (m, 2H), 8.06 (m, 2H), 8.17 (s, 1H). MS (DCI/NH₃) m/z 429 (M+H)⁺, 446 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁FN₂O₄S: C, 61.67; H, 4.94; N, 6.54. Found: C, 61.59; H, 5.02; N, 6.45.

Example 418

2-(3-Chlorophenyl)-4-cyclopropanemethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 335, substituting cyclopropane methanol in place of isobutanol (yield: 0.0917 g, 64%). mp 158-161 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.22 (m, 2H), 0.46 (m, 2H), 1.13 (m, 1H), 3.31 (s, 3H), 4.31 (d, J=7 Hz, 2H), 7.57 (m, 3H), 7.75 (m, 1H), 7.96 (m, 2H), 8.08 (m, 2H), 8.23 (s, 1H). MS (DCI/NH₃) m/z 431 (M+H)⁺, 448 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₉ClN₂O₄S.0.25 H₂O: C, 57.92; H, 4.51; N, 6.43. Found: C, 57.86; H, 4.35; N, 6.27.

Example 419

2-(3-Chlorophenyl)-4-(2-cyclopropane-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2-cyclopropane ethanol in place of isobutanol (yield: 0.114 g, 78%). mp 124-128 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.00 (m, 2H), 0.32 (m, 2H), 0.61 (m, 1H), 1.49 (q, J=6 Hz, 2H), 3.30 (s, 3H), 4.50 (t, J=6 Hz, 2H), 7.58 (m, 3H), 7.76 (m, 1H), 7.91 (m,

2H), 8.07 (m, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 445 (M+H)⁺, 462 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁ClN₂O₄S: C, 59.39; H, 4.76; N, 6.30. Found: C, 58.92; H, 4.94; N, 6.15.

Example 420

5 2-(4-Fluorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 362, substituting 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 4-methylpentane-1-magnesium bromide for
10 cyclopentyl magnesium chloride (yield: 0.165 g, 99%). mp 112-115 °C. ¹H NMR (300 MHz, DMSO d₆) δ 0.75 (d, J=7 Hz, 6H), 1.07 (q, J=7 Hz, 2H), 1.32-1.53 (m, 3H), 2.45 (t, 2H), 3.31 (s, 3H), 7.37 (m, 2H), 7.66 (m, 2H), 7.76 (m, 2H), 8.00 (s, 1H), 8.10 (m, 2H). MS (DCI/NH₃) m/z 429 (M+H)⁺, 446 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₅FN₂O₃S: C, 64.47; H, 5.88; N, 6.54. Found: C, 64.44; H, 5.90; N, 6.49.

15

Example 421

2-(3-Chlorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 362, substituting 4-methylpentane-1-magnesium bromide in place of cyclopentyl magnesium
20 chloride (yield: 165 mg, 98%). oil. ¹H NMR (300 MHz, DMSO d₆) δ 0.76 (d, J=6 Hz, 6H), 1.07 (m, 2H), 1.33-1.55 (m, 3H), 2.45 (m, 2H), 3.32 (s, 3H), 7.51-7.65 (m, 4H), 7.76 (m, 2H), 8.03 (s, 1H), 8.11 (m, 2H). MS (DCI/NH₃) m/z 445 (M+H)⁺, 462 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₃ClN₂O₃S: C, 62.06; H, 5.66; N, 6.30. Found: C, 61.86; H, 5.64; N, 6.18.

25

Example 422

2-(4-Fluorophenyl)-4-(3-methyl-2-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 3-methyl-2-buten-1-ol in place of isobutanol (yield: 0.1284 g, 88%). mp 128-132 °C. ¹H NMR (300 MHz, DMSO d₆) δ 1.58 (s, 3H), 1.67 (s, 3H), 3.30 (s, 3H), 4.95 (d, J=7 Hz, 2H), 5.31 (m, 1H), 7.38 (m, 2H), 7.65 (m, 2H), 7.89 (m, 2H), 8.06 (m, 2H), 8.18 (s, 1H). MS (DCI/NH₃) m/z 429 (M+H)⁺, 446 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁FN₂O₄S: C, 61.67; H, 4.94; N, 6.54. Found: C, 61.41; H, 4.95; N, 6.47.

Example 423

2-(3-Chlorophenyl)-4-(3-methyl-2-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 3-methyl-2-buten-1-ol in place of isobutanol (yield: 0.119 g, 81%). mp 113-115 °C. ¹H NMR (300 MHz, DMSO d₆) δ 1.58 (s, 3H), 1.67 (s, 3H), 3.31 (s, 3H), 4.96 (m, 2H), 5.32 (m, 1H), 7.58 (m, 3H), 7.75 (m, 1H), 7.89 (m, 2H), 8.07 (m, 2H), 8.21 (s, 1H). MS (APCI+Q1MS) 445 (M+H)⁺, (APCI-Q1MS) 479 (M+35)⁺. Anal. calc. for C₂₂H₂₁ClN₂O₄S: C, 59.39; H, 4.76; N, 6.30. Found: C, 59.14; H, 4.66; N, 6.16.

Example 424

2-(4-Fluorophenyl)-4-(4-methyl-3-pentenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 4-methyl-3-penten-1-ol in place of isobutanol (yield: 0.1165 g, 77%). mp 111-114 °C. ¹H NMR (300 MHz, DMSO d₆) δ 1.46 (s, 3H), 1.56 (s, 3H), 2.26 (m, 2H), 3.30 (s, 1H), 4.43 (t, J=7 Hz, 2H), 4.96 (m, 1H), 7.37 (m, 2H), 7.65 (m, 2H), 7.91 (m, 2H), 8.06 (m, 2H), 8.18 (s, 1H). MS (DCI/NH₃) m/z 443 (M+H)⁺, 460

(M+NH₄)⁺. Anal. calc. for C₂₃H₂₃FN₂O₄S: C, 62.43; H, 5.24; N, 6.33. Found: C, 62.32; H, 5.30; N, 6.25.

Example 425

5 2-(4-Fluorophenyl)-4-(3-methyl-3-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 335, substituting 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3-chlorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 3-methyl-3-butene-1-ol in place of isobutanol (yield: 0.1327 g, 91%). mp 109-111 °C. ¹H NMR (300 MHz, DMSO d₆) δ 1.61 (s, 3H), 2.32 (t, J=7 Hz, 2H), 3.30 (s, 3H), 4.56 (t, J=7 Hz, 2H), 4.63 (bs, 1H), 4.68 (bs, 1H), 7.37 (m, 2H), 7.66 (m, 2H), 7.90 (m, 2H), 8.05 (m, 2H), 8.19 (s, 1H). MS (DCI/NH₃) m/z 429 (M+H)⁺, 446 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁FN₂O₄S: C, 61.67; H, 4.94; N, 6.54. Found: C, 61.50; H, 5.00; N, 6.45.

Example 426

20 2-(3-Chlorophenyl)-4-(4-methyl-3-pentenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 335, substituting 4-methyl-3-pentene-1-ol in place of isobutanol (yield: 0.1149 g, 76%). mp 110-111 °C. ¹H NMR (300 MHz, DMSO d₆) δ 1.47 (s, 3H), 1.55 (s, 3H), 2.27 (m, 2H), 3.30 (s, 3H), 4.44 (t, J=6 Hz, 2H), 4.96 (m, 1H), 7.52-7.64 (m, 3H), 7.75 (m, 1H), 7.91 (m, 2H), 8.06 (m, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 459 (M+H)⁺, 476 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₃ClN₂O₄S: C, 60.19; H, 5.05; N, 6.10. Found: C, 60.06; H, 4.90; N, 5.96.

Example 427

25 2-(3-Chlorophenyl)-4-(3-methyl-3-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone

The title compound was prepared according to the method of Example 335, substituting 3-methyl-3-butene-1-ol in place of isobutanol (yield: 0.1159 g, 79%). mp 110-112 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.62 (s, 3H), 2.32 (t, J=7 Hz, 2H), 3.30 (s, 3H), 4.57 (t, J=6 Hz, 2H), 4.63 (bs, 1H), 4.68 (bs, 1H), 7.51-7.64 (m, 3H), 7.76 (m, 1H), 7.90 (m, 2H), 8.05 (m, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 445 (M+H)⁺, 462 (M+NH₄)⁺. Anal. calc. for C₂₂H₂₁ClN₂O₄S: C, 59.39; H, 4.76; N, 6.30. Found: C, 59.27; H, 4.68; N, 6.18.

Example 428

2-(4-Fluorophenyl)-4-(1,5-hexadienyl-3-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, substituting 1,5-hexadien-3-ol in place of 2-ethyl-1-hexanol (yield: 150 mg, 85%). mp 104-105 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 2.42 (m, 2H), 3.30 (s, 3H), 5.00 (m, 2H), 5.17 (m, 2H), 5.64 (m, 2H), 7.36 (t, J=9 Hz, 2H), 7.64 (m, 2H), 7.92 (d, J=9 Hz, 2H), 8.06 (d, J=9 Hz, 2H), 8.19 (s, 1H). MS (APCI+) m/z 441 (M+H)⁺; (APCI-) m/z 475 (M+Cl)⁺. Anal. calc. for C₂₃H₂₁FN₂O₄S: C, 62.71; H, 4.80; N, 6.35. Found: C, 62.96; H, 4.93; N, 5.85.

Example 429

2-(4-Fluorophenyl)-4-(5-methyl-2-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, substituting 5-methyl-2-hexanol in place of 2-ethyl-1-hexanol (yield: 150 mg, 82%). mp 102-103 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.73 (d, J=7 Hz, 6H), 1.04 (m, 2H), 1.14 (d, J=7 Hz, 3H), 1.40 (m, 3H), 3.29 (s, 3H), 5.12 (m, 1H), 7.36 (t, J=9 Hz, 2H), 7.66 (m, 2H), 7.92 (d, J=9 Hz, 2H), 8.07 (d, J=9 Hz, 2H), 8.19 (s, 1H). MS (APCI+) m/z 459 (M+H)⁺; (APCI-) m/z 493 (M+Cl)⁺. Anal. calc. for C₂₄H₂₇FN₂O₄S: C, 62.86; H, 5.93; N, 6.10. Found: C, 62.83; H, 5.99; N, 6.07.

Example 4302-(4-Fluorophenyl)-4-(2-ethyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound was prepared according to the method of Example 178, substituting 2-ethyl-1-butanol in place of 2-ethyl-1-hexanol (yield: 140 mg, 80%). mp 107-108 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.73 (t, J=7 Hz, 6H), 1.20 (quintet, J=7 Hz, 4H), 1.40 (m, 1H), 3.29 (s, 3H), 4.29 (d, J=7 Hz, 2H), 7.37 (t, J=9 Hz, 2H), 7.66 (m, 2H), 7.90 (d, J=9 Hz, 2H), 8.07 (d, J=9 Hz, 2H), 8.19 (s, 1H). MS (APCI+) m/z 445 (M+H)⁺; (APCI-) m/z 479 (M+Cl)⁻. Anal. calc. for C₂₃H₂₅FN₂O₄S: C, 62.14; H, 5.66; N, 6.30. Found: C, 62.05; H, 5.86; N, 6.30.

Example 4322-(4-Fluorophenyl)-4-(2-thioisopropyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

15 The title compound was prepared according to the method of Example 178, substituting 2-(isopropylthio)ethanol in place of 2-ethyl-1-hexanol (yield: 138 mg, 74%). mp 137-139 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.13 (d, J=7 Hz, 6H), 2.77 (t, J=7 Hz, 2H), 2.88 (quintet, J=7 Hz, 1H), 3.29 (s, 3H), 4.58 (t, J=7 Hz, 2H), 7.37 (t, J=9 Hz, 2H), 7.66 (m, 2H), 7.92 (d, J=9 Hz, 2H), 8.06 (d, J=9 Hz, 2H), 8.18 (s, 1H). MS (APCI+) m/z 463 (M+H)⁺. Anal. calc. for C₂₂H₂₃FN₂O₄S₂: C, 57.12; H, 5.01; N, 6.05. Found: C, 56.82; H, 4.91; N, 5.99.

Example 433

25 2-(4-Fluorophenyl)-4-(3-methylthio-1-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

 The title compound was prepared according to the method of Example 178, substituting 3-(methylthio)-1-hexanol in place of 2-ethyl-1-hexanol (yield: 155 mg, 79%). mp 90-92 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.78 (t, J=7 Hz, 3H), 1.30 (m, 4H), 1.76

(m, 2H), 2.82 (s, 3H), 2.38 (m, 1H), 3.29 (s, 3H), 4.55 (m, 2H), 7.37 (t, J=9 Hz, 2H), 7.66 (m, 2H), 7.92 (d, J=9 Hz, 2H), 8.06 (d, J=9 Hz, 2H), 8.18 (s, 1H). MS (APCI+) m/z 491 (M+H)⁺; (APCI-) m/z 525 (M+Cl)⁻. Anal. calc. for C₂₄H₂₇FN₂O₄S₂: C, 58.75; H, 5.54; N, 5.70. Found: C, 58.66; H, 5.54; N, 5.66.

5

Example 434

2-(4-Fluorophenyl)-4-(2-methyl-4-penten-1-ol)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, substituting 2-methyl-4-penten-1-ol in place of 2-ethyl-1-hexanol (yield: 135 mg, 76%). mp 106-107 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.76 (d, J=7 Hz, 3H), 1.78 (m, 2H), 2.00 (m, 1H), 3.29 (s, 3H), 4.25 (m, 2H), 4.90 (m, 2H), 5.67 (m, 1H), 7.37 (t, J=9 Hz, 2H), 7.66 (m, 2H), 7.92 (d, J=9 Hz, 2H), 8.06 (d, J=9 Hz, 2H), 8.18 (s, 1H). MS (APCI+) m/z 443 (M+H)⁺; (APCI-) m/z 477 (M+Cl)⁻. Anal. calc. for C₂₃H₂₃FN₂O₄S: C, 62.42; H, 5.23; N, 6.33. Found: C, 62.13; H, 5.12; N, 6.22.

15

Example 435

2-(3,4-Difluorophenyl)-4-(3-trifluoromethyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a solution of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (189mg, 0.5 mmol), Ph₃P (262 mg, 1 mmol) and 3-trifluoromethyl-1-butanol (66 mg, 0.5 mmol) in THF (25 mL) was added dropwise a solution of DIAD (0.2 mL, 1 mmol) in THF (5 mL) and the resulting mixture was stirred at room temperature for 8 hours. The mixture was concentrated in vacuo and the residue was chromatographed (silica gel, 1:1 hexanes-ethyl acetate) to provide the desired product, (yield: 180 mg 71%). mp 126-128 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.96 (d, J=7 Hz, 3H), 1.55 (m, 1H), 1.97 (m, 1H), 2.30 (m, 1H), 3.29 (s, 3H), 4.46 (m, 2H), 7.52 (m, 1H), 7.62 (m, 1H), 7.81 (m, 1H), 7.90 (d, J=9 Hz, 2H), 8.08 (d, J=9 Hz, 2H), 8.22 (s, 1H). MS (APCI+) m/z 503

25

(M+H)⁺; (APCI-) m/z 537 (M+Cl)⁻. Anal. calc. for C₂₂H₁₉F₃N₂O₄S: C, 52.59; H, 3.81; N, 5.57. Found: C, 52.70; H, 3.73; N, 5.63.

Example 436

5 2-(3,4-Difluorophenyl)-4-ethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, starting with 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting ethanol in place of 2-ethyl-1-hexanol (yield: 25 mg, 12%).
10 mp 121-123 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.23 (t, J=7 Hz, 3H), 3.30 (s, 3H), 4.51 (q, J=7 Hz, 2H), 7.52 (m, 1H), 7.62 (m, 1H), 7.81 (m, 1H), 7.90 (d, J=9 Hz, 2H), 8.08 (d, J=9 Hz, 2H), 8.22 (s, 1H). MS (APCI+) m/z 407 (M+H)⁺; (APCI-) m/z 441 (M+Cl)⁻.
Anal. calc. for C₁₉H₁₆F₂N₂O₄S.0.25 H₂O: C, 55.53; H, 4.04; N, 6.81. Found: C, 55.58; H, 4.21; N, 6.61.

15

Example 437

2-(3,4-Difluorophenyl)-4-(4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, starting
20 with 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 4-methyl-1-pentanol in place of 2-ethyl-1-hexanol (yield: 120 mg, 52%). mp 98-99 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.73 (d, J=7 Hz, 6H), 1.02 (m, 2H), 1.29 (m, 1H), 1.54 (m, 2H), 3.30 (s, 3H), 4.40 (t, J=7 Hz, 2H), 7.52 (m, 1H),
25 7.62 (m, 1H), 7.81 (m, 1H), 7.90 (d, J=9 Hz, 2H), 8.08 (d, J=9 Hz, 2H), 8.22 (s, 1H). MS (APCI+) m/z 463 (M+H)⁺; (APCI-) m/z 497 (M+Cl)⁻. Anal. calc. for C₂₃H₂₄F₂N₂O₄S: C, 59.72; H, 5.23; N, 6.05. Found: C, 59.57; H, 5.28; N, 6.01.

Example 438

2-(3,4-Difluorophenyl)-4-(4-methyl-2-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, starting with 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 4-methyl-2-pentanol for 2-ethyl-1-hexanol (yield: 115 mg, 50%). mp 132-133 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.80 (d, J=7 Hz, 3H), 0.87 (d, J=7 Hz, 3H), 1.10 (d, J=7 Hz, 3H), 1.26 (m, 1H), 1.50 (m, 1H), 1.63 (m, 1H), 3.30 (s, 3H), 5.31 (m, 1H), 7.52 (m, 1H), 7.62 (m, 1H), 7.81 (m, 1H), 7.90 (d, J=9 Hz, 2H), 8.08 (d, J=9 Hz, 2H), 8.22 (s, 1H). MS (APCI+) m/z 463 (M+H)⁺; (APCI-) m/z 497 (M+Cl)⁻. Anal. calc. for C₂₃H₂₄F₂N₂O₄S: C, 59.72; H, 5.23; N, 6.05. Found: C, 59.44; H, 5.26; N, 5.99.

Example 439

2-(3,4-Difluorophenyl)-4-(2-cyclopentyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, starting with 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 2-cyclopentyl-1-ethanol in place of 2-ethyl-1-hexanol (yield: 115 mg, 60%). mp 100-101 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.00 (m, 2H), 1.38 (m, 2H), 1.57 (m, 7H), 3.30 (s, 3H), 4.42 (t, J=7 Hz, 2H), 7.52 (m, 1H), 7.62 (m, 1H), 7.81 (m, 1H), 7.90 (d, J=9 Hz, 2H), 8.08 (d, J=9 Hz, 2H), 8.22 (s, 1H). MS (APCI+) m/z 475 (M+H)⁺; (APCI-) m/z 509 (M+Cl)⁻. Anal. calc. for C₂₄H₂₄F₂N₂O₄S.0.25 H₂O: C, 60.17; H, 5.15; N, 5.84. Found: C, 60.12; H, 5.14; N, 5.76.

Example 440

2-(3,4-Difluorophenyl)-4-(2-cyclopent-2-enyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, starting with 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 2-cyclopent-2-enyl-1-ethanol in place of 2-ethyl-1-hexanol (yield: 95 mg, 48%). mp 126-127 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 1.30 (m, 1H), 1.57 (sextet, J=7 Hz, 1H), 1.69 (sextet, J=7 Hz, 1H), 1.87 (m, 2H), 2.57 (m, 1H), 3.30 (s, 3H), 4.45 (m, 2H), 5.60 (m, 1H), 5.68 (m, 1H), 7.52 (m, 1H), 7.62 (m, 1H), 7.81 (m, 1H), 7.90 (d, J=9 Hz, 2H), 8.08 (d, J=9 Hz, 2H), 8.22 (s, 1H). MS (APCI+) m/z 473 (M+H)⁺; (APCI-) m/z 507 (M+Cl)⁻. Anal. calc. for C₂₄H₂₂F₂N₂O₄S: C, 61.00; H, 4.69; N, 5.92. Found: C, 60.76; H, 4.65; N, 5.80.

Example 441

2-(2-Hydroxy-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A mixture of the product from Example 46, 2-phenacyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (700 mg, 1.5 mmol), and sodium borohydride (69 mg, 1.8 mmol) in ethanol (200 mL), was stirred at 40 °C for 2 hours. The reaction mixture was then concentrated in vacuo and the residue was partitioned between ethyl acetate and 2 N aqueous hydrochloric acid. The organic layer was washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo to provide a pale yellow solid which was crystallized from ethyl acetate/hexanes to provide the title compound as white crystals (yield: 540 mg, 78%). mp 205-207 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.07 (s, 3H), 3.75 (br s, 1H), 4.63-4.47 (m, 2H), 5.33 (dd, J=9 Hz, 3 Hz, 1H), 7.00 (t, J=9 Hz, 2H), 7.20 (dd, J=9 Hz, 3 Hz, 2H), 7.30-7.45 (m, 5H), 7.52 (d, J=9 Hz, 2H), 7.91 (s, 1H), 7.91 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 465 (M+H)⁺. Anal. calc. for C₂₅H₂₁FN₂O₄S: C, 64.64; H, 4.55; N, 6.03. Found: C, 64.34; H, 4.66; N, 5.93.

Example 442

2-(2-Methoxy-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A mixture of the product from Example 441, 2-(2-hydroxy-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (210 mg, 0.45 mmol),
5 iodomethane (56 μ L, 0.90 mmol), and an 80% oil dispersion of sodium hydride (18 mg, 0.59 mmol) in anhydrous DMF (16 mL) was stirred at room temperature for 18 hours. The reaction mixture was partitioned between ethyl acetate and 2 N aqueous hydrochloric acid. The organic layer was washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to provide a yellow oil which was purified by column
10 chromatography (silica gel, 70:30 hexanes/ethyl acetate). Fractions containing product were combined and concentrated in vacuo, and the residue was triturated with hexanes to provide the title compound (yield: 75 mg, 34.7%). mp 135-137 $^{\circ}\text{C}$. ^1H NMR (300 MHz, CDCl_3) δ 3.07 (s, 3H), 3.26 (s, 3H), 4.33-4.52 (m, 2H), 4.91 (dd, $J=9$ Hz, 3 Hz, 1H), 6.99 (t, $J=9$ Hz, 2H), 7.20 (dd, $J=9$ Hz, 3 Hz, 2H), 7.31-7.50 (m, 7H), 7.87 (s, 1H), 7.89 (d, $J=9$
15 Hz, 2H). MS (DCI/ NH_3) m/z 479 ($\text{M}+\text{H}$) $^+$. Anal. calc. for $\text{C}_{26}\text{H}_{23}\text{FN}_2\text{O}_4\text{S}$: C, 65.25; H, 4.84; N, 5.85. Found: C, 64.98; H, 4.83; N, 5.81.

Example 443

2-(2-Methoxyimino-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A mixture of the product from Example 46, 2-phenacyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (220 mg, 0.476 mmol), methoxylamine hydrochloride (318 mg, 3.8 mmol), and sodium acetate (518 mg, 3.8 mmol) in methanol (100 mL) was stirred at reflux for 48 hours. The reaction mixture was concentrated in
25 vacuo, and the residue was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic layer was washed with brine then dried over MgSO_4 , and filtered. The filtrate was concentrated in vacuo to provide a brown oil which was purified by column chromatography (silica gel, 70:30 hexanes/ethyl acetate). Fractions containing product were combined and concentrated in vacuo. The residue was

crystallized from methanol/water to provide the title compound as a mixture of E and Z oximes (yield: 82 mg, 35%). mp 95-99 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.03 (s, 3H), 4.07 (s, 3H), 5.57 (s, 2H), 6.94 (t, J=9 Hz, 2H), 7.07 (dd, J=9 Hz, 3 Hz, 2H), 7.24 (d, J=9 Hz, 2H), 7.31-7.37 (m, 3H), 7.60-7.67 (m, 2H), 7.74 (s, 1H), 7.83 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 492 (M+H)⁺. Anal. calc. for C₂₆H₂₂FN₃O₄S: C, 63.53; H, 4.51; N, 8.54. Found: C, 63.40; H, 4.51; N, 8.31.

Example 444

2-(3,4-Difluorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 255, substituting 1-bromo-4-methylpentane in place of 3,4-difluorobenzyl bromide (yield: 145 mg, 58%). mp 111-113 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, 6H), 1.09 (m, 2H), 1.4 (m, 3H), 2.48 (m, 2H), 3.4 (s, 3H), 7.61 (m, 2H), 7.75 (d, 2H), 7.81 (m, 1H), 8.02 (s, 1H), 8.1 (d, 2H). MS (DCI/NH₃) m/z 447 (M+H)⁺, 464 (M+NH₄)⁺. Anal. calc. for C₂₃H₂₄F₂N₂O₃S: C, 61.87; H, 5.42; N, 6.27. Found: C, 61.76; H, 5.55; N, 6.11.

Example 445

2-(3,4-Difluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared as described in Example 384, substituting 2-(3,4-difluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 347) in place of 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 248 mg, 42%). mp 149-151 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 0.8 (d, J=6 Hz, 6H), 1.48 (m, 2H), 1.54 (m, 1H), 4.4 (t, 2H), 7.51 (m, 3H), 7.6 (m, 1H), 7.85 (m, 3H), 7.95 (d, J=9 Hz, 2H), 8.21 (s, 1H). MS (DCI/NH₃) m/z 450 (M+H)⁺, 467 (M+NH₄)⁺. Anal. calc. for C₂₁H₂₁F₂N₃O₄S: C, 56.12; H, 4.71; N, 9.35. Found, C, 56.12; H, 4.67; N, 9.15.

Example 4462-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The intermediate, 2-(2,2,2-trifluoroethyl)-4-hydroxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone prepared in Example 90C was reacted with 2,2-dimethylpropanol to provide 2-(2,2,2-trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone according to the method of Example 90D.

The product was oxidized with one equivalent of meta-chloroperoxybenzoic acid to provide the methyl sulfoxide. The sulfoxide was converted to the title compound according to the method of Example 68, substituting 2-(2,2,2-trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone for 2-(2,2,2-trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone (yield: 125 mg, 53%). mp 123-124 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.82 (s, 9H), 4.18 (s, 2H), 4.82 (q, J=9 Hz, 2H), 4.84 (s, 2H), 7.70 (d, J=9 Hz, 2H), 7.81 (s, 1H), 8.04 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 420 (M+H)⁺. Anal. calc. for C₁₇H₂₀F₃N₃O₄S: C, 48.68; H, 4.80; N, 10.01. Found: C, 48.76; H, 4.77; N, 9.94.

Example 4472-(2,2,2-Trifluoroethyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 83, substituting 3-methyl-1-butanol in place of isopropanol (yield: 65 mg, 85%). mp 111-113 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.84 (d, J=6 Hz, 6H), 1.51 (m, 2H), 1.63 (m, 1H), 3.11 (s, 3H), 4.54 (t, J=6 Hz, 2H), 4.83 (q, J=9 Hz, 2H), 7.73 (d, J=9 Hz, 2H), 7.82 (s, 1H), 8.05 (d, J=9 Hz, 2H); MS (DCI/NH₃) m/z 419 (M+H)⁺. Anal. calc. for C₁₈H₂₁F₃N₃O₄S: C, 51.66; H, 5.05; N, 6.69. Found: C, 51.91; H, 5.06; N, 6.56.

Example 448

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The intermediate, 2-(2,2,2-trifluoroethyl)-4-hydroxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone prepared in Example 90C was reacted with 3-methyl-1-butanol to provide 2-(2,2,2-trifluoroethyl)-4-(3-methylbutoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone according to the method of Example 90D.

The product was oxidized with one equivalent of meta-chloroperoxybenzoic acid to provide the methyl sulfoxide. The sulfoxide was converted to the title compound according to the method of Example 68, substituting 2-(2,2,2-trifluoroethyl)-4-(3-methylbutoxy)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone for 2-(2,2,2-trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone (yield: 65 mg, 50%). mp 123-124 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.84 (d, J=6 Hz, 6H), 1.52 (q, J=6 Hz, 2H), 1.60 (h, J=7.5 Hz, 1H), 4.52 (t, J=6 Hz, 2H), 4.83 (q, J=9 Hz, 2H), 4.90 (s, 2H), 7.69 (d, J=9 Hz, 2H), 7.82 (s, 1H), 8.04 (d, J=9 Hz, 2H). MS (DCI/NH₃) m/z 420 (M+H)⁺. Anal. calc. for C₁₇H₂₀F₃N₃O₄S: C, 48.68; H, 4.80; N, 10.01. Found: C, 48.86; H, 4.83; N, 9.92.

Example 449

2-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The intermediate, 2-(2,2,2-trifluoroethyl)-4-hydroxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone prepared in Example 90C was reacted with 2-methyl-1-propanol to provide 2-(2,2,2-trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone according to the method of Example 90D.

The product was oxidized with one equivalent of meta-chloroperoxybenzoic acid to provide the methyl sulfoxide. The sulfoxide was converted to the title compound according to the method of Example 68, substituting 2-(2,2,2-trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone for 2-(2,2,2-trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone

(yield: 120 mg, 40%). mp 170-172 °C. ¹H NMR (300 MHz, CDCl₃) δ 0.83 (d, J=6 Hz, 6H), 1.9 (m, 1H), 4.3 (m, 2H), 4.82 (s, 2H), 4.88 (m, 2H), 7.70 (d, J=9 Hz, 2H), 7.79 (s, 1H), 8.03 (d, J=9 Hz, 2H); MS (DCI/NH₃) m/z 406 (M+H)⁺. Anal. calc. for C₁₆H₁₈F₃N₃O₄S: C, 47.4; H, 4.47; N, 10.36. Found: C, 47.48; H, 4.36; N, 10.25.

5

Example 450

2-(2,3,3-Trifluoropropenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The product of Example 4, 2-benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone, was N-debenzylated by the method of Example 11 to provide 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone. The intermediate was mixed with one equivalent of 1-methylsulfonyloxy-2,3,3-trifluoro-2-propene, (Example 88A) in ethyl acetate, followed by one equivalent of cesium carbonate. The reaction mixture was heated to 50 °C for 5 hours. Aqueous work-up, followed by chromatography provided 2-(2,3,3-trifluoropropenyl)-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (650 mg, 63%). The product was oxidized with one equivalent of meta-chloroperoxybenzoic acid to provide the methyl sulfoxide which was converted to the title compound according to the method of Example 68, substituting 2-(2,3,3-trifluoropropenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone for 2-(2,2,2-trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-3(2H)-pyridazinone (yield: 65 mg, 35%). mp 190-193°C. ¹H NMR (300 MHz, CDCl₃) δ 5.07 (s, 2H), 5.10 (dt, J=21 Hz, J=3 Hz, 2H), 7.05 (m, 4H), 7.19 (dd, J=9 Hz, J=6 Hz, 2H), 7.84 (s, 1H), 7.87 (t, J=7.5 Hz, 1H). MS (ESI-NH₃) m/z 456 (M-H)⁺. Anal. calc. for C₁₉H₁₂F₃N₃O₃S: C, 49.89; H, 2.64; N, 9.18. Found: C, 49.89; H, 2.73; N, 9.03.

25

Example 451

2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, substituting 3-methyl-1,3-butanediol in place of 2-ethyl-1-hexanol (yield: 110 mg, 61%). mp 133-134 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.04 (s, 6H), 1.72 (t, J = 7 Hz, 2H), 3.29 (s, 3H), 4.32 (s, 1H), 4.53 (t, J = 7 Hz, 2H), 7.37 (t, J = 9 Hz, 2H), 7.66 (m, 2H), 7.90 (d, J = 9 Hz, 2H), 8.07 (d, J = 9 Hz, 2H), 8.19 (s, 1H); MS (APCI+) m/z 447 (M+H)⁺; (APCI-) m/z 481 (M+Cl)⁺; Anal. calc. for C₂₂H₂₃FN₂O₅·0.25 H₂O: C, 58.59; H, 5.25; N, 6.21. Found: C, 58.42; H, 5.00; N, 6.02.

Example 4522-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, substituting 2-(3,4-difluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(4-fluorophenyl)-4-tosyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 2-methyl-1,2-propanediol in place of 2-ethyl-1-hexanol (yield: 55 mg, 31%). ¹H NMR (300 MHz, DMSO-d₆) δ 0.97 (s, 6H), 3.30 (s, 3H), 4.20 (s, 2H), 4.54 (s, 1H), 7.52 (m, 1H), 7.62 (m, 1H), 7.81 (m, 1H), 7.98 (d, J = 9 Hz, 2H), 8.05 (d, J = 9 Hz, 2H), 8.21 (s, 1H); MS (APCI+) m/z 451 (M+H)⁺; (APCI-) m/z 485 (M+Cl)⁺; Anal. calc. for C₂₁H₂₀F₂N₂O₅S: C, 55.99; H, 4.47; N, 6.21. Found: C, 56.00; H, 4.48; N, 5.87.

Example 453

2-(3,4-Difluorophenyl)-4-methoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was isolated from the reaction mixture in Example 233, as a product of oxidation of unreacted starting material (yield: 22 mg, 8%). mp 113-115 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.3 (s, 3H), 4.1 (s, 3H), 7.53 (m, 1H), 7.63 (m, 1H), 7.8 (m, 1H), 8.15 (d, 2H), 8.2 (s, 2H). MS (DCI/NH₃) m/z 393 (M+H)⁺, 410 (M+NH₄)⁺. Anal. calc. for C₁₈H₁₄F₂N₂O₄S: C, 55.10; H, 3.60; N, 7.14.

Example 454

2-(2,3,4,5,6-Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-(dimethylamino)methylaminosulfonylphenyl]-3(2H)-pyridazinone

The title compound was isolated from the reaction mixture in Example 125, as a product resulting from a reaction with the solvent, N,N-dimethylformamide (yield: 53 mg, 16%). mp 194-196 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 3.17 (s, 3H), 5.49 (s, 2H), 6.97 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, 6 Hz, 2H), 7.20 (d, J=9 Hz, 2H), 7.81 (s, 1H), 7.82 (d, J=9 Hz, 2H), 8.14 (s, 1H). MS (DCI/NH₃) m/z 581 (M+H)⁺. Anal. calc. for C₂₆H₁₈F₆N₄O₃S: C, 53.79; H, 3.12; N, 9.65. Found: C, 53.50; H, 3.24; N, 9.56.

Example 455

2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(dimethylamino)methylaminosulfonylphenyl]-3(2H)-pyridazinone

The title compound was isolated from the reaction mixture in Example 124, as a product resulting from a reaction with the solvent, N,N-dimethylformamide (yield: 55 mg, 18%). mp 193-195 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.03 (s, 3H), 3.16 (s, 3H), 5.43 (s, 2H), 6.88 (m, 2H), 6.95 (t, J=9 Hz, 2H), 7.18 (dd, J=9 Hz, 6 Hz, 2H), 7.20 (d, J=9 Hz, 2H), 7.52 (m, 1H), 7.81 (d, J=9 Hz, 2H), 7.84 (s, 1H), 8.13 (s, 1H). MS (DCI/NH₃) m/z 527 (M+H)⁺. Anal. calc. for C₂₆H₂₁F₃N₄O₃S: C, 59.30; H, 4.02; N, 10.64. Found: C, 59.08; H, 3.97; N, 10.48.

Example 456

(4-Fluorophenyl)-5-[4-(methylselenonyl)phenyl]-3(2H)-pyridazinone

Example 456A

4-Bromoselenoanisole

Freshly crushed magnesium turnings (6.1 g, 0.25 mol) were suspended with vigorous stirring in a solution of diethyl ether (360 mL) and 1,4-dibromobenzene (10 g, 0.04 mol). The solution was brought to reflux for 30 minutes, without initiation. Several crystals of iodine were added which initiated the reaction to a self-sustained reflux. The

reflux was maintained as the remainder of the 1,4-dibromobenzene (49 g, 0.21 mol) was slowly added. The reaction was refluxed for an additional 2 hours after addition of the 1,4-dibromobenzene was completed. When nearly all of the magnesium turnings had been consumed, the yellow/gray heterogeneous solution was cooled to 23 °C, and selenium (19 g, 0.24 mol) was added in small portions via spatula so as to maintain a gentle reflux. The selenium that became stuck to the sides of the flask was washed in with additional diethyl ether. After addition, the solution was stirred for 20 minutes at 23 °C and then was cooled to 0 °C. A diethyl ether (20 mL) solution of methyl iodide (35.5 g, 0.25 mol) was slowly added dropwise to the reaction mixture. Upon completion of addition, the cooling bath was removed, and the solution stirred for 3 hours at 23 °C. The reaction solution was slowly poured into ice water/1 M HCl, and then the biphasic solution filtered through a glass wool plug. The ethereal layer was separated and the aqueous phase extracted twice more with diethyl ether. The combined ethereal extracts were dried over MgSO₄, filtered, and concentrated in vacuo to provide a semi-viscous orange oil. On standing overnight at -20 °C, large yellow needles formed. The residual oil was drawn off via pipette to provide 17 g (27%) of crystalline product. (J. Org. Chem., 1983, 48, 4169) ¹H NMR (300 MHz, CDCl₃) δ 2.46 (s, 3H), 7.12 (d, J=8.7 Hz, 2H), 7.39 (d, J=8.7 Hz, 2H). MS (APCI+) m/z 248 (Se₇₆ M+H)⁺, m/z 250 (Se₇₈ M+H)⁺, m/z 252 (Se₈₀ M+H)⁺, and m/z 254 (Se₈₂ M+H)⁺.

20

Example 456B

2,4-Bis(4-fluorophenyl)-5-[4-(methylseleno)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 228, substituting 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylseleno)phenyl]-3(2H)-pyridazinone (prepared according to the method of Example 194C, substituting 4-(methylseleno)benzeneboronic acid from Example 1 in place of 4-(methylthio)benzeneboronic acid) in place of 2-(4-fluorophenyl)-4-methoxy-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone and substituting 4-fluorophenyl magnesium bromide in place of cyclohexylmagnesium chloride (yield: 44 mg, 69%). ¹H NMR (300 MHz, CDCl₃) δ 2.37 (s, 3H), 6.98 (dd, J=8.8, 8.8 Hz, 2H), 7.05 (d, J=8.7 Hz, 2H), 7.17

(dd, J=8.7, 8.7 Hz, 2H), 7.23-7.31 (m, 2H), 7.32 (d, J=8.7 Hz, 2H), 7.65-7.72 (m, 2H), 8.00 (s, 1H). MS (APCI+) m/z 455 (M+H)⁺.

Example 456C

5 2,4-Bis(4-fluorophenyl)-5-[4-(methylselenonyl)phenyl]-3(2H)-pyridazinone

A stirred solution of the 2,4-bis(4-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylseleno)phenyl]-3(2H)-pyridazinone (40 mg, 88.1 mmol) in methylene chloride (2 mL) was treated with 3-chloroperoxybenzoic acid (100 mg, 342 mmol, 57-86%) at 23 °C. After 2 hours, the reaction appeared to be only slightly more than 50% completed.

10 Additional 3-chloroperoxybenzoic acid (80 mg, 274 mmol, 57-86%) was added. The reaction ran to completion over the next 16 hours of stirring at 23 °C. The solution was diluted with ethyl acetate and carefully shaken with a NaHSO₃ solution (two times) for several minutes to consume the excess 3-chloroperoxybenzoic acid. The ethyl acetate solution was subsequently washed with a saturated Na₂CO₃ solution (two times), water, and brine and dried over MgSO₄, filtered, and concentrated in vacuo. The residue was
15 chromatographed (flash silica gel, acetone/methylene chloride/hexanes 2:2:1) to provide the product (yield: 40 mg, 93%). (J. Chem. Soc., Chem. Commun., 1985, 569). mp 110-150 °C. ¹H NMR (300 MHz, CDCl₃) δ 3.32 (s, 3H), 6.91 (dd, J=8.7, 8.7 Hz, 2H), 7.14-7.27 (m, 4H), 7.48 (d, J=8.4 Hz, 2H), 7.65-7.73 (m, 2H), 7.97 (s, 1H), 8.00 (d, J=8.4 Hz,
20 2H). MS (APCI+) m/z 487 (M+H)⁺ and m/z 504 (M+NH₄)⁺. Anal. calc. for C₂₃H₁₆F₂N₂O₃Se.0.5 H₂O: C, 55.88; H, 3.46; N, 5.66. Found: C, 55.60; H, 3.61; N, 5.29.

Example 457

25 2-(3,4-Difluorophenyl)-4-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared as described in Example 62, starting with 4-(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 3,4-difluorobromobenzene in place of 1-bromo-4-fluorobenzene (yield: 185 mg, 46.5%). mp

182-185 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.23 (s, 3 H), 6.98 (d, J=9 Hz, 1H), 7.18 (m, 2H), 7.32 (m, 1H), 7.52 (d, J=9 Hz, 2 H), 7.6 (m, 2H), 7.85 (m, 1 H), 7.9 (d, J=9 Hz, 2H), 8.3 (s, 1 H). MS (DCI/NH₃) m/z 457 (M+H)⁺, 474 (M+NH₄)⁺.

5

Example 4582-(4-Fluorophenyl)-4-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared as described in Example 62, substituting 4-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 135 mg, 34%).
mp 199-201 °C. ¹H NMR (300 MHz, DMSO-d₆) δ 3.24 (s, 3H), 6.98 (d, J=9 Hz, 1H), 7.18 (m, 2H), 7.32 (m, 1H), 7.39 (t, 1H), 7.54 (d, J=9 Hz, 2 H), 7.71 (m, 2H), 7.91(d, J=9 Hz, 2 H), 8.27 (s, 1 H). MS (DCI/NH₃) m/z 439 (M+H)⁺, 456 (M+NH₄)⁺.

10

Example 459

15 2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

To a solution of 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (139 mg, 0.309 mmol) and di-*t*-butylazodicarboxylate (71.2 mg, 0.309 mmol) in THF (25 mL) at -78 °C was added dropwise a 1M solution of NaHMDS (0.93 mL, 0.928 mmol) in THF. After addition the reaction was stirred another 45 min at -78 °C (or until TLC indicated a disappearance of starting material) and then was treated with 1N NaOH (20 mL). The reaction mixture was stirred at room temperature for the next 18 h. Sodium acetate trihydrate (758 mg, 5.57 mmol) was added followed by addition of hydroxylamine-O-sulphonic acid (630 mg, 5.57 mmol) and H₂O (50 mL). The resulting mixture was stirred at ambient temperature for the next 18 hours and then extracted with EtOAc. The extract was washed with water, brine, dried over MgSO₄ and concentrated in vacuo. The residue was purified by chromatography (silica gel, 1:1 hexanes-EtOAc) to provide the title compound (yield: 25 mg; 18%). mp 65-69°C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.0 (s, 6H), 4.2 (s, 2H), 4.56

20


25

(s, 1H), 7.51 (m, 3H), 7.6 (m, 1H), 7.85 (m, 1H), 7.95 (s, 4H), 8.21 (s, 1H); MS (DCI/NH₃) m/z 451 (M+H)⁺, 467 (M+NH₄)⁺.

Example 460

5 2-(3,4-Difluorophenyl)-4-(2-oxo-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A solution of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (378 mg, 1 mmol), Ph₃P (524 mg, 2 mmol) and acetol (74 mg, 1 mmol) in THF (25 mL) at room temperature was treated dropwise with a solution of DIAD (0.4 mL, 2 mmol) in THF (5 mL). The mixture was stirred at room temperature for 6 hours and concentrated in vacuo. The residue was chromatographed (silica gel, 1:1 hexanes-ethyl acetate) to provide the desired product (yield: 205 mg, 48%). mp 169-170 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 2.08 (s, 3H), 3.30 (s, 3H), 5.30 (s, 2H), 7.48 (m, 1H), 7.62 (q, J = 10 Hz, 1H), 7.75 (m, 1H), 7.94 (d, J = 9 Hz, 2H), 8.05 (d, J = 9 Hz, 2H), 8.21 (s, 1H); MS (APCI⁺) m/z 435 (M+H)⁺, (APCI⁻) m/z 469 (M+Cl)⁻; Anal. calc. for C₂₀H₁₆F₂N₂O₅S·0.75H₂O: C, 53.62; H, 3.93; N, 6.25. Found: C, 53.26; H, 3.61; N, 6.08.



Example 461

20 2-(3,4-Difluorophenyl)-4-[2-(methoxyimino)-1-propoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A mixture of 2-(3,4-difluorophenyl)-4-(2-oxo-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone from Example 460 (150 mg, 0.3 mmol) in H₂O (10 mL) and dioxane (20 mL) was treated with methoxyamine hydrochloride (84 mg, 1 mmol) and sodium acetate trihydrate (138 mg, 1 mmol). The mixture was stirred at room temperature for 6 hours. The reaction mixture was extracted with ethyl acetate and

purified by column chromatography (silica gel, 1:1 hexanes-ethyl acetate) to provide the title compound (yield: 20 mg, 15%). mp 143-145 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.63 (s, 3H), 3.30 (s, 3H), 3.74 (s, 3H), 4.93 (s, 2H), 7.54 (m, 1H), 7.65 (q, J = 10 Hz, 1H), 7.82 (m, 1H), 7.92 (d, J = 9 Hz, 2H), 8.07 (d, J = 9 Hz, 2H), 8.24 (s, 1H); MS (APCI+) m/z 464 (M+H)⁺; (APCI-) m/z 498 (M+Cl)⁻. Anal. calc. for C₂₁H₁₉F₂N₃OS: C, 54.42; H, 4.13; N, 9.06. Found: C, 54.33; H, 3.93; N, 8.92.

Example 462

(S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methanesulfonyl)phenyl]-3(2H)-pyridazinone

Example 462A

(R)-3-t-Butoxy-2-methyl-1-propanol

A solution of (S)-(+)-methyl 3-hydroxy-2-methylpropionate (1.18 g, 10 mmol) in t-butyl acetate (30 mL) was treated with 70% HClO₄ (0.1 mL) and the reaction mixture was left at room temperature in a tightly closed flask for 24 hours. The mixture was then poured into a saturated solution of NaHCO₃ and extracted with ethyl ether. The ether was removed in vacuo and the residue was dissolved in THF (50 mL). To the resulting solution was added NaBH₄ (925 mg, 25 mmol) and at 55 °C dropwise methanol (10 mL). The reaction was continued at 55 °C for 1 hours, then it was cooled to ambient temperature, acidified with 10% citric acid to pH 5 and extracted with ethyl acetate. The acetate extract was washed with water, brine, dried with MgSO₄ and concentrated in vacuo. The residue was chromatographed (silica gel, 2:1 hexane-ethyl acetate) to provide (R)-3-t-butoxy-2-methyl-1-propanol (yield: 1 g, 68%). ¹H NMR (300 MHz, CDCl₃) δ 0.85 (d, J = 7 Hz, 3H), 1.20 (s, 9H), 2.03 (m, 1H), 3.30 (t, J = 12 Hz, 1H), 3.53 (dd, J = 4.5 Hz, 12 Hz, 1H), 3.70 (m, 2 H); MS (DCI/NH₃) m/z 164 (M+NH₄)⁺.

Example 462B

(S)-2-(3,4-Difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a solution 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (378 mg, 1 mmol), Ph_3P (524 mg, 2 mmol) and Example 462A (146 mg, 1 mmol) in THF (25 mL) at room temperature was added dropwise a solution of DIAD (0.4 mL, 2 mmol) in THF (5 mL). The mixture was then stirred at room temperature for 6 hours and concentrated in vacuo. The residue was passed through a silica gel pad (hexane-ethyl acetate as an eluent) to provide 550 mg of roughly purified (S)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, still contaminated with reduced DIAD. MS (APCI+) m/z 507 ($\text{M}+\text{H}$)⁺; (APCI-) m/z 541 ($\text{M}+\text{Cl}$)⁻.

Example 462C

(S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A mixture of Example 462B (100 mg, ~0.2 mmol) in TFA (5 mL) was left at ambient temperature for 24 hours. The mixture was then concentrated in vacuo, the residue was neutralized with saturated solution of NaHCO_3 and extracted with ethyl acetate. Purification on a column (silica gel, 1:2 hexanes-EtOAc) gave a foamy product (yield: 51 mg, 56%). ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 0.75 (d, $J = 7$ Hz, 3H), 1.81 (sextet ($J = 7$ Hz, 1H), 3.21 (d, $J = 6$ Hz, 2H), 3.30 (s, 3H), 4.29 (dd, $J = 6$ Hz, 12 Hz, 1H), 4.40 (dd, $J = 6$ Hz, 12 Hz, 1H), 4.48 (br s, 1H), 7.52 (m, 1H), 7.61 (m, 1H), 7.80 (m, 1H), 7.91 (d, $J = 9$ Hz, 2H), 8.07 (d, $J = 9$ Hz, 2H), 8.20 (s, 1H); MS (APCI+) m/z 451 ($\text{M}+\text{H}$)⁺; (APCI-) m/z 485 ($\text{M}+\text{Cl}$)⁻; Anal. calc. for $\text{C}_{21}\text{H}_{20}\text{F}_2\text{N}_2\text{O}_5\text{S}$: C, 55.99; H, 4.47; N, 6.21. Found: C, 55.65; H, 4.65; N, 5.92.

Example 463

(R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared by the method described in Example 462, substituting (R)-(-)-methyl 3-hydroxy-2-methylpropionate in place of (S)-(+)-methyl 3-hydroxy-2-methylpropionate (yield: 65 mg, 61%). ¹H NMR (300 MHz, DMSO-d₆) δ 0.75 (d, J = 7 Hz, 3H), 1.81 (sextet, J = 7 Hz, 1H), 3.21 (t, J = 6 Hz, 2H), 3.30 (s, 3H), 4.29 (dd, J = 6 Hz and 12 Hz, 1H), 4.40 (dd, J = 6 Hz, 12 Hz, 1H), 4.49 (t, J = 6 Hz, 1H), 7.52 (m, 1H), 7.61 (m, 1H), 7.80 (m, 1H), 7.91 (d, J = 9 Hz, 2H), 8.07 (d, J = 9 Hz, 2H), 8.20 (s, 1H); MS (APCI+) m/z 451 (M+H)⁺; (APCI-) m/z 485 (M+Cl)⁻. Anal. calc. for C₂₁H₂₀F₂N₂O₅S: C, 55.99; H, 4.47; N, 6.21. Found: C, 55.62; H, 4.52; N, 6.06.

Example 464

(S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

To a solution of (S)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 462B, 450 mg, ~0.9 mmol) and DBAD (207 mg, 0.9 mmol) in THF (25 mL) at -78 °C was added dropwise a 1M solution of LiHMDS (3 mL, 3 mmol) and the resulting mixture was stirred at -78 °C for 2 hours. The mixture was warmed to room temperature and 1N NaOH (5 mL, 5 mmol) was added. After 12 hours at ambient temperature, sodium acetate trihydrate (2.76 g, 20 mmol) and water (10 mL) followed by hydroxylamine-O-sulfonic acid (2g, 15 mmol) were added and the mixture was stirred at room temperature for 5 hours. The product was extracted with ethyl acetate and purified by chromatography (silica gel, 1:2 hexanes-EtOAc) to afford crude intermediate (yield: 160 mg, 35%). MS (APCI+) m/z 508 (M+H)⁺; (APCI-) m/z 542 (M+Cl)⁻.

TFA (5 mL) was added to the above intermediate and the resulting solution was left at room temperature for 24 hours. The TFA was removed in vacuo, then the residue was neutralized with saturated NaHCO₃ and extracted with ethyl acetate. The organic layer was dried over MgSO₄ then filtered. The filtrate was concentrated in vacuo and the residue was purified by column chromatography (silica gel, 1:2 hexane-ethyl acetate) to provide the title compound (yield: 50 mg, 33%). ¹H NMR (300 MHz, DMSO-d₆) δ 0.76

(d, J = 7 Hz, 3H), 1.81 (sextet, J = 7 Hz, 1H), 3.22 (t, J = 6 Hz, 2H), 4.28 (dd, J = 6 Hz, 12 Hz, 1H), 4.40 (dd, J = 6 Hz, 12 Hz, 1H), 4.50 (t, J = 6 Hz, 1H), 7.51 (m, 3H), 7.61 (m, 1H), 7.80 (m, 1H), 7.84 (d, J = 9 Hz, 2H), 7.95 (d, J = 9 Hz, 2H), 8.20 (s, 1H); MS (APCI+) m/z 452 (M+H)⁺; (APCI-) m/z 486 (M+Cl)⁻.

5

Example 465

(R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The desired material was prepared according to the procedure of Example 464 substituting (R)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of (S)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 30 mg, 20%). ¹H NMR (300 MHz, DMSO-d₆) δ 0.76 (d, J = 7 Hz, 3H), 1.81 (sextet, J = 7 Hz, 1H), 3.22 (t, J = 6 Hz, 2H), 4.28 (dd, J = 6 Hz, 12 Hz, 1H), 4.40 (dd, J = 6 Hz and 12 Hz, 1H), 4.50 (t, J = 6 Hz, 1H), 7.51 (m, 3H), 7.61 (m, 1H), 7.80 (m, 1H), 7.84 (d, J = 9 Hz, 2H), 7.95 (d, J = 9 Hz, 2H), 8.20 (s, 1H); MS (APCI+) m/z 452 (M+H)⁺; (APCI-) m/z 486 (M+Cl)⁻. Anal. calc. for C₂₀H₁₉F₂N₃O₅S: C, 53.21; H, 4.24; N, 9.30. Found: C, 53.45; H, 5.53; N, 9.50.

20

Example 466

2-(4-Fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, substituting 2-methyl-1,4-butanediol in place of 2-ethyl-1-hexanol and separating the regioisomeric products by multiple preparative thin layer chromatography runs, eluting with 4:1 ethyl acetate/hexanes (yield: 65 mg, 19%). ¹H NMR (300 MHz, CDCl₃) δ 0.87 (d, J = 8.1 Hz, 3H), 1.48-1.87 (m, 4H), 3.13 (s, 3H), 3.41 (dd, J = 6.3, 13.5 Hz, 1H), 3.46 (dd, J = 6.3, 13.5 Hz, 1H), 4.48-4.63 (m, 2H), 7.15-7.24 (m, 2H), 7.58-7.66 (m, 2H), 7.79

(d, J = 10.5 Hz, 2H), 7.91 (s, 1H), 8.07 (d, J = 10.5 Hz, 2H); MS (APCI+) m/z 447 (M+H)⁺.

Example 467

5 2-(3,4-Difluorophenyl)-4-(3-oxo-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 460 substituting 4-hydroxy-2-butanone in place of acetol. (yield: 95.0 mg, 21%). mp 134-135 °C; ¹H NMR (300 MHz, CDCl₃) δ 2.06 (s, 3H), 2.81 (t, J = 9 Hz, 2H), 3.13 (s, 3H), 4.75 (t, J = 9 Hz, 2H), 7.30 (m, 1H), 7.45 (m, 1H), 7.58 (m, 1H), 7.73 (d, J = 9 Hz, 2H), 7.89 (s, 10 1H), 8.05 (d, J = 9 Hz, 2H); MS (DCI/NH₃) m/z 449 (M+H)⁺. 466 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₈F₂N₂O₅S: C, 56.25; H, 4.02; N, 6.25. Found: C, 55.97; H, 4.17; N, 6.11.

Example 468

15 2-(4-Fluorophenyl)-4-(3-oxo-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 460 starting with 2-(4-fluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone and substituting 4-hydroxy-2-butanone in place of acetol. (yield: 85.0 mg, 20 20%). mp 133-136 °C; ¹H NMR (300 MHz, CDCl₃) δ 2.04 (s, 3H), 2.80 (t, J = 9 Hz, 2H), 3.13 (s, 3H), 4.76 (t, J = 9 Hz, 2H), 7.20 (t, J = 9 Hz, 2H), 7.55 (m, 2H), 7.75 (d, J = 9 Hz, 2H), 7.91 (s, 1H), 8.05 (d, J = 9 Hz, 2H). MS (DCI/NH₃) m/z 431 (M+H)⁺, 448 (M+NH₄)⁺. Anal. calc. for C₂₁H₁₉FN₂O₅S: C, 58.60; H, 4.42; N, 6.52. Found: C, 58.87; H, 4.55; N, 6.51.

25

Example 469

2-(4-Fluorophenyl)-4-(4-hydroxy-2-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 178, substituting 2-methyl-1,4-butanediol in place of 2-ethyl-1-hexanol and separating the regioisomeric products by multiple preparative thin layer chromatography runs, eluting with 4:1 ethyl acetate/hexanes (yield: 43 mg, 12%). ¹H NMR (300 MHz, CDCl₃) δ 0.87 (d, J = 8.1 Hz, 3H), 1.33-1.46 (m, 1H), 1.50-1.67 (m, 2H), 1.93-2.04 (m, 1H), 3.13 (s, 3H), 3.54-3.72 (m, 2H), 4.29 (dd, J = 6.0, 9.3 Hz, 1H), 4.43 (dd, J = 6.0, 9.3 Hz, 1H), 7.15-7.24 (m, 2H), 7.58-7.66 (m, 2H), 7.79 (d, J = 10.5 Hz, 2H), 7.91 (s, 1H), 8.07 (d, J = 10.5 Hz, 2H); MS (APCI+) m/z 447 (M+H)⁺.

Example 470

2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 459, substituting 2-(4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 600 mg, 60%). mp 163-164°C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.05 (s, 6H), 1.73 (t, J = 6 Hz, 2H), 4.30 (s, 1H), 4.52 (t, J = 6 Hz, 2H), 7.37 (t, J = 9 Hz, 1H), 7.47 (s, 2H), 7.65 (dd, J = 9 Hz, J = 3 Hz, 2H), 8.83 (d, J = 9 Hz, 2H), 8.95 (d, J = 9 Hz, 2H), 8.18 (s, 1H); MS (DCI/NH₃) m/z 448 (M+H)⁺. Anal. calcd. for C₂₁H₂₂FN₃O₅S: C, 56.36; H, 4.95; N, 9.39. Found: C, 55.96; H, 4.89; N, 9.09.

Example 471

2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 471A

3,4-Difluorophenylhydrazine

A stirred mixture of 3,4-difluoroaniline (12.9 g, 0.1 mol) in concentrated hydrochloric acid (60 mL) was chilled to -10°C with an ice/methanol bath. A solution of sodium nitrite (6.9 g, 0.1 mol) in water (30 mL) was added at a rate which maintained the temperature of the reaction mixture below 10°C. After stirring for 2 hours, the reaction mixture was cooled to 0°C and a solution of tin(II) chloride (56.88 g, 0.3 mol) in concentrated hydrochloric acid (50 mL) was added dropwise with vigorous stirring. Additional concentrated hydrochloric acid (150 mL) was added to the reaction mixture and stirring was continued for 2 hours. The reaction mixture was filtered to collect the precipitated hydrochloride salt of the title compound. This precipitate was dissolved in water (75 mL) and the resulting solution was basified with 50% aqueous sodium hydroxide and extracted with ethyl acetate. The organic extracts were dried (Na₂SO₄) and filtered. The filtrate was concentrated in vacuo to provide the title intermediate as a brown oil (8.11 g, 57.4%).

Example 471B

2-(3,4-Difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone

The title intermediate was prepared by the method of Example 194A, substituting 3,4-difluorophenylhydrazine (Example 471A) for 4-fluorophenylhydrazine hydrochloride.

Example 471C

2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-bromo-3(2H)-pyridazinone

The dibromo-intermediate from Example 471B was reacted according to the procedure described in Example 194B, substituting 3-methyl-1,3-butanediol in place of methanol, to selectively react at the 4-position and provide the title intermediate.

Example 471D

2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The product from Example 471C (12.79 g, 32.86 mmol) was coupled to 4-(methylthio)phenylboronic acid (6.07 g, 36.15 mmol) with K_2CO_3 (10 g, 72.3 mmol) and $PdCl_2(PPh_3)_2$ (1.15 g, 1.64 mmol) in ethanol (200 mL) at 60-65 °C for 40-70 minutes to provide the title intermediate (yield: 9.16 g, 64.5%).

5

Example 471E

2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The sulfide from Example 471D was oxidized to the title compound by the method of Example 10 (yield: 7.46 g, 76%). m.p. 131-133°C; 1H NMR (300 MHz, DMSO- d_6) δ 1.04 (s, 6H), 1.73 (t, J = 6 Hz, 2H), 3.29 (s, 3H), 4.43 (s, 1H), 4.54 (t, J = 6 Hz, 2H), 7.52 (m, 1H), 7.62 (ddd, J = 9 Hz, J = 9 Hz, J = 1.5 Hz, 1H), 7.82 (ddd, J = 9 Hz, J = 9 Hz, J = 3 Hz, 1H), 7.91 (d, J = 9 Hz, 1H), 8.08 (d, J = 9 Hz, 2H), 8.20 (s, 1H); MS (DCI- NH_3) m/e 465 (M+H) $^+$. Anal. calcd. for $C_{22}H_{22}F_2N_2O_5S$: C, 56.88; H, 4.77; N, 6.03. Found: C, 56.92; H, 4.88; N, 5.94.

15

Example 472

2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 459, substituting 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (yield: 300 mg, 50%). mp 181-181°C; 1H NMR (300 MHz, DMSO- d_6) δ 1.04 (s, 6H), 1.72 (t, J = 6 Hz, 2H), 4.43 (s, 1H), 4.53 (t, J = 6 Hz, 2H), 7.49 (s, 2H), 7.53 (m, 1H), 7.63 (ddd, J = 9 Hz, J = 9 Hz, J = 1.5 Hz, 1H), 7.79 (ddd, J = 9 Hz, J = 9 Hz, J = 3 Hz, 1H), 7.83 (d, J = 9 Hz, 1H), 7.95 (d, J = 9 Hz, 2H), 8.19 (s, 1H); MS (DCI/ NH_3) m/z 466 (M+H) $^+$. Anal. calcd. for $C_{21}H_{21}F_2N_2O_5S$: C, 54.12; H, 4.66; N, 8.81. Found: C, 54.19; H, 4.55; N, 9.03.

25

Example 4732-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound was prepared according to the sequence of reactions described in Example 471, substituting 3-chloro-4-fluorophenylhydrazine in place of 3,4-difluorophenylhydrazine (yield: 200 mg, 89%). mp 108-110°C; ¹H NMR (300 MHz, CDCl₃) δ 1.24 (s, 6H), 1.89 (t, 2H, J = 6 Hz), 2.34 (s, 1H), 3.12 (s, 3H), 4.57 (t, J = 6 Hz, 2H), 7.25 (t, J = 9 Hz, 1H), 7.60 (m, 1H), 7.78 (d, J = 6 Hz, 1H), 7.79 (d, J = 9 Hz, 2H),
10 7.92 (s, 1H), 8.08 (d, J = 9 Hz, 2H); MS (DCI/NH₃) m/z 481 (M+H)⁺; Anal. calcd. for C₂₂H₂₂FCIN₂O₅S: C, 54.94; H, 4.61; N, 5.82. Found: C, 54.87; H, 4.65; N, 5.72.

Example 4742-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

15 The title compound was prepared according to the method of Example 459, substituting 2-(3-chloro-4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 473) in place of 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
20 pyridazinone (yield: 160 mg, 45%). mp 59-62°C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.05 (s, 6H), 1.73 (t, 2H, J = 6 Hz), 4.32 (s, 1H), 4.54 (t, J = 6 Hz, 2H), 7.50 (s, 2H), 7.60 (t, J = 9 Hz, 1H), 7.66 (m, 1H), 7.73 (d, J = 9 Hz, 2H), 7.74 (d, J = 9 Hz, 2H), 7.75 (m, 1H), 8.22 (s, 1H); MS (DCI/NH₃) m/z 482 (M+H)⁺. Anal. calcd. for C₂₁H₂₁FCIN₃O₅S: C, 52.33; H, 4.39; N, 8.71. Found: C, 52.30; H, 5.03; N, 8.10.

25

Example 4752-(3-Chlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the sequence of reactions described in Example 471, substituting 3-chlorophenylhydrazine in place of 3,4-difluorophenylhydrazine (yield: 200 mg, 89%). ¹H NMR (300 MHz, CDCl₃) δ 8.04 (d, J = 8.5 Hz, 2H), 7.91 (s, 1H), 7.77 (d, J = 8.5 Hz, 2H), 7.67 (m, 1H), 7.57 (m, 1H), 7.40 (t, J = 8.8 Hz, 1H), 7.36 (m, 1H), 4.54 (t, J = 6.3 Hz, 2H), 3.10 (s, 3H), 2.56 (s, 1H), 1.86 (t, J = 6.3 Hz, 2H), 1.20 (s, 6H), MS (DCI/NH₃) m/z 462(M+H)⁺.

Example 476

2-(3-Chlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 459, substituting 2-(3-chlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 475) in place of 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone. ¹H NMR (300 MHz, CDCl₃) δ 8.03 (d, J = 8.7 Hz, 2H), 7.91 (s, 1H), 7.70 (d, J = 8.7 Hz, 2H), 7.68 (m, 1H), 7.57 (m, 1H), 7.41 (m, 1H), 7.38 (m, 1H), 5.65 (s, 2H), 4.51 (t, J = 6.6 Hz, 2H), 2.70 (br s, 1H), 1.87 (t, J = 6.6 Hz, 2H), 1.20 (s, 6H); MS (DCI/NH₃) m/z 463 (M+H)⁺.

Example 477

2-(4-Fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the sequence of reactions described in Example 471, substituting 4-fluorophenylhydrazine in place of 3,4-difluorophenylhydrazine and substituting 2-methyl-1,2-propanediol (prepared by the LAH reduction of methyl 2-hydroxyisobutyrate) in place of 3-methyl-1,3-butanediol. mp 152-154°C, ¹H NMR (300 MHz, CDCl₃) δ 8.10 (d, 2H, J = 18 Hz), 7.95 (s, 1H), 7.83 (d, 2H, J = 18 Hz), 7.63 (d, 1H, J = 18 Hz), 7.61 (d, 1H, J = 18 Hz), 4.18 (s, 2H), 3.13 (s, 3H), 1.19

(s, 6H), MS (DCI/NH₃) m/z 433 (M+H)⁺, 450 (M+NH₄)⁺, Analysis for C₂₁H₂₁FN₂O₅S,
Calcd: C, 58.32; H, 4.89; N, 6.48. Found: C, 58.42; H, 5.05; N, 6.43.

Example 478

5 2-(4-Fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-
 3(2H)-pyridazinone

The title compound was prepared according to the method of Example 459,
substituting 2-(4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methyl-
sulfonyl)phenyl]-3(2H)-pyridazinone (Example 477) in place of 2-(3,4-difluoro-phenyl)-4-
10 (2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone. mp
155-158°C; ¹H NMR (300 MHz, DMSO-d₆) δ 8.17 (s, 1H), 7.92 (s, 4H), 7.67 (d, 1H, J =
18 Hz), 7.64 (d, 1H, J = 18 Hz), 7.49 (s, 2H), 7.38 (d, 1H, J = 18 Hz), 7.35 (d, 1H, J = 18
Hz), 4.54 (s, 1H), 4.19 (s, 2H), 1.00 (s, 6H), MS (ESI⁺): m/z 434 (M+H)⁺, 456 (M+Na)⁺,
889 (2M+Na)⁺; Analysis for C₂₀H₂₀FN₃O₅S, Calcd: C, 55.42; H, 4.65; N, 9.69. Found: C,
15 55.64; H, 4.85; N, 9.53.

Example 479

2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-
 (methylsulfonyl)phenyl]-3(2H)-pyridazinone

20 The title compound was prepared according to the sequence of reactions described
in Example 471, substituting 3-chloro-4-fluorophenylhydrazine in place of 3,4-
difluorophenylhydrazine and substituting 2-methyl-1,2-propanediol (prepared by the LAH
reduction of methyl 2-hydroxyisobutyrate) in place of 3-methyl-1,3-butanediol. mp 122-
124 °C, ¹H NMR (300 MHz, CDCl₃) δ 0.98 (s, 6H), 3.29 (s, 3H), 4.21 (s, 2H), 4.56 (s,
25 1H), 7.61 (dd, 1H, J = 7, 17 Hz), 7.67 (ddd, 1H, J = 2, 4, 7 Hz), 7.93 (dd, 1H, J = 2, 7 Hz),
7.98 (d, 2H, J = 8 Hz), 8.06 (d, 2H, J = 8 Hz), 8.22 (s, 1H); MS (DCI/NH₃) m/z 465 (M-H)⁺
; Anal. Calcd for C₂₁H₂₀ClFN₂O₅S: C 54.02, H 4.32, N 6.00. Found: C 54.06, H 4.57, N
5.95.

Example 4802-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 459, substituting 2-(3-chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 479) in place of 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone. mp 176-178 °C, ¹H NMR (300 MHz, CDCl₃) δ 1.00 (s, 6H), 4.19 (s, 2H), 4.54 (s, 1H), 7.49 (s, 2H), 7.62 (t, 1H, J = 9 Hz), 7.66 (ddd, 1H, J = 2,5,9 Hz), 7.92 (s, 4.5H), 7.94 (d, 0.5H, J = 2 Hz), 8.20 (s, 1H); MS (DCI/NH₃) m/z 468 (M+H)⁺; 1 Cl, 490 (M+Na)⁺; 1 Cl; Anal. Calcd for C₂₀H₁₉ClFN₂O₃S: C 51.34, H 4.09, N 8.98. Found: C 51.33, H 4.23, N 8.76.

Example 4812-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the sequence of reactions described in Example 471, substituting 3-chlorophenylhydrazine in place of 3,4-difluorophenylhydrazine and substituting 2-methyl-1,2-propanediol (prepared by the LAH reduction of methyl 2-hydroxyisobutyrate) in place of 3-methyl-1,3-butanediol. ¹H NMR (300 MHz, CDCl₃) δ 8.15 (m, 2H), 7.98 (s, 1H), 7.85 (m, 2H), 7.76 (m, 1H), 7.62 (m, 1H), 7.43 (m, 2H), 4.22 (s, 2H), 3.15 (s, 3H), 1.21 (s, 6H); MS (DCI/NH₃) m/z 449 (M+H)⁺; Anal. Calcd for C₂₁H₂₁ClN₂O₃S: C 56.18, H 4.72, N 6.24. Found: C 56.08, H 4.67, N 6.23.

Example 4822-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 459, substituting 2-(3-chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 481) in place of 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone. ¹H NMR (400 MHz, DMSO-d₆) δ 8.19 (s, 1H), 7.93 (m, 4H), 7.75 (m, 1H), 7.61-7.48 (m, 5H), 4.53 (s, 2H), 4.20 (s, 3H), 1.00 (s, 6H); MS (ESI-) m/z 448 (M-H)⁻; Anal. Calcd for C₂₀H₂₀ClN₃O₅S: C 53.39, H 4.48, N 9.34. Found: C 53.11, H 4.82, N 9.24.

Example 483

2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the sequence of reactions described in Example 471, substituting 2,2,2-trifluoroethylhydrazine in place of 3,4-difluorophenylhydrazine and substituting 2-methyl-1,2-propanediol (prepared by the LAH reduction of methyl 2-hydroxyisobutyrate) in place of 3-methyl-1,3-butanediol. ¹H NMR (300MHz, CDCl₃) δ 1.18 (s, 6H), 2.62 (br s, 1H), 3.15 (s, 3H), 4.20 (s, 2H), 4.85 (q, J = 9 Hz, 2H), 7.78 (d, J = 9 Hz, 2H), 7.85 (s, 1H), 8.08 (d, J = 9 Hz, 2H); MS (DCI/NH₃) m/z 421 (M+1)⁺; Analysis calculated for C₁₇H₁₉F₃N₃O₅S: C, 48.57; H, 4.56; N, 6.66. Found: C, 48.72; H, 4.78; N, 6.56.

Example 484

2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared by the following sequence of reactions. Mucobromic acid and 2,2,2-trifluoroethylhydrazine hydrochloride were reacted to provide 2-(2,2,2-trifluoroethyl)-4,5-dibromo-3(2H)-pyridazinone following the procedure in Example 194A. The dibromo-intermediate was reacted according to the procedure described in Example 194B, substituting 2-methyl-1,2-propanediol in place of methanol,

to selectively react at the 4-position and provide 2-(2,2,2-trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-bromo-3(2H)-pyridazinone. This 5-bromo-compound was coupled to 4-[2-(tetrahydropyranyl)thio]phenylboronic acid (prepared from THP-protected 4-bromothiophenol and triisopropyl borate) with K_2CO_3 and $PdCl_2(PPh_3)_2$ in ethanol at 60-65 °C for 40-70 minutes to provide 2-(2,2,2-trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-[2-(tetrahydropyranyl)thio]phenyl]-3(2H)-pyridazinone. This intermediate THP-sulfide was then converted to the title compound by treatment with N-chlorosuccinimide (3.5 equivalents) at 0 °C in THF/H₂O for 15 minutes to an hour followed by addition of excess ammonium hydroxide at 0 °C and stirring at ambient temperature for 3 hours. Aqueous work-up and column chromatographic purification (80:20 pentane/ethyl acetate) provided the title compound. ¹H NMR (300MHz, CDCl₃) δ 1.18 (s, 6H), 2.65 (br s, 1H), 4.15 (s, 2H), 4.85 (q, J = 9 Hz, 2H), 4.9 (s, 2H), 7.75 (d, J = 9 Hz, 2H), 7.85 (s, 1H), 8.05 (d, J = 9 Hz, 2H); MS (DCI/NH₃) m/z 422 (M+H)⁺; Analysis calculated for C₁₆H₁₈F₃N₃O₅S: C, 45.60; H, 4.30; N, 9.97. Found: C, 45.86; H, 4.63; N, 9.81.

Example 485

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 483, substituting neopentyl glycol in place of 2-methyl-1,2-propanediol.

Example 486

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 484, substituting neopentyl glycol in place of 2-methyl-1,2-propanediol.

Example 487

2-(4-Fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 459, substituting 2-(4-fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 466) for 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 488

2-(3,4-Difluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the sequence of reactions described in Example 471, substituting 2-methyl-1,4-butanediol for 3-methyl-1,3-butanediol, then separating the regioisomeric products by multiple preparative thin layer chromatography runs.

Example 489

2-(3-Chloro-4-fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the sequence of reactions described in Example 471, substituting 3-chloro-4-fluorophenylhydrazine for 3,4-difluorophenylhydrazine and substituting 2-methyl-1,4-butanediol for 3-methyl-1,3-butanediol, then separating the regioisomeric products by multiple preparative thin layer chromatography runs.

Example 490

2-(3-Chlorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the sequence of reactions described in Example 471, substituting 3-chlorophenylhydrazine for 3,4-

difluorophenylhydrazine and substituting 2-methyl-1,4-butanediol for 3-methyl-1,3-butanediol, then separating the regioisomeric products by multiple preparative thin layer chromatography runs.

5

Example 491

2-(3,4-Difluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 459, substituting 2-(3,4-difluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 488) for 2-(3,4-difluorophenyl)-4-
10 (2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 492

2-(3-Chloro-4-fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 459, substituting 2-(3-chloro-4-fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 489) for 2-(3,4-difluorophenyl)-4-
15 (2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

20

Example 493

2-(3-Chlorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 459, substituting 2-(3-chlorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 490) for 2-(3,4-difluorophenyl)-4-
25 (2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 494

(S)-2-(4-Fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 464, substituting (S)-2-(4-fluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone for (S)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 495

(R)-2-(4-Fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 465, substituting (R)-2-(4-fluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone for (R)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 496

(S)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 462, substituting 2-(3-chloro-4-fluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 497

(S)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound can be prepared according to the method of Example 464, substituting (S)-2-(3-chloro-4-fluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of (S)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 498

5 (R)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 463, substituting 2-(3-chloro-4-fluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-
10 3(2H)-pyridazinone.

Example 499

(R)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

15 The title compound may be prepared according to the method of Example 464, substituting (R)-2-(3-chloro-4-fluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of (S)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

20 Example 500

(S)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 462, substituting 2-(3-chlorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
25 pyridazinone in place of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 501

(S)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 464, substituting (S)-2-(3-chlorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of (S)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 502

(R)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone

The title compound can be prepared according to the method of Example 463, substituting 2-(3-chlorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 503

(R)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone

The title compound can be prepared according to the method of Example 464, substituting (R)-2-(3-chlorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of (S)-2-(3,4-difluorophenyl)-4-(3-t-butoxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 504

(S)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 462, substituting 2-(2,2,2-trifluoroethyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone in place of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 505

5 (S)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 484, substituting (R)-3-t-butoxy-2-methyl-1-propanol (Example 462A) in place of 2-methyl-1,2-propanediol. After Suzuki coupling with 4-[2-(tetrahydropyranyl)thio]phenylboronic
10 acid, the resulting intermediate is treated with NCS and NH₄OH as in Example 484. This sulfonamide product is then treated with TFA (as in Example 462C) to cleave the t-butyl ether and provide the title compound.

Example 506

15 (R)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 463, substituting 2-(2,2,2-trifluoroethyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-
20 3(2H)-pyridazinone.

Example 507

(R)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

25 The title compound may be prepared according to the method of Example 505, substituting (S)-3-t-butoxy-2-methyl-1-propanol in place of (R)-3-t-butoxy-2-methyl-1-propanol.

Example 508

2-(4-Fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone

The title compound may be prepared according to the sequence of reactions described in Example 471, substituting 4-fluorophenylhydrazine in place of 3,4-difluorophenylhydrazine and substituting neopentyl glycol in place of 3-methyl-1,3-butanediol.

Example 509

2-(4-Fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 459, substituting 2-(4-fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone for 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 510

2-(3,4-Difluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the sequence of reactions described in Example 471, substituting neopentyl glycol in place of 3-methyl-1,3-butanediol (yield: 300 mg, 71%). mp 161-162°C; ¹H NMR (300 MHz, DMSO-d₆) δ 0.72 (s, 6H), 3.05 (d, J = 6 Hz, 2H), 3.30 (s, 3H), 4.19 (s, 2H), 4.54 (t, J = 6 Hz, 1H), 7.52 (m, 1H), 7.62 (dd, J = 9 Hz, J = 9 Hz, 1H), 7.82 (ddd, J = 9 Hz, J = 9 Hz, J = 3 Hz, 1H), 7.92 (d, J = 9 Hz, 1H), 8.08 (d, J = 9 Hz, 2H), 8.21 (s, 1H); MS (DCI/NH₃) m/z 465 (M+H)⁺; Anal. calcd. for C₂₂H₂₂F₂N₂O₅S: C, 56.88; H, 4.77; N, 6.03. Found: C, 56.84; H, 4.83; N, 5.99.

Example 511

2-(3,4-Difluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 459, substituting 2-(3,4-difluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone for 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

5

Example 512

2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the sequence of reactions described in Example 471, substituting 3-chloro-4-fluorophenylhydrazine in place of 3,4-difluorophenylhydrazine and substituting neopentyl glycol in place of 3-methyl-1,3-butanediol.

10

Example 513

2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

15

The title compound may be prepared according to the method of Example 459, substituting 2-(3-chloro-4-fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone for 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

20

Example 514

2-(3-Chlorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

25

The title compound may be prepared according to the sequence of reactions described in Example 471, substituting 3-chlorophenylhydrazine in place of 3,4-difluorophenylhydrazine and substituting neopentyl glycol in place of 3-methyl-1,3-butanediol.

Example 515

2-(3-Chlorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the method of Example 459, substituting 2-(3-chlorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone for 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

Example 516

N-[[4-[2-(3,4-Difluorophenyl)-4-(2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide

A mixture of 2-(3,4-difluorophenyl)-4-(2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone (Example 403, 1 equivalent), acetic anhydride (3 equivalents), 4-(dimethylamino)pyridine (0.3 equivalents), and triethylamine (1.2 equivalents) is stirred at room temperature for 16 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine then dried over MgSO₄ and filtered. The filtrate is concentrated in vacuo to give the title compound.

Example 517

N-[[4-[2-(3,4-Difluorophenyl)-4-(2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt

To a suspension of N-[[4-[2-(3,4-Difluorophenyl)-4-(2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide (Example 516, 1 equivalent) in absolute ethanol is added a solution of sodium hydroxide (1 equivalent) in absolute ethanol. The mixture is stirred at room temperature for 10 minutes and concentrated in vacuo. The residue is dried at high vacuum to provide the title compound.

Example 518

N-[[4-[2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide

A mixture of 2-(4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone (Example 470, 1 equivalent), acetic anhydride (3 equivalents), 4-(dimethylamino)pyridine (0.3 equivalents), and triethylamine (1.2 equivalents) is stirred at room temperature for 16 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine then dried over MgSO₄ and filtered. The filtrate is concentrated in vacuo to give the title compound.

Example 519

N-[[4-[2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt

To a suspension of N-[[4-[2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide (Example 518, 1 equivalent) in absolute ethanol is added a solution of sodium hydroxide (1 equivalent) in absolute ethanol. The mixture is stirred at room temperature for 10 minutes and concentrated in vacuo. The residue is dried at high vacuum to provide the title compound.

Example 520

N-[[4-[2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide

A mixture of 2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone (Example 459, 1 equivalent), acetic anhydride (3 equivalents), 4-(dimethylamino)pyridine (0.3 equivalents), and triethylamine (1.2 equivalents) is stirred at room temperature for 16 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine then dried over MgSO₄ and filtered. The filtrate is concentrated in vacuo to give the title compound.

Example 521

N-[[4-[2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt

5 To a suspension of N-[[4-[2-(3,4-difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide (Example 520, 1 equivalent) in absolute ethanol is added a solution of sodium hydroxide (1 equivalent) in absolute ethanol. The mixture is stirred at room temperature for 10 minutes and concentrated in vacuo. The residue is dried at high vacuum to provide the title compound.

Example 522

N-[[4-[2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide

15 A mixture of 2-(3-chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone (Example 480, 1 equivalent), acetic anhydride (3 equivalents), 4-(dimethylamino)pyridine (0.3 equivalents), and triethylamine (1.2 equivalents) is stirred at room temperature for 16 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine then dried over MgSO₄ and filtered. The filtrate is concentrated in vacuo to give the title
20 compound.

Example 523

N-[[4-[2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt

25 To a suspension of N-[[4-[2-(3-chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide (Example 522, 1 equivalent) in absolute ethanol is added a solution of sodium hydroxide (1 equivalent) in absolute ethanol. The mixture is stirred at room temperature for 10 minutes and concentrated in vacuo. The residue is dried at high vacuum to provide the title compound.

Example 524

N-[[4-[2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide

5 A mixture of 2-(3-chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(amino-sulfonyl)phenyl]-3(2H)-pyridazinone (Example 482, 1 equivalent), acetic anhydride (3 equivalents), 4-(dimethylamino)pyridine (0.3 equivalents), and triethylamine (1.2 equivalents) is stirred at room temperature for 16 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine then
10 dried over MgSO₄ and filtered. The filtrate is concentrated in vacuo to give the title compound.

Example 525

N-[[4-[2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt

15 To a suspension of N-[[4-[2-(3-chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide (Example 525, 1 equivalent) in absolute ethanol is added a solution of sodium hydroxide (1 equivalent) in absolute ethanol. The mixture is stirred at room temperature for 10 minutes and concentrated in
20 vacuo. The residue is dried at high vacuum to provide the title compound.

Example 526

N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide

25 A mixture of 2-(2,2,2-trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone (Example 484, 1 equivalent), acetic anhydride (3 equivalents), 4-(dimethylamino)pyridine (0.3 equivalents), and triethylamine (1.2 equivalents) is stirred at room temperature for 16 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine then

dried over MgSO₄ and filtered. The filtrate is concentrated in vacuo to give the title compound.

Example 527

5 N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt

To a suspension of N-[[4-[2-(2,2,2-trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide (Example 526, 1 equivalent) in absolute ethanol is added a solution of sodium hydroxide (1 equivalent) in absolute
10 ethanol. The mixture is stirred at room temperature for 10 minutes and concentrated in vacuo. The residue is dried at high vacuum to provide the title compound.

Example 528

15 N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide

A mixture of 2-(2,2,2-trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone (Example 486, 1 equivalent), acetic anhydride (3 equivalents), 4-(dimethylamino)pyridine (0.3 equivalents), and triethylamine (1.2 equivalents) is stirred at room temperature for 16 hours. The reaction mixture is
20 partitioned between ethyl acetate and water. The organic layer is washed with brine then dried over MgSO₄ and filtered. The filtrate is concentrated in vacuo to give the title compound.

Example 529

25 N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt

To a suspension of N-[[4-[2-(2,2,2-trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide (Example 528, 1 equivalent) in absolute ethanol is added a solution of sodium hydroxide (1 equivalent) in absolute

ethanol. The mixture is stirred at room temperature for 10 minutes and concentrated in vacuo. The residue is dried at high vacuum to provide the title compound.

Example 530

5 2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-
 3(2H)-pyridazinone

The title compound was prepared according to the sequence of reactions described in Example 471, substituting 2,2,2-trifluoroethylhydrazine in place of 3,4-difluorophenylhydrazine. ¹H NMR (300 MHz, CDCl₃) δ 1.25 (s, 6H), 1.88 (t, 2H, J = 9 Hz), 2.35 (br s, 1H), 3.15 (s, 3H), 4.55 (t, 2H, J = 7.5 Hz), 4.85 (q, 2H, J = 9 Hz), 7.75 (d, 2H J = 9 Hz), 7.65 (s, 1H), 8.05 (d, 2H J = 9 Hz); MS (DCI/NH₃) m/z 435 (M+H)⁺; Analysis calculated for C₁₈H₂₁F₃N₂O₅S: C, 49.77; H, 4.87; N, 6.45. Found: C, 49.71; H, 4.90; N, 6.45.

15 Example 531

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-
 3(2H)-pyridazinone

The title compound was prepared according to the method of Example 484, substituting 3-methyl-1,3-butanediol in place of 2-methyl-1,2-propanediol. ¹H NMR (300 MHz, CDCl₃) δ 1.85 (t, 2H, J = 6 Hz), 2.78 (s, 6H), 4.55 (t, 2H, J = 6 Hz), 4.85 (q, 2H, J = 9 Hz), 5.3 (s, 2H), 7.68 (d, 2H J = 9 Hz), 7.85 (s, 1H), 8.05 (d, 2H J = 9 Hz), 8.45 (br s, 1H); MS (DCI/NH₃) m/z 436 (M+H)⁺; Analysis calculated for C₁₇H₂₀F₃N₃O₅S: C, 46.89; H, 4.62; N, 9.65. Found: C, 47.18; H, 4.93; N, 9.86.

25 Example 532

2-(3,4-Dichlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-
 3(2H)-pyridazinone

The title compound was prepared according to the sequence of reactions described in Example 471, substituting 3,4-dichlorophenylhydrazine in place of 3,4-

5 difluorophenylhydrazine. mp 118-120°C; ¹H NMR (300 MHz, CDCl₃) δ 1.25 (s, 6H), 1.92 (t, J = 6 Hz, 2H), 3.13 (s, 3H), 4.07 (t, J = 6 Hz, 2H), 7.58 (d, J = 9 Hz, 1H), 7.59 (dd, J = 9 Hz, J = 2 Hz, 1H), 7.80 (d, J = 9 Hz, 2H), 7.87 (d, J = 2 Hz, 1H), 7.84 (s, 1H), 8.19 (d, J = 9 Hz, 2H); MS (DCI/NH₃) m/z 497 (M+H)⁺. Anal. calcd. for C₂₂H₂₂Cl₂N₂O₅S: C, 53.12; H, 4.45; N, 5.63. Found: C, 52.80; H, 4.53; N, 5.35.

Example 533

2-[(3-Trifluoromethyl)phenyl]-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

10 The title compound was prepared according to the sequence of reactions described in Example 471, substituting 3-(trifluoromethyl)phenylhydrazine in place of 3,4-difluorophenylhydrazine and substituting 2-methyl-1,2-propanediol (prepared by the LAH reduction of methyl 2-hydroxyisobutyrate) in place of 3-methyl-1,3-butanediol (yield: 200 mg, 75%). mp 143-144°C; ¹H NMR (300 MHz, CDCl₃) δ 1.20 (s, 6H), 3.13 (s, 3H), 4.11
15 (s, 2H), 7.64 (m, 2H), 7.84 (d, J = 9 Hz, 2H), 7.90 (d, J = 9 Hz, 1H), 7.97 (d, J = 9 Hz, 1H), 7.98 (s, 1H), 8.13 (d, J = 9 Hz, 2H); MS (DCI/NH₃) m/z 483 (M+H)⁺; Anal. calcd. for C₂₂H₂₁F₃N₂O₅S·0.5C₄H₁₀O₂: C, 54.75; H, 4.79; N, 5.32. found: C, 55.15; H, 4.77; N, 5.09.

Example 534

2-(3,4-Dichlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

20 The title compound was prepared according to the sequence of reactions described in Example 471, substituting 3,4-dichlorophenylhydrazine in place of 3,4-difluorophenylhydrazine and substituting 2-methyl-1,2-propanediol (prepared by the LAH
25 reduction of methyl 2-hydroxyisobutyrate) in place of 3-methyl-1,3-butanediol (yield: 1.7 g, 75%). mp 108-110°C; ¹H NMR (300 MHz, DMSO-d₆) δ 0.96 (s, 6H), 3.38 (s, 3H), 4.20 (s, 2H), 4.52 (s, 1H), 7.68 (dd, J = 9 Hz, J = 3 Hz, 1H), 7.83 (d, J = 9 Hz, 1H), 7.78 (d, J = 9 Hz, 2H), 7.79 (d, J = 3 Hz, 1H), 8.04 (d, J = 9 Hz, 2H), 8.22 (s, 1H); MS (DCI/NH₃) m/z

483 (M+H)⁺; Anal. calcd. for C₂₁H₂₀Cl₂N₂O₅S: C, 52.18; H, 4.17; N, 5.79. Found: C, 52.41; H, 4.22; N, 5.53.

Example 535

5 (R,S)-2-(4-Fluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared by reacting the product from Example 468, 2-(4-fluorophenyl)-4-(3-oxo-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (20 mg, 0.05 mmol) in methanol (5 mL) at 0°C with sodium borohydride (4 mg, 0.1 mmol).
10 The reaction mixture was allowed to warm to room temperature, then volatile components were removed under reduced pressure. The residue was treated with water and 10% aqueous citric acid solution was added to bring the pH to 7. The resulting precipitate was collected by filtration and dried to provide the title compound as an off-white solid (11 mg, 50.9%). mp 63-66°C; ¹H NMR (300 MHz, CDCl₃) δ 1.21 (d, J = 6 Hz, 3H), 1.60-1.73 (m, 1H), 1.84-1.96 (m, 1H), 3.14(s, 3H), 4.01-4.14 (m, 1H), 4.20-4.28 (m, 1H), 4.64
15 (dt, J = 3 Hz, J = 9 Hz, 1H), 7.20 (t, J = 9 Hz, 2H), 7.43-7.55 (m, 2H), 7.81 (d, J = 9 Hz, 2H), 7.96 (s, 1H), 8.10 (d, J = 9 Hz, 2H); MS (DCI/NH₃) m/z 433 (M+H)⁺.

Example 536

20 2-(3,4-Difluorophenyl)-4-(1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 536A

2-(3,4-Difluorophenyl)-4-(1-butoxy)-5-chloro-3(2H)-pyridazinone

To a stirred, room temperature solution of n-butanol (0.81 g, 10.93 mmol, 1.1 equiv.) in THF (20 mL) was slowly added 1.0 M sodium bis(trimethylsilyl)amide in THF (12 mL, 12 mmol, 1.2 equiv.). The reaction mixture was stirred for 0.5 hours, then it was transferred to a solution of 2-(3,4-difluorophenyl)-4,5-dichloro-3(2H)-pyridazinone (2.88 g, 10.4 mmol, 1.0 equiv.) in THF (80 mL). The resulting reaction mixture was stirred for 0.5 hours at room temperature to provide the title compound (2.5 g, 79.4%).
25

Example 536B2-(3,4-Difluorophenyl)-4-(1-butoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

A slurry of palladium(II) acetate (9.0 mg, 0.04 mmol), triphenylphosphine (21.0 mg, 0.08 mmol) and isopropanol (1 mL) was stirred at room temperature for 10 minutes. To this mixture was added 2-(3,4-Difluorophenyl)-4-(1-butoxy)-5-chloro-3(2H)-pyridazinone (Example 536A, 0.63 g, 2 mmol), 4-(methylthio)benzeneboronic acid (0.403 mg, 2.4 mmol) and isopropanol (4 mL). A solution of K_3PO_4 (0.66 g, 3 mmol) in water (1 mL) was also added and the resulting reaction mixture was deoxygenated by bubbling nitrogen through it for 2 minutes. The reaction mixture was then stirred under a nitrogen atmosphere for 15 hours at 70 °C. The reaction mixture was then cooled to room temperature and water (15 mL) was added to provide a precipitate. The precipitate was collected by filtration and rinsed with water then hexane to give after drying the title compound (0.77 g, 95%).

Example 536C2-(3,4-Difluorophenyl)-4-(1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

To a solution of 2-(3,4-difluorophenyl)-4-(1-butoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (Example 536B, 0.6 g, 1.5 mmol) in acetone (10 mL) at -20 °C was slowly added over 5 minutes a 32% solution of peracetic acid in acetic acid (3.75 mmol). The reaction mixture was allowed to warm to room temperature at which point water (30 mL) was added. Stirring was continued for 0.5 hours, then the precipitate was collected by filtration and washed with water to provide the title compound (0.61 g, 94%). mp 129-132°C; 1H NMR (300 MHz, $CDCl_3$) δ 0.88 (t, J = 6 Hz, 3H), 1.20-1.36 (m, 2H), 1.54-1.68 (m, 2H), 3.14 (s, 3H), 4.52 (t, J = 6 Hz, 2H), 7.25-7.34 (m, 1H), 7.44-7.50 (m, 1H), 7.55-7.62 (m, 2H), 7.77-7.82 (m, 2H), 7.92 (s, 1H), 8.05-8.10 (m, 2H); MS (DCI/ NH_3) m/z 435 (M+H) $^+$; Anal. calcd. for $C_{21}H_{20}F_2N_2O_4S$: C, 58.06; H, 4.64; N, 6.44. Found: C, 57.82; H, 4.53; N, 6.31.

Example 5372-(3-Chloro-4-fluorophenyl)-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 536 substituting 2-methyl-1-propanol in place of n-butanol and substituting 2-(3-chloro-4-fluorophenyl)-4,5-dibromo-3(2H)-pyridazinone for 2-(3,4-difluorophenyl)-4,5-dichloro-3(2H)-pyridazinone in Example 536A. The resulting intermediate was subjected to the conditions in Example 536B, substituting the catalyst $\text{PdCl}_2(\text{PPh}_3)_2$ in place of the palladium(II) acetate-triphenylphosphine slurry. The resulting intermediate was then oxidized by the method of Example 536C to provide the title compound (0.58 g, 92%). mp 116-120°C; ^1H NMR (300 MHz, CDCl_3) δ 0.86 (d, J = 6 Hz, 6H), 1.85-1.94 (m, 1H), 3.14 (s, 3H), 4.32 (d, J = 6 Hz, 2H), 7.24-7.30 (m, 1H), 7.56-7.62 (m, 1H), 7.77-7.83 (m, 3H), 7.86 (m, 1H), 7.92 (s, 1H), 8.05-8.10 (m, 2H); MS (DCI/ NH_3) m/z 451 (M+H) $^+$; Anal. calcd. for $\text{C}_{21}\text{H}_{20}\text{ClFN}_2\text{O}_4\text{S}$: C, 55.94; H, 4.47; N, 6.21. Found: C, 55.81; H, 4.38; N, 6.18.

Example 5382-(3-Chloro-4-fluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 536 substituting 3-methyl-1-butanol in place of n-butanol to provide the title compound (0.62 g, 92%). mp 148-152°C; ^1H NMR (300 MHz, CDCl_3) δ 0.86 (d, J = 6 Hz, 6H), 1.50-1.70 (m, 3H), 3.14 (s, 3H), 4.54 (t, J = 6 Hz, 2H), 7.24-7.30 (m, 1H), 7.56-7.62 (m, 1H), 7.77-7.83 (m, 3H), 7.86 (m, 1H), 7.92 (s, 1H), 8.05-8.10 (m, 2H); MS (DCI/ NH_3) m/z 465 (M+H) $^+$; Anal. calcd. for $\text{C}_{22}\text{H}_{22}\text{ClFN}_2\text{O}_4\text{S}$: C, 56.83; H, 4.77; N, 6.02. Found: C, 56.70; H, 4.77; N, 6.11.

Example 5392-(3,4-Dichlorophenyl)-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 536 substituting 2-methyl-1-propanol in place of n-butanol and substituting 2-(3,4-dichlorophenyl)-4,5-dibromo-3(2H)-pyridazinone for 2-(3,4-difluorophenyl)-4,5-dichloro-3(2H)-pyridazinone to provide the title compound (0.63 g, 98%). mp 127-129°C; ¹H NMR (300 MHz, CDCl₃) δ 0.86 (d, J = 6 Hz, 6H), 1.82-1.94 (m, 1H), 3.14 (s, 3H), 4.30 (d, J = 6 Hz, 2H), 7.56-7.62 (m, 2H), 7.77-7.82 (m, 2H), 7.86 (m, 1H), 7.92 (s, 1H), 8.06-8.10 (m, 2H); MS (DCI/NH₃) m/z 467 (M+H)⁺; Anal. calcd. for C₂₁H₂₀Cl₂N₂O₄S: C, 53.97; H, 4.31; N, 5.99. Found: C, 53.82; H, 4.29; N, 5.89.

10

Example 540

2-(3,4-Dichlorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 536 substituting 3-methyl-1-butanol in place of n-butanol to provide the title compound (0.63 g, 98%). mp 130-134 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.86 (d, J = 6 Hz, 6H), 1.50-1.68 (m, 3H), 3.14 (s, 3H), 4.51 (t, J = 6 Hz, 2H), 7.56-7.62 (m, 2H), 7.77-7.82 (m, 2H), 7.86 (m, 1H), 7.92 (s, 1H), 8.06-8.10 (m, 2H); MS (DCI/NH₃) m/z 481 (M+H)⁺; Anal. calcd. for C₂₂H₂₂Cl₂N₂O₄S: C, 54.89; H, 4.61; N, 5.82. Found: C, 54.72; H, 4.56; N, 5.73.

15

20

Example 541

2-(3,4-Difluorophenyl)-4-(4-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 536 substituting 1,4-butanediol in place of n-butanol and substituting 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone for 2-(3,4-difluorophenyl)-4,5-dichloro-3(2H)-pyridazinone to provide the title compound (0.61 g, 95%). mp 110-113°C; ¹H NMR (300 MHz, CDCl₃) δ 1.52-1.60 (m, 2H), 1.72-1.82 (m, 2H), 3.15 (s, 3H), 3.62 (t, J = 6 Hz, 2H), 4.52 (t, J = 6 Hz, 2H), 7.25-7.34 (m, 1H), 7.44-7.50 (m, 1H), 7.55-7.62 (m, 1H), 7.77-7.82

25

(m, 2H), 7.92 (s, 1H), 8.05-8.10 (m, 2H); MS (DCI/NH₃) m/z 468 (M+H)⁺; Anal. calcd. for C₂₁H₂₀F₂N₂O₅S: C, 55.99; H, 4.48; N, 6.22. Found: C, 55.79; H, 4.41; N, 5.96.

Example 542

5 2-[3-(Trifluoromethyl)phenyl]-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-
 3(2H)-pyridazinone

The title compound was prepared according to the method of Example 536 substituting 2-methylpropanol for n-butanol and substituting 2-[3-(trifluoromethyl)phenyl]-4,5-dibromo-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4,5-dichloro-3(2H)-pyridazinone to provide the title compound (0.58 g, 90%). mp 125-127 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.84 (d, J = 6 Hz, 6H), 1.86-1.98 (m, 1H), 3.14 (s, 3H), 4.30 (d, J = 6 Hz, 2H), 7.60-7.70 (m, 2H), 7.79-7.84 (m, 2H), 7.94 (s, 1H), 7.88-7.98 (m, 2H), 8.06-8.12 (m, 2H); MS (DCI/NH₃) m/z 484 (M+H)⁺; Anal. calcd. for C₂₂H₂₁F₃N₂O₄S: C, 56.65; H, 4.54; N, 6.00. Found: C, 56.49; H, 4.56; N, 5.81.

15

Example 543

2-[3-(Trifluoromethyl)phenyl]-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-
 3(2H)-pyridazinone

The title compound was prepared according to the method of Example 536 substituting 3-methyl-1-butanol in place of n-butanol and substituting 2-[3-(trifluoromethyl)phenyl]-4,5-dibromo-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4,5-dichloro-3(2H)-pyridazinone to provide the title compound (0.53 g, 74%). mp 82-85 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.95 (d, J = 6 Hz, 6H), 1.52-1.64 (m, 3H), 3.14 (s, 3H), 4.52 (d, J = 6 Hz, 2H), 7.60-7.70 (m, 2H), 7.79-7.84 (m, 2H), 7.94 (s, 1H), 7.88-7.98 (m, 2H), 8.06-8.12 (m, 2H); MS (DCI/NH₃) m/z 498 (M+H)⁺; Anal. calcd. for C₂₃H₂₃F₃N₂O₄S: C, 57.49; H, 4.82; N, 5.83. Found: C, 57.47; H, 4.94; N, 5.60.

25

Example 544

2-[3-(Trifluoromethyl)phenyl]-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 536 substituting 3-methyl-1,3-butanediol in place of n-butanol and substituting 2-[3-(trifluoromethyl)phenyl]-4,5-dibromo-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4,5-dichloro-3(2H)-pyridazinone to provide the title compound (1.2 g, 75%). mp 90-93 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.14 (s, 6H), 1.90 (t, J = 6 Hz, 2H), 3.14 (s, 3H), 4.58 (t, J = 6 Hz, 2H), 7.60-7.70 (m, 2H), 7.79-7.84 (m, 2H), 7.94 (s, 1H), 7.88-7.98 (m, 2H), 8.06-8.12 (m, 2H); MS (DCI/NH₃) m/z 514 (M+H)⁺; Anal. calcd. for C₂₃H₂₃F₃N₂O₃S: C, 55.64; H, 4.67; N, 5.64. Found: C, 56.01; H, 4.83; N, 5.06.

Example 545

(R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 545A

Ethyl (R)-3-(tert-butyldimethylsiloxy)butanoate

To a stirred, room temperature solution of ethyl (R)-3-hydroxybutanoate (5.00 g, 37.8 mmol) and tert-butyldimethylsilyl chloride (6.85 g, 45.5 mmol) in DMF (90 mL) was added imidazole (3.87 g, 56.9 mmol). This reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was partitioned between hexane (300 mL) and water (100 mL). The organic layer was washed with water (2 X 100 mL) then dried (MgSO₄) and filtered. The filtrate was concentrated under reduced pressure to give the title compound.

Example 545B

(R)-3-(tert-Butyldimethylsiloxy)-1-butanol

The crude product from Example 545A (~37 mmol) was dissolved in dichloromethane (100 mL). To this stirred solution, chilled to -78°C, was added dropwise

a 1M solution of diisobutylaluminum hydride in dichloromethane (185 mL, 185 mmol). The reaction mixture was stirred at -78°C for two hours, then it was allowed to warm to -30°C and stirred an additional 0.5 hours. Methanol was then added carefully at -20°C to quench any remaining hydride. The reaction mixture was then diluted with methyl tert-butylether (200 mL) and washed with aqueous sodium tartrate solution (4 X 100 mL) and brine (2 X 100 mL). The organic layer was dried (MgSO₄) and filtered. The filtrate was concentrated under reduced pressure to give the crude title compound (6.3 g, 83%).

Example 545C

10 (R)-2-(3,4-Difluorophenyl)-4-[3-(tert-butyl)dimethylsiloxy]-1-butoxy]-5-bromo-3(2H)-pyridazinone

To a stirred, 0°C solution of the product from Example 545B (3.4 g, 10 mmol) in THF (20 mL) was added 1M sodium bis(trimethylsilyl)amide in THF (12 mL, 12 mmol). The reaction mixture was stirred at room temperature for 0.5 hours, then it was transferred to a stirred, -30°C solution of 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone (3.66 g, 10 mmol) in THF (100 mL). The reaction mixture was stirred at -30°C for 1 hour, then overnight while warming to room temperature. The reaction was quenched with saturated aqueous ammonium chloride solution (100 mL) and extracted with ethyl acetate (2 X 100 mL). The organic layer was washed with brine (2 X 20 mL), then dried (MgSO₄), and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, 90:10 hexane/ethyl acetate) to provide the title intermediate (2.5 g, 51%).

Example 545D

25 (R)-2-(3,4-Difluorophenyl)-4-[3-(tert-butyl)dimethylsiloxy]-1-butoxy]-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

Under a nitrogen atmosphere, a mixture of the product from Example 545C (0.98 g, 2 mmol), 4-(methylthio)benzeneboronic acid (0.4 g, 2.4 mmol), K₃PO₄ (1.2 g, 6 mmol), PdCl₂(PPh₃)₂ (28 mg, 0.04 mmol), isopropanol (9 mL), and water (1 mL) was stirred at 70°

C for 4 hours. The reaction mixture was then cooled to room temperature, water (30 mL) was added and stirring was continued for 2 hours. The crude black precipitate was collected by filtration then washed with water (10 mL) and hexane (10 mL). This title intermediate was used without further purification in the following oxidation/deprotection step.

Example 545E

(R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

A stirred solution of the product from step Example 545D (~2 mmol) in acetone (10 mL) was chilled to 0°C. To this was added 32% peracetic acid in acetic acid solution (1.42 mL, 6 mmol). The reaction mixture was stirred for 1 hour while warming to room temperature. At this point the oxidation was complete, but some of the product's hydroxy group was still silylated so 1M tetrabutylammonium fluoride in THF (4 mL, 4 mmol) was added and stirring was continued for 0.5 hours. The reaction mixture was then treated with 5% aqueous sodium thiosulfate solution (30 mL) for 2 hours. The precipitated product was collected by filtration, washed with water (10 mL) and hexane (10 mL). The solid was stirred in isopropanol (5 mL) for 6 hours then collected by filtration and dried to provide the title compound (0.78 g, 87%). mp 126-129 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.22 (d, J = 6 Hz, 3H), 1.62-1.74 (m, 1H), 1.84-1.94 (m, 1H), 3.16 (s, 3H), 3.30 (s br, 1H), 4.00-4.10 (m, 1H), 4.20-4.30 (m, 1H), 4.63 (td, J = 9.6 Hz, J = 4 Hz, 1H), 7.25-7.34 (m, 1H), 7.46-7.52 (m, 1H), 7.56-7.64 (m, 1H), 7.78-7.84 (m, 2H), 7.97 (s, 1H), 8.06-8.12 (m, 2H); MS (DCI/NH₃) m/z 468 (M+NH₄)⁺.

Example 546

(S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound was prepared according to the method of Example 545 substituting ethyl (S)-3-hydroxybutanoate in place of ethyl (R)-3-hydroxybutanoate (0.72

g, 80%). mp 128-130 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.22 (d, J = 6 Hz, 3H), 1.62-1.74 (m, 1H), 1.84-1.94 (m, 1H), 3.16 (s, 3H), 3.30 (s br, 1H), 4.00-4.10 (m, 1H), 4.20-4.30 (m, 1H), 4.63 (td, J = 9.6 Hz, J = 4 Hz, 1H), 7.25-7.34 (m, 1H), 7.46-7.52 (m, 1H), 7.56-7.64 (m, 1H), 7.78-7.84 (m, 2H), 7.97 (s, 1H), 8.06-8.12 (m, 2H); MS (DCI/NH₃) m/z 468 (M+NH₄)⁺.

Example 547

(S)-2-(3,4-Difluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 547A

Methyl (S)-2-hydroxy-3-methylbutanoate

The title compound (CAS Registry # [17392-84-6]) is prepared by literature procedures (e.g. Journal of Organic Chemistry, (1994) 59(7), 1933-1936).

Example 547B

Methyl (S)-2-(tert-butyldimethylsiloxy)-3-methylbutanoate

The title compound is prepared by the method of Example 545A, substituting methyl (S)-2-hydroxy-3-methylbutanoate (Example 547A) in place of ethyl (R)-3-hydroxybutanoate.

Example 547C

(S)-2-(tert-Butyldimethylsiloxy)-3-methyl-1-butanol

The title compound is prepared by the method of Example 545B, substituting methyl (S)-2-(tert-butoxydimethylsiloxy)-3-methylbutanoate (Example 547B) in place of ethyl (R)-3-(tert-butyldimethylsiloxy)butanoate (Example 545A).

Example 547D

(S)-2-(3,4-Difluorophenyl)-4-[2-(tert-butyldimethylsiloxy)-3-methyl-1-butoxy]-5-bromo-3(2H)-pyridazinone

The title compound is prepared by the method of Example 545C, substituting (S)-2-tert-butyldimethylsiloxy-3-methyl-1-butanol (Example 547C) in place of (R)-3-(tert-butyldimethylsiloxy)-1-butanol (Example 545B).

Example 547E

2-(3,4-Difluorophenyl)-4-[(S)-2-(tert-butyldimethylsiloxy)-3-methyl-1-butoxy]-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone

The title intermediate is prepared by the method of Example 545D, substituting (S)-2-(3,4-difluorophenyl)-4-[2-(tert-butyldimethylsiloxy)-3-methyl-1-butoxy]-5-bromo-3(2H)-pyridazinone (Example 547D) in place of (R)-2-(3,4-difluorophenyl)-4-[3-(tert-butyldimethylsiloxy)-1-butoxy]-5-bromo-3(2H)-pyridazinone (Example 545C).

Example 547F

(S)-2-(3,4-Difluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound is prepared by the method of Example 545E, substituting (S)-2-(3,4-difluorophenyl)-4-[2-(tert-butyldimethylsiloxy)-3-methyl-1-butoxy]-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (Example 547E) in place of (R)-2-(3,4-difluorophenyl)-4-[3-(tert-butyldimethylsiloxy)-1-butoxy]-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone (Example 545D).

Examples 548-558

The following compounds may be prepared according to the sequence of reactions described in Example 547, substituting the appropriate 2-(X-phenyl)-4,5-dibromo-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

Example Number	X
548	4-F
549	4-Cl

550	3-F
551	3-Cl
552	3-Br
553	3-CF ₃
554	3-Cl-4-F
555	4-Cl-3-F
556	3,4-di-Cl
557	4-F-3-CF ₃
558	3-Br-4-F

Example 559

(R)-2-(3,4-Difluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound may be prepared according to the sequence of reactions described in Example 547, substituting methyl (R)-2-hydroxy-3-methyl-butanoate [17392-84-6] prepared as described in (Tetrahedron, 1995, 51(38), 10513-10522) in place of methyl (S)-2-hydroxy-3-methylbutanoate.

10

Examples 560-570

The following compounds can be prepared according to the sequence of reactions described in Example 559, substituting the appropriate 2-(X-phenyl)-4,5-dibromo-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

Example Number	X
560	4-F
561	4-Cl
562	3-F
563	3-Cl
564	3-Br

565	3-CF ₃
566	3-Cl-4-F
567	4-Cl-3-F
568	3,4-di-Cl
569	4-F-3-CF ₃
570	3-Br-4-F

Example 571

2-(3,4-Difluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

- 5 The title compound may be prepared according to the sequence of reactions described in Example 547, substituting methyl (R)-2,3-dihydroxy-3-methylbutanoate [37504-90-8] (Australian Journal of Chemistry, (1986) 39(11), 1907-1909) in place of methyl (S)-2-hydroxy-3-methylbutanoate.

10

Examples 572-582

The following compounds may be prepared according to the sequence of reactions described in Example 571, substituting the appropriate 2-(X-phenyl)-4,5-dibromo-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

Example Number	X
572	4-F
573	4-Cl
574	3-F
575	3-Cl
576	3-Br
577	3-CF ₃
578	3-Cl-4-F
579	4-Cl-3-F

580	3,4-di-Cl
581	4-F-3-CF ₃
582	3-Br-4-F

Example 583

2-(3,4-Difluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound may be prepared according to the sequence of reactions described in Example 547, substituting methyl (S)-2,3-dihydroxy-3-methylbutanoate [75347-92-1] (Journal of Organic Chemistry, 1980, 45(25), 5218-5220) in place of methyl (S)-2-hydroxy-3-methylbutanoate.

10

Examples 584-594

The following compounds may be prepared according to the sequence of reactions described in Example 571, substituting the appropriate 2-(X-phenyl)-4,5-dibromo-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

Example Number	X
584	4-F
585	4-Cl
586	3-F
587	3-Cl
588	3-Br
589	3-CF ₃
590	3-Cl-4-F
591	4-Cl-3-F
592	3,4-di-Cl
593	4-F-3-CF ₃
594	3-Br-4-F

Example 595

2-(3,4-Difluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

5 The title compound may be prepared according to the sequence of reactions described in Example 471, substituting 4-methyl-1,4-pentanediol [1462-10-8] (Journal of Organic Chemistry, (1972) 37, 3310-3322) in place of methyl 3-methyl-1,3-butanediol.

Example 596-606

10 The following compounds may be prepared according to the sequence of reactions described in Example 471, substituting 4-methyl-1,4-pentanediol [1462-10-8] (Journal of Organic Chemistry, (1972) 37, 3310-3322) in place of methyl 3-methyl-1,3-butanediol and substituting the appropriate 2-(X-phenyl)-4,5-dibromo-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

Example Number	X
596	4-F
597	4-Cl
598	3-F
599	3-Cl
600	3-Br
601	3-CF ₃
602	3-Cl-4-F
603	4-Cl-3-F
604	3,4-di-Cl
605	4-F-3-CF ₃
606	3-Br-4-F

15

Example 607

2-(3,4-Difluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared by a carbodiimide-mediated coupling (method described in Angew. Chem., Int. Ed. Engl., (1979) 18(9), 686) of 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 471) with an N-protected-glycine (such as N-Fmoc-glycine); followed by an amino group deprotection step (such as treatment at room temperature with tetrabutylammonium fluoride in DMF).

Examples 608-618

The following compounds may be prepared by the method of Example 607, substituting the appropriate 2-(X-phenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 471).

Example Number	X
608	4-F
609	4-Cl
610	3-F
611	3-Cl
612	3-Br
613	3-CF ₃
614	3-Cl-4-F
615	4-Cl-3-F
616	3,4-di-Cl
617	4-F-3-CF ₃
618	3-Br-4-F

Example 619

2-(3,4-Difluorophenyl)-4-[3-{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared in a manner similar to that described in J. Chem. Soc., Chem Commun., (1993) 410-412, reacting 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 471) with an appropriately protected L-tartaric acid diester (such as below), followed by deprotection.

Example 619A

dibenzyl (2R,3R)-2,3-bis{[tert-butyl(diphenyl)silyl]oxy}butanedioate

The alcohol groups of (+)-dibenzyl-L-tartrate can be protected as the tert-butyl diphenylsilyl ethers by standard methods as described in (Greene, TW, Wuts, PGM; Protective Groups in Organic Synthesis; 3rd Edition; 1999; John Wiley & Sons, Inc.; NY, NY; 141-144) to provide the title intermediate.

Example 619B

(2R,3R)-2,3-bis{[tert-butyl(diphenyl)silyl]oxy}butanedioic acid

The dibenzyl ester of Example 619A can be cleaved by standard hydrogenolysis procedures as described in (Greene, TW, Wuts, PGM; Protective Groups in Organic Synthesis; 3rd Edition; 1999; John Wiley & Sons, Inc.; NY, NY; 415-419) to provide the title intermediate.

Example 619C

(3R,4R)-3,4-bis{[tert-butyl(diphenyl)silyl]oxy}dihydro-2,5-furandione

Example 619B may be reacted by standard methods as described in (Journal of Organic Chemistry, (1987) 52(3), 455-457) with trifluoroacetic anhydride to provide the title intermediate.

Example 619D

(2R,3R)-2,3-bis{[tert-butyl(diphenyl)silyl]oxy}-4-methoxy-4-oxobutanoic acid

Example 619C may be reacted with anhydrous methanol by standard methods as described in (Organic Syntheses, Collective Volume III, (1955) 169-171) to provide the title intermediate.

5

Example 619E

1-isopropenyl 4-methyl (2R,3R)-2,3-bis{[tert-butyl(diphenyl)silyl]oxy}butanedioate

Example 619D may be reacted with isopropenyl acetate in the presence of catalytic boron trifluoride etherate and mercury(II) acetate as described in (J. Chem. Soc., Chem Commun., (1993) 410-412) to provide the title intermediate.

10

Example 619F

2-(3,4-Difluorophenyl)-4-{3-[(2R,3R)-2,3-bis{[tert-butyl(diphenyl)silyl]oxy}-4-methoxy-4-oxobutanoyl]oxy}-3-methylbutoxy}-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

15

Example 619E may be coupled to 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 471) in the presence of catalytic 4-toluene sulfonic acid by the method described in (J. Chem. Soc., Chem Commun., (1993) 410-412) to provide the title intermediate.

20

Example 619G

2-(3,4-Difluorophenyl)-4-[3-{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

Example 619F can be treated with aqueous sodium hydroxide in methanol as described in (J. Chem. Soc., Chem Commun., (1993) 410-412) to provide the title compound.

25

Example 620-630

The following compound may be prepared by the method of Example 619F, substituting the appropriate 2-(X-phenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 471), followed by treatment with aqueous sodium hydroxide in methanol as in Example 619G.

Example Number	X
620	4-F
621	4-Cl
622	3-F
623	3-Cl
624	3-Br
625	3-CF ₃
626	3-Cl-4-F
627	4-Cl-3-F
628	3,4-di-Cl
629	4-F-3-CF ₃
630	3-Br-4-F

5

Example 631

3-({2-(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate

The title compound may be prepared as described in (Kosolapoff, GM and Maier, L, Organic Phosphorus Compounds, (1973) Volume 6, John Wiley & Sons, NY,NY); such
 10 as reacting 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 471) with 2-cyanoethylphosphate (Fieser, LF and Fieser, M, Reagents for Organic Synthesis, 1967, Volume 1, 172-173, John Wiley & Sons, NY, NY) in the presence of DCC and pyridine. Mild alkaline
 15 hydrolysis of the cyanoethyl ester selectively provides the title compound.

Example 632-642

The following compounds may be prepared by the method of Example 631, substituting the appropriate 2-(X-phenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone in place of 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 471).

Example Number	X
632	4-F
633	4-Cl
634	3-F
635	3-Cl
636	3-Br
637	3-CF ₃
638	3-Cl-4-F
639	4-Cl-3-F
640	3,4-di-Cl
641	4-F-3-CF ₃
642	3-Br-4-F

Example 643

2-(tert-Butyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared according to the sequence of reactions described in Example 471, substituting 2-tert-butyl-4,5-dichloro-3(2H)-pyridazinone (Example 330A) in place of 2-(3,4-difluorophenyl)-4,5-dibromo-3(2H)-pyridazinone.

Example 644

2-(tert-Butyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone

The title compound may be prepared by the method of Example 607, substituting

2-(tert-butyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 643) in place of 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone (Example 471).

5

Example 645

2-(tert-Butyl)-4-[3-{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy]-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)-phenyl]-3(2H)-pyridazinone

The title compound may be prepared by the method of Example 619, substituting 2-(tert-butyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)-phenyl]-3(2H)-pyridazinone (Example 643) in place of 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)-phenyl]-3(2H)-pyridazinone (Example 471).

10

Example 646

3-({2-(tert-Butyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate

15

The title compound may be prepared by the method of Example 631, substituting 2-(tert-butyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)-phenyl]-3(2H)-pyridazinone (Example 643) in place of 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)-phenyl]-3(2H)-pyridazinone (Example 471).

20

Prostaglandin Inhibition Determination

Compound Preparation and Administration

For oral administration, test compounds were suspended on the day of use in 100% polyethyleneglycol (PEG 400) with a motorized homogenizer equipped with a Teflon-coated pestle (TRI-R Instrument, Jamaica, NY).

25

To compare the mean responses of the treatment groups, analysis of variance was applied. Percent inhibition values were determined by comparing the individual treatment mean values to the mean of the control group. Linear regression was used to estimate IC_{50} 's/ ED_{50} 's in appropriate assays.

EIA Determination of Prostaglandins

EIA reagents for prostaglandin determination were purchased from Perseptive Diagnostics, (Cambridge, MA). Prostaglandin E₂ (PGE₂) levels in lavage fluids were determined after the samples were dried under nitrogen and reconstituted with assay buffer. PGE₂ levels in enzyme assays or cell culture media were measured against standards prepared in the same milieu. The immunoassays were conducted as recommended by the manufacturer. The EIA was conducted in 96 well microtiter plates (Nunc Roskilde, Denmark) and optical density was measured using a microplate reader (Vmax, Molecular Devices Corp., Menlo Park, CA).

Recombinant Human PGHS-1 and PGHS-2 Enzyme Assays

Inhibition of prostaglandin biosynthesis in vitro was evaluated using recombinant human Cox-1 (r-hu Cox1) and Cox-2 (r-hu Cox-2) enzyme assays. Representative compounds dissolved in DMSO (3.3% v/v) were preincubated with microsomes from recombinant human PGHS-1 or PGHS-2 expressed in the baculovirus/Sf9 cell system (Gierse, J. K., Hauser, S. D., Creely, D. P., Koboldt, C., Rangwala, S., H., Isakson, P. C., and Seibert, K. Expression and selective inhibition of the constitutive and inducible forms of cyclooxygenase, Biochem J. 1995, 305: 479.), together with the cofactors phenol (2 mM) and hematin (1 μ M) for 60 minutes prior to the addition of 10 μ M arachidonic acid. The reaction was allowed to run for 2.5 minutes at room temperature prior to quenching with HCl and neutralization with NaOH. PGE₂ production in the presence and absence of the drug was determined by EIA analysis. The EIA was conducted in 96 well microtiter plates (Nunc Roskilde, Denmark) and optical density was measured using a microplate reader (Vmax, Molecular Devices Corp., Menlo Park, CA). EIA reagents for prostaglandin determination were purchased from Perseptive Diagnostics (Cambridge, MA). PGE₂ levels were measured against standards prepared in the same milieu. The immunoassays were conducted as recommended by the manufacturer.

The data illustrating the inhibition of prostaglandin biosynthesis in vitro by compounds of this invention is shown in Table 1. The compounds are designated by the Example Number. Column 2 shows Cox-1 percent inhibition at the particular micromolar

dose level and Column 3 shows Cox-2 percent inhibition at the particular nanomolar dose level. Values for Cox-1 and Cox-2 inhibition that are parenthetical indicate IC₅₀

Table 1

Example Number	RHUCX1 % Inh. at Dose (μM)	RHUCX2 % Inh. at Dose (μM)
10	2 @ 100	(0.014)
12	0 @ 100	97 @ 10 77 @ 1 9 @ 0.1
20	10 @ 100	86 @ 0.1 9 @ 0.01
21	19 @ 100	(0.92)
22	25 @ 100	91 @ 0.03 35 @ 0.01
23	0 @ 100	68 @ 0.1 27 @ 0.01
24	60 @ 100 0 @ 10	99 @ 1 61 @ 0.1 45 @ 0.01
25	1 @ 100	93 @ 1 66 @ 0.1
26	10 @ 100	91 @ 1 44 @ 0.1 44 @ 0.01
32	20 @ 100	96 @ 1 83 @ 0.1
34	16 @ 100	(0.92)

35	34 @ 100	(0.017)
36	21 @ 10	(0.57)
39	0 @ 100	(0.44)
40	76 @ 10 69 @ 1	97 @ 1 89 @ 0.1
41	13 @ 100	49 @ 1 17 @ 0.1
42	0 @ 100	99 @ 1 92 @ 0.1
43	8 @ 100	100 @ 1 96 @ 0.1
45	5 @ 100	85 @ 1 63 @ 0.1
48	0 @ 100	73 @ 1 2 @ 0.1
50	23 @ 100	99 @ 1 59 @ 0.1
52	32 @ 10	99 @ 1 83 @ 0.1
53	10 @ 100	99 @ 1 77 @ 0.1
54	0 @ 100	95 @ 1 58 @ 0.1
58	0 @ 100	(0.95)
60	7 @ 100	100 @ 1,000
62	6 @ 100	(0.624)
64	68 @ 1	34 @ 1 36 @ 0.1

65	13 @ 100	98 @ 1 65 @ 0.1
68	32 @ 100	(0.297)
69	2 @ 100	88 @ 1 29 @ 0.1 30 @ 0.01
72	0 @ 100	65 @ 1 18 @ 0.1
73	9 @ 100	(1.34)
74	11 @ 100	86 @ 1 75 @ 0.1
77	35 @ 100	82 @ 10 39 @ 1
80	41 @ 10 37 @ 1	(0.064)
81	6 @ 100	97 @ 1 44 @ 0.1
84	49 @ 10 9 @ 1	87 @ 0.3
88	0 @ 100	97 @ 1,000 35 @ 0.1
89	62 @ 30 40 @ 10	(0.35)
97	35 @ 100	(0.332)
100	62 @ 10 65 @ 1	100 @ 10 61 @ 0.1
105	85 @ 1	98 @ 1 52 @ 0.1

106	19 @ 200	(0.135)
107	88 @ 10 50 @ 1	86 @ 1 36 @ 0.1
108	0 @ 100	(0.279)
109	6 @ 100	(0.147)
110	5 @ 100	93 @ 1 50 @ 0.1
111	13 @ 100	(0.052)
112	5 @ 100	(0.136)
118	31 @ 100	72 @ 0.1 17 @ 0.01
119	(0.178)	(0.027)
120	15 @ 100	97 @ 1 45 @ 0.1
121	0 @ 100	(0.005)
122	1 @ 100	(0.285)
124	26 @ 100	(0.044)
127	50 @ 10 30 @ 1	74 @ 1 51 @ 0.1
128	14 @ 100	(0.477)
132	93 @ 1	88 @ 1 43 @ 0.1
133	23 @ 100	(0.358)
134	54 @ 100 35 @ 10	(0.053)
140	(3.06)	(0.022)
141	55 @ 100 62 @ 10	99 @ 1 95 @ 0.1

142	80 @ 10 53 @ 1	96 @ 1 45 @ 0.1 32 @ 0.01
143	62 @ 100 43 @ 10	(0.076)
144	(0.058)	88 @ 1 78 @ 0.1 65 @ 0.01
145	(0.238)	86 @ 0.1 56 @ 0.01
146	82 @ 10 53 @ 1	100 @ 1 73 @ 0.1
147	(0.067)	100 @ 1 64 @ 0.1 0 @ 0.03
149	45 @ 10 40 @ 1	(0.003)
150	56 @ 100 39 @ 10	100 @ 0.1
153	54 @ 100 35 @ 10	(0.062)
154	(0.126)	(0.018)
165	0 @ 100	(1.08)
166	3 @ 100	(0.199)
168	0 @ 100	85 @ 1 93 @ 0.1

171	0 @ 100	82 @ 10 74 @ 1 61 @ 0.1
178	6 @ 100	92 @ 1,000 34 @ 10
180	8 @ 100	78 @ 1 48 @ 0.1
182	(5.01)	(0.07)
183	25 @ 100	97 @ 1 51 @ 0.1
187	2 @ 100	(0.094)
188	18 @ 100	(0.526)
190	(1.88)	(0.134)
194	35 @ 100	90 @ 10 73 @ 1 72 @ 0.1
198	10 @ 100	68 @ 1 23 @ 0.1
207		97 @ 1 81 @ 0.1
209	0 @ 100	79 @ 1 55 @ 0.1 40 @ 0.01
213	0 @ 100	(0.812)
219	20 @ 100	90 @ 1 75 @ 0.1
220	51 @ 100 38 @ 1	96 @ 1 90 @ 0.1

226	0 @ 100	(1.09)
228	7 @ 100	(0.209)
230	4 @ 100	(0.215)
231	7 @ 100	90 @ 1 68 @ 0.1
232	23 @ 100	(0.024)
234	0 @ 100	(0.328)
235	22 @ 100	(0.21)
237	54 @ 10 44 @ 1	89 @ 0.1
240	14 @ 100	(0.297)
241	0 @ 100	(0.028)
245	9 @ 100	(1.38)
246	0 @ 100	(0.054)
247	72 @ 10 55 @ 1	99 @ 10 71 @ 1 51 @ 0.1
248	13 @ 100	(0.08)
249	6 @ 100	98 @ 1 68 @ 0.1 43 @ 0.01
252	0 @ 100	87 @ 0.1 26 @ 0.01
253	77 @ 100 29 @ 10	(0.272)
254	7 @ 100	84 @ 1 48 @ 0.1
256	0 @ 100	(0.134)

257	0 @ 100	(0.04)
260	8 @ 100	2 @ 10
261	0 @ 200	(0.161)
262	15 @ 100	(0.432)
263	1 @ 100	85 @ 10 76 @ 1 53 @ 0.1
265	8 @ 100	53 @ 10 48 @ 1 33 @ 0.1
272	0 @ 100	70 @ 1 55 @ 0.1
273	16 @ 100	54 @ 10 42 @ 1
278	36 @ 100	96 @ 1 91 @ 0.1
279	0 @ 100	60 @ 1 31 @ 0.1
281	7 @ 100	71 @ 1 52 @ 0.1 47 @ 0.01
283	0 @ 100	90 @ 10 71 @ 1 54 @ 0.1
287	0 @ 100	93 @ 10 79 @ 1 25 @ 0.1

314	7 @ 100	51 @ 10 4 @ 1
318	23 @ 100	97 @ 1 77 @ 0.1
321	4 @ 100	(0.192)
322	39 @ 100 54 @ 10	(0.058)
323	1 @ 100	(0.365)
325		(0.199)
330	15 @ 100	85 @ 1 72 @ 0.03 5 @ 0.01
335	5 @ 100	(0.001)
338	0 @ 100	100 @ 1 83 @ 0.1
339	2 @ 100	(0.088)
344	16 @ 100	(0.897)
345	0 @ 100	(0.242)
346	14 @ 100	94 @ 1 76 @ 0.1 48 @ 0.01
347	11 @ 100	(0.075)
349	0 @ 100	(0.086)
351	3 @ 100	91 @ 1 63 @ 0.1 42 @ 0.01
352	0 @ 100	(0.154)
353	6 @ 100	(0.826)

354	0 @ 100	45 @ 10 45 @ 1 36 @ 0.1
355	0 @ 100	79 @ 10 66 @ 1 46 @ 0.1
358	30 @ 100	(2.45)
361	3 @ 100	(0.011)
362	1 @ 100	84 @ 10 49 @ 1
364	0 @ 100	86 @ 1 0 @ 0.1
366	0 @ 100	(0.03)
367	0 @ 100	(0.077)
368	13 @ 100	96 @ 1 65 @ 0.1
369	0 @ 100	70 @ 1 48 @ 0.1
370	8 @ 100	(0.048)
371	8 @ 100	(0.166)
372	0 @ 100	94 @ 10 88 @ 1 59 @ 0.1
374	2 @ 100	(0.02)
375	46 @ 100 31 @ 10	(0.18)
376	12 @ 100	(0.027)
381	0 @ 100	(0.188)

384	82 @ 100 49 @ 10	99 @ 1 78 @ 0.1
386	58 @ 100 47 @ 1	83 @ 1 63 @ 0.1 58 @ 0.01
387	57 @ 10 60 @ 1	76 @ 1 65 @ 0.1 56 @ 0.01
388	74 @ 10 36 @ 1	(0.049)
390	88 @ 10 45 @ 1	99 @ 10 72 @ 1 60 @ 0.1
392	56 @ 100 35 @ 10	82 @ 0.1 65 @ 0.01
393	15 @ 100	85 @ 1 58 @ 0.1
394	86 @ 100 38 @ 10	94 @ 1 64 @ 0.1 20 @ 0.01
395	91 @ 100 35 @ 10	93 @ 1 77 @ 0.1 34 @ 0.01
396	22 @ 100	(0.059)
397	25 @ 100	93 @ 1 58 @ 0.1 39 @ 0.01
398	26 @ 100	(0.202)

400	27 @ 100	(0.142)
401	(0.753)	96 @ 1 62 @ 0.1 48 @ 0.01
402	89 @ 1	(0.221)
403	(150.76)	92 @ 1 64 @ 0.1 36 @ 0.01
404	77 @ 100 47 @ 10	92 @ 0.1 57 @ 0.01
405	90 @ 100 61 @ 10	(0.198)
406	23 @ 100	100 @ 1 64 @ 0.1 18 @ 0.01
407	32 @ 100	(0.17)
408	0 @ 100	(0.279)
410	48 @ 100 1 @ 10	67 @ 0.035 47 @ 0.017
411	96 @ 10 81 @ 1	(0.009)
412	31 @ 100	(0.002)
413	0 @ 100	(0.11)
414	0 @ 100	87 @ 1 76 @ 0.1
418	33 @ 100	85 @ 1 52 @ 0.1 53 @ 0.025

419	12 @ 100	(0.1)
420	29 @ 100	(0.323)
421	(0.269)	92 @ 1 81 @ 0.1 38 @ 0.01
422	53 @ 100 82 @ 10 76 @ 1	52 @ 1 37 @ 0.1
423	0 @ 100	87 @ 1 68 @ 0.1 36 @ 0.01
424	7 @ 100	75 @ 1 58 @ 0.1 33 @ 0.01
425	12 @ 100	69 @ 0.1 31 @ 0.01
426	1 @ 100	(0.057)
434	0 @ 100	(0.081)
437	16 @ 100	(0.124)
438	0 @ 100	(0.127)
440	20 @ 100	84 @ 1 59 @ 0.1 22 @ 0.01
442	55 @ 100	90 @ 0.1 56 @ 0.01
443	35 @ 100	86 @ 0.1 74 @ 0.01

444	0 @ 100	83 @ 1 62 @ 0.1 14 @ 10
445	(56.62)	(0.069)
446	0 @ 200	(0.373)
447	0 @ 100	90 @ 1 57 @ 0.1 35 @ 0.01
449	5 @ 200	(0.129)
450	29 @ 100	87 @ 1 40 @ 0.1 22 @ 0.01
451	10 @ 100	(0.470)
452	14 @ 100	15 @ 1
467	4@100	(1.96)
475	0@100	(0.71)
471	(3.68)	(0.49)
478	33 @100	(0.81)
528	(3.4)	(0.72)

IL-1 β Induced PGE₂ Production in WISH Cells

Human amnionic WISH cells were grown to 80% confluence in 48 well plates. Following removal of the growth medium and two washings with Gey's Balanced Salt Solutn, 5 ng IL-1 β /ml (UBI, Lake Placid, NY) was added to the cells with or without test compound in DMSO (0.01% v/v) in Neuman-Tytell Serumless Medium (GIBCO, Grand Island, NY). Following an 18 hour incubation to allow for the maximal induction of PGHS-2, the conditioned medium was removed and assayed for PGE₂ content by EIA analysis as described above.

Monocyte U937 (ATCC, Rockville, MD) cells were grown in a similar fashion to the WISH cells. After incubation, the conditioned medium was removed and assayed for Cox-1 content by EIA analysis as described above.

The data illustrating the inhibition of prostaglandin biosynthesis in vitro by compounds of this invention is shown in Table 2. U937 values indicate Cox-1 percent inhibition at the particular micromolar dose level while partenthetical values indicate IC₅₀ values. WISH cell values indicate percent inhibition at the particular micromolar dose level while parenthetical values indicate IC₅₀ values.

Human Whole Platelet Cyclooxygenase-1 Assay (HWCX)

Blood from normal healthy volunteers is collected into tubes containing ACD (acid citrate dextrose) as the anticoagulant. This blood is centrifuged at 175 x g to prepare platelet rich plasma. The platelet rich plasma is then centrifuged at 100 x g to pellet the white blood cells, leaving the platelets in the supernatant. The supernatant is layered on a cushion of 0.7 mL of 10% bovine serum albumin in Tyrodes solution (Gibco; Grand Island, NY) and then centrifuged at 1000 x g. The resulting supernatant from this centrifugation is then removed and 11 mL of Tyrodes solution is added to the remaining pellet of platelets. The platelets are then aliquoted at 120 μ l into a 96 well plate. Experimental compounds are added and allowed to pre-incubate for 10 minutes. At the end of this pre-incubation period, the calcium ionophore A23187 is added to a final concentration of 8.8 μ M and the incubation is continued for ten minutes. The reaction is stopped by adding cold 6 mM EDTA, the incubation mixture is centrifuged at 220 x g, and the supernatants are then analyzed for thromboxane using a commercial kit from Cayman Chemical (Ann Arbor, MI).

Table 2

Example Numbers	U937 % Inhib. at Dose (μ M)	HWPX % Inhib. at Dose (μ M)	Wish % Inhib. at Dose (μ M)
10		(4.1)	(0.014)

20	33 @ 1		(0.001)
24	(0.19)		(0.007)
43		86 @ 10 9 @ 1	(0.008)
53		78 @ 10 8 @ 1	90 @ 0.1 44 @ 0.01
65			(0.02)
69		(1.14)	(0.02)
72		(25)	(0.072)
75		84 @ 10 0 @ 3	(0.001)
77		(8.8)	(0.126)
85			(0.47)
86			52 @ 1 47 @ 0.01
89	(3.8)	(2.1)	(0.05)
100		(0.13)	(0.02)
102			(0.05)
105		62 @ 1	(0.018)
106		(17.5)	(0.03)
108		(8)	(0.097)
109		(2.693)	(0.018)
119		(0.076)	(0.001)
120		74 @ 3 58 @ 1	(0.025)
121			(0.041)
123		90 @ 1 29 @ .1	(0.001)

126			(0.05)
129			(0.04)
132			100 @ 0.1 36 @ 0.01
140		(0.773)	(0.01)
141		56 @ 0.3	(0.004)
142		(7.53)	(0.088)
143			(0.007)
145		72 @ 1 30 @ .3	(0.009)
146		84 @ 10 46 @ 3	(0.044)
147		84 @ 0.3	(0.029)
148		51 @ 0.3	(0.042)
149		89 @ 10 34 @ 3	(0.03)
152			(0.029)
153		(2.95)	(0.046)
154		81 @ .3 48 @ .1	100 @ 0.1 69 @ 0.01
160		(7.2)	(0.03)
162			(0.034)
165		(1.9)	(0.030)
166		(9.4)	(0.02)
168		47 @ 1	(0.009)
171			90 @ 1 56 @ 0.1
187		(12.6)	(0.015)

189		31 @ 100	(0.041)
190		(9.96)	(0.03)
191			(0.06)
194		(28.09)	(0.069)
198			(0.184)
203			77 @ 1 23 @ 0.1
207			(0.068)
228		(19.6)	(0.086)
241			(0.0474)
243			(0.03)
244		(3.67)	(0.019)
245			(0.046)
246			(0.02)
247		(7.76)	(0.02)
248		82 @ 30 17 @ 10	(0.005)
252			(0.044)
256		(4.7)	(0.028)
261		(34)	(0.099)
271			52 @ 1 15 @ 0.1
278			(0.07)
279			(0.391)
287			(0.16)
317			(0.027)
320		29 @ 3	78 @ .1 15 @ .01

321			50 @ 0.01
322			(0.026)
323			57 @ 0.01
324			(0.047)
325		(2.3)	(0.04)
326			(0.05)
330		(16.7)	(0.005)
335			(0.023)
338		(14.93)	(0.004)
339		(0.393)	(0.026)
343		(0.191)	(0.016)
344			(0.1)
345			(0.03)
349		34 @ 100	(0.041)
352		(5.5)	(6.048)
358			69 @ 1 0 @ 0.1
366		(1.615)	(0.002)
367		50 @ 1 8 @ .3	(0.018)
368		(13.7)	64 @ 0.03 33 @ 0.01
370		(8.4)	(0.02)
375		(2.04)	(0.089)
381		31 @ 30 91 @ 100	(0.075)
385		(2.18)	(0.023)
388		0 @ .3	(0.032)

392		(1.95)	(0.02)
394			(0.019)
396		(12.7)	(0.02)
397		(13.8)	(0.04)
399			82 @ 0.1 39 @ 0.03
400		(0.3)	(0.026)
401		(0.32)	(0.017)
403		(0.902)	(0.018)
404		(0.337)	96 @ 0.1 58 @ 0.01
406		(1.61)	(0.026)
408			(0.029)
410			(0.053)
414			54 @ 1 46 @ 0.1
418		(14.25)	(0.25)
430		34 @ 10 89 @ 100	(0.054)
442			(0.42)
445		100 @ 100 22 @ 10	(0.025)
446		(24.4)	(0.02)
449		(40)	(0.089)
450			(0.05)
451		(22.4)	(0.15)
452			56 @ 1 1 @ 0.1

475		50 @ 100	(0.44)
467			(0.135)
471		(0.32)	(0.04)
478		(0.5)	(0.108)
528		(3.5)	(0.054)

Carrageenan Induced Paw Edema (CPE) in Rats

Hindpaw edema was induced in male rats as described by Winter et al., Proc. Soc. Exp. Biol. Med., 1962, 111, 544. Briefly, male Sprague-Dawley rats weighing between 170
5 and 190 g were administered test compounds orally 1 hour prior to the subplantar injection of 0.1 ml of 1% sodium carrageenan (lambda carrageenan, Sigma Chemical Co., St Louis, MO) into the right hindpaw. Right paw volumes (ml) were measured immediately following injection of carrageenan for baseline volume measurements using a Buxco plethysmograph (Buxco Electronics, Inc., Troy, NY). Three hours after the injection of
10 carrageenan, right paws were remeasured and paw edema calculated for each rat by subtracting the zero time reading from the 3 hour reading. Data are reported as mean percent inhibition +/- SEM. Statistical significance of results was analyzed by Dunnetts multiple comparison test where $p < 0.05$ was considered statistically significant.

Rat Carrageenan Pleural Inflammation (CIP) Model

15 Pleural inflammation was induced in male adrenalectomized Sprague-Dawley rats following the method of Vinegar et al., Fed. Proc. 1976, 35, 2447-2456. Animals were orally dosed with experimental compounds, 30 minutes prior to the intrapleural injection of 2% lambda carrageenan (Sigma Chemical Co., St. Louis MO). Four hours later the animals were euthanized and the pleural cavities lavaged with ice cold saline. The lavage
20 fluid was then added to two volumes of ice cold methanol (final methanol concentration 66%) to lyse cells and precipitate protein. Eicosanoids were determined by EIA as described above.

The data illustrating the inhibition of prostaglandin biosynthesis in vivo by the compounds of this invention is shown in Table 3. Values reported are percent inhibition at 10 milligrams per kilogram body weight.

Carrageenan induced air pouch prostaglandin biosynthesis model (CAP)

5 Air pouches are formed in the backs of male Sprague Dawley rats by injecting 20 mL of sterile air on day 0. Three days later the pouch was reinflated with an additional 10 mL of sterile air. On day 7, 1 mL of saline containing 0.2 % lambda carrageenan (Sigma Chemical Co.) is injected into the pouch to induce the inflammatory reaction that is characterized by the release of prostaglandins. Test compounds are dosed at 0.1 to 10
10 mg/kg 30 minutes prior to carrageenan. Four hours after the carrageenan injection the pouch is lavaged and levels of prostaglandins are determined by enzyme immuno-assay using commercially available kits. Percent inhibitions are calculated by comparing the response in animals which have received vehicle to those which received compound. Values for Cox-2 inhibition that are parenthetical indicate ED₅₀ values.

15 The data illustrating the inhibition of prostaglandin biosynthesis in vivo by the compounds of this invention is shown in Table 3. Values reported are percent inhibition at 10 milligrams per kilogram body weight for CIP and CPE tests and at 3 milligrams per kilogram body weight for CAP testing.

Table 3

Example Numbers	CIP % Inhib. @ 10 mpk	CPE % Inhib. @ 10 mpk	CAP % Inhib. @ 3 mpk
10	44		
12	42	25	
34	36	31	
54	31	30	
58	42	14	67
62	57	21	

66	59	7	0
67	40 @ 3mpk		
68	64	40.3	
69	61	45.5 ED ₃₀ = 5.4	87
72			
73		46	29
74	46.5	18	34
77	51	21	
80	60	28.5	91
89	68.3 ED ₅₀ = 3.4	45.5	94
106			47
109		13	71
112		21	42.5
119	82	27	76
120	5	11	
121	19	8	
123			23
143			59
153			51
160	56	35	
166	40		59
168	0	6	
180	34.5		
182	59	27	98
185	59	20	53
187	51	28	30

190	60	28	71
205			54
226		21	40.5
243			7
245			47
246			48
248			49
256			47
257			60
261		28	79
330			4.5
335			45
339		43	90.5 $ED_{50} = 0.58$
346			49.5
347		27	66.5
349			63
351/64			0
352			89 $ED_{50} = 5.0$
353/63			0
361			65
366			63 $ED_{50} = 1.5$
367			48
375		47	77.5 $ED_{50} = 0.57$
376		17	77.5

378			59
384/33	51	15	51
385			65
388		28	80
390			60
391			61
392			60
394			70
395			71
396		23	85
397			70
400	65	41	82.5
403		43	68.5 $ED_{50} = 0.35$
405			53
406		23	66.5
407			61
419			48
427			78
445		15	73
446		44	92 $ED_{50} = 0.5$
449		23	76 $ED_{50} = 1.8$
450			86
451		$ED_{30}=0.82$	80.5 $ED_{50} = 0.7$
452			71

459			45
464			70
475		33	ED ₅₀ =1.4
467		ED ₃₀ =1.7	ED ₅₀ =0.4
471		41	ED ₅₀ =0.9
478		26	75
528		40	ED ₅₀ =1.4

Human whole blood assays

Cyclooxygenase-1

Heparin anticoagulated blood was incubated with drugs dissolved in DMSO. The samples are incubated at 37 degrees Celsius for 4.5 hours after which calcium ionophore at a final concentration of 30 μ M was added and the mixture allowed to incubate for 30 minutes. The reaction was stopped with the addition of EGTA and cold methanol (50% final concentration). After 18 hours at -70 degrees Celsius, the plates were centrifuged and supernatants analyzed for TXB₂.

10

Cyclooxygenase-2

Heparin anticoagulated blood was incubated with drugs dissolved in DMSO. The samples are incubated at 37 degrees Celsius for 15 minutes. E. coli lipopolysaccharide (LPS) 5 μ g/ml was then added and the samples incubated for 5 hours. The reaction was stopped with the addition of EGTA and cold methanol (50% final concentration). After 18 hours at -70 degrees Celsius, the plates were centrifuged and supernatants analyzed for TXB₂.

15

Example 451- Human whole blood Cox-1 IC₅₀ = 29.12 micromolar

20

Example 451-Human whole blood Cox-2 IC₅₀ = 0.47 micromolar

Example 471- Human whole blood Cox-1 = 55.5% at 30 micromolar

Example 471- Human whole blood Cox-2 = 85% at 0.03 micromolar

The 4-hydroxyalkoxy-3(2H)-pyridazinone Cox-2 inhibition and in vivo activity has been found to be surprisingly good. In addition, when compared to the 4-alkoxy-3(2H)-pyridazinones, the hydroxyalkoxy compounds typically possess a superior oral pharmacokinetic profile, such as better plasma half-life, plasma concentration maxima, and area under the curve. For example, Example 375 shows a 14 day plasma micromolar concentration (based on 10mg/kg dosage) of 0.0 while Example 451 shows a 3.43 micromolar level. In addition, the half life of Rat IV (3mg/kg) for Example 375 was 2.9 while Example 451 showed 5.2. The AUC value (micromolar/hour) for Example 375 was 1.8 while Example 451 was 69.

It is anticipated that the 4-hydroxyalkoxy compounds are preferred to parent alkoxy compounds with regard to once-a-day dosing to achieve predictable exposure levels across a wide range of doses while producing an antiinflammatory effect.

Pharmaceutical Compositions

The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's

5 solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the procedures and judgements well known to one skilled in the art. The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, or as an oral or nasal spray.

10 The compounds of the present invention may be potentially useful in the treatment of several illness or disease states such as inflammatory diseases, dysmenorrhea, asthma, premature labor, adhesions and in particular pelvic adhesions, osteoporosis, and ankylosing spondylitis. Current Drugs Ltd, ID Patent Fast Alert, AG16, May 9, 1997.

15 The compounds of the present invention may also be potentially useful in the treatment of cancers, and in particular, colon cancer. Proc. Natl. Acad. Sci., 94, pp. 3336-3340, 1997.

The compounds of the present invention may be useful by providing a pharmaceutical composition for inhibiting prostaglandin biosynthesis comprising a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, ester, or prodrug thereof, and a pharmaceutically acceptable carrier.

20 In addition, the compounds of the present invention may be useful by providing a method for inhibiting prostaglandin biosynthesis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, ester, or prodrug thereof.

25 In addition, the compounds of the present invention may be useful by providing a method for treating pain, fever, inflammation, rheumatoid arthritis, osteoarthritis, adhesions, and cancer comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the

active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (such as, for example, cottonseed, groundnut, corn, germ, olive, castor, sesame oils, and the like), glycerol, tetrahydrofurfuryl alcohol, poly-ethyl-ene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Injectable preparations, such as, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, such as, for example, a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, isotonic sodium chloride solution, and the like. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectable preparations.

The injectable formulations can be sterilized by any method known in the art, such as, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or

suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and thus melt in the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is usually mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as, for example, sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as, for example, glycerol, d) disintegrating agents such as, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as, for example, paraffin, f) absorption accelerators such as, for example, quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as, for example, kaolin and bentonite clay, and i) lubricants such as, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients such as, for example, lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

5 Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using excipients such as, for example, lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release
10 controlling coatings and other coatings well known in the pharmaceutical formulation art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as, for example, sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g.,
15 tableting lubricants and other tableting aids such as, for example, magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

20 Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are
25 also contemplated as being within the scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as, for example, animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of this invention, excipients such as, for example, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

5 Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

10 According to the methods of treatment of the present invention, a patient, such as a human or mammal, is treated by administering to the patient a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to achieve the desired result. By a "therapeutically effective amount" of a compound of the invention is meant a sufficient amount of the compound to provide the relief desired, at
15 a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of
20 the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

25 The total daily dose of the compounds of this invention administered to a human or other mammal in single or in divided doses can be in amounts, for example, from 0.001 to about 1000 mg/kg body weight daily or more preferably from about 0.1 to about 100 mg/kg body weight for oral administration or 0.01 to about 10 mg/kg for parenteral


administration daily. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

The reagents required for the synthesis of the compounds of the invention are readily available from a number of commercial sources such as Aldrich Chemical Co. (Milwaukee, WI, USA); Sigma Chemical Co. (St. Louis, MO, USA); and Fluka Chemical Corp. (Ronkonkoma, NY, USA); Alfa Aesar (Ward Hill, MA 01835-9953); Eastman Chemical Company (Rochester, New York 14652-3512); Lancaster Synthesis Inc. (Windham, NH 03087-9977); Spectrum Chemical Manufacturing Corp. (Janssen Chemical) (New Brunswick, NJ 08901); Pfaltz and Bauer (Waterbury, CT. 06708). Compounds which are not commercially available can be prepared by employing known methods from the chemical literature.

WE CLAIM:

1. A compound of formula I:



5 or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

X is selected from the group consisting of O, S, -NR^d, -NOR^a, and -NNR^bR^c;

R^d is selected from the group consisting of alkenyl, alkyl, aryl, arylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclic, and
 10 heterocyclic alkyl;

R^a, R^b, and R^c are independently selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, and cycloalkylalkyl;

R is selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxyiminoalkoxy, alkyl, alkylcarbonylalkyl, alkylsulfonylalkyl, alkynyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, arylalkynyl, arylhaloalkyl, arylhydroxyalkyl, aryloxy, aryloxyhaloalkyl, aryloxyhydroxyalkyl, arylcarbonylalkyl, carboxyalkyl, cyanoalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylidenealkyl, haloalkenyl, haloalkoxyhydroxyalkyl, haloalkyl, haloalkynyl, heterocyclic, heterocyclic
 15 alkoxy, heterocyclic alkyl, heterocyclic oxy, hydroxyalkyl, hydroxyiminoalkoxy, -
 (CH₂)_nC(O)R⁵, -(CH₂)_nCH(OH)R⁵, -(CH₂)_nC(NOR^d)R⁵, -(CH₂)_nCH(NOR^d)R⁵, -
 (CH₂)_nCH(NR^dR^e)R⁵, -R⁶R⁷, -(CH₂)_nC≡CR⁷,
 20 -(CH₂)_n[CH(CX')]_m(CH₂)_pR⁷, -(CH₂)_n(CX')_m(CH₂)_pR⁷, and -(CH₂)_n(CHX')_m(CH₂)_pR⁷;

R⁵ is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkenyl, haloalkyl, haloalkynyl, heterocyclic, and
 25 heterocyclic alkyl;

R^6 is selected from the group consisting of alkenylene, alkylene, halo-substituted alkenylene, and halo-substituted alkylene;

R^7 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

5 R^d and R^e are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

X' is halogen;


m is an integer from 0-5;

10 n is an integer from 0-10; and

p is an integer from 0-10; and

R^1 , R^2 , and R^3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyiminoalkoxy, alkoxyiminoalkyl, alkyl, alkylcarbonylalkoxy, 15 alkylcarbonylamino, alkylcarbonylaminoalkyl, alkynyl, aminoalkoxy, aminoalkylcarbonyloxyalkoxy aminocarbonylalkyl, aryl, arylalkenyl, arylalkyl, arylalkynyl, carboxyalkylcarbonyloxyalkoxy, cyano, cycloalkenyl, cycloalkyl, cycloalkylidenealkyl, haloalkenyloxy, haloalkoxy, haloalkyl, halogen, heterocyclic, hydroxyalkoxy, hydroxyiminoalkoxy, hydroxyiminoalkyl, mercaptoalkoxy, nitro, 20 phosphonatoalkoxy, Y, and W; provided that one of R^1 , R^2 , or R^3 must be W, and further provided that only one of R^1 , R^2 , or R^3 is W;

W is selected from the group consisting of



25 X^1 is selected from the group consisting of $S(O)_2$, $S(O)(NR^{10})$, $S(O)$, $Se(O)_2$, $P(O)(OR^{11})$, and $P(O)(NR^{12}R^{13})$;

X^2 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl and

halogen;

R⁹ is selected from the group consisting of alkenyl, alkoxy, alkyl, alkylamino, alkylcarbonylamino, alkynyl, amino, cycloalkenyl, cycloalkyl, dialkylamino, -NHNH₂, and -NCHN(R¹⁰)R¹¹;

5 R¹⁰, R¹¹, R¹², and R¹³ are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl, or R¹² and R¹³ can be taken together, with the nitrogen to which they are attached, to form a 3-6 membered ring containing 1 or 2 heteroatoms selected from the group consisting of O, S, and NR⁷;

Y is selected from the group consisting of -OR¹⁴, -SR¹⁴, -C(R¹⁶)(R¹⁷)R¹⁴, -C(O)R¹⁴,
10 -C(O)OR¹⁴, -N(R¹⁶)C(O)R¹⁴, -NC(R¹⁶)R¹⁴, and -N(R¹⁶)R¹⁴;

R¹⁴ is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylthioalkyl, alkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, heterocyclic alkyl, hydroxyalkyl, and NR¹⁸R¹⁹; and

15 R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, cycloalkenyl, cycloalkyl, aryl, arylalkyl, heterocyclic, and heterocyclic alkyl.

2. A compound according to claim 1 wherein

R² is W;


20 X¹ is selected from the group consisting of S(O)₂, S(O), Se(O)₂, and S(O)(NR¹⁰);
and

R⁹ is selected from the group consisting of alkenyl, alkoxy, alkyl, alkylamino, alkylcarbonylamino, alkynyl, amino, cycloalkenyl, cycloalkyl, and dialkylamino.

25 3. A compound according to claim 1 wherein,

R² is W;

W is



X^1 is selected from the group consisting of $S(O)_2$, $S(O)$, $Se(O)_2$, and $S(O)(NR^{10})$;

and

R^9 is selected from the group consisting of alkenyl, alkoxy, alkyl, alkylamino, alkylcarbonylamino, alkynyl, amino, cycloalkenyl, cycloalkyl, and dialkylamino.

4. A compound according to claim 3 wherein

X^2 is selected from the group consisting of hydrogen and halogen;

R is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, alkylcarbonylalkyl, alkylsulfonylalkyl, carboxyalkyl, cyanoalkyl, haloalkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkenyl, arylalkynyl, heterocyclic, heterocyclic alkyl, arylalkyl, $-(CH_2)_n C(O)R^5$, $-(CH_2)_n C \equiv CR^7$, and $-(CH_2)_n [CH(CX^3)]_m (CH_2)_p R^7$; and

R^1 and R^3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminocarbonylalkyl, aryl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, halogen, nitro, and Y.

5. A compound according to claim 3 wherein

X^2 is selected from the group consisting of hydrogen and halogen;

R is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, alkylcarbonylalkyl, alkylsulfonylalkyl, carboxyalkyl, cyanoalkyl, haloalkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkenyl, arylalkynyl, heterocyclic, heterocyclic alkyl, arylalkyl, and $-(CH_2)_n C(O)R^5$; and

R^1 and R^3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylamino, alkylcarbonylaminoalkyl,

aminocarbonylalkyl, aryl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, halogen, heterocyclic, heterocyclic alkyl, nitro, and Y.

6. A compound according to claim 3 wherein

5 X² is selected from the group consisting of hydrogen and halogen;

R is selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, heterocyclic, heterocyclic alkyl, and -(CH₂)_nC(O)R⁵; and

R¹ and R³ are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminocarbonylalkyl, aryl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, halogen, heterocyclic, heterocyclic alkyl, nitro, and Y.

7. A compound according to claim 3 wherein

X² is selected from the group consisting of hydrogen and halogen;

15 R is selected from the group consisting of alkyl, aryl, haloalkyl, heterocyclic, heterocyclic alkyl, and arylalkyl wherein the aryl portion is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halogen; and

R¹ is selected from the group consisting of aryl, arylalkyl, heterocyclic, heterocyclic alkyl, hydroxyalkoxy, and Y.

20

8. A compound according to claim 3 wherein

X² is selected from the group consisting of hydrogen and halogen;

R is selected from the group consisting of alkyl, aryl, haloalkyl, heterocyclic, heterocyclic alkyl and arylalkyl wherein the aryl portion is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from halogen;

25

R¹ is selected from the group consisting of aryl, arylalkyl, heterocyclic, heterocyclic alkyl, hydroxyalkoxy, and Y;

Y is -OR¹⁴;

R¹⁴ is selected from the group consisting of alkenyl, alkyl, and aryl; and

R³ is hydrogen.

9. A compound according to claim 3 wherein
X¹ is S(O)₂;
5 X² is selected from the group consisting of hydrogen and halogen;
R is selected from the group consisting of aryl, haloalkyl, heterocyclic,
heterocyclic alkyl and arylalkyl wherein the aryl portion is optionally substituted with 1, 2,
3, 4, or 5 substituents selected from halogen;
R¹ is aryl optionally substituted with 1, 2, or 3 substituents independently selected
10 from the group consisting of chlorine and fluorine; and
R³ is hydrogen.

10. A compound according to claim 3 wherein
X is O;
15 X¹ is S(O)₂;
R⁹ is selected from the group consisting of alkyl and amino;
X² is selected from the group consisting of hydrogen and halogen;
R is selected from the group consisting of alkenyl, alkyl, alkynyl, aryl, arylalkyl,
and haloalkyl;
20 R¹ is selected from the group consisting of alkyl, aryl, arylalkyl, haloalkoxy,
hydroxyalkoxy, and Y;
Y is -OR¹⁴;
R¹⁴ is selected from the group consisting of alkenyl, alkyl, and aryl; and
R³ is hydrogen.

- 25
11. A compound according to claim 3 wherein
X¹ is S(O)₂;
R⁹ is selected from the group consisting of alkyl and amino;
X² is selected from the group consisting of hydrogen and fluorine;

R is selected from the group consisting of haloalkyl, aryl, and alkyl;

R¹ is selected from the group consisting of isobutyloxy, isopentyloxy, 1-(3-methyl-3-butenyl)oxy, 2-hydroxy-2-methyl-propyloxy, 3-hydroxy-3-methylbutoxy, neopentyloxy, isopentyl, aryloxy, 4-fluorophenoxy, and aryl optionally substituted with 1, 2, or 3

5 substituents independently selected from the group consisting of chlorine and fluorine; and

R³ is hydrogen.

12. A compound according to claim 3 wherein

X is O;

10 X¹ is selected from the group consisting of S(O)₂ and S(O)(NR¹⁰);

R⁹ is alkyl;

X² is selected from the group consisting of hydrogen and fluorine;

R is selected from the group consisting of alkenyl, alkyl, alkynyl, aryl, arylalkyl and haloalkyl;

15 R¹ is selected from the group consisting of alkyl, aryl, hydroxyalkoxy and Y;

Y is -OR¹⁴;

R¹⁴ is selected from the group consisting of alkenyl, alkyl, and aryl; and

R³ is hydrogen.

20 13. A compound according to claim 3 wherein

X is O;

X¹ is S(O)₂;

R⁹ is amino;

X² is selected from the group consisting of hydrogen and fluorine;

25 R is selected from the group consisting of alkenyl, alkyl, alkynyl, aryl, arylalkyl, and haloalkyl;

R¹ is selected from the group consisting of alkyl, aryl, hydroxyalkoxy and Y;

Y is -OR¹⁴;

R¹⁴ is selected from the group consisting of alkenyl, alkyl, and aryl; and

R³ is hydrogen.

14. A compound according to claim 3 wherein

X is O;

5 X¹ is SO₂;

R⁹ is methyl;

X² is hydrogen;

R is selected from the group consisting of t-butyl, 3-chlorophenyl, 3,4-difluorophenyl, 4-fluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, and
10 2,2,2-trifluoroethyl;

R¹ is selected from the group of consisting of isobutoxy, isopentyloxy, (3-methyl-3-butenyl)oxy, 2-hydroxy-2-methyl-propoxy, 3-hydroxy-3-methylbutoxy, neopentyloxy, isopentyl, 4-fluorophenyl, 4-chlorophenyl, 4-chloro-3-fluoro-phenyl, 4-fluorophenoxy and
Y;

15 Y is -OR¹⁴;

R¹⁴ is aryl; and

R³ is hydrogen.

15. A compound according to claim 3 wherein

20 X is O;

X¹ is S(O)₂;

R⁹ is amino;

X² is hydrogen;

R is selected from the group of consisting t-butyl, 3-chlorophenyl, 3,4-difluorophenyl, 4-fluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, and
25 2,2,2-trifluoroethyl;

R¹ is selected from the group consisting of isobutoxy, isopentyloxy, (3-methyl-3-butenyl)oxy, 2-hydroxy-2-methyl-propoxy, 3-hydroxy-3-methylbutoxy, neopentyloxy,

isopentyl, 4-fluorophenyl, 4-chlorophenyl, 4-chloro-3-fluoro-phenyl, 4-fluorophenoxy and Y;

Y is -OR¹⁴;

R¹⁴ is aryl; and

5 R³ is hydrogen.

16. A compound according to claim 3 selected from the group consisting of
- 2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone;
 - 2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 10 2-Benzyl-4-(4-fluorophenyl)-5-methoxy-3(2H)-pyridazinone;
 - 2-Benzyl-4-(4-fluorophenyl)-5-hydroxy-3(2H)-pyridazinone;
 - 2-Benzyl-4-(4-fluorophenyl)-5-(trifluoromethylsulfonyloxy)-3(2H)-pyridazinone;
 - 2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone;
 - 2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 15 2-Phenyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 2-(4-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 2-(Phenylpropargyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 20 2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 2-(Methyl-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 2-(3-Methyl-2-butenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 25 2-(2-Trifluoromethylbenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
 - 2-(Cyclopropylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-Pyridylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(6-Fluoroquinolin-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(Quinolin-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinethione

2-Benzyl-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3,3-Dichloro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Phenyl-2-propenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(4-Carboxyphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(5-Methylthiazol-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(5-Chlorothiazol-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2,3,3,4,4,4-Hexafluorobuten-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,4-Difluorophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(5-Chlorothien-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(5-Methylthien-2-ylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(4-Diethylaminophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

5 3(2H)-pyridazinone;

2-(2,3,4,5,6-Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(Phenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

10 2-(4-Chlorophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(Propargyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Cyanophenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

15 pyridazinone;

2-(α -Methyl-4-fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-Phenethyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(3-chloro-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

20 pyridazinone;

2-Benzyl-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-chloro-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(4-Trifluoromethoxyphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

25 3(2H)-pyridazinone;

2-(4-Trifluoromethylphenacyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-[2-(Benzo[b]thien-3-yl)-2-oxoethyl]-4-(4-fluorophenyl)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,3-Dimethyl-2-oxobutyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-Thienylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2-Benzo[b]thienylmethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2,4-Bis(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-6-methyl-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-6-methyl-3(2H)-pyridazinone;

2-Benzyl-4-(3,4-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(2,2,2-Trifluoroethyl)-4-(4-n-propylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2,4-Bis(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-

- 3(2H)-pyridazinone;
2-Benzyl-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-Benzyl-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
5 pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-Benzyl-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
10 pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(4-chloro-3-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(3,4-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
15 2-Benzyl-4-(2-propylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-cyclohexyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
20 2-(2,2,2-Trifluoroethyl)-4-cyclopentyloxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2-propylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-Benzyl-4-(4-morpholino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
25 2-(2,3,3-Trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2,4-Bis(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-cyclopropylmethoxy-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-propen-1-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluoro- α -methylbenzyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-[4-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2,5-Bis[4-(methylsulfonyl)phenyl]-4-(4-fluorophenyl)-3(2H)-pyridazinone;

2-(3-Methyl-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(2-Trifluoromethyl-4-nitrophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[3-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-[3-(Methylsulfonyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(5-Chloro-2-thienyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3-Trifluoromethylphenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3-Fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[2-(Methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(5-Nitro-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Benzothienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(4-Fluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-Bromophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,5-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(4-Nitrobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Acetoxybenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(4-Hydroxybenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Nitrobenzyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4,4-Trifluoro-3-butenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2-Hexynyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,3-Dichloro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-Cyclohexyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-Cyclopentyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-Cyclobutyl-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

5 pyridazinone;

2-(3-Methyl-2-butenyl)-4-(4-fluorophenyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

10 2-(Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Cyclohexenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(3,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,3-Dihydro-1H-inden-2-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,3-Dihydro-1H-inden-1-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

20 2-(4-Tetrahydro-2H-pyran-4-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

25 2-(2-Adamantyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(1-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluoro-3-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(6-methyl-3-heptenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

5 2-(3,4-Difluorophenyl)-4-(3-cyclopropylidenepropyl)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(5-methyl-3-hexenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

10 2-(3,4-Difluorophenyl)-4-(5-methylhexyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chloro-1-methyl-2E-propenyl)-4-(4-fluorophenyl)-5-[4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,3,3-Trifluoro-2-propen-1-yl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

15 2-(1,1,2-Trifluoro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,3-Difluoro-2-propenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

20 2-(α -Methyl-3-fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(1-Cyclohexenylmethyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(α -Methyl-2,3,4-trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(α -Methyl-3,5-difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(α -Methyl-3,4-difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Fluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,4,6-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

5 pyridazinone;

2-(2,4,5-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,3,4-Trifluorobenzyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-

pyridazinone;

10 2-(4,4,4-Trifluoro-3-methyl-2E-butenyl)-4-(4-fluorophenyl)-5-[4-

(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Biphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Bromophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

15 pyridazinone;

2-(4-Nitrophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Phenoxyphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

20 2-(4-t-Butylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

25 pyridazinone;

2-(3-Vinylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2-Formylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2-Nitrophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

5 2-(3-Bromophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Cyanophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

10 2-(5-Methyl-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Biphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,5-Dimethylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(3,4-Difluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

20 2-(2-Thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Trifluoromethylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-[4-(1-Pyrrolyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

25 2-(5-Chloro-2-thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(2-ethyl-1-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Thienyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,5-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

5 pyridazinone;

2-(2,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

10 2-(3-Furyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Fluoro-4-methoxyphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(2-Fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

15 2-[4-(Aminosulfonyl)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(3,5-Dichlorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

20 pyridazinone;

2-(4-Fluoro-3-methylphenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(4-Chloro-3-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone; :

25 2-(4-Chloro-2-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone; :

2-(1-Adamantylloxycarbonyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Fluorophenyl)-4-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-
5 3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-phenoxymethyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(t-butylthiomethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

10 2-(4-Fluorophenyl)-4-(2-methylpropylthiomethyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylthio)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(3-Chlorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Fluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Bromophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
20 pyridazinone;

2-(2,5-Difluorophenyl)-4-(2-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[3-methyl-4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluorophenoxymethyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(benzoyloxymethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluoro-3-methylphenyl)-5-[4-

5 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3,5-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

10 2-(2,2,2-Trifluoroethyl)-4-(4-trifluoromethylphenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

15 pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[3-(trifluoromethyl)phenyl]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(3-fluoro-4-methoxyphenyl)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-fluoro-4-methylphenyl)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3,5-difluoro-4-methoxyphenyl)-5-[4-

25 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-propenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-buten-2-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(2,2,2-Trifluoroethyl)-4-(1-cyclohexenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(2,2,2-Trifluoroethyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(4-Fluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(phenylethynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3,4-Difluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3,4-Difluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-vinyl-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(1-propynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,4-Difluorophenyl)-4-t-butyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-

5 pyridazinone;

2-(3-Chlorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(4-Fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

10 2-(3,4-Difluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-

15 3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3-Chloro-4-fluorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-

3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-

25 3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3,5-difluoro-4-methoxyphenyl)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[3-fluoro-4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-fluorobenzyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(phenylethynyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3,4-Difluorophenyl)-4-(3,4-difluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[4-Fluoro-3-(methylthio)phenyl]-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-Benzyl-4-(4-fluorophenyl)-5-[4-(trifluoromethylsulfonyl)phenyl]-3(2H)-pyridazinone ;

2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-fluoro-5-trifluoromethylphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-cyanophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2,2,2-Trifluoroethyl)-4-(3-pyridyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-n-propylphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[4-(methylsulfonyl)phenoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-phenylphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[2-(methylthio)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(phenylmethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-furylmethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[2-(3,4-dimethoxyphenyl)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[2-(4-morpholino)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[2-(1-piperidinyloxy)ethoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[4-(carboxamido)phenoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(1-indanyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-[4-(acetamido)phenoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(1-methylcyclopropylmethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3,3-dimethylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-chlorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-bromophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(cyclopentylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(2,2,2-Trifluoroethyl)-4-(1H-1,2,4-triazole-3-ylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-phenylmethylthio-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(2,2,2-Trifluoroethyl)-4-(4-fluorophenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(cyclohexylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-chloro-4-fluorophenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(2,2,2-Trifluoroethyl)-4-(2,2,2-trifluoroethylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(tert-butylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(4-acetamidophenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-propylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-methylprop-1-ylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(2,2,2-Trifluoroethyl)-4-amino-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-methoxypropylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(cyclopentylamino)-5-[4-(methylsulfonyl)phenyl]-

- 3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(cyclobutylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(3,4-dimethoxyphenethylamino)-5-[4-
5 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(cyclohexylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-[2-(1-piperidinyl)ethylamino]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
10 2-(2,2,2-Trifluoroethyl)-4-(2-tetrahydrofurfurylamino)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(cyclopropylmethylamino)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2,3-dihydro-1H-inden-1-ylamino)-5-[4-
15 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(1-piperidinyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(3-hydroxypropylamino)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
20 2-(2,2,2-Trifluoroethyl)-4-[3-(1H-imidazol-1-yl)propylamino]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2R-hydroxylpropylamino)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(2-cyanoethylamino)-5-[4-(methylsulfonyl)phenyl]-
25 3(2H)-pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-(4-cyanoanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(2,2,2-Trifluoroethyl)-4-[3-methoxy-5-(trifluoromethyl)anilino]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-anilino-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2,5-dimethoxyphenylamino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(2,2,2-Trifluoroethyl)-4-(3-fluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2,4-difluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(2,2,2-Trifluoroethyl)-4-(2,3,5-trifluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(4-fluoroanilino)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(3-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(2-benzofuranyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-Benzyl-4-(1-oxo-1,3-dihydro-2-benzofuran-5-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(5-chloro-2-thienyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(4-vinylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-Benzyl-4-(4-trifluormethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(2-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(3,4-dimethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-Benzyl-4-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(2-methoxypyrid-3-yl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(3-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

- 2-Benzyl-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-(2H)-pyridazinone;
2-(tert-Butyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chlorophenyl)-4-methoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
5 2-(3-Chlorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-Chlorophenyl)-4-chloro-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chlorophenyl)-4-(t-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
10 pyridazinone;
2-(3-Chlorophenyl)-4-(cyclohexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chlorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
15 2-(3-Chlorophenyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chlorophenyl)-4-(3-octyn-1-yloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3-Chlorophenyl)-4-[2-(dimethylamino)ethoxy]-5-[4-(methylsulfonyl)phenyl]-
20 3(2H)-pyridazinone;
2-(3-Chlorophenyl)-4-[2-methyl-1-(1-methylethyl)propoxy]-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3-Chlorophenyl)-4-(phenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
25 2-(3-Chlorophenyl)-4-[3-(dimethylamino)phenoxy]-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;
2-(3-Chlorophenyl)-4-(4-methoxyphenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;
2-(3,4-Difluorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[3-fluoro-4-
5 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-[2-(isopropoxy)ethoxy]-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

10 2-(3,4-Difluorophenyl)-4-(3-methylpentylloxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-methyl-3-penten-1-yloxy)-5-[4-
(methylsulfonyl)phenyl]-5-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-[3-(methoxy)butoxy]-5-[4-(methylsulfonyl)phenyl]-
15 3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(N-methylbenzylamino)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone; :

2-(4-Fluorophenyl)-4-(1-piperidinyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

20 2-(4-Fluorophenyl)-4-(1-pyrrolidinyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(4-methylphenylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(2-pyridylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
25 pyridazinone;

2-(3-Chlorophenyl)-4-(phenylmethylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(2-furylmethylthio)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-[2-(methylpropyl)thio]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(cyclopentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-Chlorophenyl)-4-(2-methylpropyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(cyclopentylmethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-Chlorophenyl)-4-(2-cyclopentylethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-benzyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3-Chlorophenyl)-4-cyclohexyl-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(phenethyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(benzyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-methylpropoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-fluorobenzyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(4-Fluorophenyl)-4-(3-methylbutyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(Tetrahydro-2H-pyrano-2-yl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-(4-Fluorophenyl)phenyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-Benzyl-4-(4-fluorobenzyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-Benzyl-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-fluoro-4-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3-Chloro-4-fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-

3(2h)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

5 2-(3-Chlorophenyl)-4-(phenethyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

10 2-(4-Fluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

15 2-(4-Fluorophenyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(t-Butyl)-4-(3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

20 2-(3-Chloro-4-fluorophenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluoro-3-methylphenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

25 2-(3,4-Difluorophenyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-methylbutyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2,2-dimethylpropoxy)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-fluorophenoxy)-5-[3-fluoro-4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3,3-Difluoro-2-propenyl)-4-(4-fluorophenyl)-5-[3-fluoro-4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-[2-(2-propoxy)ethoxy]-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

10 2-(3,4-Difluorophenyl)-4-(4-methyl-3-pentenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-fluorophenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(2-methylpropoxy)-5-[3-fluoro-4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

15 2-(3-Chlorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-hydroxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(4-Fluorophenyl)-4-cyclopropylmethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(4-Fluorophenyl)-4-(2-cyclopropyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

25 2-(3-Chlorophenyl)-4-cyclopropanemethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(2-cyclopropane-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3-Chlorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-methyl-2-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-Chlorophenyl)-4-(3-methyl-2-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-methyl-3-pentenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(4-Fluorophenyl)-4-(3-methyl-3-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-methyl-3-pentenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-methyl-3-butenoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(4-Fluorophenyl)-4-(1,5-hexadienyl-3-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(5-methyl-2-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(4-Fluorophenyl)-4-(2-ethyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(2-thioisopropyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-methylthio-1-hexyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(4-Fluorophenyl)-4-(2-methyl-4-pentenyl-1-oxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-trifluoromethyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-ethoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-

pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-methyl-2-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-
5 3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2-cyclopentyl-1-ethoxy)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(2-cyclopent-2-enyl-1-ethoxy)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(2-Hydroxy-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2-Methoxy-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2-Methoxyimino-2-phenylethyl)-4-(4-fluorophenyl)-5-[4-
15 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-methylpentyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

20 2-(2,2,2-Trifluoroethyl)-4-(2,2-dimethylpropoxy)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-methylbutoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
25 pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-methylpropoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-
pyridazinone;

2-(2,3,3-Trifluoropropenyl)-4-(4-fluorophenyl)-5-[4-(aminosulfonyl)phenyl]-
3(2H)-pyridazinone;


- 2-(2,3,4,5,6-Pentafluorobenzyl)-4-(4-fluorophenyl)-5-[4-(dimethylamino)methylaminosulfonylphenyl]-3(2H)-pyridazinone;
2-(2,4-Difluorobenzyl)-4-(4-fluorophenyl)-5-[4-(dimethylamino)methylaminosulfonylphenyl]-3(2H)-pyridazinone;
5 (4-Fluorophenyl)-5-[4-(methylselenonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-Fluorophenyl)-4-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
10 2-(3,4-Difluorophenyl)-4-(2-oxo-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-[2-(methoxyimino)-1-propoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(3-oxo-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; and
15 2-(4-Fluorophenyl)-4-(3-oxo-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

17. A pharmaceutical composition for inhibiting prostaglandin biosynthesis
20 comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition for inhibiting prostaglandin biosynthesis
comprising a therapeutically effective amount of the compound of claim 2 and a
25 pharmaceutically acceptable carrier.

19. A pharmaceutical composition for inhibiting prostaglandin biosynthesis
comprising a therapeutically effective amount of the compound of claim 3 and a
pharmaceutically acceptable carrier.

20. A method for inhibiting prostaglandin biosynthesis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 5 21. A method for inhibiting prostaglandin biosynthesis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.
- 10 22. A method for inhibiting prostaglandin biosynthesis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 3.
- 15 23. A method for treating pain, fever, inflammation, rheumatoid arthritis, osteoarthritis, adhesions, and cancer comprising administering to a therapeutically effective amount of a compound of claim 1.
- 20 24. A method for treating pain, fever, inflammation, rheumatoid arthritis, osteoarthritis, adhesions, and cancer comprising administering to a therapeutically effective amount of a compound of claim 2.
- 25 25. A method for treating pain, fever, inflammation, rheumatoid arthritis, osteoarthritis, adhesions, and cancer comprising administering to a therapeutically effective amount of a compound of claim 3.
26. A method of preparing a compound of formula III



wherein

5 X is selected from the group consisting of O, S, -NR⁴, -NOR^a, and -NNR^bR^c;

R⁴ is selected from the group consisting of alkenyl, alkyl, aryl, arylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclic, and heterocyclic alkyl;

R^a, R^b, and R^c are independently selected from the group consisting of alkyl, aryl, 10 arylalkyl, cycloalkyl, and cycloalkylalkyl;

X¹ is selected from the group consisting of S(O)₂, S(O)(NR¹⁰), S(O), Se(O)₂, P(O)(OR¹¹), and P(O)(NR¹²R¹³);

R⁹ is selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, amino, 15 cycloalkenyl, cycloalkyl, dialkylamino, -NHNH₂, and -NCHN(R¹⁰)R¹¹;

R¹⁰, R¹¹, R¹², and R¹³ are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl, or R¹² and R¹³ can be taken together, with the nitrogen to which they are attached, to form a 3-6 membered ring containing 1 or 2 heteroatoms selected from the group consisting of O, S, and NR⁷;

20

X² is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl and halogen;

R is selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, 25 alkylcarbonylalkyl, alkylsulfonylalkyl, alkynyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, arylalkynyl, arylhaloalkyl, arylhydroxyalkyl, aryloxy, aryloxyhaloalkyl,

aryloxyhydroxyalkyl, arylcarbonylalkyl, carboxyalkyl, cyanoalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkenyl, haloalkoxyhydroxyalkyl, haloalkyl, haloalkynyl, heterocyclic, heterocyclic alkoxy, heterocyclic alkyl, heterocyclic oxy, hydroxyalkyl, $-(CH_2)_n C(O)R^5$, $-(CH_2)_n CH(OH)R^5$, $-(CH_2)_n C(NOR^d)R^5$, -
 5 $(CH_2)_n CH(NOR^d)R^5$, $-(CH_2)_n CH(NR^d R^e)R^5$, $-R^6 R^7$, $-(CH_2)_n C \equiv CR^7$, -
 $(CH_2)_n [CH(CX'_1)]_m (CH_2)_n R^7$, $-(CH_2)_n (CX'_2)_m (CH_2)_n R^7$, and $-(CH_2)_n (CHX')_m (CH_2)_n R^7$;

R^5 is selected from the group consisting of alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkenyl, haloalkyl, haloalkynyl, heterocyclic, and heterocyclic alkyl;

10 R^6 is selected from the group consisting of alkenylene, alkylene, halo-substituted alkenylene, and halo-substituted alkylene;

R^7 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

R^d and R^e are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

X' is halogen;

n is an integer from 0-10;

m is an integer from 0-5;

20

R^1 and R^3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylalkoxy, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminoalkoxy, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyl, arylalkynyl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylidenealkyl, haloalkenyloxy, haloalkoxy, haloalkyl, halogen, heterocyclic, heterocyclic alkyl, hydroxyalkoxy, hydroxyalkylamino, hydroxyalkylthio, mercaptoalkoxy, nitro, and Y;

25

Y is selected from the group consisting of $-OR^{14}$, $-SR^{14}$, $-C(R^{16})(R^{17})R^{14}$, $-C(O)R^{14}$, $-C(O)OR^{14}$, $-N(R^{16})C(O)R^{14}$, $-NC(R^{16})R^{14}$, and $-N(R^{16})R^{14}$;

R¹⁴ is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylthioalkyl, alkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, heterocyclic alkyl and NR¹⁸R¹⁹; and

5 R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, cycloalkenyl, cycloalkyl, aryl, arylalkyl, heterocyclic, and heterocyclic alkyl;

comprising the step of treating a compound of formula III wherein R is hydrogen with an alkylating agent.

10 27. The method according to claim 26 wherein the alkylating agent has the formula R⁹⁹-Q wherein Q is a leaving group and R⁹⁹ is selected from the group consisting of methyl, ethyl, 1,1,1-trifluoroethyl, cyclopropylmethyl, 3-(2-methyl)propenyl, 4-(2-methyl)but-2-enyl, 1,1-dichloropropen-3-yl, 2,2-dimethyl-3-oxo-4-butyl, 2,3,3,4,4,4-hexafluorobuten-1-yl, propargyl, phenylpropargyl, phenyl, phenethyl, 1-phenylpropen-3-yl, benzyl, α -methyl-4-fluorobenzyl, 2,3,4,5,6-pentafluorobenzyl, 4-trifluomethoxyphenacyl, 4-fluorobenzyl, 4-fluorophenyl, 2-trifluoromethylbenzyl, 2,4-difluorobenzyl, 2,4-difluorophenacyl, 4-trifluomethylphenacyl, phenacyl, 4-carboxyphenacyl, 4-chlorophenacyl, 4-cyanophenacyl, 4-diethylaminophenacyl, 3-thienylmethyl, 5-methylthien-2-ylmethyl, 5-chlorothien-2-ylmethyl, 2-benzo[b]thienylmethyl, 3-benzothienacyl, 5-chlorothiazol-2-ylmethyl, 5-methylthiazol-2-ylmethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, quinolin-2-ylmethyl, and fluoroquinolin-2-ylmethyl.

25 28. The method according to claim 26 wherein the alkylating agent has the formula R⁹⁹-Q wherein Q is a leaving group and R⁹⁹ is selected from the group consisting of methyl, ethyl, 1,1,1-trifluoroethyl, cyclopropylmethyl, 3-(2-methyl)propenyl, 4-(2-methyl)but-2-enyl, 1,1-dichloropropen-3-yl, 2,3,3,4,4,4-hexafluorobuten-1-yl, propargyl, phenylpropargyl, phenyl, phenethyl, 1-phenylpropen-3-yl, benzyl, α -methyl-4-fluorobenzyl, 2,3,4,5,6-pentafluorobenzyl, 4-trifluomethoxyphenacyl, 4-fluorobenzyl, 4-

fluorophenyl, 2,4-difluorobenzyl, 2,4-difluorophenacyl, 4-trifluomethylphenacyl, phenacyl, 4-carboxyphenacyl, 4-chlorophenacyl, 4-cyanophenacyl, 4-diethylaminophenacyl, 3-thienylmethyl, 5-methylthien-2-ylmethyl, 5-chlorothien-2-ylmethyl, 2-benzo[b]thienylmethyl, and 3-benzothienacyl.

5

29. The method according to claim 28 wherein the alkylating agent has the formula R^{99} -Q wherein Q is a leaving group and R^{99} is selected from the group consisting of 1,1,1-trifluoroethyl, 3-(2-methyl)propenyl, 4-(2-methyl)but-2-enyl, 1,1-dichloropropen-3-yl, 2,3,3,4,4,4-hexafluorobuten-1-yl, propargyl, phenylpropargyl, phenyl, benzyl, α -methyl-4-fluorobenzyl, 2,3,4,5,6-pentafluorobenzyl, 4-fluorobenzyl, 4-fluorophenyl, 2,4-difluorobenzyl, 3-thienylmethyl, 5-methylthien-2-ylmethyl, 5-chlorothien-2-ylmethyl, and 2-benzo[b]thienylmethyl.

10

30. The method according to claim 26 wherein the alkylating agent has the formula R^{99} -Q wherein Q is a leaving group and R^{99} is selected from the group consisting of 1,1,1-trifluoroethyl, phenyl, benzyl, α -methyl-4-fluorobenzyl, 4-fluorobenzyl, 4-fluorophenyl, and 2,4-difluorobenzyl.

15


31. The method according to claim 26 wherein the alkylating agent has the formula R^{99} -Q wherein Q is a leaving group and R^{99} is selected from the group consisting of 1,1,1-trifluoroethyl, benzyl, and 4-fluorophenyl.

20

32. A method for regioselectively preparing a 4,5-disubstituted pyridazinone comprising the steps of

25

a) treating a compound of formula IV



IV,

wherein R^{98} is an alkyl or aryl group; and X is a leaving group;
with a nucleophilic agent to displace the X group;


5 b) converting the $-OR^{98}$ to a leaving group; and

c) treating the compound with a second nucleophilic agent to provide the 4,5-disubstituted pyridazinone.

10 33. The method according to claim 32 wherein the benzyl group is removed using a Lewis acid.

34. A method for regioselectively preparing a 4,5-disubstituted pyridazinone comprising the steps of treating a compound of formula V

15



wherein

20 R^1 and R^3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkynyl, alkylcarbonylalkoxy, alkylcarbonylamino, alkylcarbonylaminoalkyl, aminoalkoxy, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyl, arylalkynyl, cyano, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylidenealkyl, haloalkenyloxy, haloalkoxy, haloalkyl, halogen, heterocyclic, heterocyclic alkyl, hydroxyalkoxy, hydroxyalkylamino, hydroxyalkylthio,

25 mercaptoalkoxy, nitro, and Y;

Y is selected from the group consisting of $-OR^{14}$, $-SR^{14}$, $-C(R^{16})(R^{17})R^{14}$, $-C(O)R^{14}$, $-C(O)OR^{14}$, $-N(R^{16})C(O)R^{14}$, $-NC(R^{16})R^{14}$, and $-N(R^{16})R^{14}$;

R^{14} is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkylthioalkyl, alkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, heterocyclic alkyl and $NR^{18}R^{19}$; and

R^{16} , R^{17} , R^{18} , and R^{19} are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkyl, cycloalkenyl, cycloalkyl, aryl, arylalkyl, heterocyclic, and heterocyclic alkyl;

X^1 is selected from the group consisting of $S(O)_2$, $S(O)(NR^{10})$, $S(O)$, $Se(O)_2$, $P(O)(OR^{11})$, and $P(O)(NR^{12}R^{13})$;

R^9 is selected from the group consisting of alkenyl, alkoxy, alkyl, alkynyl, amino, cycloalkenyl, cycloalkyl, dialkylamino, $-NHNH_2$, and $-NCHN(R^{10})R^{11}$; and

R^{10} , R^{11} , R^{12} , and R^{13} are independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl, or R^{12} and R^{13} can be taken together, with the nitrogen to which they are attached, to form a 3-6 membered ring containing 1 or 2 heteroatoms selected from the group consisting of O, S, and NR^7 ;

R^7 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

20

with a hydrazine having the formula $RNHNH_2$ wherein R is selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl, alkylcarbonylalkyl, alkylsulfonylalkyl, alkynyl, aryl, arylalkenyl, arylalkoxy, arylalkyl, arylalkynyl, arylhaloalkyl, arylhydroxyalkyl, aryloxy, aryloxyhaloalkyl, aryloxyhydroxyalkyl, arylcarbonylalkyl, carboxyalkyl, cyanoalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, haloalkenyl, haloalkoxyhydroxyalkyl, haloalkyl, haloalkynyl, heterocyclic, heterocyclic alkoxy, heterocyclic alkyl, heterocyclic oxy, hydroxyalkyl, $-(CH_2)_n C(O)R^5$, $-(CH_2)_n CH(OH)R^5$, $-(CH_2)_n C(NOR^d)R^5$, $-(CH_2)_n CH(NOR^d)R^5$, -

25

$(\text{CH}_2)_n\text{CH}(\text{NR}^d\text{R}^e)\text{R}^5$, $-\text{R}^6\text{R}^7$, $-(\text{CH}_2)_n\text{C}\equiv\text{CR}^7$, $-(\text{CH}_2)_n[\text{CH}(\text{CX}'_3)]_m(\text{CH}_2)_n\text{R}^7$, $-(\text{CH}_2)_n(\text{CX}'_2)_m(\text{CH}_2)_n\text{R}^7$, and $-(\text{CH}_2)_n(\text{CHX}')_m(\text{CH}_2)_n\text{R}^7$;

R^5 is selected from the group consisting of alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkenyl, haloalkyl, haloalkynyl, heterocyclic, and heterocyclic alkyl;

R^6 is selected from the group consisting of alkenylene, alkylene, halo-substituted alkenylene, and halo-substituted alkylene;

R^7 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclic, and heterocyclic alkyl;


R^d and R^e are independently selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, haloalkyl, heterocyclic, and heterocyclic alkyl;

X' is halogen;

n is an integer from 0-10;

m is an integer from 0-5;

to furnish the pyridazinone of formula III



III,

wherein X^1 , R , R^1 , R^3 , and R^9 are as previously defined;

X is selected from the group consisting of O, S, $-\text{NR}^4$, $-\text{NOR}^a$, and $-\text{NNR}^b\text{R}^c$;


R^4 is selected from the group consisting of alkenyl, alkyl, aryl, arylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclic, and heterocyclic alkyl;

R^a , R^b , and R^c are independently selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, and cycloalkylalkyl; and

X^2 is selected from the group consisting of hydrogen, alkenyl, alkyl, alkynyl and halogen.

5

35. A compound of formula VI



VI,

or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

10

R is selected from the group consisting of alkyl, aryl, arylalkyl, haloalkyl, and haloalkenyl;

R^1 is selected from the group consisting of alkoxy, aminoalkylcarbonyloxyalkoxy, carboxyalkylcarbonyloxyalkoxy, hydroxyalkoxy, hydroxyalkyl, and phosphonatoalkoxy,

R^9 is selected from the group consisting of alkyl, alkylcarbonylamino, and amino.

15

36. A compound according to claim 35 wherein

R is aryl;

R^1 is hydroxyalkoxy; and

R^9 is selected from the group of consisting of alkyl and amino.

20

37. A compound according to claim 35 wherein

R is aryl;

R^1 is hydroxyalkoxy; and

R^9 is methyl.

25

38. A compound according to claim 35 wherein
R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently
selected from the group consisting of halogen and haloalkyl;
R¹ is hydroxyalkoxy; and
5 R⁹ is selected from the group consisting of alkyl and amino.
39. A compound according to claim 35 wherein
R is phenyl optionally substituted with 1 or 2 substituents independently selected
from the group of consisting chlorine and fluorine;
10 R¹ is hydroxyalkoxy; and
R⁹ is selected from the group consisting of alkyl and amino.
40. A compound according to claim 38 selected from the group consisting of
2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-
15 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
20 (S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
(S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-
25 (aminosulfonyl)phenyl]-3(2H)-pyridazinone;
(R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-
(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
2-(4-Fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-
(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

- 2-(4-Fluorophenyl)-4-(4-hydroxy-2-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
- 5 2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
- 10 2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 15 2-(3-Chlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(4-Fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(4-Fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
- 20 2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;
- 25 2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-Chloro-4-fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3,4-Difluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(4-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

15 (S)-2-(4-Fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(4-Fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

20 (S)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 (R)-2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 (R)-2-(3-Chlorophenyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-Fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(4-Fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)-phenyl]-3(2H)-pyridazinone;

15 2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3-Chlorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chlorophenyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Dichlorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-[(3-Trifluoromethyl)phenyl]-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Dichlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R,S)-2-(4-Fluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-[3-(Trifluoromethyl)phenyl]-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 (S)-2-(3,4-Difluorophenyl)-4-(3-hydroxy-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3,4-Difluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 (S)-2-(4-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 (S)-2-(3-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3-bromophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3-trifluoromethylphenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 (S)-2-(3-chloro-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(3-fluoro-4-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

- (S)-2-(3,4-dichlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (S)-2-(3-trifluoromethyl-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 5 (S)-2-(3-bromo-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(3,4-Difluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-
- 10 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(4-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(3-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 15 (R)-2-(3-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(3-bromophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(3-trifluoromethylphenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-
- 20 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(3-chloro-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(3-fluoro-4-chlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 25 (R)-2-(3,4-dichlorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(3-trifluoromethyl-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- (R)-2-(3-bromo-4-fluorophenyl)-4-(2-hydroxy-3-methyl-1-butoxy)-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

5 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-chlorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-chlorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-bromophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-trifluoromethylphenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

15 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chloro-4-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluoro-4-chlorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3,4-dichlorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-trifluoromethyl-4-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-

[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-bromo-4-fluorophenyl)-4-[(S)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

25 (methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-

(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-chlorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-chlorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-bromophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-trifluoromethylphenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chloro-4-fluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluoro-4-chlorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3,4-dichlorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluoro-3-trifluoromethylphenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3-bromo-4-fluorophenyl)-4-[(R)-2,3-dihydroxy-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Difluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(4-chlorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chlorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-bromophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-trifluoromethylphenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chloro-4-fluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-fluoro-4-chlorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluoro-3-trifluoromethylphenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; and

15 2-(3-bromo-4-fluorophenyl)-4-(4-hydroxy-4-methyl-1-pentyloxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

41. A compound according to claim 35 wherein

R is haloalkyl; and

20 R¹ is hydroxyalkoxy; and

R⁹ is selected from the group of consisting of alkyl and amino.

42. A compound according to claim 41 selected from the group consisting of

25 2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

(S)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 (S)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

(R)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 (R)-2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2-methyl-1-propoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone;

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; and

2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(aminosulfonyl)phenyl]-3(2H)-pyridazinone.

15

43. A compound according to claim 35 wherein

R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen and haloalkyl;

R¹ is aminoalkylcarbonyloxyalkoxy; and

20 R⁹ is selected from the group of consisting of alkyl and amino.

44. A compound according to claim 43 selected from the group consisting of

2-(3,4-Difluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(4-fluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-chlorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

- 2-(3-fluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-chlorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 5 2-(3-bromophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-trifluoromethylphenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 10 2-(3-chloro-4-fluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3-fluoro-4-chlorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 2-(3,4-dichlorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;
- 15 2-(4-fluoro-3-trifluoromethylphenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; and
- 2-(3-bromo-4-fluorophenyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.
- 20 45. A compound according to claim 35 wherein
- R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group consisting of halogen and haloalkyl;
- R¹ is carboxyalkylcarbonyloxyalkoxy; and
- R⁹ is selected from the group of consisting of alkyl and amino.
- 25 46. A compound according to claim 45 selected from the group consisting of
- 2-(3,4-Difluorophenyl)-4-[3-{{(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl}oxy}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-fluorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(4-chlorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

5 2-(3-fluorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-chlorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

10 2-(3-bromophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-trifluoromethylphenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

15 2-(3-chloro-4-fluorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-fluoro-4-chlorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(3,4-dichlorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-trifluoromethyl-4-fluorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; and

25 2-(3-bromo-4-fluorophenyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

47. A compound according to claim 35 wherein

R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group consisting of halogen and haloalkyl;

R¹ is phosphonatoalkoxy; and

R⁹ is selected from the group consisting of alkyl and amino.

5

48. A compound according to claim 47 selected from the group consisting of
3-({2-(3,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-trifluoromethylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-chloro-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-fluoro-4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3,4-dichlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate;

3-({2-(3-trifluoromethyl-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate; and

3-({2-(3-bromo-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate.

49. A compound according to claim 35 wherein

5 R is phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group consisting of halogen and haloalkyl;

R¹ is hydroxyalkoxy; and

R⁹ is alkylcarbonylamino.

10 50. A compound according to claim 49 selected from the group consisting of

N-[[4-[2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide;

N-[[4-[2-(4-Fluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt;

15 N-[[4-[2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide;

N-[[4-[2-(3,4-Difluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt;

20 N-[[4-[2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide;

N-[[4-[2-(3-Chloro-4-fluorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt;

N-[[4-[2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide;

25 N-[[4-[2-(3-Chlorophenyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt;

N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide;

N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(2-hydroxy-2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt;

N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide; and

5 N-[[4-[2-(2,2,2-Trifluoroethyl)-4-(3-hydroxy-2,2-dimethyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide, sodium salt.

51. A compound according to claim 35 wherein

R is selected from the group consisting of haloalkyl and phenyl optionally
10 substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen and haloalkyl;

R¹ is alkoxy; and

R⁹ is selected from the group consisting of alkyl, alkylcarbonylamino, and amino.

15 52. A compound according to claim 51 selected from the group consisting of 2-(3,4-Difluorophenyl)-4-methoxy-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

N-[[4-[2-(3,4-Difluorophenyl)-4-(2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]sulfonyl]acetamide;

20 N-[[4-[2-(3,4-Difluorophenyl)-4-(2-methyl-1-propoxy)-2H-pyridazin-3-on-5-yl]phenyl]-sulfonyl]acetamide, sodium salt;

2-(3,4-Difluorophenyl)-4-(1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

25 2-(3-Chloro-4-fluorophenyl)-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3-Chloro-4-fluorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Dichlorophenyl)-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(3,4-Dichlorophenyl)-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-[3-(Trifluoromethyl)phenyl]-4-(2-methyl-1-propoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; and

5 2-[3-(Trifluoromethyl)phenyl]-4-(3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.

53. A compound according to claim 35 wherein

R is tert-butyl;

10 R¹ is selected from the group consisting of aminoalkylcarbonyloxyalkoxy, carboxyalkylcarbonyloxyalkoxy, hydroxyalkoxy, and phosphonatoalkoxy; and

R⁹ is selected from the group consisting of alkyl, alkylcarbonylamino, and amino.

54. A compound according to claim 53 selected from the group consisting of

15 2-(tert-Butyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

2-(tert-Butyl)-4-[3-(2-aminoacetyloxy)-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone;

20 2-(tert-butyl)-4-[3-{{[(2R,3R)-3-carboxy-2,3-dihydroxypropanoyl]oxy}}-3-methylbutoxy]-3-methyl-1-butoxy]-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone; and

3-{{2-(tert-butyl)-5-[4-(methylsulfonyl)phenyl]-3-oxo-2,3-dihydro-4-pyridazinyl}oxy)-1,1-dimethylpropyl dihydrogen phosphate.

55. 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-

25 (methylsulfonyl)phenyl]-3(2H)-pyridazinone or a pharmaceutically acceptable salt, ester, or prodrug thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/25234

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D237/14 A61K31/50 C07D405/04 C07D409/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 10331 A (ABBOTT LABORATORIES;USA) 4 March 1999 (1999-03-04) see the whole document, especially definitions of formula I and examples ---	2-16,18, 19, 21-31, 34-55
P,X	WO 99 10332 A (ABBOTT LABORATORIES;USA) 4 March 1999 (1999-03-04) see definitions for formula I and examples --- -/--	2-16,18, 19, 21-31, 34-55



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

27 January 2000

Date of mailing of the international search report

[1] 1. 02.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/25234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 41511 A (MERCK FROSST CANADA INC ; LAU CHEUK K (CA); LI CHUN SING (CA); THER) 24 September 1998 (1998-09-24)</p> <p>see the whole application, especially examples</p> <p>-----</p>	<p>2-16, 18, 19, 21-31, 34-55</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/25234

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 20-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1,17,20,32,33
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Claims Nos.: 1,17,20,32,33

Present claims 1,17,20 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of formula I wherein R2 is W as all of the approx. 500 examples relate to these compounds.

Claims 32 and 33 are directed to a process for the preparation of a 4,5-disubstituted pyridazinone, but the desired end product is not clearly defined, and the preparation steps are only very general. The description only provides support for the preparation of compounds of the formula I, and no support for this general procedure is evident. Thus support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found only for the preparation of compounds of formula I.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US 99/25234

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9910331 A	04-03-1999	AU 8697698 A	16-03-1999
WO 9910332 A	04-03-1999	NONE	
WO 9841511 A	24-09-1998	AU 6491398 A	12-10-1998